



Scott and White Health Plan

**SeniorCare Advantage (PPO)
SeniorCare Advantage (HMO)**

2019 Prior Authorization Criteria

ACTEMRA IV (S)

Products Affected

- Actemra INJ 200MG/10ML, 400MG/20ML, 80MG/4ML

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Rheumatoid Arthritis (RA) (Initial): Diagnosis of moderately to severely active RA. One of the following: Trial and failure, contraindication, or intolerance to both Enbrel (etanercept) and Humira (adalimumab), or attestation demonstrating a trial may be inappropriate, OR for continuation of prior Actemra therapy. Systemic Juvenile Idiopathic arthritis (SJIA) (Initial): Diagnosis of active SJIA. Trial and failure, contraindication, or intolerance to one NSAID or systemic glucocorticoid. Polyarticular Juvenile Idiopathic Arthritis (PJIA) (Initial): Diagnosis of active PJIA. One of the following: Trial and failure, contraindication, or intolerance to both Enbrel (etanercept) and Humira (adalimumab), or attestation demonstrating a trial may be inappropriate, OR for continuation of prior Actemra therapy. RA, SJIA, PJIA (Initial, reauth): Patient is not receiving Actemra in combination with a biologic DMARD [eg, Enbrel (etanercept), Humira (adalimumab), Cimzia (certolizumab), Simponi (golimumab)]. Cytokine Release Syndrome (CRS) Risk due to CAR T-cell Therapy: Patient will receive or is receiving chimeric antigen receptor (CAR) T-cell immunotherapy [i.e., Kymriah (tisagenlecleuce), Yescarta (axicabtagene ciloleuce)].
Age Restrictions	N/A
Prescriber Restrictions	RA, SJIA, PJIA (initial): Prescribed by or in consultation with a rheumatologist. CRS Risk due to CAR T-cell Therapy: Prescribed by or in consultation with an oncologist or hematologist.
Coverage Duration	RA, SJIA, PJIA (Initial, reauth): 12 months. CRS risk due to CAR T-cell therapy: 2 months
Other Criteria	RA, SJIA, PJIA (Reauth): Documentation of positive clinical response to Actemra therapy.

ACTEMRA SC (S)

Products Affected

- Actemra INJ 162MG/0.9ML
- Actemra Actpen

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Rheumatoid Arthritis (RA) (Initial): Diagnosis of moderately to severely active RA. One of the following: Trial and failure, contraindication, or intolerance to both Enbrel (etanercept) and Humira (adalimumab), or attestation demonstrating a trial may be inappropriate, OR for continuation of prior Actemra therapy. Giant Cell Arteritis (GCA) (Initial): Diagnosis of GCA. Trial and failure, contraindication, or intolerance to a glucocorticoid (i.e., prednisone). Systemic Juvenile Idiopathic Arthritis (SJIA) (Initial): Diagnosis of active SJIA. Trial and failure, contraindication, or intolerance to one of the following: NSAID or systemic glucocorticoid. Polyarticular Juvenile Idiopathic Arthritis (PJIA) (Initial): Diagnosis of active PJIA. One of the following: Trial and failure, contraindication, or intolerance to both Enbrel (etanercept) and Humira (adalimumab), or attestation demonstrating a trial may be inappropriate, OR for continuation of prior Actemra therapy.
Age Restrictions	N/A
Prescriber Restrictions	RA, GC, SJIA, PJIA (initial): Prescribed by or in consultation with a rheumatologist.
Coverage Duration	RA, GC, SJIA, PJIA (initial, reauth): 12 months
Other Criteria	RA, GC, SJIA, PJIA (Reauth): Documentation of positive clinical response to Actemra therapy.

Prior Authorization Criteria
Scott and White
Effective: December 1, 2019

ACTIMMUNE (S)

Products Affected

- Actimmune

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Diagnosis of one of the following: 1) Chronic granulomatous disease (CGD), or 2) severe malignant osteopetrosis (SMO).
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	Approve for continuation of prior therapy.

Prior Authorization Criteria
Scott and White
Effective: December 1, 2019

ADAGEN (S)

Products Affected

- Adagen

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	Excluded if patient has severe thrombocytopenia
Required Medical Information	Adenosine deaminase (ADA) deficiency: Diagnosis of ADA deficiency in a patient with severe combined immunodeficiency disease (SCID) AND patient is not a suitable candidate for, or who has failed, bone marrow transplantation, hematopoietic stem cell transplant, or gene therapy.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	Approve for continuation of prior therapy.

Prior Authorization Criteria
 Scott and White
 Effective: December 1, 2019

ADCIRCA (S)

Products Affected

- Adcirca
- Alyq
- Tadalafil TABS 20MG

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Pulmonary arterial hypertension (PAH) (Initial): Diagnosis of PAH. PAH is symptomatic. One of the following: A) Diagnosis of PAH was confirmed by right heart catheterization or B) Patient is currently on any therapy for the diagnosis of PAH.
Age Restrictions	N/A
Prescriber Restrictions	PAH (initial): Prescribed by or in consultation with a pulmonologist or cardiologist.
Coverage Duration	PAH: Initial: 6 months. Reauth: 12 months.
Other Criteria	PAH (Reauth): Documentation of positive clinical response to therapy.

Prior Authorization Criteria
Scott and White
Effective: December 1, 2019

ADDERALL XR (S)

Products Affected

- Amphetamine/dextroamphetamine
CP24

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	One of the following: a) diagnosis of attention deficit hyperactivity disorder (ADHD), OR b) diagnosis of attention deficit disorder (ADD)
Age Restrictions	PA applies to members 19 years of age or older
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	N/A

Prior Authorization Criteria
 Scott and White
 Effective: December 1, 2019

ADEMPAS (S)

Products Affected

- Adempas

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Pulmonary arterial hypertension (PAH) (Initial): Diagnosis of PAH AND PAH is symptomatic AND One of the following: A) Diagnosis of PAH was confirmed by right heart catheterization or B) Patient is currently on any therapy for the diagnosis of PAH. Chronic thromboembolic pulmonary hypertension (CTEPH) (Initial): One of the following: A) Both of the following: 1) Diagnosis of inoperable or persistent/recurrent CTEPH and 2) CTEPH is symptomatic OR B) Patient is currently on any therapy for the diagnosis of CTEPH.
Age Restrictions	N/A
Prescriber Restrictions	PAH, CTEPH (initial): Prescribed by or in consultation with a pulmonologist or cardiologist.
Coverage Duration	PAH, CTEPH: Initial: 6 months. Reauth: 12 months.
Other Criteria	PAH, CTEPH (Reauth): Documentation of positive clinical response to therapy.

AFINITOR (S)

Products Affected

- Afinitor

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Subependymal Giant Cell Astrocytoma (SEGA) associated with tuberous sclerosis complex (TSC): Diagnosis of SEGA associated with TSC that requires therapeutic intervention but patient is not a candidate for curative surgical resection. Renal cell carcinoma: Diagnosis of advanced or metastatic renal cell carcinoma AND trial and failure, contraindication, or intolerance to SUTENT (sunitinib) or NEXAVAR (sorafenib). Neuroendocrine tumors of pancreatic origin (pNET): Diagnosis of progressive pNET that are unresectable, locally advanced, or metastatic. Renal angiomyolipoma: Diagnosis of renal angiomyolipoma and TSC AND Patient does not require immediate surgery. Breast Cancer: Patient is a postmenopausal woman AND Diagnosis of advanced hormone receptor-positive, HER2-negative breast cancer AND trial and failure, contraindication, or intolerance to FEMARA (letrozole) or ARIMIDEX (anastrozole) AND Afinitor will be used in combination with AROMASIN (exemestane). Neuroendocrine tumors of gastrointestinal (GI) or lung origin: Diagnosis of progressive, well-differentiated, non-functional NET of GI or lung origin AND patient has unresectable, locally advanced or metastatic disease.
Age Restrictions	N/A
Prescriber Restrictions	All uses: Prescribed by or in consultation with an oncologist
Coverage Duration	All uses: 12 months
Other Criteria	All Indications: Approve for continuation of prior therapy.

Prior Authorization Criteria
 Scott and White
 Effective: December 1, 2019

AFINITOR DISPERZ (S)

Products Affected

- Afinitor Disperz

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Subependymal Giant Cell Astrocytoma (SEGA): Diagnosis of SEGA associated with tuberous sclerosis complex (TSC) that requires therapeutic intervention but patient is not a candidate for curative surgical resection. TSC-associated partial-onset seizures: Diagnosis of TSC-associated partial-onset seizures. Used as adjunctive therapy.
Age Restrictions	N/A
Prescriber Restrictions	SEGA: Prescribed by or in consultation with an oncologist. TSC-associated partial-onset seizures: Prescribed by or in consultation with a neurologist.
Coverage Duration	12 months
Other Criteria	Approve for continuation of prior therapy.

AIMOVIG (S)

Products Affected

- Aimovig

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	<p>Episodic Migraines (EM) (initial): Diagnosis of EM. Patient has 4 to 14 migraine days per month, but no more than 14 headache days per month.</p> <p>Chronic Migraines (CM) (initial): Diagnosis of CM. Medication overuse headache has been considered and potentially offending medication(s) have been discontinued. Patient has greater than or equal to 15 headache days per month, of which at least 8 must be migraine days for at least 3 months.</p> <p>All Indications (initial): Not used in combination with another calcitonin gene-related peptide (CGRP) inhibitor. Two of the following:</p> <p>a) History of failure (after at least a two month trial) or intolerance to Elavil (amitriptyline) or Effexor (venlafaxine), OR patient has a contraindication to both Elavil (amitriptyline) and Effexor (venlafaxine),</p> <p>b) History of failure (after at least a two month trial) or intolerance to Depakote/Depakote ER (divalproex sodium) or Topamax (topiramate), OR patient has a contraindication to both Depakote/Depakote ER (divalproex sodium) and Topamax (topiramate), or c) History of failure (after at least a two month trial) or intolerance to one of the following beta blockers: atenolol, propranolol, nadolol, timolol, or metoprolol, OR patient has a contraindication to all of the following beta blockers: atenolol, propranolol, nadolol, timolol, or metoprolol.</p>
Age Restrictions	EM, CM (initial): 18 years of age or older.
Prescriber Restrictions	EM, CM (initial, reauth): Prescribed by or in consultation with a neurologist or pain specialist.
Coverage Duration	EM, CM (initial): 6 months. EM, CM (reauth): 12 months.

Prior Authorization Criteria

Scott and White

Effective: December 1, 2019

Other Criteria	EM, CM (reauth): Patient has experienced a positive response to therapy, demonstrated by a reduction in headache frequency and/or intensity. Use of acute migraine medications (e.g., non-steroidal anti-inflammatory drugs [NSAIDs], triptans) has decreased since the start of CGRP therapy. CM (reauth): Patient continues to be monitored for medication overuse headache.
-----------------------	---

Prior Authorization Criteria
Scott and White
Effective: December 1, 2019

ALDURAZYME (S)

Products Affected

- Aldurazyme

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Mucopolysaccharidosis I: confirmed diagnosis of Hurler and Hurler-Scheie forms of Mucopolysaccharidosis I (MPS I), OR confirmed diagnosis of Scheie form of Mucopolysaccharidosis I (MPS I) who have moderate to severe symptoms.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	N/A

Prior Authorization Criteria
Scott and White
Effective: December 1, 2019

ALECENSA (S)

Products Affected

- Alecensa

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Non-small cell lung cancer (NSCLC): A) Diagnosis of metastatic NSCLC AND B) Patient has anaplastic lymphoma kinase (ALK)-positive disease as detected with an FDA-approved test or at a Clinical Laboratory Improvement Amendments-approved facility.
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with an oncologist.
Coverage Duration	12 months
Other Criteria	Approve for continuation of prior therapy.

Prior Authorization Criteria
Scott and White
Effective: December 1, 2019

ALIQOPA (S)

Products Affected

- Aliqopa

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Relapsed Follicular Lymphoma: Diagnosis of relapsed follicular lymphoma AND patient has received at least two prior systemic therapies.
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with a hematologist/oncologist.
Coverage Duration	12 months
Other Criteria	Approve for continuation of prior therapy.

Prior Authorization Criteria
 Scott and White
 Effective: December 1, 2019

ALPHA-1 PROTEINASE INHIBITOR, NON-PREFERRED (S)

Products Affected

- Aralast Np
- Glassia
- Zemaira

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Alpha-1 proteinase inhibitor (alpha-1 antitrypsin) deficiency: All of the following: A) Patient has an alpha-1 proteinase inhibitor (alpha-1 antitrypsin) deficiency AND B) Diagnosis of emphysema AND C) One of the following: 1) Patient has a high risk phenotype: PiZZ, PiZ(null), or Pi(null)(null) OR 2) Patient has serum alpha-1 antitrypsin concentrations of less than 11 µM/L (80 mg/dL), AND D) One of the following: FEV1 level is between 30% and 65% of predicted OR the patient has experienced a rapid decline in lung function (i.e., reduction of FEV1 more than 120 mL/year) that warrants treatment, AND E) Trial and failure, or intolerance to Prolastin-C.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	N/A

Prior Authorization Criteria
 Scott and White
 Effective: December 1, 2019

ALPHA-1 PROTEINASE INHIBITOR, PROLASTIN (S)

Products Affected

- Prolastin-c INJ 1000MG

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Alpha-1 proteinase inhibitor (alpha-1 antitrypsin) deficiency: All of the following: A) Patient has an alpha-1 proteinase inhibitor (alpha-1 antitrypsin) deficiency AND B) Diagnosis of emphysema AND C) One of the following: 1) Patient has a high risk phenotype: PiZZ, PiZ(null), or Pi(null)(null) OR 2) Patient has serum alpha-1 antitrypsin concentrations of less than 11 µM/L (80 mg/dL) AND D) One of the following: FEV1 level is between 30% and 65% of predicted OR the patient has experienced a rapid decline in lung function (i.e., reduction of FEV1 more than 120 mL/year) that warrants treatment.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	N/A

Prior Authorization Criteria
Scott and White
Effective: December 1, 2019

ALUNBRIG (S)

Products Affected

- Alunbrig

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Non-small cell lung cancer (NSCLC): Diagnosis of metastatic NSCLC. Patient has an anaplastic lymphoma kinase (ALK)-positive tumor as detected with an FDA-approved test or at a Clinical Laboratory Improvement Amendments-approved facility. Trial and failure or intolerance to Xalkori (crizotinib).
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	12 months
Other Criteria	Approve for continuation of prior therapy.

Prior Authorization Criteria
Scott and White
Effective: December 1, 2019

AMPHETAMINE (S)

Products Affected

- Amphetamine/dextroamphetamine
TABS

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	One of the following: a) diagnosis of ADHD, OR b) diagnosis of attention deficit disorder (ADD), OR c) diagnosis of narcolepsy as confirmed by a sleep study (unless the prescriber provides justification confirming that a sleep study would not be feasible).
Age Restrictions	PA applies to members 19 years of age or older
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	N/A

Prior Authorization Criteria
 Scott and White
 Effective: December 1, 2019

AMPYRA (S)

Products Affected

- Ampyra

- Dalfampridine Er

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Multiple Sclerosis (MS) (initial): Diagnosis of MS. Physician confirmation that patient has difficulty walking (eg, timed 25 foot walk test). One of the following: expanded disability status scale (EDSS) score less than or equal to 7, or not restricted to using a wheelchair (if EDSS is not measured).
Age Restrictions	N/A
Prescriber Restrictions	MS (initial): Prescribed by or in consultation with a neurologist.
Coverage Duration	MS (Initial): 6 months. (Reauth): 12 months.
Other Criteria	MS (Reauth): Physician confirmation that the patient's walking improved with Ampyra therapy. One of the following: EDSS score less than or equal to 7, or not restricted to using a wheelchair (if EDSS is not measured).

Prior Authorization Criteria
 Scott and White
 Effective: December 1, 2019

ANADROL-50 (S)

Products Affected

- Anadrol-50

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Anemia (initial): Diagnosis of anemia caused by deficient red cell production AND trial and failure or intolerance to standard therapies for anemia (i.e., erythropoiesis-stimulating agents, immunosuppressants) AND Treatment will not replace other supportive measures (e.g., transfusion, correction of iron, folic acid, vitamin B12 or pyridoxine deficiency, antibacterial therapy, corticosteroids).
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Initial, reauth: 12 months
Other Criteria	Anemia (reauth): patient has experienced an objective improvement in anemia (e.g., increased hemoglobin, increased reticulocyte count, reduction/elimination for need of blood transfusions).

ANDROXY (S)

Products Affected

- Androxy

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Hypogonadism (HG) (Initial): Diagnosis (dx) of HG in a male patient at birth. 1) Two pre-treatment serum total testosterone (T) levels less than reference range for the lab OR 2) Both of the following: Has a condition that may cause altered sex-hormone binding globulin (SHBG) (eg, thyroid disorder, HIV disease, liver disorder, diabetes, obesity), and one pre-treatment calculated free or bioavailable T level less than 5 ng/dL (0.17 nmol/L) or less than reference range for the lab, OR 3) History of bilateral orchiectomy, panhypopituitarism, or a genetic disorder known to cause HG (eg, congenital anorchia, Klinefelter's syndrome). Delayed puberty (DP): Dx of DP in males at birth. Breast cancer (BC): Dx for the palliative treatment of inoperable BC in females at birth. Gender Identity Disorder (GID) (off-label): Dx of GID. Patient is a female-to-male transsexual.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	HG(init): (New to T tx:6 mo. Cont T tx:12 mo), (reauth): 12 mo. BC, GID: 12 mo. DP: 6 mo.
Other Criteria	HG (Reauth): 1) Total serum T level within or below the normal limits of the reporting lab, or 2) Total serum T level outside of upper limits of normal for the reporting lab and the dose is adjusted, OR 3) Has a condition that may cause altered SHBG (eg, thyroid disorder, HIV disease, liver disorder, diabetes, obesity), and one of the following: Calculated free or bioavailable T level within or below the normal limits of the reporting lab, or calculated free or bioavailable T level outside of upper limits of normal for the reporting lab and the dose is adjusted.

Prior Authorization Criteria
Scott and White
Effective: December 1, 2019

APOKYN (S)

Products Affected

- Apokyn INJ 30MG/3ML

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	PD (Initial): Patient is using Apokyn with any 5-HT3 antagonist (eg, ondansetron, granisetron, dolasetron, palonosetron, alosetron)
Required Medical Information	Parkinson's disease (PD) (Initial): Diagnosis of advanced PD. Patient is experiencing acute intermittent hypomobility (defined as “off” episodes characterized by muscle stiffness, slow movements, or difficulty starting movements). Patient is receiving Apokyn in combination with other medications for the treatment of PD (e.g., carbidopa/levodopa, pramipexole, ropinirole, benztropine, etc.).
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	PD (Initial, reauth): 12 months
Other Criteria	PD (Reauth): Documentation of positive clinical response to Apokyn therapy.

ARANESP (S)

Products Affected

- Aranesp Albumin Free INJ
 100MCG/0.5ML, 100MCG/ML,
 10MCG/0.4ML, 150MCG/0.3ML,
 200MCG/0.4ML, 200MCG/ML,
 25MCG/0.42ML, 25MCG/ML,
 300MCG/0.6ML, 300MCG/ML,
 40MCG/0.4ML, 40MCG/ML,
 500MCG/ML, 60MCG/0.3ML,
 60MCG/ML

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Anemia with Chronic Kidney Disease (CKD) (Initial): Diagnosis (Dx) of CKD. Anemia by lab values (Hct less than 30% or Hgb less than 10 g/dL) collected within 30 days of request. One of the following: a) both of the following: Patient is on dialysis, patient is without ESRD OR b) all of the following: patient is not on dialysis, the rate of hemoglobin decline indicates the likelihood of requiring a red blood cell (RBC) transfusion, and reducing the risk of alloimmunization and/or other RBC transfusion-related risks is a goal. Anemia with chemo (Initial): Other causes of anemia have been ruled out. Anemia by lab values (Hct less than 30%, Hgb less than 10 g/dL) collected within the prior 2 weeks of request. Cancer is a non-myeloid malignancy. Patient is concurrently on chemo, or will receive concomitant chemo for a minimum of 2 months, or anemia is caused by cancer chemo. Will not be approved if patient is not receiving cancer chemotherapy. Anemia in Myelodysplastic Syndrome (MDS) (Initial): Dx of MDS. Serum erythropoietin level is 500 mU/mL or less, or dx of transfusion-dependent MDS. CKD (init, reauth), Chemo (init), MDS (init): Verify iron evaluation for adequate iron stores.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	CKD (Init): 6 mo. CKD (reauth): 12 mo. Chemo(init, reauth): 3 mo. MDS: (init) 3 mo,(reauth) 12 mo.

Prior Authorization Criteria

Scott and White

Effective: December 1, 2019

Other Criteria	Subject to ESRD review. CKD (Reauth): Dx of CKD. Most recent or average (avg) Hct over 3 mo is 33% or less OR most recent or avg Hgb over 3 months is 11 g/dL or less. Decrease in the need for blood transfusion or Hgb increased by 1 g/dL or more from pre-treatment level. Chemo (Reauth): Anemia by lab values (Hgb less than 10 g/dl or Hct less than 30%) collected within the prior 2 weeks of request. Decrease in the need for blood transfusion or Hgb increased by 1 g/dL or more from pre-treatment level. Patient is concurrently on chemo, or will receive concomitant chemo for a minimum of 2 months, or anemia is caused by cancer chemo. Will not be approved if patient is not receiving cancer chemotherapy. MDS (Reauth): Most recent or avg Hct over 3 months is 36% or less, OR most recent or avg Hgb over 3 months is 12 g/dl or less. Decrease in the need for blood transfusion or Hgb increased by 1 g/dL or more from pre-treatment level. Off-label uses (except MDS): Will not be approved if patient has Hgb greater than 10 g/dL or Hct greater than 30%.
-----------------------	---

Prior Authorization Criteria
 Scott and White
 Effective: December 1, 2019

ARCALYST (S)

Products Affected

- Arcalyst

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Cryopyrin-Associated Periodic Syndromes (CAPS) (Initial): Diagnosis of CAPS, including Familial Cold Auto-inflammatory Syndrome (FCAS) and/or Muckle-Wells Syndrome (MWS). The medication will not be used in combination with another biologic.
Age Restrictions	CAPS (Initial): 12 years of age or older
Prescriber Restrictions	CAPS (initial): Prescribed by or in consultation with an immunologist, allergist, dermatologist, rheumatologist, neurologist or other medical specialist.
Coverage Duration	CAPS (initial, reauth): 12 months
Other Criteria	CAPS (Reauth): Patient has experienced disease stability or improvement in clinical symptoms while on therapy as evidence by one of the following: A) improvement in rash, fever, joint pain, headache, conjunctivitis, B) decreased number of disease flare days, C) normalization of inflammatory markers (CRP, ESR, SAA), D) corticosteroid dose reduction, OR E) improvement in MD global score or active joint count.

Prior Authorization Criteria
 Scott and White
 Effective: December 1, 2019

ARZERRA (S)

Products Affected

- Arzerra

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Refractory chronic lymphocytic leukemia (CLL): Diagnosis of CLL. Disease is refractory to both fludarabine and alemtuzumab. Previously untreated CLL: Diagnosis of CLL. Patient is previously untreated for CLL. Patient is not an appropriate candidate for fludarabine-based therapy. Used in combination with chlorambucil. Recurrent or progressive Chronic Lymphocytic Leukemia (CLL): Diagnosis of chronic lymphocytic leukemia (CLL). Disease is recurrent or progressive. Arzerra is used for an extended treatment for patients who are in complete or partial response after at least two lines of therapy. Relapsed Chronic Lymphocytic Leukemia (CLL): Diagnosis of CLL. Disease has relapsed. Used in combination with fludarabine and cyclophosphamide.
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with an oncologist/hematologist.
Coverage Duration	12 months
Other Criteria	Approve for continuation of prior therapy.

Prior Authorization Criteria
Scott and White
Effective: December 1, 2019

AUBAGIO (S)

Products Affected

- Aubagio

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Multiple Sclerosis (MS): Diagnosis of a relapsing form of MS (eg, relapsing-remitting MS, secondary-progressive MS with relapses, progressive-relapsing MS with relapses).
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	N/A

Prior Authorization Criteria
Scott and White
Effective: December 1, 2019

AURYXIA (S)

Products Affected

- Auryxia

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	Exclude if used for iron deficiency anemia in chronic kidney disease (CKD) not on dialysis.
Required Medical Information	Hyperphosphatemia in chronic kidney disease: Diagnosis of hyperphosphatemia. Patient has chronic kidney disease (CKD). Patient is on dialysis.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	N/A

Prior Authorization Criteria
 Scott and White
 Effective: December 1, 2019

AUSTEDO (S)

Products Affected

- Austedo

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Chorea associated with Huntington's disease (initial): Diagnosis of Chorea associated with Huntington's disease. Tardive dyskinesia (initial): Diagnosis of moderate to severe tardive dyskinesia. One of the following: 1) Patient has persistent symptoms of tardive dyskinesia despite a trial of dose reduction, tapering, or discontinuation of the offending medication or 2) Patient is not a candidate for a trial of dose reduction, tapering, or discontinuation of the offending medication.
Age Restrictions	N/A
Prescriber Restrictions	Huntington's disease chorea (initial): Prescribed by a neurologist. Tardive dyskinesia (initial): Prescribed by or in consultation with a neurologist or psychiatrist.
Coverage Duration	Initial: 3 months. Reauth: 12 months
Other Criteria	All indications (Reauth): Documentation of positive clinical response to Austedo therapy.

Prior Authorization Criteria
 Scott and White
 Effective: December 1, 2019

BALVERSA (S)

Products Affected

- Balversa

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Urothelial Carcinoma: Diagnosis of urothelial carcinoma (UC). One of the following: Locally advanced or Metastatic AND Patient has fibroblast growth factor receptor (FGFR) 3 or FGFR2 genetic alterations as detected by an U.S. Food and Drug Administration (FDA)-approved test (therascreen FGFR RGQ RT-PCR Kit) or a test performed at a facility approved by Clinical Laboratory Improvement Amendments (CLIA). One of the following: 1) Patient has progressed during or following at least one line of prior chemotherapy or immunotherapy OR 2) Patient has progressed within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	12 months
Other Criteria	Approve for continuation of prior therapy.

Prior Authorization Criteria
Scott and White
Effective: December 1, 2019

BAVENCIO (S)

Products Affected

- Bavencio

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Merkel Cell Carcinoma (MCC): Diagnosis of metastatic Merkel cell carcinoma. Urothelial Carcinoma (UC): Diagnosis of locally advanced or metastatic urothelial carcinoma. One of the following: 1) Patient has disease progression during or following platinum-containing chemotherapy, OR 2) Patient has disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy
Age Restrictions	MCC: Patient is 12 years of age or older.
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	12 months
Other Criteria	Approve for continuation of prior therapy.

Prior Authorization Criteria
Scott and White
Effective: December 1, 2019

BELEODAQ (S)

Products Affected

- Beleodaq

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Peripheral T-cell lymphoma (PTCL): Diagnosis of PTCL. Trial and failure, contraindication, or intolerance to at least one prior therapy (e.g., conventional chemotherapy).
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with a hematologist/oncologist
Coverage Duration	12 months
Other Criteria	Approve for continuation of prior therapy.

Prior Authorization Criteria
 Scott and White
 Effective: December 1, 2019

BENLYSTA (S)

Products Affected

- Benlysta

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Systemic lupus erythematosus (SLE) (init): Diagnosis of active SLE. Autoantibody positive (ie, anti-nuclear antibody [ANA] titer greater than or equal to 1:80 or anti-dsDNA level greater than or equal to 30 IU/mL). Currently receiving at least one standard of care treatment for active SLE (eg, antimalarials [eg, Plaquenil (hydroxychloroquine)], corticosteroids [eg, prednisone], or immunosuppressants [eg, methotrexate, Imuran (azathioprine)]).
Age Restrictions	N/A
Prescriber Restrictions	SLE (init): Prescribed by or in consultation with a rheumatologist
Coverage Duration	SLE (init, reauth): 6 months
Other Criteria	SLE (reauth): Documentation of positive clinical response to Benlysta therapy.

Prior Authorization Criteria
 Scott and White
 Effective: December 1, 2019

BENZODIAZEPINES (S)

Products Affected

- Alprazolam TABS
- Alprazolam Er
- Alprazolam Intensol
- Alprazolam Odt
- Alprazolam Xr
- Chlordiazepoxide Hcl CAPS 10MG, 5MG
- Chlordiazepoxide Hydrochloride
- Estazolam
- Lorazepam CONC
- Lorazepam INJ 2MG/ML, 4MG/ML
- Lorazepam TABS
- Lorazepam Intensol
- Oxazepam
- Temazepam

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Verify the medication is being used for an FDA-approved diagnosis or compendia-supported indication.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	N/A

Prior Authorization Criteria
Scott and White
Effective: December 1, 2019

BERINERT (S)

Products Affected

- Berinert

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Treatment of hereditary angioedema (HAE) attacks: Diagnosis of HAE. For the treatment of acute HAE attacks. Not used in combination with other approved treatments for acute HAE attacks.
Age Restrictions	N/A
Prescriber Restrictions	HAE: Prescribed by or in consultation with an immunologist, allergist, or rheumatologist
Coverage Duration	12 months
Other Criteria	N/A

Prior Authorization Criteria
Scott and White
Effective: December 1, 2019

BESPONSA (S)

Products Affected

- Besponsa

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	B-cell precursor acute lymphoblastic leukemia (ALL): Diagnosis of B-cell precursor acute lymphoblastic leukemia (ALL). Disease is relapsed or refractory.
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with a hematologist/oncologist
Coverage Duration	12 months
Other Criteria	Approve for continuation of prior therapy.

Prior Authorization Criteria
Scott and White
Effective: December 1, 2019

BLINCYTO (S)

Products Affected

- Blincyto

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL): Diagnosis of relapsed or refractory B-cell precursor acute lymphoblastic leukemia/acute lymphoblastic lymphoma.
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with a hematologist/oncologist
Coverage Duration	12 months
Other Criteria	Subject to Part B vs. Part D review. Approve for continuation of prior therapy.

Prior Authorization Criteria
Scott and White
Effective: December 1, 2019

BORTEZOMIB (S)

Products Affected

- Bortezomib

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Multiple myeloma (MM): Diagnosis of MM. Mantle cell lymphoma (MCL): Diagnosis of MCL AND patient has received at least one prior therapy for MCL.
Age Restrictions	N/A
Prescriber Restrictions	MM, MCL: Prescribed by or in consultation with an oncologist/hematologist
Coverage Duration	12 months
Other Criteria	Approve for continuation of prior therapy.

Prior Authorization Criteria
Scott and White
Effective: December 1, 2019

BOSULIF (S)

Products Affected

- Bosulif

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Chronic myelogenous/myeloid leukemia (CML): Diagnosis of Philadelphia chromosome-positive (Ph+) CML.
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with an oncologist or hematologist
Coverage Duration	12 months
Other Criteria	Approve for continuation of prior therapy.

BOTOX (S)

Products Affected

- Botox

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	<p>Neuromuscular Disorders (init): Strabismus, blepharospasm associated with dystonia (eg, benign essential blepharospasm), treatment of upper or lower limb spasticity, VII cranial nerve disorders (hemifacial spasms), cervical dystonia Hyperhidrosis(HH): (Init) Dx of primary axillary HH. Score of 3 or 4 on the Hyperhidrosis Disease Severity Scale (HDSS) or skin maceration with secondary infection. Migraine:(Init) Dx of chronic migraines (greater than or equal to 15 migraine headache days per month with headache lasting 4 hours a day or longer). TF/C/I to prophylactic therapy with at least two of the following agents, each given for a trial of at least two months: antidepressants [ie, Effexor (venlafaxine)], antiepileptics [ie, Depakote/Depakote ER (divalproex sodium), Topamax (topiramate)], beta-blockers [eg, atenolol, Inderal (propranolol), nadolol, timolol, Toprol XL (metoprolol)] Achalasia:(Init) High risk of complication from or failure to pneumatic dilation or myotomy, or prior dilation caused esophageal perforation, or patient has an epiphrenic diverticulum or hiatal hernia. Anal Fissure (AF)(Init): Dx of chronic AF. At least 2 months of either nocturnal pain and bleeding or postdefecation pain. Chronic Back Pain (CBP):(Init) Dx of low back pain lasting greater than or equal to six months. Urinary incont (UI):(init) Neurogenic detrusor overactivity associated with a neurologic condition (eg, spinal cord injury [SCI], multiple sclerosis) or detrusor sphincter dyssynergia with SCI. Overactive bladder (OAB): (init) Dx of OAB. One of the following symptoms: urge urinary incontinence, urgency, frequency.</p>
Age Restrictions	N/A
Prescriber Restrictions	<p>Migraine (initial): Prescribed by a neurologist or pain specialist. CBP (initial): Prescribed by a neurologist, neurosurgeon, orthopedist, or pain specialist. UI, OAB (initial): Prescribed by a neurologist, neurosurgeon, or urologist.</p>
Coverage Duration	Achalasia: 6moCBP:1 tx(series of injxs)UI:3mo(1 dose,200units)Other:3mo

Prior Authorization Criteria

Scott and White

Effective: December 1, 2019

Other Criteria	UI, OAB, CBP, Neuromuscular Disorders:(Reauth) Confirmed improvement in symptoms with initial Botox treatment. At least 3 months have or will have elapsed since the last treatment with Botox HH:(Reauth) At least a 2-point improvement in HDSS. Migraine:(Reauth) Reduction in headache frequency or intensity. Confirmation of decreased utilization of pain medications (eg, narcotic analgesics, NSAIDs) or triptans, or a reduction in the number of ER visits. Achalasia:(Reauth) Documentation of improvement or reduction in symptoms of achalasia (ie, dysphagia, regurgitation, chest pain). At least 6 months have or will have elapsed since last series of injections AF: (Reauth) Incomplete healing of fissure or recurrence of fissure. Improved symptoms with prior treatment with Botox.
-----------------------	--

Prior Authorization Criteria
Scott and White
Effective: December 1, 2019

BRAFTOVI (S)

Products Affected

- Braftovi

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Melanoma: Diagnosis of unresectable melanoma or metastatic melanoma. Cancer is BRAF V600E or V600K mutant type (MT) as detected by an FDA-approved test (THxID-BRAF Kit) or performed at a facility approved by Clinical Laboratory Improvement Amendments (CLIA). Used in combination with Mektovi (binimetinib).
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	12 months
Other Criteria	Approve for continuation of prior therapy

Prior Authorization Criteria
 Scott and White
 Effective: December 1, 2019

CABLIVI (S)

Products Affected

- Cablivi

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Acquired thrombocytic thrombocytopenic purpura (aTTP): Diagnosis of aTTP. First dose was/will be administered by a healthcare provider as a bolus intravenous injection. Used in combination with immunosuppressive therapy (e.g. rituximab, glucocorticoids). One of the following: 1) Used in combination with plasma exchange or 2) both of the following: patient has completed plasma exchange and less than 59 days have or will have elapsed beyond the last plasma exchange.
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with a hematologist or oncologist.
Coverage Duration	3 months
Other Criteria	N/A

Prior Authorization Criteria
 Scott and White
 Effective: December 1, 2019

CABOMETYX (S)

Products Affected

- Cabometyx

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Renal cell carcinoma (RCC): Diagnosis of RCC. RCC is advanced. Hepatocellular Carcinoma (HCC): Diagnosis of HCC. One of the following: a) Trial and failure or intolerance to Nexavar (sorafenib tosylate), or b) Patient has metastatic disease, or c) Patient has extensive liver tumor burden, or d) Patient is inoperable by performance status or comorbidity (local disease or local disease with minimal extrahepatic disease only), or e) Disease is unresectable.
Age Restrictions	N/A
Prescriber Restrictions	RCC: Prescribed by or in consultation with an oncologist. HCC: Prescribed by or in consultation with one of the following: oncologist, hepatologist, or gastroenterologist.
Coverage Duration	12 months
Other Criteria	Approve for continuation of prior therapy.

Prior Authorization Criteria
Scott and White
Effective: December 1, 2019

CALQUENCE (S)

Products Affected

- Calquence

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Mantle Cell Lymphoma: Diagnosis of mantle cell lymphoma (MCL) AND patient has received at least one prior therapy for MCL.
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with a hematologist/oncologist
Coverage Duration	12 months
Other Criteria	Approve for continuation of prior therapy.

Prior Authorization Criteria
Scott and White
Effective: December 1, 2019

CAPRELSA (S)

Products Affected

- Caprelsa

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Thyroid Cancer: Diagnosis of medullary thyroid cancer (MTC).
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with oncologist or endocrinologist.
Coverage Duration	12 months
Other Criteria	Approve for continuation of prior therapy.

Prior Authorization Criteria
Scott and White
Effective: December 1, 2019

CARISOPRODOL (S)

Products Affected

- Carisoprodol TABS

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	The drug is being prescribed for an FDA-approved indication. If the patient is 65 years of age or older, the prescribing physician has been made aware that the requested drug is considered a high risk medication for elderly patients (age 65 years and older) and wishes to proceed with the originally prescribed medication.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	N/A

Prior Authorization Criteria
Scott and White
Effective: December 1, 2019

CAYSTON (S)

Products Affected

- Cayston

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Cystic fibrosis (CF) (Initial, Reauth): Diagnosis of CF AND Patient has evidence of Pseudomonas aeruginosa in the lungs.
Age Restrictions	CF (Initial): 7 years of age or older
Prescriber Restrictions	N/A
Coverage Duration	CF (Initial, reauth): 12 months
Other Criteria	CF (Reauth): Patient is benefiting from treatment (i.e. improvement in lung function [forced expiratory volume in one second (FEV1)], decreased number of pulmonary exacerbations).

Prior Authorization Criteria
 Scott and White
 Effective: December 1, 2019

CERDELGA (S)

Products Affected

- Cerdelga

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Gaucher disease (Initial): Diagnosis of Gaucher disease type 1. Patient is an extensive metabolizer (EM), intermediate metabolizer (IM), or poor metabolizer (PM) of cytochrome P450 enzyme (CYP) 2D6 as detected by an FDA-cleared test.
Age Restrictions	Gaucher disease (initial): 18 years of age or older
Prescriber Restrictions	N/A
Coverage Duration	Gaucher disease (initial, reauth): 12 months
Other Criteria	Gaucher disease (Reauth): Patient's condition has not progressed, as defined by ALL of the following: A) Hemoglobin level decreased greater than 1.5 g/dL from baseline, AND B) Platelet count decreased greater than 25% from baseline, AND C) Spleen volume increased greater than 25% from baseline, AND D) Liver volume increased greater than 20% from baseline.

Prior Authorization Criteria
Scott and White
Effective: December 1, 2019

CEREZYME (S)

Products Affected

- Cerezyme

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Gaucher disease: Diagnosis of type 1 Gaucher disease. Patient has evidence of symptomatic disease (e.g., moderate to severe anemia, thrombocytopenia, bone disease, hepatomegaly, or splenomegaly).
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Gaucher disease: 12 months
Other Criteria	N/A

Prior Authorization Criteria
 Scott and White
 Effective: December 1, 2019

CHOLBAM (S)

Products Affected

- Cholbam

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Bile acid synthesis disorders due to single enzyme defects (BAS) (initial): diagnosis of a bile acid synthesis disorder due to a single enzyme defect. Peroxisomal disorders (PD) (initial): All of the following: 1) diagnosis of peroxisomal disorder, 2) patient exhibits at least one of the following: a) liver disease (eg, jaundice, elevated serum transaminases), OR b) steatorrhea, OR c) complications from decreased fat-soluble vitamin absorption (eg, poor growth), AND 3) Cholbam will be used as an adjunctive treatment.
Age Restrictions	N/A
Prescriber Restrictions	All uses (initial): Prescribed by a hepatologist, medical geneticist, pediatric gastroenterologist, OR other specialist that treats inborn errors of metabolism.
Coverage Duration	All uses (initial, reauth): 12 months
Other Criteria	All uses (reauth): documentation of positive clinical response to Cholbam therapy.

Prior Authorization Criteria
 Scott and White
 Effective: December 1, 2019

CHORIONIC GONADOTROPIN (S)

Products Affected

- Chorionic Gonadotropin INJ
- Novarel
- Pregnyl W/diluent Benzyl Alcohol/nacl

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Prepubertal Cryptorchidism: Diagnosis of prepubertal cryptorchidism not due to anatomical obstruction. Male Hypogonadotropic Hypogonadism (MHH) (initial): Diagnosis of male hypogonadism secondary to pituitary deficiency, and low testosterone (below normal reference value provided by the physician's laboratory) and one of the following: a) low LH (below normal reference value provided by the physician's laboratory) or b) low FSH (below normal reference value provided by the physician's laboratory).
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Prepubertal Cryptorchidism: 6 wks. MHH (initial, reauth): 12 months.
Other Criteria	Excluded if used to promote fertility. MHH (Reauth): Documentation of positive clinical response to therapy.

Prior Authorization Criteria
Scott and White
Effective: December 1, 2019

CIALIS (S)

Products Affected

- Tadalafil TABS 2.5MG, 5MG

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	Concurrent use of nitrates.
Required Medical Information	Diagnosis of benign prostatic hyperplasia (BPH). Trial and failure, contraindication, or intolerance to an alpha-blocker (e.g., doxazosin, prazosin, tamsulosin) or a 5-alpha reductase inhibitor (e.g., dutasteride, finasteride).
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	N/A

Prior Authorization Criteria
 Scott and White
 Effective: December 1, 2019

CICLOPIROX (S)

Products Affected

- Ciclopirox Nail Lacquer
- Ciclodan SOLN

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	All of the following: 1) Patient does not have dermatophytomas or lunula (matrix) involvement, 2) one of the following: a) Diagnosis of onychomycosis of the toenails, OR b) Diagnosis of onychomycosis of the fingernails, 3) Diagnosis of onychomycosis has been confirmed by one of the following: a) positive potassium hydroxide (KOH) preparation, OR b) culture, OR c) histology, 4) If toenail onychomycosis, patient has mild to moderate disease involving at least 1 great toenail, AND 5) Trial and inadequate response, intolerance or hypersensitivity to oral terbinafine.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	48 weeks.
Other Criteria	N/A

CIMZIA (S)

Products Affected

- Cimzia

- Cimzia Starter Kit

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Rheumatoid Arthritis (RA, initial): Diagnosis (dx) of moderately to severely active RA. TF/C/I to both Enbrel and Humira, or attestation demonstrating a trial may be inappropriate, OR for continuation of prior Cimzia therapy. Crohn's Disease (CD, initial): Dx of moderately to severely active CD. Trial and failure, contraindication, or intolerance (TF/C/I) to one of the following conventional therapies: 6-mercaptopurine (Purinethol), Azathioprine (Imuran), Corticosteroid (eg, prednisone, methylprednisolone), Methotrexate (Rheumatrex, Trexall). TF/C/I to Humira OR for continuation of prior Cimzia therapy. Psoriatic Arthritis (PsA, initial): Dx of active PsA. TF/C/I to both Enbrel and Humira, or attestation demonstrating a trial may be inappropriate, OR for continuation of prior Cimzia therapy. Ankylosing Spondylitis (AS, initial): Dx of active AS. TF/C/I to both Enbrel and Humira, or attestation demonstrating a trial may be inappropriate, OR for continuation of prior Cimzia therapy. Plaque Psoriasis (initial): Dx of moderate to severe plaque psoriasis. TF/C/I to Cosentyx AND either Humira or Enbrel OR for continuation of prior Cimzia therapy. Non-radiographic axial spondyloarthritis (nr-axSpA, initial): Dx of nr-axSpA with objective signs of inflammation (eg, C-reactive protein [CRP] levels above the upper limit of normal and/or sacroiliitis on magnetic resonance imaging [MRI], indicative of inflammatory disease, but without definitive radiographic evidence of structural damage on sacroiliac joints.) TF/C/I to two non-steroidal anti-inflammatory drugs (NSAIDs).
Age Restrictions	N/A
Prescriber Restrictions	CD (init): Prescribed by or in consultation with a gastroenterologist. RA, AS, nr-axSpA (init): Prescribed by or in consultation with a rheumatologist. PsA (init): Prescribed by or in consultation with a dermatologist or rheumatologist. Plaque psoriasis (init): Prescribed by or in consultation with a dermatologist.

Prior Authorization Criteria

Scott and White

Effective: December 1, 2019

Coverage Duration	RA, PsA, AS, Plaque psoriasis, nr-axSpA (init, reauth): 12 mos. CD (init): 16 wks. (reauth): 12 mos.
Other Criteria	Reauth (all indications): Documentation of positive clinical response to Cimzia therapy.

Prior Authorization Criteria
Scott and White
Effective: December 1, 2019

CINRYZE (S)

Products Affected

- Cinryze

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Prophylaxis of hereditary angioedema (HAE) attacks: Diagnosis of HAE. For prophylaxis against HAE attacks.
Age Restrictions	N/A
Prescriber Restrictions	HAE (prophylaxis): Prescribed by or in consultation with an immunologist, allergist, or rheumatologist
Coverage Duration	12 months
Other Criteria	N/A

Prior Authorization Criteria
Scott and White
Effective: December 1, 2019

COMETRIQ (S)

Products Affected

- Cometriq

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Medullary thyroid cancer (MTC): Diagnosis of Metastatic MTC.
Age Restrictions	N/A
Prescriber Restrictions	MTC: Prescribed by or in consultation with an oncologist/hematologist or endocrinologist.
Coverage Duration	All uses: 12 months
Other Criteria	Approve for continuation of prior therapy.

Prior Authorization Criteria
 Scott and White
 Effective: December 1, 2019

COPIKTRA (S)

Products Affected

- Copiktra

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Diagnosis of CLL or SLL. Disease is relapsed or refractory. Trial and failure, contraindication, or intolerance to at least two prior therapies for CLL/SLL (e.g., Leukeran [chlorambucil], Gazyva [obinutuzumab], Arzerra [ofatumumab], Bendeka [bendamustine], Imbruvica [ibrutinib], Rituxan [rituximab], etc.). Follicular Lymphoma: Diagnosis of follicular lymphoma. Disease is relapsed or refractory. Trial and failure, contraindication, or intolerance to at least two prior systemic therapies for follicular lymphoma (e.g., Leukeran [chlorambucil], Gazyva [obinutuzumab], Arzerra [ofatumumab], Bendeka [bendamustine], Imbruvica [ibrutinib], Rituxan [rituximab], etc.).
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with a hematologist/oncologist
Coverage Duration	12 months
Other Criteria	Approve for continuation of prior therapy.

CORLANOR (S)

Products Affected

- Corlanor

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Chronic heart failure (CHF) (initial): Diagnosis of CHF. Patient has NYHA Class II, III, or IV symptoms. Patient has a left ventricular ejection fraction less than or equal to 35%. Patient is in sinus rhythm. Patient has a resting heart rate of greater than or equal to 70 beats per minute. One of the following: patient is on a beta-blocker at a maximally tolerated dose, or patient has a contraindication or intolerance to beta-blocker therapy. Patient has been hospitalized for worsening HF in the previous 12 months. Trial and failure, contraindication, or intolerance to maximally tolerated doses of an ACE inhibitor or ARB. Dilated Cardiomyopathy (DCM) (initial): Diagnosis of heart failure due to DCM. Patient has NYHA Class II, III, or IV symptoms. Patient is in sinus rhythm. Patient has an elevated heart rate. Trial and failure, contraindication or intolerance to one of the following: 1) Beta blocker (e.g., bisoprolol, metoprolol succinate extended release), 2) Angiotensin-converting enzyme (ACE) inhibitor (e.g., captopril, enalapril), or 3) Diuretic Agent (e.g., spironolactone, furosemide).
Age Restrictions	N/A
Prescriber Restrictions	CHF, DCM (initial): Prescribed by or in consultation with a cardiologist
Coverage Duration	CHF, DCM (initial, reauth): 12 months
Other Criteria	CHF, DCM (reauth): Documentation of positive clinical response to therapy.

Prior Authorization Criteria
 Scott and White
 Effective: December 1, 2019

COSENTYX (S)

Products Affected

- Cosentyx

- Cosentyx Sensoready Pen

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Plaque psoriasis (Initial): Diagnosis of moderate to severe plaque psoriasis. One of the following: Trial and failure, contraindication, or intolerance to Enbrel (etanercept) OR Humira (adalimumab), OR for continuation of prior Cosentyx therapy. Psoriatic Arthritis (PsA) (Initial): Diagnosis of active PsA. One of the following: Trial and failure, contraindication, or intolerance to Enbrel (etanercept) and Humira (adalimumab), or attestation demonstrating a trial may be inappropriate, OR for continuation of prior Cosentyx therapy. Ankylosing Spondylitis (AS) (Initial): Diagnosis of active AS. One of the following: Trial and failure, contraindication, or intolerance to Enbrel (etanercept) and Humira (adalimumab), or attestation demonstrating a trial may be inappropriate, OR for continuation of prior Cosentyx therapy.
Age Restrictions	N/A
Prescriber Restrictions	Plaque psoriasis (initial): Prescribed by or in consultation with a dermatologist. PsA (initial): Prescribed by or in consultation with a rheumatologist or dermatologist. AS (initial): Prescribed by or in consultation with a rheumatologist.
Coverage Duration	All uses (initial, reauth): 12 months
Other Criteria	All indications (Reauth): Documentation of positive clinical response to Cosentyx therapy.

Prior Authorization Criteria
Scott and White
Effective: December 1, 2019

COTELLIC (S)

Products Affected

- Cotellic

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Melanoma: Diagnosis of unresectable or metastatic melanoma. Patient has a BRAF V600E or V600K mutation as detected by an FDA-approved test (e.g., cobas 4800 BRAF V600 Mutation Test) or performed at a facility approved by Clinical Laboratory Improvement Amendments (CLIA). Used in combination with vemurafenib.
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	12 months
Other Criteria	Approve for continuation of prior therapy.

Prior Authorization Criteria
Scott and White
Effective: December 1, 2019

CRINONE (S)

Products Affected

- Crinone

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	All indications: Excluded if for fertility uses.
Required Medical Information	Secondary amenorrhea: Diagnosis of secondary amenorrhea (the absence of menses in women who have already started menstruation who are not pregnant, breastfeeding, or in menopause).
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	N/A

CYRAMZA (S)

Products Affected

- Cyramza

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Gastric cancer: All of the following: 1) diagnosis of one of the following: a) gastric adenocarcinoma, OR b) gastro-esophageal junction (GEJ) adenocarcinoma, AND 2) disease is one of the following: a) locally advanced, OR b) metastatic, AND 3) disease has progressed on or after one of the following first-line therapies: a) fluoropyrimidine-containing chemotherapy (eg, fluorouracil, capecitabine), OR b) platinum-containing chemotherapy (eg, cisplatin, carboplatin, oxaliplatin). Non-small cell lung cancer: All of the following: 1) diagnosis of metastatic non-small cell lung cancer, AND 2) used in combination with docetaxel, AND 3) disease has progressed on or after platinum-based chemotherapy (eg, cisplatin, carboplatin, oxaliplatin). Metastatic colorectal cancer (mCRC): 1) Diagnosis of metastatic CRC AND 2) Patient had disease progression on or after prior therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine.
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	12 months
Other Criteria	Approve for continuation of prior therapy.

Prior Authorization Criteria
Scott and White
Effective: December 1, 2019

CYSTARAN (S)

Products Affected

- Cystaran

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Cystinosis: Diagnosis of cystinosis, confirmed by elevated leukocyte cystine levels (LCL), genetic analysis of the CTNS gene or corneal cystine crystal accumulation AND Patient is concomitantly receiving treatment with oral cysteamine.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	N/A

Prior Authorization Criteria
Scott and White
Effective: December 1, 2019

DACOGEN (S)

Products Affected

- Decitabine

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Myelodysplastic syndrome (MDS): Diagnosis of myelodysplastic syndrome.
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with a hematologist/oncologist
Coverage Duration	12 months
Other Criteria	Approve for continuation of prior therapy.

DAKLINZA (S)

Products Affected

- Daklinza

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	<p>Criteria will be applied consistent with current AASLD/IDSA guideline. For genotype 1, ONE of the following: 1) Patient has had a trial and failure, contraindication or intolerance to both of the following: a) Harvoni or Epclusa AND b) Mavyret OR 2) For continuation of prior Daklinza therapy. For genotype 1 liver transplant recipient, ONE of the following: 1) Patient has had a trial and failure, contraindication or intolerance to Harvoni OR Mavyret OR 2) For continuation of prior Daklinza therapy. For genotype 2 or 3 (except liver transplant recipients), ONE of the following: 1) Patient has had a trial and failure, contraindication or intolerance to both of the following: Epclusa AND Mavyret OR 2) For continuation of prior Daklinza therapy. For genotype 2 or 3 liver transplant recipients without cirrhosis, ONE of the following: 1) Patient has had a trial and failure, contraindication or intolerance to Mavyret OR 2) For continuation of prior Daklinza therapy. For genotype 2 or 3 liver transplant recipients with decompensated cirrhosis, ONE of the following: 1) Patient has had a trial and failure, contraindication or intolerance to Epclusa OR 2) For continuation of prior Daklinza therapy. All: A) Diagnosis of chronic hepatitis C AND B) One of the following: 1) Patient has not failed a prior HCV NS5A-containing regimen (eg, Daklinza) OR 2) patient has failed prior therapy with an NS5A-containing regimen AND patient does not have NS5A inhibitor resistance-associated variants detected using commercially available assays.</p>
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with one of the following: Hepatologist, Gastroenterologist, Infectious disease specialist, HIV specialist certified through the American Academy of HIV Medicine.
Coverage Duration	12 to 24 weeks. Criteria will be applied consistent with current AASLD/IDSA guideline.
Other Criteria	N/A

Prior Authorization Criteria
Scott and White
Effective: December 1, 2019

DALIRESP (S)

Products Affected

- Daliresp

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Chronic Obstructive Pulmonary Disease (COPD): (Initial) Diagnosis of COPD. History of COPD exacerbations which required the use of systemic corticosteroids, antibiotics, or hospital admission. Trial and failure, intolerance, or contraindication to two prior therapies for COPD.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	COPD (init, reauth): 12 months
Other Criteria	COPD (reauth): Documentation of positive clinical response to Daliresp therapy.

DARAPRIM (S)

Products Affected

- Daraprim

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Toxoplasmosis: 1) Patient is using Daraprim for the treatment of toxoplasmic encephalitis, secondary prophylaxis of toxoplasmic encephalitis, or treatment of congenital toxoplasmosis OR 2) Patient is using Daraprim for the primary prophylaxis of toxoplasmic encephalitis, patient has experienced intolerance to prior prophylaxis with trimethoprim-sulfamethoxazole (TMP-SMX), and one of the following: patient has been re-challenged with TMP-SMX using a desensitization protocol and is still unable to tolerate, or evidence of life-threatening reaction to TMP-SMX in the past (eg, toxic epidermal necrolysis, Stevens-Johnson syndrome). Malaria: Patient is using Daraprim for the treatment of acute malaria or chemoprophylaxis of malaria. Patient does not have megaloblastic anemia due to folate deficiency. The provider acknowledges that Daraprim is not recommended by the Centers for Disease Control and Prevention (CDC) for the treatment and/or prophylaxis of malaria.
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with an infectious disease specialist
Coverage Duration	12 months
Other Criteria	Toxoplasmosis only: Approve for continuation of prior therapy.

DARZALEX (S)

Products Affected

- Darzalex

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Multiple Myeloma (MM): Diagnosis of MM. One of the following: A) Patient has received at least three prior treatment regimens which included both a proteasome inhibitor (eg, bortezomib [Velcade], carfilzomib [Kyprolis]) and an immunomodulatory agent (eg, lenalidomide [Revlimid], thalidomide [Thalomid]) or patient is double-refractory to a proteasome inhibitor and an immunomodulatory agent. OR B) Patient has received at least one prior therapy (e.g., bortezomib [Velcade], carfilzomib [Kyprolis], ixazomib [Ninlaro], lenalidomide [Revlimid], thalidomide [Thalomid]). Darzalex will be used in combination with either 1) lenalidomide and dexamethasone or 2) bortezomib and dexamethasone. OR C) Both of the following: used in combination with both pomalidomide and dexamethasone, AND patient has received at least two prior therapies including lenalidomide and a proteasome inhibitor (e.g., bortezomib [Velcade], carfilzomib [Kyprolis]).
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with an oncologist/hematologist
Coverage Duration	12 months
Other Criteria	Approve for continuation of prior therapy.

Prior Authorization Criteria
Scott and White
Effective: December 1, 2019

DAURISMO (S)

Products Affected

- Daurismo

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Acute myeloid leukemia (AML): Diagnosis of newly-diagnosed acute myeloid leukemia (AML) AND Used in combination with low-dose cytarabine AND One of the following: 1) Patient is greater than or equal to 75 years old, or 2) Patient has comorbidities that preclude the use of intensive induction chemotherapy.
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with a hematologist/oncologist
Coverage Duration	12 months
Other Criteria	Approve for continuation of prior therapy.

DEFERASIROX (S)

Products Affected

- Deferasirox
- Exjade
- Jadenu
- Jadenu Sprinkle

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Chronic Iron Overload Due to Blood Transfusions (Initial): Diagnosis of chronic iron overload due to blood transfusions (transfusional hemosiderosis). Patient has a baseline ferritin level more than 1,000 mcg/L. Patient has required the transfusion of at least 100 mL/kg packed red blood cells. Myelodysplastic Syndrome (MDS) (Initial): Diagnosis of MDS. Patient has Low or Intermediate-1 disease or is a potential transplant patient. Patient has received more than 20 red blood cell transfusions. Chronic iron overload due to non-transfusion-dependent thalassemia (NTDT) (Initial): Diagnosis of chronic iron overload due to NTDT. Liver iron concentration (LIC) 5 milligrams of iron per gram of liver dry weight (mg Fe/g dw) or higher. Serum ferritin level greater than 300 mcg/L.
Age Restrictions	Iron Overload Due to Blood Transfusions (initial): 2 years of age or older. NTDT (initial): 10 years of age or older
Prescriber Restrictions	N/A
Coverage Duration	Iron Overload Due to Blood Transfusions, MDS (initial, reauth):12 mo. NTDT (initial, reauth): 6mo.
Other Criteria	Iron Overload Due to Blood Transfusions, MDS (Reauth): Patient experienced a reduction from baseline in serum ferritin level or LIC. NTDT (Reauth): Patient has LIC 3 mg Fe/g dw or higher. Patient experienced a reduction from baseline in serum ferritin level or LIC.

Prior Authorization Criteria
 Scott and White
 Effective: December 1, 2019

DEXMETHYLPHENIDATE (S)

Products Affected

- Dexmethylphenidate Hcl
- Dexmethylphenidate Hcl Er
- Dexmethylphenidate Hydrochloride
 TABS 2.5MG, 5MG

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	One of the following: a) diagnosis of attention deficit hyperactivity disorder (ADHD), OR b) diagnosis of attention deficit disorder (ADD).
Age Restrictions	PA applies to members 19 years of age or older
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	N/A

Prior Authorization Criteria
 Scott and White
 Effective: December 1, 2019

DEXTROAMPHETAMINE (S)

Products Affected

- Dexedrine TABS
- Dextroamphetamine Sulfate SOLN
- Dextroamphetamine Sulfate TABS
- Dextroamphetamine Sulfate Er
- Zenzedi

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	One of the following: a) diagnosis of attention deficit hyperactivity disorder (ADHD), OR b) diagnosis of attention deficit disorder (ADD), OR c) diagnosis of narcolepsy as confirmed by a sleep study (unless the prescriber provides justification confirming that a sleep study would not be feasible).
Age Restrictions	PA applies to members 19 years of age or older
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	N/A

Prior Authorization Criteria
Scott and White
Effective: December 1, 2019

DOXEPIN TOPICAL (S)

Products Affected

- Doxepin Hydrochloride CREA

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Diagnosis of moderate pruritus. Patient has atopic dermatitis or lichen simplex chronicus. Trial and failure, contraindication, or intolerance to at least one medium potency topical corticosteroid, or is not a candidate for topical corticosteroids (e.g., treatment is on face, axilla, or groin).
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	14 days
Other Criteria	N/A

Prior Authorization Criteria
Scott and White
Effective: December 1, 2019

DUOBRII (S)

Products Affected

- Duobrii

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Plaque Psoriasis: Diagnosis of plaque psoriasis. Both of the following: 1) Trial and failure, intolerance or contraindication to one high potency corticosteroid topical treatment (e.g., halobetasol propionate, clobetasol propionate, fluocinonide) AND 2) Trial and failure or intolerance to tazarotene.
Age Restrictions	N/A
Prescriber Restrictions	Plaque Psoriasis: Prescribed by or in consultation with a dermatologist.
Coverage Duration	Plaque Psoriasis: 12 months
Other Criteria	N/A

DUPIXENT (S)

Products Affected

- Dupixent

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	<p>Atopic dermatitis (initial): Diagnosis of moderate to severe atopic dermatitis. Trial and failure, contraindication, or intolerance to one medium to high potency topical corticosteroid. One of the following: A) Trial and failure or intolerance to Elidel (pimecrolimus) topical cream, unless the patient is not a candidate for Elidel therapy (e.g., immunocompromised, severe atopic dermatitis), B) Trial and failure or intolerance to tacrolimus topical ointment, unless the patient is not a candidate for tacrolimus ointment therapy (e.g., immunocompromised).</p> <p>Eosinophilic Asthma (initial): Diagnosis of moderate to severe asthma. Asthma is an eosinophilic phenotype as defined by a baseline (pre-Dupixent treatment) peripheral blood eosinophil level greater than or equal to 150 cells per microliter. One of the following: 1) Patient has had at least one or more asthma exacerbations requiring systemic corticosteroids within the past 12 months, 2) Any prior intubation for an asthma exacerbation, or 3) Prior asthma-related hospitalization within the past 12 months. Corticosteroid Dependent Asthma (initial): Diagnosis of moderate to severe asthma. Patient is currently dependent on oral corticosteroids for the treatment of asthma. Eosinophilic Asthma, Corticosteroid Dependent Asthma (initial): Patient is currently being treated with ONE of the following unless there is a contraindication or intolerance to these medications: 1) High-dose inhaled corticosteroid (ICS) [e.g., greater than 500 mcg fluticasone propionate equivalent/day] and additional asthma controller medication [e.g., leukotriene receptor antagonist, long-acting beta-2 agonist (LABA), theophylline] OR 2) One maximally-dosed combination ICS/LABA product (e.g., Advair [fluticasone propionate/salmeterol], Dulera [mometasone/formoterol], Symbicort [budesonide/formoterol]).</p>
Age Restrictions	Asthma (initial): Age greater than or equal to 12 years. Atopic dermatitis: no age restriction.

Prior Authorization Criteria

Scott and White

Effective: December 1, 2019

<p>Prescriber Restrictions</p>	<p>Atopic dermatitis (Initial): Prescribed by or in consultation with one of the following: dermatologist, allergist/immunologist. Asthma (initial, reauth): Prescribed by or in consultation with a pulmonologist or allergist/immunologist. CRSwNP (initial, reauth): Prescribed by or in consultation with an otolaryngologist or allergist/immunologist.</p>
<p>Coverage Duration</p>	<p>12 months</p>
<p>Other Criteria</p>	<p>Chronic rhinosinusitis with nasal polyposis (CRSwNP) (initial): Diagnosis of CRSwNP. Unless contraindicated, the patient has had an inadequate response to 2 months of treatment with an intranasal corticosteroid (eg, fluticasone, mometasone). Used in combination with another agent for CRSwNP (eg, intranasal corticosteroid). Atopic dermatitis (reauth): Documentation of a positive clinical response to Dupixent therapy (e.g., reduction in body surface area involvement, reduction in pruritus severity). Eosinophilic Asthma, Corticosteroid Dependent Asthma (reauth): Documentation of a positive clinical response to Dupixent therapy (e.g., reduction in exacerbations). Patient is currently being treated with ONE of the following unless there is a contraindication or intolerance to these medications: 1) Inhaled corticosteroid (ICS) and additional asthma controller medication [e.g., leukotriene receptor antagonist, long-acting beta-2 agonist (LABA), theophylline] OR 2) A combination ICS/LABA product (e.g., Advair [fluticasone propionate/salmeterol], Dulera [mometasone/formoterol], Symbicort [budesonide/formoterol]). CRSwNP (reauth): Documentation of a positive clinical response to therapy (e.g., reduction in nasal polyps score [NPS, 0-8 scale], improvement in nasal congestion/obstruction score [NC, 0-3 scale]). Used in combination with another agent for CRSwNP (eg, intranasal corticosteroid).</p>

Prior Authorization Criteria
 Scott and White
 Effective: December 1, 2019

EGRIFTA (S)

Products Affected

- Egrifta

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	HIV-associated lipodystrophy (initial): All of the following: 1) diagnosis of HIV-associated lipodystrophy, 2) one of the following: a) waist-circumference of greater than or equal to 95 cm (37.4 inches) in men, OR b) waist-circumference of greater than or equal to 94 cm (37 inches) for women, 3) one of the following: a) Waist-to-hip ratio of greater than or equal to 0.94 for men, OR b) waist-to-hip ratio of greater than or equal to 0.88 for women, 4) body mass index (BMI) greater than 20 kg/m ² , AND 5) fasting blood glucose (FBG) levels less than or equal to 150 mg/dL (8.33 mmol/L), AND 6) patient has been on a stable regimen of antiretrovirals (eg, NRTIs, NNRTI, Protease Inhibitors, Integrase Inhibitors) for at least 8 weeks.
Age Restrictions	Initial: 18 years of age or older.
Prescriber Restrictions	N/A
Coverage Duration	Initial, reauth: 6 months
Other Criteria	(reauth): documentation of clinical improvement (eg, improvement in visceral adipose tissue [VAT], decrease in waist circumference, belly appearance, etc) while on Egrifta therapy.

Prior Authorization Criteria
Scott and White
Effective: December 1, 2019

ELAPRASE (S)

Products Affected

- Elaprase

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Diagnosis of Hunter Syndrome (Mucopolysaccharidosis II (MPS II))
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	N/A

Prior Authorization Criteria
Scott and White
Effective: December 1, 2019

ELIGARD (S)

Products Affected

- Eligard

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Prostate Cancer: Diagnosis of advanced or metastatic prostate cancer. Trial and failure, contraindication, or intolerance to Lupron Depot (7.5 mg, 22.5 mg, 30 mg, and 45 mg).
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	Approve for continuation of prior therapy.

Prior Authorization Criteria
 Scott and White
 Effective: December 1, 2019

EMFLAZA (S)

Products Affected

- Emflaza

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Initial: Diagnosis of Duchenne muscular dystrophy (DMD). Patient has received genetic testing for a mutation of the dystrophin gene. One of the following: A) Documentation of a confirmed mutation of the dystrophin gene or B) Muscle biopsy confirmed an absence of dystrophin protein. Patient has had a trial and failure or intolerance to prednisone or prednisolone. Dose will not exceed 0.9 milligrams per kilogram of body weight once daily.
Age Restrictions	Initial: Patient is 2 years of age or older
Prescriber Restrictions	Initial: Prescribed by or in consultation with a neurologist who has experience treating children
Coverage Duration	Initial, Reauth: 12 months
Other Criteria	Reauth: Patient has experienced a benefit from therapy (e.g., improvement or preservation of muscle strength). Dose will not exceed 0.9 milligrams per kilogram of body weight once daily.

Prior Authorization Criteria
Scott and White
Effective: December 1, 2019

EMPLICITI (S)

Products Affected

- Empliciti

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Multiple myeloma: Diagnosis of multiple myeloma. Patient has received at least one prior therapy for multiple myeloma [eg, Revlimid (lenalidomide), Thalomid (thalidomide), Velcade (bortezomib)]. Used in combination with both of the following: Revlimid (lenalidomide) and dexamethasone.
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with a hematologist/oncologist.
Coverage Duration	12 months
Other Criteria	Approve for continuation of prior therapy.

ENBREL (S)

Products Affected

- Enbrel
- Enbrel Mini
- Enbrel Sureclick

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Rheumatoid Arthritis (RA) (Initial): Diagnosis of moderately to severely active RA. Trial and failure, contraindication, or intolerance to one disease-modifying antirheumatic drug (DMARD) [eg, methotrexate (Rheumatrex/Trexall), Arava (leflunomide), Azulfidine (sulfasalazine)]. Polyarticular Juvenile Idiopathic Arthritis (PJIA) (Initial): Diagnosis of moderately to severely active PJIA. Trial and failure, contraindication, or intolerance to one of the following DMARDs: Arava (leflunomide) or methotrexate (Rheumatrex/Trexall). Psoriatic Arthritis (PsA) (Initial): Diagnosis of active PsA. Plaque psoriasis (Initial): Diagnosis of moderate to severe chronic plaque psoriasis. Ankylosing Spondylitis (AS) (Initial): Diagnosis of active AS. Trial and failure, contraindication, or intolerance to two NSAIDs.
Age Restrictions	N/A
Prescriber Restrictions	RA (initial), PJIA (initial), AS (initial): Prescribed by or in consultation with a rheumatologist. PsA (initial): Prescribed by or in consultation with a rheumatologist or dermatologist. Plaque Psoriasis (initial): Prescribed by or in consultation with a dermatologist.
Coverage Duration	All uses (initial, reauth): 12 months
Other Criteria	All indications (Reauth): Documentation of positive clinical response to Enbrel therapy.

Prior Authorization Criteria
 Scott and White
 Effective: December 1, 2019

ENDARI (S)

Products Affected

- Endari

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Sickle cell disease (initial): Diagnosis of sickle cell disease. Used to reduce acute complications of sickle cell disease. One of the following: (a) Patient is using Endari with concurrent hydroxyurea therapy, OR (b) Patient has a contraindication or intolerance to hydroxyurea. Patient has had 2 or more painful sickle cell crises within the past 12 months.
Age Restrictions	N/A
Prescriber Restrictions	Sickle cell disease (initial): Prescribed by or in consultation with a hematologist/oncologist
Coverage Duration	Sickle cell disease (initial, reauth): 12 months
Other Criteria	Sickle cell disease (reauth): Documentation of positive clinical response to Endari therapy.

ENTYVIO (S)

Products Affected

- Entyvio

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Ulcerative Colitis (UC) (init): Diagnosis (Dx) of moderately to severely active UC. Trial and failure, contraindication, or intolerance (F/C/I) to one of the following conventional therapies: 6-mercaptopurine (Purinethol), aminosalicylates [eg, mesalamine (Asacol, Pentasa, Rowasa), olsalazine (Dipentum), sulfasalazine (Azulfidine, Sulfazine)], azathioprine (Imuran), corticosteroids (eg, prednisone, methylprednisolone). F/C/I to one tumor necrosis factor (TNF) inhibitor [eg, Humira (adalimumab), infliximab]. Crohn's Disease (CD) (init): Dx of moderately to severely active CD. F/C/I to one of the following medications: 6-mercaptopurine (Purinethol), azathioprine (Imuran), corticosteroids (eg, prednisone, methylprednisolone), methotrexate (Rheumatrex, Trexall). F/C/I to one TNF inhibitor [eg, Humira (adalimumab), infliximab]. UC, CD (init, reauth): Patient is not receiving Entyvio in combination with Tysabri (natalizumab), or a TNF inhibitor [eg, Enbrel (etanercept), Humira (adalimumab), Cimzia (certolizumab), Simponi (golimumab), infliximab].
Age Restrictions	N/A
Prescriber Restrictions	UC, CD (init): Prescribed by or in consultation with a gastroenterologist
Coverage Duration	UC, CD (init): 14 weeks. UC, CD (reauth): 12 months.
Other Criteria	UC, CD (reauth): Documentation of positive clinical response to Entyvio therapy.

Prior Authorization Criteria
Scott and White
Effective: December 1, 2019

EPCLUSA (S)

Products Affected

- Epclusa

- Sofosbuvir/velpatasvir

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Criteria will be applied consistent with current AASLD/IDSA guideline. Diagnosis of chronic hepatitis C. Patient is not receiving Epclusa in combination with another HCV direct acting antiviral agent [e.g., Sovaldi (sofosbuvir)].
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with one of the following: Hepatologist, Gastroenterologist, Infectious disease specialist, HIV specialist certified through the American Academy of HIV Medicine.
Coverage Duration	12 to 24 weeks. Criteria will be applied consistent with current AASLD/IDSA guideline.
Other Criteria	N/A

Prior Authorization Criteria
Scott and White
Effective: December 1, 2019

EPIDIOLEX (S)

Products Affected

- Epidiolex

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Lennox-Gastaut syndrome (LGS): Diagnosis of seizures associated with LGS. Trial of, contraindication, or intolerance to two formulary anticonvulsants (e.g., topiramate, lamotrigine, valproate). Dravet syndrome (DS): Diagnosis of seizures associated with DS.
Age Restrictions	N/A
Prescriber Restrictions	LGS, DS: Prescribed by or in consultation with a neurologist
Coverage Duration	12 months
Other Criteria	Approve for continuation of prior therapy.

Prior Authorization Criteria
 Scott and White
 Effective: December 1, 2019

EPOETIN ALFA (S)

Products Affected

- Procrit

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	<p>Anemia with Chronic Kidney Disease (CKD) (Initial): Diagnosis (Dx) of CKD. Anemia by lab values (Hct less than 30% or Hgb less than 10 g/dL) collected within 30 days of request. One of the following: a) both of the following: Patient is on dialysis, patient is without ESRD OR b) all of the following: patient is not on dialysis, the rate of hemoglobin decline indicates the likelihood of requiring a red blood cell (RBC) transfusion, and reducing the risk of alloimmunization and/or other RBC transfusion-related risks is a goal. Anemia with HIV (Initial): Anemia by lab values (Hgb less than 12 g/dL or Hct less than 36%) collected within 30 days of request. Serum erythropoietin level less than or equal to 500 mU/mL. Receiving zidovudine therapy or dx of HIV. Anemia with chemo (Initial): Other causes of anemia have been ruled out. Anemia by lab values (Hct less than 30%, Hgb less than 10 g/dL) collected within the prior 2 weeks of request. Cancer is a non-myeloid malignancy. Patient is concurrently on chemo, or will receive concomitant chemo for a minimum of 2 mos, or anemia is caused by cancer chemo. Will not be approved if patient is not receiving cancer chemotherapy. Preoperative for reduction of allogeneic blood transfusion: Patient is scheduled to undergo elective, non-cardiac, non-vascular surgery. Hgb is greater than 10 to less than or equal to 13 g/dL. Patient is at high risk for perioperative transfusions. Patient is unwilling or unable to donate autologous blood pre-operatively. Anemia in hepatitis C virus (HCV)-infected pts due to ribavirin in combination with interferon or peg-interferon (Initial): Dx of HCV infection. Anemia by labs (Hct less than 36% or Hgb less than 12 g/dL) collected within 30 days of request. Patient is receiving ribavirin and one of the following: interferon alfa or peginterferon alfa. Anemia in Myelodysplastic Syndrome (MDS) (Initial): Dx of MDS. Serum erythropoietin level is 500 mU/mL or less, or dx of transfusion-dependent MDS.</p>
Age Restrictions	N/A

Prior Authorization Criteria
 Scott and White
 Effective: December 1, 2019

Prescriber Restrictions	N/A
Coverage Duration	CKD,HIV(Init):6mo. CKD,HIV(reauth):12mo. Chemo,HCV(all):3mo. MDS:(init) 3mo,(reauth)12mo. Preop:1mo.
Other Criteria	<p>Subject to ESRD review. CKD (Reauth): Dx of CKD. Most recent or average (avg) Hct over 3 months is 33% or less OR most recent or avg Hgb over 3 months is 11 g/dL or less. Decrease in the need for blood transfusion or Hgb increased by 1 g/dL or more from pre-treatment level. HIV (Reauth): Most recent or avg Hct over 3 months is below 36% or most recent or avg Hgb over 3 months is below 12 g/dl. Decrease in the need for blood transfusion or Hgb increased by 1 g/dL or more from pre-treatment level. Chemo (Reauth): Anemia by lab values (Hgb less than 10 g/dl or Hct less than 30%) collected within the prior 2 weeks of request. Decrease in the need for blood transfusion or Hgb increased by 1 g/dL or more from pre-treatment level. Patient is concurrently on chemo, or will receive concomitant chemo for a minimum of 2 months, or anemia is caused by cancer chemo. Will not be approved if patient is not receiving cancer chemotherapy. HCV (Reauth): Most recent or avg Hct over 3 months is 36% or less, OR most recent or avg Hgb over 3 months is 12 g/dl or less. Decrease in the need for blood transfusion or Hgb increased by 1 g/dL or more from pre-treatment level. If patient has demonstrated response to therapy, authorization will be issued for the full course of ribavirin therapy. MDS (Reauth): Most recent or avg Hct over 3 months is 36% or less, OR most recent or avg Hgb over 3 months is 12 g/dl or less. Decrease in the need for blood transfusion or Hgb increased by 1 g/dL or more from pre-treatment level. Off-label uses (except MDS): Will not be approved if patient has Hgb greater than 10 g/dL or Hct greater than 30%. CKD (init, reauth), HIV (init), Chemo (init), Preop, MDS (init), HCV (init): Verify iron evaluation for adequate iron stores.</p>

Prior Authorization Criteria
Scott and White
Effective: December 1, 2019

EPOPROSTENOL (S)

Products Affected

- Epoprostenol Sodium

- Veletri

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Pulmonary arterial hypertension (PAH) (Initial): Diagnosis of PAH. PAH is symptomatic. One of the following: A) Diagnosis of PAH was confirmed by right heart catheterization or B) Patient is currently on any therapy for the diagnosis of PAH.
Age Restrictions	N/A
Prescriber Restrictions	PAH (initial): Prescribed by or in consultation with a pulmonologist or cardiologist.
Coverage Duration	PAH (Initial): 6 months. (Reauth): 12 months
Other Criteria	Subject to Part B vs D review. PAH (Reauth): Documentation of positive clinical response to therapy.

ERBITUX (S)

Products Affected

- Erbitux

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	<p>Head and Neck Cancer: Diagnosis of locally or regionally advanced squamous cell head and neck cancer and used in combination with radiation therapy, or diagnosis of recurrent or metastatic squamous cell head and neck cancer and 1 of the following: trial and failure of platinum-based chemotherapy, or used in combination with 1 of the following: cisplatin (Platinol AQ), carboplatin (Paraplatin), cisplatin (Platinol AQ) plus 5-FU (Acrucil), or carboplatin (Paraplatin) plus 5-FU (Acrucil).</p> <p>Colorectal Cancer: Diagnosis of metastatic carcinoma of the colon or rectum. One of the following: Used in combination with either FOLFOX (fluorouracil, leucovorin, and oxaliplatin) or FOLFIRI (fluorouracil, leucovorin, and irinotecan), OR trial and failure or intolerance to irinotecan-based chemotherapy, oxaliplatin-based chemotherapy, or intensive therapy (eg, FOLFOX or FOLFIRI), OR used as monotherapy in patients not appropriate for intensive therapy. Tumor expresses wild-type KRAS gene and wild type NRAS gene. Non-Small Cell Lung Cancer (NSCLC): Diagnosis of recurrent or metastatic NSCLC stage IIIB or IV. One of the following: Used in combination with vinorelbine (Navelbine) and cisplatin (Platinol AQ), OR used as a single-agent for continuation maintenance therapy and Erbitux was given first-line with chemotherapy. Epidermal growth factor receptor (EGFR) expression by immunohistochemistry.</p>
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	12 months.
Other Criteria	Approve for continuation of prior therapy.

Prior Authorization Criteria
Scott and White
Effective: December 1, 2019

ERIVEDGE (S)

Products Affected

- Erivedge

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Basal cell carcinoma: One of the following: A) Diagnosis of metastatic basal cell carcinoma OR B) Both of the following: 1) Diagnosis of locally advanced basal cell carcinoma AND 2) One of the following: a) Disease recurred following surgery or b) Patient is not a candidate for surgery and radiation.
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with an oncologist or dermatologist
Coverage Duration	12 months
Other Criteria	Approve for continuation of prior therapy.

Prior Authorization Criteria
Scott and White
Effective: December 1, 2019

ERLEADA (S)

Products Affected

- Erleada

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Non-metastatic castration-resistant or castration-recurrent prostate cancer (NM-CRPC): Diagnosis of non-metastatic, castration-resistant (chemical or surgical) or recurrent prostate cancer. One of the following: 1) Used in combination with a gonadotropin-releasing hormone (GnRH) analog OR 2) Patient received bilateral orchiectomy.
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with an oncologist or urologist
Coverage Duration	12 months
Other Criteria	Approve for continuation of prior therapy.

Prior Authorization Criteria
 Scott and White
 Effective: December 1, 2019

ESBRIET (S)

Products Affected

- Esbriet

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Idiopathic pulmonary fibrosis (IPF) (initial): Both of the following: 1) diagnosis of IPF as documented by all of the following: a) exclusion of other known causes of interstitial lung disease (ILD) (eg, domestic and occupational environmental exposures, connective tissue disease, drug toxicity), AND b) one of the following: i) in patients not subjected to surgical lung biopsy, the presence of a usual interstitial pneumonia (UIP) pattern on high-resolution computed tomography (HRCT) revealing IPF or probable IPF, OR ii) in patients subjected to a lung biopsy, both HRCT and surgical lung biopsy pattern revealing IPF or probable IPF, AND 2) not used in combination with Ofev (nintedanib).
Age Restrictions	N/A
Prescriber Restrictions	IPF (initial): Prescribed by a pulmonologist
Coverage Duration	initial, reauth: 12 months
Other Criteria	IPF (reauth): Documentation of positive clinical response to Esbriet therapy.

EVENTITY (S)

Products Affected

- Eventity

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Diagnosis of postmenopausal osteoporosis or osteopenia. One of the following: Set I) Both of the following: A) Bone mineral density (BMD) T-score of -2.5 or lower in the lumbar spine, femoral neck, total hip, or radius (one-third radius site) AND B) One of the following: 1) history of low-trauma fracture of the hip, spine, proximal humerus, pelvis, or distal forearm, or 2) trial and failure, contraindication, or intolerance (TF/C/I) to one anti-resorptive treatment (e.g., alendronate, risedronate, zoledronic acid, Prolia [denosumab]), or Set II) Both of the following: A) BMD T-score between -1.0 and -2.5 in the lumbar spine, femoral neck, total hip, or radius (one-third radius site) AND B) One of the following: 1) history of low-trauma fracture of the hip, spine, proximal humerus, pelvis, or distal forearm, or 2) both of the following: i) TF/C/I to one anti-resorptive treatment (e.g., alendronate, risedronate, zoledronic acid, Prolia [denosumab]) and ii) one of the following FRAX (Fracture Risk Assessment Tool) 10-year probabilities: a) major osteoporotic fracture at 20% or more in the U.S., or the country-specific threshold in other countries or regions, or b) hip fracture at 3% or more in the U.S., or the country-specific threshold in other countries or regions. Trial of, contraindication, or intolerance to one of the following: Forteo (teriparatide) or Tymlos (abaloparatide). Treatment duration of Eventity (romosozumab-aqqg) has not exceeded a total of 12 months during the patient's lifetime.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	12 months (max 12 months of therapy per lifetime)
Other Criteria	N/A

EXONDYS 51 (S)

Products Affected

- Exondys 51

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Initial: Diagnosis of Duchenne muscular dystrophy (DMD). Documentation of a confirmed mutation of the dystrophin gene amenable to exon 51 skipping. Patient is ambulatory. Initial/Reauth: Exondys 51 dosing for DMD is in accordance with the United States Food and Drug Administration approved labeling: maximum dosing of 30 mg/kg infused once weekly. Patient's condition has been evaluated via the 6-minute walk test (6MWT) or North Star ambulatory assessment (NSAA) [documentation of the patient's most recent results must be provided].
Age Restrictions	N/A
Prescriber Restrictions	Initial/Reauth: Prescribed by or in consultation with a neurologist who has experience treating children
Coverage Duration	Initial: 6 months. Reauth: 12 months
Other Criteria	Reauth: One of the following: 1) All of the following: Patient has been on therapy for less than 12 months, patient is maintaining ambulatory status, and patient is tolerating therapy, OR 2) All of the following: Patient has been on therapy for 12 months or more, Patient is maintaining ambulatory status, patient has experienced a benefit from therapy (e.g., disease amelioration compared to untreated patients), and patient is tolerating therapy.

Prior Authorization Criteria
Scott and White
Effective: December 1, 2019

EYLEA (S)

Products Affected

- Eylea

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Diagnosis of one of the following: A) Neovascular (wet) age-related macular degeneration OR B) Macular edema following retinal vein occlusion, OR C) Diabetic macular edema OR D) Diabetic retinopathy in patients with diabetic macular edema.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	N/A

Prior Authorization Criteria
Scott and White
Effective: December 1, 2019

FABRAZYME (S)

Products Affected

- Fabrazyme

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Fabry Disease: Diagnosis of Fabry disease.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Fabry Disease: 12 months
Other Criteria	N/A

Prior Authorization Criteria
Scott and White
Effective: December 1, 2019

FARYDAK (S)

Products Affected

- Farydak

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Multiple Myeloma (MM): Diagnosis of MM. Used in combination with both of the following: Velcade (bortezomib) and dexamethasone. Patient has received at least two prior treatment regimens which included both of the following: Velcade (bortezomib) and an immunomodulatory agent [eg, Revlimid (lenalidomide), Thalomid (thalidomide)].
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with an oncologist/hematologist
Coverage Duration	12 months
Other Criteria	Approve for continuation of prior therapy.

Prior Authorization Criteria
Scott and White
Effective: December 1, 2019

FASENRA (S)

Products Affected

- Fasenra
- Fasenra Pen

Prior Authorization Criteria
 Scott and White
 Effective: December 1, 2019

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Severe asthma (initial): Diagnosis of severe asthma. Asthma is an eosinophilic phenotype as defined by a baseline blood eosinophil level greater than or equal to 150 cells per microliter. One of the following: 1) Patient has had at least one or more asthma exacerbations requiring systemic corticosteroids within the past 12 months, OR 2) Any prior intubation for an asthma exacerbation, OR 3) Prior asthma-related hospitalization within the past 12 months. Patient is currently being treated with one of the following unless there is a contraindication or intolerance to these medications: a) Both of the following: i) High-dose inhaled corticosteroid (ICS) [e.g., greater than 500 mcg fluticasone propionate equivalent/day] and ii) additional asthma controller medication [e.g., leukotriene receptor antagonist, long-acting beta-2 agonist (LABA), theophylline], OR b) One maximally-dosed combination ICS/LABA product [e.g., Advair (fluticasone propionate/salmeterol), Dulera (mometasone/formoterol), Symbicort (budesonide/formoterol)].
Age Restrictions	Initial: Patient is 12 years of age or older
Prescriber Restrictions	Initial/Reauth: Prescribed by or in consultation with a pulmonologist or allergy/immunology specialist
Coverage Duration	12 months
Other Criteria	Reauth: Documentation of a positive clinical response (e.g., reduction in exacerbations). Patient is currently being treated with one of the following unless there is a contraindication or intolerance to these medications: a) Both of the following: i) inhaled corticosteroid (ICS) and ii) additional asthma controller medication [e.g., leukotriene receptor antagonist, long-acting beta-2 agonist (LABA), theophylline], OR b) A combination ICS/LABA product [e.g., Advair (fluticasone propionate/salmeterol), Dulera (mometasone/formoterol), Symbicort (budesonide/formoterol)].

Prior Authorization Criteria
 Scott and White
 Effective: December 1, 2019

FENTANYL (S)

Products Affected

- Fentanyl Citrate Oral Transmucosal

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	For the management of breakthrough cancer pain. Patient is currently taking a long-acting opioid around the clock for cancer pain. Patient must have at least a one week history of ONE of the following medications to demonstrate tolerance to opioids: Morphine sulfate at doses of greater than or equal to 60 mg/day, Fentanyl transdermal patch at doses greater than or equal to 25 µg/hr, Oxycodone at a dose of greater than or equal to 30 mg/day, Oral hydromorphone at a dose of greater than or equal to 8 mg/day, Oral oxymorphone at a dose of greater than or equal to 25 mg/day, or an alternative opioid at an equianalgesic dose (e.g., oral methadone greater than or equal to 20 mg/day).
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with one of the following: Pain specialist, Oncologist, Hematologist, Hospice care specialist, or Palliative care specialist.
Coverage Duration	12 months
Other Criteria	N/A

Prior Authorization Criteria
 Scott and White
 Effective: December 1, 2019

FERRIPROX (S)

Products Affected

- Ferriprox

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Transfusional iron overload due to thalassemia syndromes (Initial): Diagnosis of transfusional iron overload due to thalassemia syndromes. Absolute neutrophil count (ANC) greater than $1.5 \times 10^9/L$. One of the following: A) Trial and failure, defined as serum ferritin greater than 2,500 mcg/L, to Desferal (deferoxamine), Exjade (deferasirox) or Jadenu (deferasirox) OR B) History of contraindication or intolerance to Desferal (deferoxamine), Exjade (deferasirox) or Jadenu (deferasirox).
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	All uses (reauth): Patient has experienced greater than or equal to 20% decline in serum ferritin levels from baseline. ANC greater than $1.5 \times 10^9/L$.

Prior Authorization Criteria
Scott and White
Effective: December 1, 2019

FIRAZYR (S)

Products Affected

- Firazyr

- Icatibant Acetate

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Treatment of hereditary angioedema (HAE) attacks: Diagnosis of HAE. For the treatment of acute HAE attacks. Not used in combination with other approved treatments for acute HAE attacks.
Age Restrictions	N/A
Prescriber Restrictions	HAE: Prescribed by or in consultation with an immunologist, allergist, or rheumatologist
Coverage Duration	12 months
Other Criteria	N/A

Prior Authorization Criteria
Scott and White
Effective: December 1, 2019

FIRDAPSE (S)

Products Affected

- Firdapse

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Lambert-Eaton Myasthenic Syndrome (LEMS) (initial): Diagnosis of LEMS. Patient has moderate to severe weakness that interferes with function.
Age Restrictions	N/A
Prescriber Restrictions	LEMS (initial): Prescribed by or in consultation with a neurologist.
Coverage Duration	LEMS (initial): 3 months. LEMS (reauth): 12 months.
Other Criteria	LEMS (reauth): Documentation of positive clinical response to Firdapse therapy (e.g., improvement in dynamometry, Timed 25-Foot Walk Test, Timed Up and Go Test).

Prior Authorization Criteria
Scott and White
Effective: December 1, 2019

FIRMAGON (S)

Products Affected

- Firmagon

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Diagnosis of advanced or metastatic prostate cancer.
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	12 months
Other Criteria	Approve for continuation of prior therapy.

Prior Authorization Criteria
Scott and White
Effective: December 1, 2019

FOLOTYN (S)

Products Affected

- Folutyn

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Peripheral T-cell lymphoma: Diagnosis of relapsed or refractory PTCL.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	Approve for continuation of prior therapy.

FORTEO (S)

Products Affected

- Forteo INJ 600MCG/2.4ML

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Postmenopausal osteoporosis or osteopenia or men with primary or hypogonadal osteoporosis or osteopenia: Diagnosis of one of the following: a) postmenopausal osteoporosis or osteopenia or b) primary or hypogonadal osteoporosis or osteopenia. One of the following: Set I) Both of the following: A) Bone mineral density (BMD) T-score of -2.5 or lower in the lumbar spine, femoral neck, total hip, or radius (one-third radius site) AND B) One of the following: 1) history of low-trauma fracture of the hip, spine, proximal humerus, pelvis, or distal forearm, or 2) trial and failure, contraindication, or intolerance (TF/C/I) to one osteoporosis treatment (e.g., alendronate, risedronate, zoledronic acid, Prolia [denosumab]), or Set II) Both of the following: A) BMD T-score between -1.0 and -2.5 in the lumbar spine, femoral neck, total hip, or radius (one-third radius site) AND B) One of the following: 1) history of low-trauma fracture of the hip, spine, proximal humerus, pelvis, or distal forearm, or 2) both of the following: i) TF/C/I to one osteoporosis treatment (e.g., alendronate, risedronate, zoledronic acid, Prolia [denosumab]) and ii) One of the following FRAX 10-year probabilities: a) Major osteoporotic fracture at 20% or more in the U.S., or the country-specific threshold in other countries or regions, or b) Hip fracture at 3% or more in the U.S., or the country-specific threshold in other countries or regions. Treatment duration of parathyroid hormones [e.g., Forteo (teriparatide), Tymlos (abaloparatide)] has not exceeded a total of 24 months during the patient's lifetime. Glucocorticoid-Induced Osteoporosis: See Other Criteria section.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	All uses: 24 months (max 24 months of therapy per lifetime)

Prior Authorization Criteria

Scott and White

Effective: December 1, 2019

Other Criteria	Glucocorticoid-Induced Osteoporosis: Diagnosis of glucocorticoid-induced osteoporosis. History of prednisone or its equivalent at a dose greater than or equal to 5mg/day for greater than or equal to 3 months. One of the following: 1) BMD T-score less than or equal to -2.5 based on BMD measurements from lumbar spine, femoral neck, total hip, or radius (one-third radius site), or 2) One of the following FRAX 10-year probabilities: a) Major osteoporotic fracture at 20% or more in the U.S., or the country-specific threshold in other countries or regions, or b) Hip fracture at 3% or more in the U.S., or the country-specific threshold in other countries or regions, or 3) History of one of the following fractures resulting from minimal trauma: vertebral compression fx, fx of the hip, fx of the distal radius, fx of the pelvis, or fx of the proximal humerus. TF/C/I to one bisphosphonate (e.g., alendronate). Treatment duration of parathyroid hormones [e.g., Forteo (teriparatide), Tymlos (abaloparatide)] has not exceeded a total of 24 months during the patient's lifetime.
-----------------------	---

FULPHILA (S)

Products Affected

- Fulphila

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	<p>Febrile neutropenia (FN) prophylaxis: One of the following: 1) Patient is receiving National Cancer Institute's Breast Intergroup, INT C9741 dose dense chemotherapy protocol for primary breast cancer, 2) patient is receiving a dose-dense chemotherapy regimen for which the incidence of FN is unknown, 3) one of the following: a) patient is receiving chemotherapy regimens associated with a greater than 20% incidence of FN, OR b) both of the following: i) patient receiving chemotherapy regimen associated with 10-20% incidence of FN, AND ii) patient has one or more risk factors associated with chemotherapy-induced infection, FN, or neutropenia, OR 4) both of the following: a) patient is receiving a myelosuppressive anticancer drug associated with neutropenia, AND b) patient has a history of FN or dose-limiting event during a previous course of chemotherapy. Treatment of FN (off-label): Both of the following: 1) patients who have received or are receiving myelosuppressive anticancer drugs associated with neutropenia, AND 2) patients with FN at high risk for infection-associated complications. Acute radiation syndrome (ARS) (off-label): Patient was/will be acutely exposed to myelosuppressive doses of radiation (hematopoietic subsyndrome of ARS).</p>
Age Restrictions	N/A
Prescriber Restrictions	All uses: Prescribed by or in consultation with a hematologist/oncologist
Coverage Duration	ARS: 1 mo. FN (prophylaxis, treatment): 3 mo or duration of tx.
Other Criteria	N/A

Prior Authorization Criteria
Scott and White
Effective: December 1, 2019

GALAFOLD (S)

Products Affected

- Galafold

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Fabry Disease (FD) (initial): Diagnosis of FD. Patient has an amenable galactosidase alpha gene (GLA) variant based on in vitro assay data. FD (initial, reauthorization): Galafold will not be used in combination with Fabrazyme (agalsidase beta).
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	FD (initial, reauth): 12 months.
Other Criteria	FD (reauthorization): Documentation of positive clinical response to Galafold therapy.

Prior Authorization Criteria
 Scott and White
 Effective: December 1, 2019

GAMASTAN S/D (S)

Products Affected

- Gamastan

- Gamastan S/d

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	Contraindications to immune globulin therapy (i.e., IgA deficiency with antibodies to IgA and a history of hypersensitivity or product specific contraindication).
Required Medical Information	Immune globulin is being used intramuscularly. The immune globulin will be administered at the minimum effective dose and appropriate frequency for the prescribed diagnosis. Patient requires immunization for hepatitis A, measles, rubella, or varicella.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	3 months (Approve one dose only)
Other Criteria	Subject to Part B vs D review.

Prior Authorization Criteria
Scott and White
Effective: December 1, 2019

GATTEX (S)

Products Affected

- Gattex

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Short Bowel Syndrome (SBS) (Initial) Diagnosis of SBS. Patient is dependent on parenteral nutrition/intravenous (PN/IV) support for at least 12 consecutive months.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	SBS (Init): 6 months. SBS (Reauth): 12 months.
Other Criteria	SBS (Reauth): Documentation of positive clinical response to Gattex therapy.

Prior Authorization Criteria
 Scott and White
 Effective: December 1, 2019

GAZYVA (S)

Products Affected

- Gazyva

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Chronic lymphocytic leukemia (CLL): Diagnosis of CLL or small lymphocytic leukemia. Used in combination with chlorambucil. Patient is previously untreated for CLL. Follicular lymphoma (FL): One of the following: 1)All of the following: 1.1)Diagnosis of FL. 1.2) Patient has relapsed after or is refractory to a rituximab-containing regimen. 1.3) Both of the following: Used in combination with bendamustine and followed by Gazyva monotherapy. OR 2) All of the following: 2.1) Diagnosis of stage II bulky, III, or IV FL 2.2) Patient has not been treated with prior therapy 2.3) Both of the following: Used in combination with chemotherapy until patient has at least achieved a partial remission and followed by Gazyva monotherapy.
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with a hematologist/oncologist.
Coverage Duration	12 months
Other Criteria	Approve for continuation of prior therapy.

Prior Authorization Criteria
Scott and White
Effective: December 1, 2019

GILENYA (S)

Products Affected

- Gilenya

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Multiple Sclerosis (MS): Diagnosis of a relapsing form of MS (eg, relapsing-remitting MS, secondary-progressive MS with relapses, progressive-relapsing MS with relapses).
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	N/A

Prior Authorization Criteria
 Scott and White
 Effective: December 1, 2019

GILOTRIF (S)

Products Affected

- Gilotrif

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Non-small cell lung cancer (NSCLC): A) Diagnosis of advanced or metastatic (stage IIIB or IV) NSCLC AND B) One of the following: 1) Both of the following: a) Tumors have non-resistant epidermal growth factor (EGFR) mutations as detected by an FDA-approved test or Clinical Laboratory Improvement Amendments-approved facility AND b) GILOTRIF will be used as first-line treatment, OR 2) All of the following: a) disease progressed after platinum-based chemotherapy and b) squamous NSCLC.
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	12 months
Other Criteria	Approve for continuation of prior therapy.

Prior Authorization Criteria
Scott and White
Effective: December 1, 2019

GLATIRAMER ACETATE (S)

Products Affected

- Copaxone INJ 20MG/ML, 40MG/ML
- Glatiramer Acetate
- Glatopa

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Multiple Sclerosis (MS): Diagnosis of a relapsing form of MS (eg, relapsing-remitting MS, secondary-progressive MS with relapses, progressive-relapsing MS with relapses).
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	N/A

Prior Authorization Criteria
 Scott and White
 Effective: December 1, 2019

GLEEVEC (S)

Products Affected

- Imatinib Mesylate

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	One of the following: A) Diagnosis of Philadelphia chromosome positive (Ph+)/BCR ABL-positive chronic myelogenous leukemia (CML) OR B) Ph+/BCR ABL+ acute lymphoblastic leukemia (ALL) OR C) Gastrointestinal stromal tumor (GIST) AND one of the following: 1) Patient has documented c-KIT (CD117) positive unresectable or metastatic malignant GIST, OR 2) Patient had resection of c-KIT (CD117) positive GIST and imatinib will be used as adjuvant therapy OR D) Dermatofibrosarcoma protuberans that is unresectable, recurrent, or metastatic OR E) Hypereosinophilic syndrome or chronic eosinophilic leukemia OR F) Myelodysplastic syndrome (MDS) or myeloproliferative disease associated with platelet-derived growth factor receptor gene rearrangements OR G) Aggressive systemic mastocytosis without the D816V c-KIT mutation or with c-KIT mutational status unknownL.
Age Restrictions	N/A
Prescriber Restrictions	All uses: Prescribed by or in consultation with an oncologist or hematologist
Coverage Duration	All uses: 12 months
Other Criteria	All uses: Approve for continuation of prior therapy.

Prior Authorization Criteria
Scott and White
Effective: December 1, 2019

GOCOVRI (S)

Products Affected

- Gocovri

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Parkinson's disease (PD) (initial): Diagnosis of Parkinson's disease, patient is experiencing dyskinesia, patient is receiving levodopa-based therapy.
Age Restrictions	N/A
Prescriber Restrictions	Initial: Prescribed by or in consultation with a neurologist
Coverage Duration	12 months
Other Criteria	Parkinson's Disease (reauthorization): Documentation of positive clinical response to Gocovri therapy (e.g., decreased "off" periods or decreased "on" time with troublesome dyskinesia).

Prior Authorization Criteria
 Scott and White
 Effective: December 1, 2019

GROWTH HORMONE (S)

Products Affected

- Genotropin
- Genotropin Miniquick
- Humatrope INJ 12MG, 24MG, 6MG
- Humatrope Combo Pack
- Norditropin Flexpro
- Norditropin Nordiflex Pen INJ 30MG/3ML
- Nutropin Aq Nuspin 10
- Nutropin Aq Nuspin 20
- Nutropin Aq Nuspin 5
- Nutropin Aq Pen
- Omnitrope INJ 10MG/1.5ML, 5MG/1.5ML
- Saizen
- Saizen Click.easy
- Saizenprep Reconstitutionkit

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A

Prior Authorization Criteria

Scott and White

Effective: December 1, 2019

<p>Required Medical Information</p>	<p>PGHD(initial):less than 4mo w/GD,or hx neonatal hypoglycemia assoc w/pituitary dz,or panhypopituitarism dx,or all of the following: PGHD dx [confrmd by ht (utilizing age and gender grwth charts related to ht) documented(doc) by ht more than 2.0SD below midparental ht or more than 2.25SD below population(pop) mean (below 1.2 percentile for age and gender),or grwth velocity more than 2SD below mean for age and gender, or delayed skeletal maturation more than 2SD below mean for age and gender (eg,delayed more than 2yrs compared w/chronological age)]. PWS(reauth):evidence of positive response to tx(eg,incr in total LBM, decr in fat mass) and expctd adult ht not attained and doc of expctd adult ht goal. GFSGA(initial):SGA dx based on catchup grwth failure in 1st 24mo of life using 0-36mo grwth chart confrmd by birth wt or length below 3rd percentile for gestational age(more than 2SD below pop mean) and ht remains at or below 3rd percentile (more than 2SD below pop mean). TS,NS(initial):ped grwth failure dx assoc w/TS w/doc female w/bone age less than 14yrs, or NS and ht below 5th percentile on grwth charts for age and gender. SHOX(initial):ped grwth failure dx w/SHOX gene deficiency confirmed by genetic testing. GFCRI(initial): ped grwth failure dx assoc w/CRI. ISS(initial):ISS dx, diagnostic eval excluded other causes assoc w/short stature(eg GHD, chronic renal insufficiency), doc ht at or below -2.25SD score below corresponding mean ht for age and gender, doc grwth velocity less than 25th percentile for bone age. PGHD,NS,SHOX,GFCRI,ISS (initial): doc male w/bone age less than 16yrs or female w/bone age less than 14yrs. PGHD,GFSGA,TS/NS,SHOX,GFCRI,ISS(reauth):expctd adult ht not attained and doc of expctd adult ht goal.</p>
<p>Age Restrictions</p>	<p>N/A</p>
<p>Prescriber Restrictions</p>	<p>PGHD, PWS, GFSGA, TS/NS, SHOX, AGHD, TPAP, IGHDA, ISS: prescribed by endocrinologist. GFCRI: prescribed by endocrinologist or nephrologist</p>
<p>Coverage Duration</p>	<p>All uses (initial, reauth): 12 months</p>

Prior Authorization Criteria

Scott and White

Effective: December 1, 2019

<p>Other Criteria</p>	<p>All(init): No prerequisites needed for Genotropin and Nutropin. All others: trial and failure or intolerance to Genotropin and Nutropin. AGHD(initial):dx of AGHD with clin records supporting dx of childhood-onset GHD, or adult-onset GHD w/clin records doc hormone deficiency d/t hypothalamic-pituitary dz from organic or known causes (eg,damage from surgery, cranial irradiation, head trauma, subarachnoid hemorrhage) and pt has 1GH stim test (insulin tolerance test [ITT], arginine/GHRH,glucagon,arginine) to confirm adult GHD w/peak GH values ([ITT at or below 5mcg/L],[GHRH+ARG at or below 11mcg/L if BMI less than 25kg/m2, at or below 8mcg/L if BMI at or above 25 and below 30kg/m2, or at or below 4mcg/L if BMI at or above 30kg/m2],[glucagon at or below 3mcg/L],[Arg at or below 0.4mcg/L],[macimorelin less than 2.8 ng/mL 30, 45, 60 and 90 mins following macimorelin administration]) or doc deficiency of 3 anterior pituitary hormones (prolactin,ACTH,TSH,FSH/LH) and IGF-1/somatomedinC below age and gender adjstd nrml range as provided by physicians lab. AGHD,IGHDA(reauth):monitoring as demonstrated by doc w/in past 12mo of IGF-1/somatomedinC level. TransitionPhaseAdolescent Pts(TPAP)(initial): attained expctd adult ht or closed epiphyses on bone radiograph, and doc high risk of GHD d/t GHD in childhood (from embryopathic/congenital defects, genetic mutations, irreversible structural hypothalamic-pituitary dz, panhypopituitarism, or deficiency of 3 anterior pituitary hormones:ACTH,TSH,prolactin,FSH/LH), w/IGF-1/somatomedinC below age and gender adj nrml range as provided by physicians lab, or pt does not have low IGF-1/somatomedinC and d/c GH tx for at least 1mo, and pt has 1 GH stim test (ITT,GHRH+ARG,ARG,glucagon) after d/c of tx for at least 1mo w/peak GH value [ITT at or below 5mcg/L], [GHRH+ARG at or below 11mcg/L if BMI less than 25kg/m2, at or below 8mcg/L if BMI at or above 25 and below 30kg/m2, or at or below 4mcg/L if BMI at or above 30kg/m2], [glucagon at or below 3mcg/L], [Arg at or below 0.4mcg/L], or at low risk of severe GHD(eg d/t isolated and/or idiopathic GHD) and d/c GH tx for at least 1mo, and pt has 1 GH stim test (ITT, GHRH+ARG, ARG, glucagon) after d/c of tx for at least 1mo w/corresponding peak GH value [ITT at or below 5mcg/L], [GHRH+ARG at or below 11mcg/L if BMI less than 25kg/m2, at or below 8mcg/L if BMI at or above 25 and below 30kg/m2, or at or below 4mcg/L if BMI at or above 30kg/m2], [glucagon at or below 3mcg/L], [Arg at or below 0.4mcg/L]. TPAP(reauth):evidence of positive response to therapy (eg,incr in total lean body mass, exercise capacity or IGF-1 and IGFBP-3). IGHDA(initial):doc GHD by failure to produce peak serum GH greater than 5 mcg/L after 2 provocative pharmacol stim tests(insulin,L-ARG,glucagon).</p>
------------------------------	--

H.P. ACTHAR GEL (S)

Products Affected

- Acthar

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	<p>Infantile Spasm (West Syndrome): Diagnosis of infantile spasms (West Syndrome). Dosing for infantile spasms (West Syndrome) is in accordance with the United States Food and Drug Administration (FDA) approved labeling: not to exceed 150U/m² daily. Multiple Sclerosis (MS): Acute exacerbations of MS. Dosing for multiple sclerosis is in accordance with the United States FDA approved labeling: not to exceed 120 units once daily. Rheumatic disorders: As adjunctive therapy for short-term administration in: psoriatic arthritis, rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy), ankylosing spondylitis. Collagen diseases: During an exacerbation or as maintenance therapy in selected cases of: systemic lupus erythematosus, systemic dermatomyositis (polymyositis). Dermatologic diseases: Severe erythema multiforme, Stevens-Johnson syndrome. Allergic states: Serum sickness. Ophthalmic diseases: Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: keratitis, iritis and iridocyclitis, diffuse posterior uveitis and choroiditis, optic neuritis, chorioretinitis, anterior segment inflammation. Respiratory diseases: Symptomatic sarcoidosis. Edematous state: To induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus. All indications except for infantile spasms: Trial and failure, contraindication, or intolerance to treatment with two corticosteroids. All indications (except infantile spasms, multiple sclerosis): Dosing is in accordance with the United States FDA approved labeling: not to exceed 80 units per day.</p>
Age Restrictions	Infantile spasms: less than 2 years old
Prescriber Restrictions	<p>Infantile Spasm, MS: neurologist. Rheumatic disorder, collagen disease: rheumatologist. Dermatologic: dermatologist. Allergic state: allergist, immunologist. Ophthalmic disease: optometrist, ophthalmologist. Respiratory diseases: pulmonologist. Edematous state: nephrologist, rheumatologist.</p>

Prior Authorization Criteria

Scott and White

Effective: December 1, 2019

Coverage Duration	Infantile Spasms: 4 weeks. MS: 3 weeks. All other FDA-approved uses: 3 months.
Other Criteria	N/A

Prior Authorization Criteria
Scott and White
Effective: December 1, 2019

HAEGARDA (S)

Products Affected

- Haegarda

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Prophylaxis of hereditary angioedema (HAE) attacks: Diagnosis of HAE. For prophylaxis against HAE attacks.
Age Restrictions	N/A
Prescriber Restrictions	HAE: Prescribed by or in consultation with an immunologist, allergist, or rheumatologist
Coverage Duration	12 months
Other Criteria	N/A

Prior Authorization Criteria
Scott and White
Effective: December 1, 2019

HALAVEN (S)

Products Affected

- Halaven

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Breast Cancer: Diagnosis of recurrent or metastatic breast cancer. Previous treatment with both of the following: one anthracycline [eg, doxorubicin, Ellence (epirubicin)] and one taxane [eg, paclitaxel, Taxotere (docetaxel)]. Liposarcoma: Diagnosis of unresectable or metastatic liposarcoma. Previous treatment with one anthracycline-containing regimen.
Age Restrictions	N/A
Prescriber Restrictions	All uses: prescribed by or in consultation with an oncologist.
Coverage Duration	12 months
Other Criteria	Approve for continuation of prior therapy.

Prior Authorization Criteria
 Scott and White
 Effective: December 1, 2019

HARVONI (S)

Products Affected

- Harvoni

- Ledipasvir/sofosbuvir

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Criteria will be applied consistent with current AASLD/IDSA guideline. ALL (including patients with genotype 5 or 6 infection AND decompensated cirrhosis): A) Diagnosis of chronic hepatitis C AND B) Patient is not receiving Harvoni in combination with another HCV direct acting antiviral agent [eg, Sovaldi (sofosbuvir).
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with one of the following: Hepatologist, Gastroenterologist, Infectious disease specialist, HIV specialist certified through the American Academy of HIV Medicine.
Coverage Duration	12 to 24 weeks. Criteria will be applied consistent with current AASLD/IDSA guideline.
Other Criteria	N/A

HERCEPTIN (S)

Products Affected

- Herceptin

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Breast cancer: Diagnosis of human epidermal growth factor receptor 2 (HER2)-overexpressing breast cancer. One of the following treatment regimens: a) As adjuvant treatment, b) metastatic disease and one of the following: 1) used in combination with a taxane (eg, docetaxel, paclitaxel), or 2) used as a single agent in a patient who has received one or more chemotherapy regimens for metastatic disease, or c) used in combination with Perjeta (pertuzumab). Gastric Cancer: Diagnosis of HER2-overexpressing gastric or gastroesophageal junction adenocarcinoma (locally advanced, recurrent, or metastatic). Used in combination with one of the following treatment regimens: a) Adrucil (5-fluorouracil), or b) Platinol (cisplatin) and Xeloda (capecitabine).
Age Restrictions	N/A
Prescriber Restrictions	All uses: Prescribed by or in consultation with an oncologist.
Coverage Duration	12 months
Other Criteria	Approve for continuation of prior therapy.

Prior Authorization Criteria
 Scott and White
 Effective: December 1, 2019

HETLIOZ (S)

Products Affected

- HetlioZ

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Non-24-Hour Sleep-Wake Disorder (Non-24) (initial): Both of the following: 1) Diagnosis of non-24-hour sleep-wake disorder (also known as free-running disorder, free-running or non-entrained type circadian rhythm sleep disorder, or hypernychthemeral syndrome), AND 2) patient is totally blind (has no light perception).
Age Restrictions	N/A
Prescriber Restrictions	Non-24 (initial): Prescribed by or in consultation with a specialist in sleep disorders or neurologist
Coverage Duration	Non-24 (initial): 6 mo. (reauth): 12 mo
Other Criteria	Non-24 (reauth): Documentation of positive clinical response to HetlioZ therapy.

HIZENTRA (S)

Products Affected

- Hizentra

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	All uses (initial, reauth): Contraindications to immune globulin therapy (i.e., IgA deficiency with antibodies to IgA and a history of hypersensitivity or product specific contraindication). Patient does not have hyperprolinemia.
Required Medical Information	Initial: Immune globulin will be administered at the minimum effective dose and appropriate frequency for the prescribed diagnosis. Medication is being used subcutaneously. Diagnosis of chronic inflammatory demyelinating polyneuropathy (CIDP) OR one of the following FDA-approved or literature supported diagnoses: 1) Common variable immunodeficiency (CVID), OR 2) Congenital agammaglobulinemia (X-linked or autosomal recessive), OR 3) Severe combined immunodeficiencies (SCID), OR 4) Wiskott-Aldrich syndrome, OR 5) Other primary immunodeficiency with an immunologic evaluation including IgG levels below the normal laboratory value for the patient's age at the time of diagnosis and the patient lacks an adequate response to protein and polysaccharide antigens (i.e., tetanus toxoid or diphtheria toxoid and pneumovax or HiB vaccine).
Age Restrictions	N/A
Prescriber Restrictions	All uses (initial, reauth): Prescribed by or in consultation with a physician who has specialized expertise in managing patients on SCIG therapy (e.g., immunologist, hematologist, neurologist, etc.).
Coverage Duration	Initial, reauth: 12 months
Other Criteria	Subject to Part B vs. Part D review. All uses (reauth): Patient has experienced an objective improvement on immune globulin therapy and the immune globulin will be administered at the minimum effective dose (by decreasing the dose, increasing the frequency, or implementing both strategies) for maintenance therapy.

HRM - ANTIHISTAMINES

Products Affected

- Cyproheptadine Hcl SYRP
- Cyproheptadine Hcl TABS
- Dexchlorpheniramine Maleate SOLN
- Dexchlorpheniramine Maleate SYRP
- Hydroxyzine Hcl INJ 25MG/ML
- Hydroxyzine Hcl SYRP
- Hydroxyzine Hcl TABS 25MG
- Hydroxyzine Hydrochloride INJ
- Hydroxyzine Hydrochloride TABS 10MG, 50MG
- Hydroxyzine Pamoate CAPS
- Meclizine Hcl TABS
- Phenadoz
- Phenergan SUPP
- Promethazine Hcl INJ
- Promethazine Hcl SUPP
- Promethazine Hcl SYRP
- Promethazine Hcl TABS 12.5MG
- Promethazine Hcl Plain
- Promethazine Hydrochloride INJ
- Promethazine Hydrochloride TABS 25MG, 50MG
- Promethazine Vc Plain SOLN
- Promethazine/phenylephrine
- Promethegan
- Ryclora

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	The drug is being prescribed for an FDA-approved indication AND the prescribing physician has been made aware that the requested drug is considered a high risk medication for elderly patients (age 65 years and older) and wishes to proceed with the originally prescribed medication.
Age Restrictions	PA applies to patients 65 years or older
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	N/A

Prior Authorization Criteria
 Scott and White
 Effective: December 1, 2019

HRM - ANTIHYPERTENSIVE AGENTS

Products Affected

- Methyldopate Hcl

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	The drug is being prescribed for an FDA-approved indication AND the patient has tried and failed at least one non-HRM alternative (One of the following: Low dose thiazide or a second generation calcium channel blocker OR ACE inhibitor, ARB, beta-blocker or combination product based on specific chronic conditions) unless alternative(s) is/are inappropriate or would not be applicable for the indication AND the prescribing physician has been made aware that the requested drug is considered a high risk medication for elderly patients (age 65 years and older) and wishes to proceed with the originally prescribed medication.
Age Restrictions	PA applies to patients 65 years or older
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	N/A

Prior Authorization Criteria
 Scott and White
 Effective: December 1, 2019

HRM - ANTIPSYCHOTICS

Products Affected

- Thioridazine Hcl TABS 100MG, 10MG, 25MG, 50MG

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	The drug is being prescribed for an FDA-approved indication AND the patient has tried and failed at least one non-HRM alternative (One of the following: haloperidol, fluphenazine, atypical antipsychotic) unless alternative(s) is/are inappropriate or would not be applicable for the indication AND the prescribing physician has been made aware that the requested drug is considered a high risk medication for elderly patients (age 65 years and older) and wishes to proceed with the originally prescribed medication.
Age Restrictions	PA applies to patients 65 years or older
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	Applies to New Starts only.

Prior Authorization Criteria
Scott and White
Effective: December 1, 2019

HRM - ANTISPASMODICS

Products Affected

- Diphenatol

- Diphenoxylate/atropine TABS

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	The drug is being prescribed for an FDA-approved indication AND the prescribing physician has been made aware that the requested drug is considered a high risk medication for elderly patients (age 65 years and older) and wishes to proceed with the originally prescribed medication.
Age Restrictions	PA applies to patients 65 years or older
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	N/A

Prior Authorization Criteria
Scott and White
Effective: December 1, 2019

HRM - CARDIOVASCULAR, CALCIUM CHANNEL BLOCKER

Products Affected

- Nifedipine CAPS

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	The drug is being prescribed for an FDA-approved indication AND the patient has tried and failed at least one non-HRM alternative (One of the following: extended-release nifedipine, nicardipine, amlodipine) unless alternative(s) is/are inappropriate or would not be applicable for the indication AND the prescribing physician has been made aware that the requested drug is considered a high risk medication for elderly patients (age 65 years and older) and wishes to proceed with the originally prescribed medication.
Age Restrictions	PA applies to patients 65 years or older
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	N/A

Prior Authorization Criteria
Scott and White
Effective: December 1, 2019

HRM - ENDOCRINE

Products Affected

- Megestrol Acetate SUSP 40MG/ML
- Megestrol Acetate TABS

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	The drug is being prescribed for an FDA-approved indication AND the prescribing physician has been made aware that the requested drug is considered a high risk medication for elderly patients (age 65 years and older) and wishes to proceed with the originally prescribed medication.
Age Restrictions	PA applies to patients 65 years or older
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	Applies to New Starts only.

HRM - PAIN MEDICATIONS

Products Affected

- Ascomp/codeine
- Butalbital Compound/codeine CAPS 325MG; 50MG; 40MG; 30MG
- Butalbital/acetaminophen
- Butalbital/acetaminophen/caffeine CAPS
- Butalbital/acetaminophen/caffeine TABS 325MG; 50MG; 40MG
- Butalbital/acetaminophen/caffeine/codeine
- Butalbital/aspirin/caffeine CAPS
- Butalbital/aspirin/caffeine/codeine
- Capacet
- Cephadyn
- Esgic CAPS
- Indomethacin INJ
- Ketorolac Tromethamine INJ 300MG/10ML
- Margesic
- Marten-tab
- Phrenilin Forte CAPS 300MG; 50MG; 40MG
- Tencon TABS 325MG; 50MG
- Vanatol Lq
- Zebutal CAPS 325MG; 50MG; 40MG

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	The drug is being prescribed for an FDA-approved indication AND the prescribing physician has been made aware that the requested drug is considered a high risk medication for elderly patients (age 65 years and older) and wishes to proceed with the originally prescribed medication.
Age Restrictions	PA applies to patients 65 years or older
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	N/A

Prior Authorization Criteria
 Scott and White
 Effective: December 1, 2019

HRM - PHENOBARBITAL, PENTOBARBITAL

Products Affected

- Pentobarbital Sodium INJ
- Phenobarbital ELIX 20MG/5ML
- Phenobarbital TABS 100MG, 15MG, 16.2MG, 30MG, 32.4MG, 60MG, 64.8MG, 97.2MG
- Phenobarbital Sodium INJ 130MG/ML, 65MG/ML

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Verify the medication is being used for an FDA-approved diagnosis AND the prescribing physician has been made aware that the requested drug is considered a high risk medication for elderly patients (age 65 years and older) and wishes to proceed with the originally prescribed medication.
Age Restrictions	PA applies to patients 65 years or older
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	Applies to New Starts only.

Prior Authorization Criteria
Scott and White
Effective: December 1, 2019

HRM - PLATELET INHIBITORS

Products Affected

- Ticlopidine Hcl

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	The drug is being prescribed for an FDA-approved indication AND the patient has tried and failed at least one non-HRM alternative (One of the following: clopidogrel, Aggrenox) unless alternative(s) is/are inappropriate or would not be applicable for the indication AND the prescribing physician has been made aware that the requested drug is considered a high risk medication for elderly patients (age 65 years and older) and wishes to proceed with the originally prescribed medication.
Age Restrictions	PA applies to patients 65 years or older
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	N/A

Prior Authorization Criteria
 Scott and White
 Effective: December 1, 2019

HRM - SEDATIVE HYPNOTIC AGENTS

Products Affected

- Eszopiclone
- Zolpidem Tartrate
- Zolpidem Tartrate Er
- Zaleplon

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	The drug is being prescribed for an FDA-approved indication AND the prescribing physician has been made aware that the requested drug is considered a high risk medication for elderly patients (age 65 years and older) when used longer than 90 days and wishes to proceed with the originally prescribed medication.
Age Restrictions	PA applies to patients 65 years or older
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	N/A

Prior Authorization Criteria

Scott and White

Effective: December 1, 2019

HRM - SKELETAL MUSCLE RELAXANTS

Products Affected

- Chlorzoxazone TABS
- Cyclobenzaprine Hydrochloride TABS
- Cyclobenzaprine Hydrochloride Er
- Methocarbamol TABS
- Orphenadrine Citrate Er

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	The drug is being prescribed for an FDA-approved indication AND the prescribing physician has been made aware that the requested drug is considered a high risk medication for elderly patients (age 65 years and older) and wishes to proceed with the originally prescribed medication.
Age Restrictions	PA applies to patients 65 years or older
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	N/A

Prior Authorization Criteria
 Scott and White
 Effective: December 1, 2019

HRM - TCA

Products Affected

- Amitriptyline Hcl TABS 100MG, 150MG, 25MG, 75MG
- Amitriptyline Hydrochloride TABS 10MG, 50MG
- Chlordiazepoxide/amitriptyline
- Doxepin Hcl CAPS 100MG, 10MG, 150MG, 50MG, 75MG
- Doxepin Hcl CONC
- Doxepin Hydrochloride CAPS 25MG
- Perphenazine/amitriptyline

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	The drug is being prescribed for an FDA-approved indication AND the prescribing physician has been made aware that the requested drug is considered a high risk medication for elderly patients (age 65 years and older) and wishes to proceed with the originally prescribed medication .
Age Restrictions	PA applies to patients 65 years or older
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	Applies to New Starts only.

HUMIRA (S)

Products Affected

- Humira
- Humira Pediatric Crohns Disease Starter Pack
- Humira Pen
- Humira Pen-cd/uc/hs Starter
- Humira Pen-ps/uv Starter

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Rheumatoid Arthritis (RA) (Initial): Diagnosis of moderately to severely active RA. Trial and failure, contraindication, or intolerance (TF/C/I) to one disease modifying antirheumatic drug (DMARD) [eg, methotrexate (Rheumatrex/Trexall), Arava (leflunomide), Azulfidine (sulfasalazine)]. Juvenile Idiopathic Arthritis (JIA) (Initial): Diagnosis of moderately to severely active polyarticular JIA. TF/C/I to one of the following DMARDs: Arava (leflunomide) or methotrexate (Rheumatrex/Trexall). Psoriatic Arthritis (PsA) (Initial): Diagnosis of active PsA. Plaque psoriasis (Initial): Diagnosis of moderate to severe chronic plaque psoriasis. Ankylosing Spondylitis (AS) (Initial): Diagnosis of active AS. TF/C/I to two NSAIDs. Crohn's Disease (CD) (Initial): Diagnosis of moderately to severely active CD. TF/C/I to one of the following conventional therapies: 6-mercaptopurine, Imuran (azathioprine), corticosteroid (eg, prednisone, methylprednisolone), methotrexate (Rheumatrex/Trexall), or failure (ie, lost response) or intolerance to infliximab. Ulcerative Colitis (UC) (Initial): Diagnosis of moderately to severely active UC. TF/C/I to one of the following conventional therapies: 6-mercaptopurine, Imuran (azathioprine), corticosteroid (eg, prednisone, methylprednisolone), aminosalicylate [eg, mesalamine (Asacol, Pentasa, Rowasa), Dipentum (olsalazine), Azulfidine (sulfasalazine)]. Hidradenitis suppurativa (Initial): Diagnosis of moderate to severe hidradenitis suppurativa (ie, Hurley Stage II or III). Uveitis (initial): Diagnosis of non-infectious uveitis, classified as intermediate, posterior, or panuveitis. All indications (initial, reauth): Patient is not receiving Humira in combination with a biologic DMARD [eg, Enbrel (etanercept), Cimzia (certolizumab), Simponi (golimumab), Orencia (abatacept)].
Age Restrictions	N/A

Prior Authorization Criteria

Scott and White

Effective: December 1, 2019

<p>Prescriber Restrictions</p>	<p>RA, AS, JIA (initial): Prescribed by or in consultation with a rheumatologist. PsA (initial): Prescribed by or in consultation with a dermatologist or rheumatologist. Plaque Psoriasis, HS (initial): Prescribed by or in consultation with a dermatologist. CD, UC (initial): Prescribed by or in consultation with a gastroenterologist. Uveitis (initial): Prescribed by or in consultation with an ophthalmologist or rheumatologist.</p>
<p>Coverage Duration</p>	<p>UC (Initial): 12 wks. UC (reauth): 12 mo. All other indications (initial, reauth): 12 mo.</p>
<p>Other Criteria</p>	<p>RA, JIA, PsA, Plaque psoriasis, AS, CD, Hidradenitis suppurativa (HS), Uveitis (Reauth): Documentation of positive clinical response to Humira therapy. UC (Reauth): For patients who initiated Humira therapy within the past 12 weeks: Documentation of clinical remission or significant clinical benefit by eight weeks (Day 57) of therapy OR For patients who have been maintained on Humira therapy for longer than 12 weeks: Documentation of positive clinical response to Humira therapy.</p>

Prior Authorization Criteria
 Scott and White
 Effective: December 1, 2019

HYDROXYPROGESTERONE (S)

Products Affected

- Hydroxyprogesterone Caproate INJ 1.25GM/5ML

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	All uses (initial): Pregnant patients.
Required Medical Information	Amenorrhea: Diagnosis of primary or secondary amenorrhea. Amenorrhea is due to hormonal imbalance in the absence of organic pathology (e.g., submucous fibroids or uterine cancer) Secretory endometrium and desquamation: Used for production of secretory endometrium and desquamation in patients with endometrial disorder. Adenocarcinoma: Diagnosis of Stage III or IV adenocarcinoma of the uterine corpus. Estrogen production test: Used for the testing of endogenous estrogen production.
Age Restrictions	N/A
Prescriber Restrictions	Adenocarcinoma (initial): Prescribed by or in consultation with an oncologist
Coverage Duration	12 months
Other Criteria	Approve for continuation of prior therapy.

Prior Authorization Criteria
 Scott and White
 Effective: December 1, 2019

IBRANCE (S)

Products Affected

- Ibrance

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Breast Cancer: Diagnosis of advanced or metastatic breast cancer. Disease is a) hormone receptor (HR)-positive, and b) human epidermal growth factor receptor 2 (HER2)-negative. One of the following: 1) used in combination with an aromatase inhibitor (e.g., anastrozole, letrozole, exemestane) and one of the following: a) patient is a male, or b) patient is a postmenopausal woman, OR 2) both of the following: used in combination with Faslodex (fulvestrant) and disease has progressed following endocrine therapy.
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with an oncologist.
Coverage Duration	12 months
Other Criteria	Approve for continuation of prior therapy.

Prior Authorization Criteria
 Scott and White
 Effective: December 1, 2019

ICLUSIG (S)

Products Affected

- Iclusig

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Chronic myelogenous leukemia: Diagnosis of chronic myelogenous leukemia AND One of the following: A) Trial and failure, resistance, relapse, contraindication, or intolerance to at least TWO other tyrosine kinase inhibitors (e.g., Gleevec [imatinib], Sprycel, Tasigna, and Bosulif) or B) Patient has the T315I mutation. Acute Lymphoblastic Leukemia: Diagnosis of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) AND One of the following: A) Trial and failure, resistance relapse, contraindication, or intolerance to at least TWO other FDA-approved tyrosine kinase inhibitors (e.g., Gleevec [imatinib], Sprycel), or B) Patient has the T315I mutation.
Age Restrictions	Acute Lymphoblastic Leukemia: 18 years of age or older
Prescriber Restrictions	All uses: Prescribed by or in consultation with an oncologist or hematologist
Coverage Duration	All uses: 12 months
Other Criteria	All uses: Approve for continuation of prior therapy.

Prior Authorization Criteria
 Scott and White
 Effective: December 1, 2019

IDHIFA (S)

Products Affected

- Idhifa

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Acute Myeloid Leukemia (AML): Diagnosis of AML. Disease is relapsed or refractory. Patient has an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test (e.g., Abbott RealTime IDH2 assay) or performed at a facility approved by Clinical Laboratory Improvement Amendments (CLIA).
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with a hematologist/oncologist.
Coverage Duration	12 months
Other Criteria	Approve for continuation of prior therapy.

ILARIS (S)

Products Affected

- Ilaris

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Periodic Fever Syndromes (Cryopyrin-Associated Periodic Syndromes (CAPS), Tumor Necrosis Factor Receptor Associated Periodic Syndrome (TRAPS), Hyperimmunoglobulin D Syndrome (HIDS)/Mevalonate Kinase Deficiency (MKD), Familial Mediterranean Fever (FMF)). (Initial) Diagnosis of one of the autoinflammatory Periodic Fever Syndromes: CAPS (including Familial Cold Auto-inflammatory Syndrome (FCAS) and/or Muckle-Wells Syndrome (MWS)), TRAPS, HIDS/MKD, or FMF, AND The medication will not be used in combination with another biologic agent. Systemic juvenile idiopathic arthritis (sJIA) (Initial): Diagnosis of active sJIA AND The medication will not be used in combination with another biologic.
Age Restrictions	SJIA (initial): 2 years of age or older
Prescriber Restrictions	Periodic Fever Syndromes (CAPS, TRAPS, HIDS/MKD, FMF) (initial): Prescribed by or in consultation with an immunologist, allergist, dermatologist, rheumatologist, neurologist or other medical specialist
Coverage Duration	All uses (initial, reauth): 12 months
Other Criteria	Periodic Fever Syndrome (CAPS, TRAPS, HIDS/MKD, FMF) ((Reauth) and SJIA (Reauth): Documentation of positive clinical response to therapy.

Prior Authorization Criteria
 Scott and White
 Effective: December 1, 2019

ILUMYA (S)

Products Affected

- Ilumya

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Plaque Psoriasis (initial): Diagnosis of moderate-to-severe plaque psoriasis. One of the following: set A) Both of the following: 1) Trial and failure, contraindication, or intolerance to Enbrel (etanercept) or Humira (adalimumab) AND 2) Trial and failure, contraindication, or intolerance to Cosentyx (secukinumab), or set B) For continuation of prior Ilumya therapy.
Age Restrictions	N/A
Prescriber Restrictions	Plaque Psoriasis (initial): Prescribed by or in consultation with a dermatologist
Coverage Duration	Initial, reauth: 12 months
Other Criteria	Plaque Psoriasis (Reauth): Documentation of positive clinical response to Ilumya therapy.

Prior Authorization Criteria
 Scott and White
 Effective: December 1, 2019

IMBRUVICA (S)

Products Affected

- Imbruvica

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Mantle cell lymphoma (MCL): Diagnosis of MCL AND patient has relapsed or is refractory to at least one prior therapy for the treatment of MCL. Chronic lymphocytic leukemia (CLL): Diagnosis of CLL. Waldenstrom's macroglobulinemia: Diagnosis of Waldenstrom's macroglobulinemia/lymphoplasmacytic lymphoma. Small lymphocytic lymphoma (SLL): Diagnosis of SLL. Marginal zone lymphoma (MZL): Diagnosis of MZL AND patient has received at least one prior anti-CD20-based therapy for MZL [e.g., Rituxan (rituximab), Zevalin (ibritumomab), Gazyva (obinutuzumab, etc.)]. Chronic graft versus host disease (cGVHD): Diagnosis of cGVHD AND trial and failure of one or more lines of systemic therapy (e.g., corticosteroids, mycophenolate).
Age Restrictions	N/A
Prescriber Restrictions	All uses (except chronic graft versus host disease): Prescribed by or in consultation with an oncologist or hematologist. Chronic graft versus host disease: Prescribed by or in consultation with a hematologist, oncologist, or physician experienced in the management of transplant patients.
Coverage Duration	All Uses: 12 months
Other Criteria	All Uses: Approve for continuation of prior therapy.

Prior Authorization Criteria
 Scott and White
 Effective: December 1, 2019

IMFINZI (S)

Products Affected

- Imfinzi

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Urothelial carcinoma: 1) Diagnosis of locally advanced or metastatic urothelial carcinoma AND 2) One of the following: a) Patient has experienced disease progression during or following platinum-containing chemotherapy OR b) Patient has experienced disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. Non-Small Cell Lung Cancer (NSCLC): 1) Diagnosis of NSCLC AND 2) Disease is stage III and unresectable AND 3) Disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy.
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	12 months
Other Criteria	Approve for continuation of prior therapy.

Prior Authorization Criteria
Scott and White
Effective: December 1, 2019

IMVEXXY (S)

Products Affected

- Imvexxy Maintenance Pack
- Imvexxy Starter Pack

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Dyspareunia (initial): Diagnosis of moderate to severe dyspareunia due to vulvar and vaginal atrophy associated with menopause.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Initial, reauth: 12 months
Other Criteria	Dyspareunia (reauth): Documentation of positive clinical response to Imvexxy therapy.

Prior Authorization Criteria
Scott and White
Effective: December 1, 2019

INBRIJA (S)

Products Affected

- Inbrija

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Parkinson's disease (PD) (initial): Diagnosis of PD. Patient is experiencing intermittent OFF episodes. Patient is receiving Inbrija in combination with a carbidopa/levodopa containing medication.
Age Restrictions	N/A
Prescriber Restrictions	PD (initial): Prescribed by or in consultation with a neurologist
Coverage Duration	PD (initial, reauth): 12 months
Other Criteria	PD (reauth): Documentation of positive clinical response to Inbrija therapy. Patient is receiving Inbrija in combination with a carbidopa/levodopa containing medication.

Prior Authorization Criteria
 Scott and White
 Effective: December 1, 2019

INCRELEX (S)

Products Affected

- Increlex

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Insulin-like Growth Factor-1 (IGF-1) deficiency (initial): Diagnosis of severe primary IGF-1 deficiency. Height standard deviation score of -3.0 or less. Basal IGF-1 standard deviation score of -3.0 or less. Normal or elevated growth hormone (GH). GH gene deletion (initial): Diagnosis of GH gene deletion in patients who have developed neutralizing antibodies to GH.
Age Restrictions	N/A
Prescriber Restrictions	Initial: Prescribed by or in consultation with a pediatric endocrinologist
Coverage Duration	Initial, reauth: 12 months
Other Criteria	(Reauth): Evidence of positive response to therapy.

INFLECTRA (S)

Products Affected

- Inflectra

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	<p>Crohn's Disease (CD) and Fistulizing Crohn's Disease (FCD) (initial): Dx of moderately to severely active CD or FCD. Ulcerative colitis (UC) (initial): Dx of moderately to severely active UC. Rheumatoid arthritis (RA) (initial): Diagnosis (Dx) of moderately to severely active RA. Ankylosing spondylitis (AS) (initial): Dx of active AS. Psoriatic arthritis (PsA) (initial): Dx of active PsA. Plaque psoriasis (initial): Dx of chronic severe (ie, extensive and/or disabling) plaque psoriasis. CD, FCD (initial): Trial and failure, contraindication or intolerance (TF/C/I) to one of the following conventional therapies: 6-mercaptopurine (Purinethol), azathioprine (Imuran), corticosteroids (eg, prednisone, methylprednisolone), methotrexate (Rheumatrex, Trexall). UC (initial): TF/C/I to one of the following conventional therapies: corticosteroids, aminosalicylate [eg, mesalamine (Asacol/Pentasa/Rowasa), olsalazine (Dipentum), sulfasalazine (Azulfidine/Sulfazine)], azathioprine (Imuran), 6-mercaptopurine (Purinethol). RA (initial): Receiving concurrent therapy with methotrexate (Rheumatrex/Trexall), or TF/C/I to methotrexate. AS (initial): TF/C/I to two or more NSAIDs. All indications (initial): One of the following: 1) Trial and failure or intolerance to Remicade or 2) For continuation of prior Inflectra therapy. All indications (Initial): Excluded if patient is receiving infliximab in combination with a Biologic Disease Modifying Antirheumatic Drug (DMARD) [eg, Enbrel (etanercept), Orencia (abatacept), Rituxan (rituximab), Kineret (anakinra), Cimzia (certolizumab)].</p>
Age Restrictions	N/A
Prescriber Restrictions	<p>RA, AS: Prescribed or recommended by a rheumatologist. PsA: Prescribed or recommended by rheumatologist or dermatologist. Crohn's Disease, Fistulizing Crohn's Disease, UC: Prescribed or recommended by a gastroenterologist. Plaque Psoriasis: Prescribed or recommended by a dermatologist.</p>

Prior Authorization Criteria

Scott and White

Effective: December 1, 2019

Coverage Duration	All uses (initial, reauth): 12 months
Other Criteria	Reauth (all indications): Documentation of positive clinical response to infliximab therapy. All indications (re-auth): Excluded if patient is receiving infliximab in combination with a Biologic Disease Modifying Antirheumatic Drug (DMARD) [eg, Enbrel (etanercept), Orencia (abatacept), Rituxan (rituximab), Kineret (anakinra), Cimzia (certolizumab)].

Prior Authorization Criteria
Scott and White
Effective: December 1, 2019

INGREZZA (S)

Products Affected

- Ingrezza

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Tardive Dyskinesia (initial): Diagnosis of moderate to severe tardive dyskinesia. One of the following: a) patient has persistent symptoms of tardive dyskinesia despite a trial of dose reduction, tapering, or discontinuation of the offending medication OR b) patient is not a candidate for a trial of dose reduction, tapering, or discontinuation of the offending medication.
Age Restrictions	N/A
Prescriber Restrictions	Initial: Prescribed by or in consultation with a neurologist or psychiatrist.
Coverage Duration	Initial: 3 months. Reauth: 12 months
Other Criteria	Tardive Dyskinesia (reauth): Documentation of positive clinical response to Ingrezza therapy.

Prior Authorization Criteria
Scott and White
Effective: December 1, 2019

INLYTA (S)

Products Affected

- Inlyta

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Renal cell cancer (RCC): Diagnosis of RCC. One of the following: (1) disease has relapsed or (2) both of the following: medically or surgically unresectable tumor and diagnosis of stage IV disease.
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	12 months
Other Criteria	Approve for continuation of prior therapy.

Prior Authorization Criteria
Scott and White
Effective: December 1, 2019

INREBIC (S)

Products Affected

- Inrebic

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Myelofibrosis: Diagnosis of one of the following: primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocythemia myelofibrosis.
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with a hematologist/oncologist
Coverage Duration	12 months
Other Criteria	Approve for continuation of prior therapy.

Prior Authorization Criteria
 Scott and White
 Effective: December 1, 2019

INTRON A (S)

Products Affected

- Intron A

- Intron A W/diluent INJ 10MU

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Chronic hepatitis B: Diagnosis of chronic hepatitis B infection, and patient is without decompensated liver disease. Chronic Hepatitis C: Diagnosis of chronic hepatitis C, patient without decompensated liver disease, patient has not previously been treated with interferon, and one of the following - 1) used in combination with ribavirin or 2) contraindication or intolerance to ribavirin. Metastatic renal cell carcinoma (RCC): diagnosis of metastatic RCC, used in combination with Avastin (bevacizumab). Other: diagnosis of condylomata acuminata (genital or perianal), diagnosis of hairy cell leukemia, diagnosis of AIDS-related Kaposi's sarcoma, diagnosis of malignant melanoma, diagnosis of Stage III or IV follicular Non-Hodgkin's Lymphoma, as maintenance therapy for the treatment of multiple myeloma.
Age Restrictions	N/A
Prescriber Restrictions	RCC: Prescribed by or in consultation with an oncologist.
Coverage Duration	HepB, HepC: 48 wks. Condylomata acuminata (genital or perianal): 6 wks. Other: 12 months
Other Criteria	Approve for continuation of prior therapy.

Prior Authorization Criteria
 Scott and White
 Effective: December 1, 2019

IRESSA (S)

Products Affected

- Iressa

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Non-small cell lung cancer (NSCLC): Diagnosis of metastatic NSCLC AND Patient has known active epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test or at a Clinical Laboratory Improvement Amendments-approved facility.
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	12 months
Other Criteria	Approve for continuation of prior therapy.

Prior Authorization Criteria
 Scott and White
 Effective: December 1, 2019

ISOTRETINOIN (S)

Products Affected

- Amnesteem
- Claravis
- Isotretinoin CAPS
- Myorisan
- Zenatane

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Acne (initial): Diagnosis of acne. One of the following: A) Prescribed by a dermatologist or, B) Trial and failure, contraindication or intolerance to an adequate trial (at least 6 weeks) on both of the following conventional therapy regimens: a) topical retinoid or retinoid-like agent [eg, Retin-A/Retin-A Micro (tretinoin)] AND b) combination therapy with benzoyl peroxide and one of the following: 1) oral antibiotic [eg, Ery-Tab (erythromycin), Minocin (minocycline)] OR 2) topical antibiotic [eg, Cleocin-T (clindamycin), erythromycin, BenzaClin (benzoyl peroxide/clindamycin), Benzamycin (benzoyl peroxide/erythromycin)].
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Acne (initial): 5 months. Acne (reauth): Retreatment - 5 months, Dose Titration - 1 month
Other Criteria	Acne, Retreatment (reauth): After more than 2 months off therapy, persistent or recurring acne is still present. Acne, Dose Titration (reauth): Confirmation that the total cumulative dose is less than 150 mg/kg.

Prior Authorization Criteria
 Scott and White
 Effective: December 1, 2019

ISTODAX (S)

Products Affected

- Istodax
- Istodax (overfill)
- Romidepsin

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Cutaneous T-cell lymphoma (CTCL): Diagnosis of CTCL. Trial and failure, contraindication, or intolerance (TF/C/I) to at least one prior therapy (eg, retinoids, corticosteroids). Peripheral T-cell lymphoma (PTCL): Diagnosis of PTCL. TF/C/I to at least one prior therapy (eg, conventional chemotherapy such as CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone), CHOEP (cyclophosphamide, doxorubicin, vincristine, etoposide, prednisone), Dose-adjusted EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin), HyperCVAD (cyclophosphamide, vincristine, doxorubicin, dexamethasone) alternating with high-dose methotrexate and cytarabine).
Age Restrictions	N/A
Prescriber Restrictions	CTCL, PTCL: Prescribed by or in consultation with an oncologist/hematologist
Coverage Duration	12 months
Other Criteria	Approve for continuation of prior therapy.

Prior Authorization Criteria
 Scott and White
 Effective: December 1, 2019

IVIG (S)

Products Affected

- Bivigam
- Carimune Nanofiltered INJ 12GM, 6GM
- Flebogamma Dif
- Gammagard Liquid
- Gammagard S/d Iga Less Than 1mcg/ml
- Gammaked
- Gammaplex
- Gamunex-c
- Octagam
- Panzyga
- Privigen

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	All uses (initial, reauth): Contraindications to immune globulin therapy (i.e., IgA deficiency with antibodies to IgA and a history of hypersensitivity or product specific contraindication). Privigen only: Hyperprolinemia. Octagam only: Allergy to corn. Gammaplex only: Hereditary intolerance to fructose. Infants for whom sucrose or fructose tolerance has not been established.

Prior Authorization Criteria

Scott and White

Effective: December 1, 2019

<p>Required Medical Information</p>	<p>Initial: Immune globulin (Ig) will be administered at the minimum effective dose and appropriate frequency for the prescribed diagnosis. For IVIG – Ig is being used intravenously (IV) AND One of the following diagnoses: [A] Primary Immunodeficiency 1) Common variable immunodeficiency. 2) Congenital agammaglobulinemia (X-linked or autosomal recessive). 3) Severe combined immunodeficiencies. 4) Wiskott-Aldrich syndrome. OR 5) Other PI with an immunologic evaluation including IgG levels below the normal laboratory value for the patient’s age at the time of diagnosis and the patient lacks an adequate response to protein and polysaccharide antigens (i.e., tetanus toxoid or diphtheria toxoid and pneumovax or HiB vaccine). [B] Secondary Acquired Antibody Deficiency 1) B-cell chronic lymphocytic leukemia with an Ig level less than 500 mg/dL OR history of recurrent bacterial infections. 2) HIV infection with an Ig level less than 400 mg/dL OR Patient has active bleeding or a platelet count less than 10 x 10⁹/L. 3) Multiple myeloma in plateau phase and patient has hypogammaglobulinemia. [C] Hematological Autoimmune Disorders 1) Acquired (pure) red cell aplasia (PRCA) that is immunologic and patient had a trial and failure, contraindication, or intolerance (TF/C/I) to a corticosteroid and an immunosuppressant (i.e., cyclophosphamide, cyclosporine) OR patient has viral PRCA caused by parvovirus B19. 2) Fetal alloimmune thrombocytopenia. 3) Hemolytic disease of the newborn and the patient has established hyperbilirubinemia. 4) Idiopathic thrombocytopenic purpura and patient had a TF/C/I to a corticosteroid OR a platelet count less than 30,000 cells/mm³. 5) Post-transfusion purpura. Continued in Other Criteria Section.</p>
<p>Age Restrictions</p>	<p>HIV (initial): patient is less than or equal to 12 years of age.</p>
<p>Prescriber Restrictions</p>	<p>All uses (initial, reauth): Prescribed by or in consultation with a physician who has specialized expertise in managing patients on immune globulin therapy (e.g., immunologist, hematologist, neurologist, etc.).</p>
<p>Coverage Duration</p>	<p>4 months: Solid organ transplant. 12 months: all other diagnoses.</p>

Other Criteria	<p>[D] Neuromuscular Autoimmune Disorders 1) Chronic inflammatory demyelinating polyneuropathy. 2) Guillain-Barré syndrome. 3) Inflammatory myopathies (dermatomyositis or polymyositis) AND Patient had a TF/C/I to a corticosteroid AND an immunosuppressant (i.e., azathioprine, methotrexate, cyclosporine A, cyclophosphamide, or tacrolimus). 4) Lambert-Eaton myasthenic syndrome AND Patient had a TF/C/I to a corticosteroid AND an immunosuppressant (e.g., azathioprine). 5) Multifocal motor neuropathy. 6) Myasthenia gravis with severe exacerbations or myasthenic crises AND Patient had a TF/C/I to a corticosteroid AND an immunosuppressant (i.e., azathioprine, cyclosporine, cyclophosphamide, or mycophenolate mofetil). 7) Stiff person syndrome AND Patient had a TF/C/I to at least 2 standard therapies (i.e., benzodiazepines, muscle relaxants, or anti-convulsants).</p> <p>[E] Other Disorders 1) Autoimmune blistering disease AND Patient had a TF/C/I to a corticosteroid AND an immunosuppressant (i.e., cyclophosphamide, dapsone, methotrexate, azathioprine, or mycophenolate mofetil). 2) Kawasaki syndrome. 3) Solid organ transplant and IVIG is being used for CMV prophylaxis, or patient is a kidney transplant recipient and has donor specific antibodies, or patient has steroid-resistant rejection and had a TF/C/I to standard therapies. For SCIG (Gamunex-C, Gammagard Liquid, Gammaked only)- Immune globulin is being used subcutaneously AND One of the following PI diagnoses: 1) Common variable immunodeficiency. 2) Congenital agammaglobulinemia (X-linked or autosomal recessive). 3) Severe combined immunodeficiencies. 4) Wiskott-Aldrich syndrome. OR 5) Other PI with an immunologic evaluation including IgG levels below the normal laboratory value for the patient's age at the time of diagnosis and patient lacks an adequate response to protein and polysaccharide antigens (i.e., tetanus toxoid or diphtheria toxoid and pneumovax or HiB vaccine).</p> <p>All products: Subject to Part B vs. Part D review. For non-oncology renewal, the patient has experienced an objective improvement on immune globulin therapy and the immune globulin will be administered at the minimum effective dose (by decreasing the dose, increasing the frequency, or implementing both strategies) for maintenance therapy.</p>
-----------------------	--

Prior Authorization Criteria
 Scott and White
 Effective: December 1, 2019

JAKAFI (S)

Products Affected

- Jakafi

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Myelofibrosis: Diagnosis of primary myelofibrosis, OR post-polycythemia vera myelofibrosis, OR post-essential thrombocythemia myelofibrosis. Polycythemia vera: Diagnosis of polycythemia vera, AND trial and failure, contraindication, or intolerance to hydroxyurea. Acute graft versus host disease (aGVHD): Diagnosis of aGVHD. Disease is steroid-refractory.
Age Restrictions	N/A
Prescriber Restrictions	Myelofibrosis, Polycythemia vera: Prescribed by or in consultation with a hematologist/oncologist. Acute graft versus host disease: Prescribed by or in consultation with one of the following: hematologist, oncologist, physician experienced in the management of transplant patients.
Coverage Duration	12 months.
Other Criteria	Approve for continuation of prior therapy.

Prior Authorization Criteria
Scott and White
Effective: December 1, 2019

JEVTANA (S)

Products Affected

- Jevtana

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Prostate Cancer: Diagnosis of castration-resistant metastatic prostate cancer AND patient has been previously treated with a docetaxel-containing regimen AND patient is receiving concurrent prednisone.
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	12 months
Other Criteria	Approve for continuation of prior therapy.

JUXTAPID (S)

Products Affected

- Juxtapid

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Homozygous familial hypercholesterolemia (HoFH) (initial): Submission of medical records (eg, chart notes, laboratory values) documenting diagnosis of HoFH as confirmed by one of the following: a) genetic confirmation of 2 mutations in the LDL receptor, ApoB, PCSK9, or LDL receptor adaptor protein 1 (ie, LDLRAP1 or ARH), or b) both of the following: 1) either untreated LDL-C greater than 500 mg/dL or treated LDL-C greater than 300 mg/dL AND 2) either xanthoma before 10 years of age or evidence of heterozygous FH in both parents. Patient is receiving other lipid-lowering therapy. Trial and failure, contraindication, or intolerance to Repatha therapy. Not used in combination with a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor.
Age Restrictions	N/A
Prescriber Restrictions	HoFH (initial, reauth): Prescribed by a cardiologist, endocrinologist, or lipid specialist.
Coverage Duration	HoFH (initial): 6 months. (reauth): 12 months
Other Criteria	HoFH (reauthorization): Patient continues to receive other lipid-lowering therapy. Submission of medical records (eg, chart notes, laboratory values) documenting LDL-C reduction while on Juxtapid therapy. Not used in combination with a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor.

Prior Authorization Criteria
Scott and White
Effective: December 1, 2019

KADCYLA (S)

Products Affected

- Kadcyła

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Breast cancer: A) Diagnosis of human epidermal growth factor receptor 2 (HER2)-positive recurrent or metastatic breast cancer AND B) Patient has been previously treated with Herceptin (trastuzumab) and a taxane (eg, docetaxel, paclitaxel).
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	12 months
Other Criteria	Approve for continuation of prior therapy.

Prior Authorization Criteria
Scott and White
Effective: December 1, 2019

KALBITOR (S)

Products Affected

- Kalbitor

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Treatment of hereditary angioedema (HAE) attacks: Diagnosis of HAE. For the treatment of acute HAE attacks. Not used in combination with other approved treatments for acute HAE attacks.
Age Restrictions	12 years of age or older
Prescriber Restrictions	HAE: Prescribed by or in consultation with an immunologist, allergist, or rheumatologist
Coverage Duration	12 months
Other Criteria	N/A

Prior Authorization Criteria
 Scott and White
 Effective: December 1, 2019

KALYDECO (S)

Products Affected

- Kalydeco

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Cystic Fibrosis (CF) (Initial): Diagnosis of cystic fibrosis. Patient has one of the following mutations on at least one allele in the cystic fibrosis transmembrane conductance regulator gene as detected by an FDA-cleared cystic fibrosis mutation test or at a Clinical Laboratory Improvement Amendments (CLIA)-approved facility: A455E, A1067T, D110E, D110H, D579G, D1152H, D1270N, E56K, E193K, E831X, F1052V, F1074L, G178R, G551D, G551S, G1069R, G1244E, G1349D, K1060T, L206W, P67L, R74W, R117C, R117H, R347H, R352Q, R1070Q, R1070W, S549N, S549R, S945L, S977F, S1251N, S1255P, 711+3A-G, 2789+5G-A, 3272-26A-G, or 3849+10kbC-T.
Age Restrictions	CF (Initial): 6 months of age or older
Prescriber Restrictions	CF (initial): Prescribed by or in consultation with a specialist affiliated with a CF care center or pulmonologist
Coverage Duration	CF (initial, reauth): 12 months
Other Criteria	CF (Reauth): Patient is benefiting from treatment (i.e. improvement in lung function [forced expiratory volume in one second (FEV1)], decreased number of pulmonary exacerbations).

Prior Authorization Criteria
Scott and White
Effective: December 1, 2019

KANUMA (S)

Products Affected

- Kanuma

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Lysosomal acid lipase deficiency: Diagnosis of lysosomal acid lipase deficiency (LAL-D). Diagnosis was confirmed by an enzymatic blood (e.g., dried blood spot test) or genetic test.
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with a specialist experienced in the treatment of inborn errors of metabolism, gastroenterologist, or lipidologist
Coverage Duration	12 months
Other Criteria	N/A

Prior Authorization Criteria
Scott and White
Effective: December 1, 2019

KEVEYIS (S)

Products Affected

- Keveyis

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Periodic paralysis (Initial): Diagnosis of one of the following: Primary hyperkalemic periodic paralysis, Primary hypokalemic periodic paralysis, or Paramyotonia Congenita with periodic paralysis.
Age Restrictions	N/A
Prescriber Restrictions	All uses (initial): Prescribed by or in consultation with a neurologist
Coverage Duration	All uses (Initial): 3 months. (Reauth): 12 months
Other Criteria	All uses (Reauth): Documentation of positive clinical response to Keveyis therapy.

Prior Authorization Criteria
 Scott and White
 Effective: December 1, 2019

KEVZARA (S)

Products Affected

- Kevzara

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Rheumatoid Arthritis (RA) (initial): Diagnosis of moderately to severely active RA. One of the following: a) Trial and failure, contraindication, or intolerance (TF/C/I) to both Enbrel (etanercept) and Humira (adalimumab), b) or attestation demonstrating a trial may be inappropriate, OR c) For continuation of prior Kevzara therapy.
Age Restrictions	N/A
Prescriber Restrictions	Initial: Prescribed by or in consultation with a rheumatologist
Coverage Duration	Initial, Reauth: 12 months
Other Criteria	RA (reauth): Documentation of positive clinical response to Kevzara therapy.

KEYTRUDA (S)

Products Affected

- Keytruda

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Melanoma: Diagnosis (dx) of melanoma and disease is unresectable or metastatic. Head and Neck Squamous Cell Carcinoma (HNSCC): Dx of recurrent or metastatic HNSCC AND Disease progression on or after platinum-containing chemotherapy (e.g., cisplatin, carboplatin). Non-Small Cell Lung Cancer (NSCLC): Dx of metastatic NSCLC. One of the following: A) Tumors express high PD-L1 [Tumor Proportion Score (TPS) greater than or equal to 50%] as determined by an FDA-approved test, patient does not have epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) genomic tumor aberrations, and prescribed medication is used as first-line treatment, B) Tumors express PD-L1 [Tumor Proportion Score (TPS) greater than or equal to 1%] as determined by an FDA-approved test, disease progression on or after platinum-containing chemotherapy, AND one of the following: 1) Patient does not have EGFR or ALK genomic tumor aberrations OR 2) both of the following: patient has an EGFR genomic tumor aberration AND disease progression on one anti-EGFR therapy [e.g., Gilotrif (afatinib), Iressa (gefitinib), Tarceva (erlotinib)] OR 3) both of the following: patient has an ALK genomic tumor aberration AND disease progression on one ALK inhibitor [e.g., Alecensa (alectinib), Xalkori (crizotinib), Zykadia (ceritinib)], or C) Both of the following: prescribed medication is being used for first line treatment in patients with nonsquamous NSCLC AND prescribed medication is being used in combination with pemetrexed and carboplatin. Classical Hodgkin Lymphoma (cHL): Dx of cHL AND one of the following: A) disease is refractory or B) disease has relapsed after 3 or more prior lines of therapy.
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with an oncologist.
Coverage Duration	12 months.

Prior Authorization Criteria

Scott and White

Effective: December 1, 2019

Other Criteria	Urothelial Carcinoma: Dx of locally advanced or metastatic urothelial carcinoma AND one of the following: 1) Patient is not eligible for cisplatin-containing chemotherapy, 2) Disease progression during or following platinum-containing chemotherapy, or 3) Disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. Microsatellite Instability-High Cancer (MSI-H): One of the following: 1) Dx of unresectable or metastatic, MSI-H or mismatch repair deficient solid tumors AND disease progression following prior treatment AND patient has no satisfactory alternative treatment options, OR 2) Dx of unresectable or metastatic, MSI-H or mismatch repair deficient colorectal cancer AND patient has experienced progression following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan. Gastric Cancer: Dx of gastric or gastroesophageal junction adenocarcinoma AND recurrent disease that is locally advanced or metastatic AND tumors express PD-L1 (Combined Positive Score [CPS] greater than or equal to 1) as determined by an FDA-approved test AND disease progression on or after two or more prior lines of therapy including fluoropyrimidine- and platinum-containing chemotherapy AND HER2/neu-targeted therapy if the patient is HER2/neu positive. All Indications: Approve for continuation of prior therapy.
-----------------------	--

KINERET (S)

Products Affected

- Kineret

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Rheumatoid Arthritis (RA) (Initial): Diagnosis of moderately to severely active RA. One of the following: Trial and failure, contraindication, or intolerance to both Enbrel (etanercept) and Humira (adalimumab), or attestation demonstrating a trial may be inappropriate, OR for continuation of prior Kineret therapy. Neonatal-Onset Multisystem Inflammatory Disease (NOMID) (initial): Diagnosis of NOMID AND dx of NOMID has been confirmed by one of the following: NLRP-3 (nucleotide-binding domain, leucine rich family [NLR], pyrin domain containing 3) gene (also known as Cold-Induced Auto-inflammatory Syndrome-1 [CIAS1]) mutation OR evidence of active inflammation including both of the following: clinical symptoms (e.g., rash, fever, arthralgia) and elevated acute phase reactants (e.g., erythrocyte sedimentation rate [ESR], C-reactive protein [CRP]).
Age Restrictions	N/A
Prescriber Restrictions	RA (initial): Prescribed by or in consultation with a rheumatologist. NOMID (initial): Prescribed by or in consultation with allergist/immunologist or rheumatologist or pediatrician.
Coverage Duration	All Uses (initial, reauth): 12 months
Other Criteria	All Uses (Reauth): Documentation of positive clinical response to Kineret therapy.

Prior Authorization Criteria
Scott and White
Effective: December 1, 2019

KISQALI (S)

Products Affected

- Kisqali

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Breast cancer: Diagnosis of advanced or metastatic breast cancer. Disease is hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative. One of the following: A) Kisqali is used in combination with an aromatase inhibitor [e.g., Femara (letrozole)] OR B) Used in combination with Faslodex (fulvestrant).
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	12 months
Other Criteria	Approve for continuation of prior therapy

Prior Authorization Criteria
Scott and White
Effective: December 1, 2019

KISQALI-FEMARA PACK (S)

Products Affected

- Kisqali Femara 200 Dose
- Kisqali Femara 400 Dose
- Kisqali Femara 600 Dose

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Breast cancer: Diagnosis of advanced or metastatic breast cancer. Cancer is hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative.
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	12 months
Other Criteria	Approve for continuation of prior therapy.

Prior Authorization Criteria
 Scott and White
 Effective: December 1, 2019

KORLYM (S)

Products Affected

- Korlym

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Cushing's syndrome (Initial): Diagnosis of endogenous Cushing's syndrome (i.e., hypercortisolism is not a result of chronic administration of high dose glucocorticoids). Diagnosis of either type 2 diabetes mellitus or diagnosis of glucose intolerance. Patient has either failed surgery or patient is not a candidate for surgery. Patient is not pregnant.
Age Restrictions	N/A
Prescriber Restrictions	Initial: Prescribed by or in consultation with an endocrinologist.
Coverage Duration	Initial, reauth: 6 months
Other Criteria	Reauth: Documentation of one of the following: patient has improved glucose tolerance while on Korlym therapy or patient has stable glucose tolerance while on Korlym therapy.

Prior Authorization Criteria
 Scott and White
 Effective: December 1, 2019

KRYSTEXXA (S)

Products Affected

- Krystexxa

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	Initial, reauth: Excluded if patient has diagnosis of glucose-6-phosphate dehydrogenase (G6PD) deficiency.
Required Medical Information	Gout (initial): Diagnosis of severe chronic gout. Patient has tried and had an inadequate response (defined as one of the following symptoms of treatment failure gout: a) greater than or equal to 3 flares in previous 18 months, b) greater than or equal to 1 gout tophus or c) gouty arthritis) to two of the following conventional therapies: allopurinol, febuxostat, probenecid or colchicine. Patient will NOT receive concurrent use of oral urate-lowering agents (i.e. Uloric). Patient will receive premedication with antihistamines and corticosteroids.
Age Restrictions	Gout (initial): 18 years of age or older
Prescriber Restrictions	N/A
Coverage Duration	Gout (initial, reauth): 12 months
Other Criteria	Gout (reauth): Serum urate level has decreased since initiating therapy. Clinical improvement in the signs and symptoms of gout (e.g., decrease in tophi size or frequency of gouty flares per year from baseline or improvement in chronic arthropathy or quality of life).

Prior Authorization Criteria
 Scott and White
 Effective: December 1, 2019

KUVAN (S)

Products Affected

- Kuvan

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Phenylketonuria (PKU) (initial): Diagnosis of PKU. Patient will have blood Phe levels measured after 1 week of therapy (new starts to therapy only) and periodically for up to 2 months of therapy to determine response.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	PKU (Init): 2 months (Reauth): 12 months
Other Criteria	PKU (reauth): Patient has had an objective response to therapy, defined as a 30% or greater reduction in phenylalanine (Phe) blood levels from baseline. Patient will continue to have blood Phe levels measured periodically during therapy.

KYNAMRO (S)

Products Affected

- Kynamro

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Homozygous familial hypercholesterolemia (HoFH) (initial): Submission of medical records (eg, chart notes, laboratory values) documenting diagnosis of HoFH as confirmed by one of the following: a) genetic confirmation of 2 mutations in the LDL receptor, ApoB, PCSK9, or LDL receptor adaptor protein 1 (ie, LDLRAP1 or ARH), or b) both of the following: 1) either untreated LDL-C greater than 500 mg/dL or treated LDL-C greater than 300 mg/dL AND 2) either xanthoma before 10 years of age or evidence of heterozygous FH in both parents. Patient is receiving other lipid-lowering therapy. Trial and failure, contraindication, or intolerance to Repatha therapy. Not used in combination with Juxtapid (lomitapide). Not used in combination with a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor.
Age Restrictions	N/A
Prescriber Restrictions	HoFH (initial, reauth): Prescribed by a cardiologist, endocrinologist, or lipid specialist.
Coverage Duration	HoFH (initial): 6 months. (reauth): 12 months
Other Criteria	HoFH (reauthorization): Patient continues to receive other lipid-lowering therapy. Submission of medical records (eg, chart notes, laboratory values) documenting LDL-C reduction while on Kynamro therapy. Not used in combination with Juxtapid (lomitapide). Not used in combination with a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor.

Prior Authorization Criteria
Scott and White
Effective: December 1, 2019

KYPROLIS (S)

Products Affected

- Kyprolis

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Multiple Myeloma (MM): Diagnosis of MM. Disease is relapsed or refractory. Patient has received at least one prior therapy for MM.
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with an oncologist/hematologist
Coverage Duration	12 months
Other Criteria	Approve for continuation of prior therapy.

Prior Authorization Criteria
Scott and White
Effective: December 1, 2019

LARTRUVO (S)

Products Affected

- Lartruvo

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Soft Tissue Sarcoma (STS): Diagnosis of STS. All of the following: A) One of the following: 1) Disease is not amenable to curative treatment with radiotherapy or 2) Disease is not amenable to curative treatment with surgery AND B) Used in combination with doxorubicin for the first 8 cycles of treatment.
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	12 months
Other Criteria	Approve for continuation of prior therapy.

LEMTRADA (S)

Products Affected

- Lemtrada

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Multiple Sclerosis (MS): Diagnosis of a relapsing form of MS (eg, relapsing-remitting MS, secondary-progressive MS with relapses, progressive-relapsing MS with relapses). One of the following: 1) Patient has not been previously treated with alemtuzumab, and failure after a trial of at least 4 weeks, contraindication, or intolerance to one of the following: Ocrevus (daclizumab) or Tysabri (natalizumab), and failure after a trial of at least 4 weeks, contraindication, or intolerance to one of the following disease-modifying therapies for MS: Aubagio (teriflunomide), Avonex (interferon beta-1a), Betaseron (interferon beta-1b), Copaxone/Glatopa (glatiramer acetate), Extavia (interferon beta-1b), Gilenya (fingolimod), Plegridy (peginterferon beta-1a), Rebif (interferon beta-1a), Tecfidera (dimethyl fumarate), or 2) Patient has previously received treatment with alemtuzumab, and at least 12 months have or will have elapsed since the first treatment with alemtuzumab, and patient has not already received the FDA-recommended lifetime limit of two (2) treatment courses of alemtuzumab. Not used in combination with another disease-modifying therapy for MS.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	MS: 12 months, max 2 yrs of therapy.
Other Criteria	N/A

Prior Authorization Criteria
 Scott and White
 Effective: December 1, 2019

LENVIMA (S)

Products Affected

- Lenvima 10 Mg Daily Dose
- Lenvima 12mg Daily Dose
- Lenvima 14 Mg Daily Dose
- Lenvima 18 Mg Daily Dose
- Lenvima 20 Mg Daily Dose
- Lenvima 24 Mg Daily Dose
- Lenvima 4 Mg Daily Dose
- Lenvima 8 Mg Daily Dose

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Differentiated thyroid cancer (DTC): Diagnosis of DTC. Disease is locally recurrent or metastatic. Patient has symptomatic or progressive disease. Disease is refractory to radioactive iodine treatment. Renal Cell Carcinoma (RCC): Diagnosis of advanced RCC. Treatment follows one prior anti-angiogenic therapy. Used in combination with everolimus. Hepatocellular Carcinoma (HCC): Diagnosis of HCC. One of the following: patient has metastatic disease, or patient has extensive liver tumor burden, or patient is inoperable by performance status or comorbidity (local disease or local disease with minimal extrahepatic disease only), or disease is unresectable.
Age Restrictions	N/A
Prescriber Restrictions	DTC/RCC: Prescribed by or in consultation with an oncologist. HCC: Prescribed by or in consultation with one of the following: oncologist, hepatologist, or gastroenterologist.
Coverage Duration	12 months
Other Criteria	Approve for continuation of prior therapy.

Prior Authorization Criteria
 Scott and White
 Effective: December 1, 2019

LETAIRIS (S)

Products Affected

- Ambrisentan

- Letairis

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Pulmonary arterial hypertension (PAH) (Initial): Diagnosis of PAH. PAH is symptomatic. One of the following: A) Diagnosis of PAH was confirmed by right heart catheterization or B) Patient is currently on any therapy for the diagnosis of PAH.
Age Restrictions	N/A
Prescriber Restrictions	PAH (initial): Prescribed by or in consultation with a pulmonologist or cardiologist.
Coverage Duration	PAH (Initial): 6 months. PAH (Reauth): 12 months
Other Criteria	PAH (Reauth): Documentation of positive clinical response to therapy.

Prior Authorization Criteria
 Scott and White
 Effective: December 1, 2019

LEUKINE (S)

Products Affected

- Leukine INJ 250MCG

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	<p>Bone marrow/stem cell transplant (BMSCT): One of the following: 1) patients with non-myeloid malignancies undergoing myeloablative chemotherapy followed by autologous or allogeneic BMT, OR 2) for mobilization of hematopoietic progenitor cells into the peripheral blood for collection by leukapheresis, OR 3) for peripheral stem cell transplant (PSCT) patients who have received myeloablative chemotherapy. Acute myeloid leukemia (AML): patients with AML following induction or consolidation chemotherapy, AND age greater than or equal to 55 years. Primary prophylaxis of chemotherapy-induced febrile neutropenia (CFN): One of the following: 1) patient is receiving chemotherapy regimens associated with a greater than 20% incidence of FN, OR 2) both of the following: a) patient receiving chemotherapy regimen associated with 10-20% incidence of FN, AND b) one or more risk factors associated with chemotherapy-induced infection, FN, or neutropenia. Secondary prophylaxis of FN (SPFN): Both of the following: 1) patients receiving myelosuppressive anticancer drugs associated with neutropenia, AND 2) patients with a history of FN or dose-limiting event during a previous course of chemotherapy. Neutropenia associated with dose-dense chemotherapy (NDDC): One of the following: 1) Patient is receiving National Cancer Institute's Breast Intergroup, INT C9741 dose dense chemotherapy protocol for primary breast cancer, OR 2) patient is receiving a dose-dense chemotherapy regimen for which the incidence of FN is unknown. Treatment of FN (off-label): Both of the following: 1) patients who have received or are receiving myelosuppressive anticancer drugs associated with neutropenia, AND 2) patients with FN at high risk for infection-associated complications. Acute radiation syndrome (ARS): Patient was/will be acutely exposed to myelosuppressive doses of radiation (hematopoietic subsyndrome of ARS).</p>
Age Restrictions	N/A

Prior Authorization Criteria

Scott and White

Effective: December 1, 2019

Prescriber Restrictions	Prescribed by or in consultation with a hematologist/oncologist except HIVN: Prescribed by or in consultation with a hematologist/oncologist or infectious disease specialist
Coverage Duration	BMSCT, AML, CFN, SPFN, NDDC, FN(treatment):3mo or duration of tx. HIVN:6mo. ARS:1 mo.
Other Criteria	HIV-related neutropenia (HIVN)(off-label): Patients infected with HIV, and ANC less than or equal to 1000 (cells/mm ³).

Prior Authorization Criteria
 Scott and White
 Effective: December 1, 2019

LIDOCAINE TOPICAL (S)

Products Affected

- 7t Lido Gel
- Glydo
- Lidocaine OINT
- Lidocaine And Tetracaine Cream
- Lidocaine Hcl EXTERNAL SOLN 4%
- Lidocaine Hcl GEL
- Lidocaine Hcl PRSY
- Lidocaine Hcl Jelly GEL
- Lidocaine/prilocaine CREA
- Lidocaine-prilocaine-cream Base CREA 2.5% ; 2.5%
- Pliaglis

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	N/A

Prior Authorization Criteria
Scott and White
Effective: December 1, 2019

LIDODERM (S)

Products Affected

- Lidocaine PTCH

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Post-herpetic neuralgia: Diagnosis of post-herpetic neuralgia.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	N/A

LONSURF (S)

Products Affected

- Lonsurf

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Colorectal Cancer: Diagnosis of metastatic colorectal cancer AND trial and failure, contraindication, or intolerance to at least one component in the following: fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy (e.g., FOLFOX, FOLFIRI, FOLFOXIRI) AND trial and failure, contraindication, or intolerance to at least one anti-VEGF therapy (e.g., Avastin) AND One of the following: A) patient has KRAS wild-type tumors and trial and failure, contraindication, or intolerance to at least one anti-EGFR therapy (e.g., Vectibix, Erbitux) OR Patient has KRAS mutant tumors. Gastric/Gastroesophageal Junction Adenocarcinoma: Diagnosis of metastatic gastric cancer or diagnosis of metastatic gastroesophageal junction adenocarcinoma. Trial and failure, contraindication or intolerance to at least two of the following: fluopyrimidine-based chemotherapy (e.g. fluorouracil), Platinum-based chemotherapy (e.g., carboplatin, cisplatin, oxaliplatin), Taxane (e.g., docetaxel, paclitaxel) or irinotecan-based chemotherapy, HER2/neu-targeted therapy (e.g., trastuzumab) (if HER2 overexpression).
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	12 months
Other Criteria	Approve for continuation of prior therapy.

Prior Authorization Criteria
 Scott and White
 Effective: December 1, 2019

LORBRENA (S)

Products Affected

- Lorbrena

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Non-small cell lung cancer (NSCLC): Diagnosis of NSCLC. Disease is metastatic and anaplastic lymphoma kinase (ALK)-positive. Metastatic disease has progressed on one of the following: 1) Xalkori (crizotinib) and at least one other ALK inhibitor [e.g., Alunbrig (brigatinib)], 2) Alecensa (alectinib) as the first ALK inhibitor therapy, or 3) Zykadia (ceritinib) as the first ALK inhibitor therapy.
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	12 months
Other Criteria	Approve for continuation of prior therapy.

Prior Authorization Criteria
 Scott and White
 Effective: December 1, 2019

LOTRONEX (S)

Products Affected

- Alosetron Hydrochloride

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Severe Diarrhea-Predominant Irritable Bowel Syndrome (IBS) in Women (initial): All of the following: 1) diagnosis of severe diarrhea-predominant IBS, 2) symptoms for at least 6 months, 3) female patient, AND 4) trial and failure, contraindication, or intolerance to an antidiarrheal agent [eg, loperamide].
Age Restrictions	Initial: 18 years of age or older
Prescriber Restrictions	N/A
Coverage Duration	IBS (initial): 12 weeks. IBS (reauth): 6 mo.
Other Criteria	IBS (reauthorization): Symptoms of IBS continue to persist, AND documentation of positive clinical response to therapy.

Prior Authorization Criteria
Scott and White
Effective: December 1, 2019

LUMIZYME-MYOZYME (S)

Products Affected

- Lumizyme

- Myozyme

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Pompe disease: Diagnosis of Pompe disease [acid alpha-glucosidase (GAA) deficiency].
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	N/A

Prior Authorization Criteria
Scott and White
Effective: December 1, 2019

LUPANETA PACK (S)

Products Affected

- Lupaneta Pack

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Endometriosis (initial): Diagnosis of endometriosis. One of the following: Patient has had surgical ablation to prevent recurrence, or trial and failure, contraindication, or intolerance to one NSAID or one oral contraceptive. Trial and failure, contraindication, or intolerance to Lupron Depot (7.5 mg, 22.5 mg, 30 mg, and 45 mg).
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Endomet (init, reauth): 6 months
Other Criteria	Endometriosis (reauthorization): Patient is experiencing recurrence of symptoms after an initial course of therapy.

Prior Authorization Criteria
 Scott and White
 Effective: December 1, 2019

LUPRON (S)

Products Affected

- Leuprolide Acetate INJ

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Prostate Cancer: Diagnosis of advanced or metastatic prostate cancer. Central Precocious Puberty (CPP) (initial): Diagnosis of CPP (idiopathic or neurogenic). Early onset of secondary sexual characteristics in females less than age 8 or males less than age 9. Advanced bone age of at least one year compared with chronologic age. One of the following: a) patient has undergone gonadotropin-releasing hormone agonist (GnRHa) testing AND Peak luteinizing hormone (LH) level above pre-pubertal range, or b) patient has a random LH level in the pubertal range.
Age Restrictions	N/A
Prescriber Restrictions	CPP (initial, reauth): Prescribed by or in consultation with a pediatric endocrinologist.
Coverage Duration	CPP (initial, reauth), Prostate CA: 12 months
Other Criteria	Approve for continuation of prior therapy.

Prior Authorization Criteria
 Scott and White
 Effective: December 1, 2019

LUPRON DEPOT (S)

Products Affected

- Lupron Depot (1-month)
- Lupron Depot (3-month)
- Lupron Depot (4-month)
- Lupron Depot (6-month)

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Prostate Cancer (7.5 mg, 22.5 mg, 30 mg, 45 mg): Diagnosis of advanced or metastatic prostate cancer. Endometriosis (3.75 mg, 11.25 mg) (initial): Diagnosis of endometriosis. One of the following: Patient has had surgical ablation to prevent recurrence, or trial and failure, contraindication, or intolerance to one NSAID and one oral contraceptive. Uterine Leiomyomata (UL) (3.75 mg, 11.25 mg): a) For use prior to surgery to reduce size of fibroids to facilitate a surgical procedure (eg, myomectomy, hysterectomy) OR b) all of the following: treatment of anemia, anemia is caused by uterine leiomyomata (fibroids), and for use prior to surgery.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Prostate CA: 12 mo. Endomet (init, reauth):6mo. UL (anemia):3 mo (fibroids):4 mo
Other Criteria	Approve for continuation of prior therapy.

Prior Authorization Criteria
 Scott and White
 Effective: December 1, 2019

LUPRON DEPOT PED (S)

Products Affected

- Lupron Depot-ped (1-month)
- Lupron Depot-ped (3-month)

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Central Precocious Puberty (CPP) (initial): Diagnosis of CPP (idiopathic or neurogenic). Early onset of secondary sexual characteristics in females less than age 8 or males less than age 9. Advanced bone age of at least one year compared with chronologic age. One of the following: a) patient has undergone gonadotropin-releasing hormone agonist (GnRHa) testing AND Peak luteinizing hormone (LH) level above pre-pubertal range, or b) patient has a random LH level in the pubertal range.
Age Restrictions	N/A
Prescriber Restrictions	CPP (initial, reauth): Prescribed by or in consultation with a pediatric endocrinologist.
Coverage Duration	CPP (init, reauth): 12 months
Other Criteria	CPP (reauthorization): LH levels have been suppressed to pre-pubertal levels.

Prior Authorization Criteria
Scott and White
Effective: December 1, 2019

LYNPARZA (S)

Products Affected

- Lynparza CAPS

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Ovarian Cancer: Diagnosis of advanced ovarian cancer. Presence of deleterious or suspected deleterious germline BRCA-mutations as detected by an FDA-approved test or at a Clinical Laboratory Improvement Amendments-approved facility. Trial and failure, contraindication, or intolerance to three or more prior lines of chemotherapy (e.g., paclitaxel with cisplatin).
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	12 months
Other Criteria	Approve for continuation of prior therapy.

LYNPARZA TABLET (S)

Products Affected

- Lynparza TABS

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	<p>Ovarian cancer, advanced disease with known or suspected BRCA mutation with 3 or more prior lines of chemotherapy: Diagnosis of advanced ovarian cancer. Presence of deleterious or suspected deleterious germline BRCA-mutations as detected by an FDA-approved test or at a Clinical Laboratory Improvement Amendments-approved facility. Trial and failure, contraindication, or intolerance to three or more prior lines of chemotherapy (e.g., paclitaxel with cisplatin). Maintenance treatment of recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer: Diagnosis of one of the following: recurrent epithelial ovarian cancer, recurrent fallopian tube cancer, or recurrent primary peritoneal cancer. Used for maintenance treatment in patients who are in a complete or partial response to platinum-based chemotherapy (e.g., cisplatin, carboplatin). Breast cancer: Diagnosis of metastatic breast cancer. Presence of a deleterious or suspected deleterious germline BRCA-mutation as detected by an FDA-approved test or at a Clinical Laboratory Improvement Amendments-approved facility. Disease is human epidermal growth factor receptor 2 (HER2)-negative. Patient has been previously treated with chemotherapy (e.g., anthracycline, taxane) in the neoadjuvant, adjuvant, or metastatic setting. One of the following: a) Disease is hormone receptor (HR) negative, or b) Disease is hormone receptor (HR)-positive and one of the following: i) patient has been treated with prior endocrine therapy or ii) patient is considered an inappropriate candidate for endocrine therapy.</p>
Age Restrictions	N/A
Prescriber Restrictions	All uses: Prescribed by or in consultation with an oncologist
Coverage Duration	12 months

Prior Authorization Criteria

Scott and White

Effective: December 1, 2019

Other Criteria	First-line maintenance treatment of BRCA-mutated advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer: Diagnosis of one of the following: advanced epithelial ovarian cancer, advanced fallopian tube cancer, or advanced primary peritoneal cancer. Presence of deleterious or suspected deleterious BRCA-mutation as detected by an FDA-approved test or at a Clinical Laboratory Improvement Amendments-approved facility. Patient has had a complete or partial response to first-line platinum-based chemotherapy (e.g., carboplatin, cisplatin). Lynparza will be used as first-line maintenance treatment. All indications: Approve for continuation of prior therapy.
-----------------------	--

Prior Authorization Criteria
 Scott and White
 Effective: December 1, 2019

MAKENA (S)

Products Affected

- Hydroxyprogesterone Caproate INJ 250MG/ML
- Makena INJ 275MG/1.1ML

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Preterm birth prophylaxis: Patient had a previous singleton (single offspring) spontaneous preterm birth. Patient is having a singleton pregnancy. Therapy will be started between 16 weeks, 0 days and 20 weeks, 6 days of gestation. Therapy will be continued until week 37 (through 36 weeks, 6 days) of gestation or delivery, whichever occurs first.
Age Restrictions	N/A
Prescriber Restrictions	Preterm birth prophylaxis: Prescribed by a specialist in obstetrics and gynecology
Coverage Duration	Preterm birth prophylaxis: 21 weeks
Other Criteria	N/A

Prior Authorization Criteria
 Scott and White
 Effective: December 1, 2019

MARINOL (S)

Products Affected

- Dronabinol

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Nausea and Vomiting Associated with Cancer Chemotherapy (CINV): Patient is receiving cancer chemotherapy. Trial and failure, contraindication, or intolerance to one 5HT-3 receptor antagonist (eg, Anzemet [dolasetron], Kytril [granisetron], or Zofran [ondansetron]). Trial and failure, contraindication, or intolerance to one of the following: Compazine (prochlorperazine), Decadron (dexamethasone), Haldol (haloperidol), Zyprexa (olanzapine). AIDS anorexia: Diagnosis of anorexia with weight loss in patients with AIDS. Patient is on antiretroviral therapy.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	CINV: 6 months. AIDS anorexia: 3 months.
Other Criteria	Subject to Part B vs. Part D review. CINV: Approve for continuation of therapy for treatment covered under Part B when patient is receiving cancer chemotherapy.

Prior Authorization Criteria
 Scott and White
 Effective: December 1, 2019

MAVENCLAD (S)

Products Affected

- Mavenclad

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Multiple Sclerosis (MS): Diagnosis of a relapsing form of MS (e.g., relapsing-remitting MS, secondary-progressive MS with relapses). One of the following: 1) Patient has not been previously treated with cladribine AND Failure after a trial of at least 4 weeks, contraindication, or intolerance to two of the following disease-modifying therapies for MS: Aubagio (teriflunomide), Avonex (interferon beta-1a), Betaseron (interferon beta-1b), Copaxone/Glatopa (glatiramer acetate), Extavia (interferon beta-1b), Gilenya (fingolimod), Lemtrada (alemtuzumab), Mayzent (siponimod), Ocrevus (ocrelizumab), Plegridy (peginterferon beta-1a), Rebif (interferon beta-1a), Tecfidera (dimethyl fumarate), Tysabri (natalizumab), Zinbryta (daclizumab), OR 2) Patient has previously received treatment with cladribine AND Patient has not already received the FDA-recommended lifetime limit of 2 treatment courses (or 4 treatment cycles total) of cladribine. Not used in combination with another disease-modifying therapy for MS.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	MS: 1 month
Other Criteria	N/A

Prior Authorization Criteria
 Scott and White
 Effective: December 1, 2019

MAVYRET (S)

Products Affected

- Mavyret

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Criteria will be applied consistent with current AASLD/IDSA guideline. All patients: Diagnosis of chronic hepatitis C, patient is without decompensated liver disease (defined as Child-Pugh Class B or C), and patient is not receiving Mavyret in combination with another HCV direct acting antiviral agent [e.g., Harvoni, Zepatier].
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with one of the following: Hepatologist, Gastroenterologist, Infectious disease specialist, HIV specialist certified through the American Academy of HIV Medicine.
Coverage Duration	8 to 16 weeks. Criteria will be applied consistent with current AASLD/IDSA guideline.
Other Criteria	N/A

Prior Authorization Criteria
Scott and White
Effective: December 1, 2019

MAYZENT (S)

Products Affected

- Mayzent

- Mayzent Starter Pack

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Multiple Sclerosis (MS): Diagnosis of a relapsing form of MS (eg, relapsing-remitting MS, secondary-progressive MS with relapses).
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	N/A

MEKINIST (S)

Products Affected

- Mekinist

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	<p>Melanoma: Diagnosis of unresectable or metastatic melanoma AND cancer is BRAF V600E or V600K mutant type as detected by an FDA-approved test (THxID-BRAF Kit) or performed at a facility approved by Clinical Laboratory Improvement Amendments (CLIA). Adjuvant Treatment for Melanoma: Diagnosis of melanoma. Cancer is BRAF V600E or V600K mutant type as detected by an FDA-approved test (THxID-BRAF Kit) or performed at a facility approved by Clinical Laboratory Improvement Amendments (CLIA). Involvement of lymph nodes following complete resection. Used as adjunctive therapy. Medication is used in combination with Tafinlar (dabrafenib).</p> <p>Non-small Cell Lung Cancer (NSCLC): All of the following: diagnosis of metastatic non-small cell lung cancer AND cancer is BRAF V600E mutant type as detected by an FDA-approved test (THxID-BRAF Kit) or performed at a facility approved by Clinical Laboratory Improvement Amendments (CLIA) AND medication is used in combination with Tafinlar (dabrafenib).</p> <p>Anaplastic Thyroid Cancer (ATC): Diagnosis of locally advanced or metastatic ATC. Cancer is BRAF V600E mutant type as detected by an FDA-approved test (THxID-BRAF Kit) or performed at a facility approved by Clinical Laboratory Improvement Amendments (CLIA). Cancer may not be treated with standard locoregional treatment options. Medication is used in combination with Tafinlar (dabrafenib).</p>
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with an oncologist.
Coverage Duration	12 months
Other Criteria	Approve for continuation of prior therapy.

Prior Authorization Criteria
Scott and White
Effective: December 1, 2019

MEKTOVI (S)

Products Affected

- Mektovi

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Melanoma: Diagnosis of unresectable melanoma or metastatic melanoma. Cancer is BRAF V600E or V600K mutant type (MT) as detected by an FDA-approved test (THxID-BRAF Kit) or performed at a facility approved by Clinical Laboratory Improvement Amendments (CLIA). Used in combination with Braftovi (encorafenib).
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	12 months
Other Criteria	Approve for continuation of prior therapy

Prior Authorization Criteria
 Scott and White
 Effective: December 1, 2019

METADATE ER-RITALIN SR (S)

Products Affected

- Metadate Er TBCR 20MG
- Methylphenidate Hcl Sr
- Methylphenidate Hydrochloride Er TBCR 10MG, 20MG

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	One of the following: a) diagnosis of attention deficit hyperactivity disorder (ADHD), OR b) diagnosis of attention deficit disorder (ADD), OR c) diagnosis of narcolepsy as confirmed by a sleep study (unless the prescriber provides justification confirming that a sleep study would not be feasible).
Age Restrictions	PA applies to members 19 years of age or older
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	N/A

Prior Authorization Criteria
 Scott and White
 Effective: December 1, 2019

METHOTREXATE INJECTION (S)

Products Affected

- Rasuvo

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	(initial): Both of the following: 1) One of the following diagnoses: a) Severe, active rheumatoid arthritis, OR b) active polyarticular juvenile idiopathic arthritis, OR c) severe psoriasis, AND 2) trial and failure or intolerance to oral methotrexate.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Initial, reauth: 12 months
Other Criteria	(reauth): Documentation of positive clinical response to therapy.

Prior Authorization Criteria
Scott and White
Effective: December 1, 2019

METHYLIN CHEW (S)

Products Affected

- Methylphenidate Hydrochloride CHEW

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	One of the following: a) diagnosis of attention deficit hyperactivity disorder (ADHD), OR b) diagnosis of attention deficit disorder (ADD), OR c) diagnosis of narcolepsy as confirmed by a sleep study (unless the prescriber provides justification confirming that a sleep study would not be feasible).
Age Restrictions	PA applies to members 19 years of age or older
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	N/A

Prior Authorization Criteria
Scott and White
Effective: December 1, 2019

METHYLPHENIDATE (S)

Products Affected

- Methylphenidate Hydrochloride SOLN
- Methylphenidate Hydrochloride TABS

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	One of the following: a) diagnosis of attention deficit hyperactivity disorder (ADHD), OR b) diagnosis of attention deficit disorder (ADD), OR c) diagnosis of narcolepsy as confirmed by a sleep study (unless the prescriber provides justification confirming that a sleep study would not be feasible).
Age Restrictions	PA applies to members 19 years of age or older
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	N/A

Prior Authorization Criteria
 Scott and White
 Effective: December 1, 2019

METHYLPHENIDATE ER (S)

Products Affected

- Methylphenidate Hydrochloride CD
 CPCR 10MG, 20MG, 30MG, 50MG, 60MG
- Methylphenidate Hydrochloride Er
 CP24
- Methylphenidate Hydrochloride Er
 CPCR 20MG, 30MG, 40MG
- Methylphenidate Hydrochloride Er
 TB24
- Methylphenidate Hydrochloride Er
 TBCR 18MG, 27MG, 36MG, 54MG, 72MG
- Methylphenidate Hydrochloride Er (la)
- Relexxii

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	One of the following: a) diagnosis of attention deficit hyperactivity disorder (ADHD), OR b) diagnosis of attention deficit disorder (ADD).
Age Restrictions	PA applies to members 19 years of age or older
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	N/A

Prior Authorization Criteria
Scott and White
Effective: December 1, 2019

METHYLTESTOSTERONE (S)

Products Affected

- Methitest
- Methyltestosterone CAPS

Prior Authorization Criteria
 Scott and White
 Effective: December 1, 2019

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Hypogonadism (HG) (Initial): Diagnosis (dx) of HG AND male patient at birth AND one of the following: 1) Two pre-treatment serum total testosterone (T) levels less than reference range for the lab OR 2) Both of the following: a) Has a condition that may cause altered sex-hormone binding globulin (SHBG) (eg, thyroid disorder, HIV disease, liver disorder, diabetes, obesity), and b) one pre-treatment calculated free or bioavailable T level less than 5 ng/dL (0.17 nmol/L) or less than reference range for the lab, OR 3) History of bilateral orchiectomy, panhypopituitarism, or a genetic disorder known to cause HG (eg, congenital anorchia, Klinefelter's syndrome). Delayed puberty (DP): Dx of DP AND male patient at birth. Breast cancer (BC): Dx of inoperable BC AND used for palliative treatment AND female patient at birth. Gender Identity Disorder or Gender Dysphoria (GID/GD) (off-label): Dx of GID/GD. Patient is a female-to-male transsexual.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	HG(init): (New to T tx:6 mo. Cont T tx:12 mo), (reauth): 12 mo. BC, GID/GD: 12 mo. DP: 6 mo.
Other Criteria	HG (Reauth): 1) Follow-up total serum T level within or below the normal limits of the reporting lab, or 2) Follow-up total serum T level outside of upper limits of normal for the reporting lab and the dose is adjusted, OR 3) Has a condition that may cause altered SHBG (eg, thyroid disorder, HIV disease, liver disorder, diabetes, obesity), and one of the following: Follow-up calculated free or bioavailable T level within or below the normal limits of the reporting lab, or follow-up calculated free or bioavailable T level outside of upper limits of normal for the reporting lab and the dose is adjusted.

Prior Authorization Criteria
Scott and White
Effective: December 1, 2019

MIRVASO (S)

Products Affected

- Mirvaso

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Rosacea (init): Diagnosis of rosacea. Patient has moderate to severe persistent (nontransient) facial erythema.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Rosacea (init, reauth): 12 months
Other Criteria	Rosacea (reauth) Documentation of positive clinical response to Mirvaso therapy.

Prior Authorization Criteria
Scott and White
Effective: December 1, 2019

MOZOBIL (S)

Products Affected

- Mozobil

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Hematopoietic Stem Cell (HSC) Mobilization: Patient with non-Hodgkin's lymphoma (NHL) or multiple myeloma (MM) who will be undergoing autologous HSC transplantation. Used in combination with granulocyte-colony stimulating factor (G-CSF) [e.g., Neupogen (filgrastim), Zarxio (filgrastim)].
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with a hematologist/oncologist
Coverage Duration	One course of therapy up to 4 days
Other Criteria	N/A

Prior Authorization Criteria
 Scott and White
 Effective: December 1, 2019

MS INTEFERONS (S)

Products Affected

- Avonex
- Avonex Pen
- Betaseron
- Extavia
- Plegridy
- Plegridy Starter Pack
- Rebif
- Rebif Rebidose
- Rebif Rebidose Titration Pack
- Rebif Titration Pack

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Multiple Sclerosis (MS): Diagnosis of a relapsing form of MS (eg, relapsing-remitting MS, secondary-progressive MS with relapses, progressive-relapsing MS with relapses).
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	N/A

Prior Authorization Criteria
Scott and White
Effective: December 1, 2019

MULPLETA (S)

Products Affected

- Mulpleta

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Thrombocytopenia Prior to Planned Procedure (TPPP): Diagnosis (dx) of thrombocytopenia. Baseline platelet count is less than 50,000/mcL. Patient has chronic liver disease and is scheduled to undergo a procedure.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	1 month
Other Criteria	N/A

Prior Authorization Criteria
 Scott and White
 Effective: December 1, 2019

MYALEPT (S)

Products Affected

- Myalept

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Lipodystrophy (initial): Diagnosis of congenital or acquired generalized lipodystrophy AND Patient is refractory to current standards of care for lipid and diabetic management AND One or more of the following metabolic abnormalities are present: A) Insulin resistance (defined as requiring more than 200 units per day), B) Hypertriglyceridemia, or C) Diabetes.
Age Restrictions	N/A
Prescriber Restrictions	Initial: Prescribed by or in consultation with an endocrinologist
Coverage Duration	Initial, reauth: 12 months
Other Criteria	Lipodystrophy (reauth): Patient has experienced an objective response to therapy, such as A) Sustained reduction in hemoglobin A1c (HbA1c) level from baseline OR B) Sustained reduction in triglyceride (TG) levels from baseline.

Prior Authorization Criteria
Scott and White
Effective: December 1, 2019

MYLOTARG (S)

Products Affected

- Mylotarg

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Acute myeloid leukemia (AML): One of the following diagnoses: Newly diagnosed AML or relapsed/refractory (R/R) AML. Disease is CD33-positive.
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with a hematologist/oncologist.
Coverage Duration	12 months
Other Criteria	Approve for continuation of prior therapy.

Prior Authorization Criteria
Scott and White
Effective: December 1, 2019

NAGLAZYME (S)

Products Affected

- Naglazyme

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Mucopolysaccharidosis (MPS VI): Diagnosis of MPS VI (Maroteaux-Lamy Syndrome).
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	MPS VI: 12 months
Other Criteria	N/A

Prior Authorization Criteria
 Scott and White
 Effective: December 1, 2019

NATPARA (S)

Products Affected

- Natpara

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Hypocalcemia (Initial): Diagnosis of hypocalcemia due to chronic hypoparathyroidism. NATPARA is not being used in the setting of acute post-surgical hypoparathyroidism. Patient does not have a known calcium-sensing receptor mutation. Patient has a documented parathyroid hormone concentration that is inappropriately low for the level of calcium, recorded on at least two occasions within the previous 12 months. Patient has normal thyroid-stimulating hormone concentrations if not on thyroid hormone replacement therapy (or if on therapy, the dose had to have been stable for greater than or equal to 3 months). Patient has normal magnesium and serum 25-hydroxyvitamin D concentrations. NATPARA will be used as an adjunct treatment.
Age Restrictions	N/A
Prescriber Restrictions	Hypocalcemia (initial): Prescribed by or in consultation with an endocrinologist.
Coverage Duration	Initial: 6 months. Reauth: 12 months
Other Criteria	Hypocalcemia (Reauth): One of the following: A) Patient has achieved and maintained serum calcium levels in the ideal range (7.5 - 10.6 mg/dL), OR B) Patient has experienced a 50% or greater reduction in oral calcium intake, OR C) Patient has experienced a 50% or greater reduction in oral vitamin D intake.

Prior Authorization Criteria
Scott and White
Effective: December 1, 2019

NERLYNX (S)

Products Affected

- Nerlynx

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Breast cancer: Diagnosis (dx) of early stage breast cancer. Disease is human epidermal growth factor receptor 2 (HER2)-positive. Patient has received adjuvant Herceptin (trastuzumab)-based therapy.
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	12 months
Other Criteria	Approve for continuation of prior therapy.

NEULASTA (S)

Products Affected

- Neulasta

- Neulasta Onpro Kit

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	<p>Primary prophylaxis of chemotherapy-induced febrile neutropenia (CFN): One of the following: 1) patient is receiving chemotherapy regimens associated with a greater than 20% incidence of FN, OR 2) both of the following: a) patient receiving chemotherapy regimen associated with 10-20% incidence of FN, AND b) one or more risk factors associated with chemotherapy-induced infection, FN, or neutropenia. Secondary prophylaxis of FN: Both of the following: 1) patients receiving myelosuppressive anticancer drugs associated with neutropenia, AND 2) patients with a history of FN or dose-limiting event during a previous course of chemotherapy. Neutropenia associated with dose-dense chemotherapy (NDDC): One of the following: 1) patient is receiving National Cancer Institute's Breast Intergroup, INT C9741 dose dense chemotherapy protocol for primary breast cancer, OR 2) patient is receiving a dose-dense chemotherapy regimen for which the incidence of FN is unknown. Treatment of FN (off-label): Both of the following: 1) patients who have received or are receiving myelosuppressive anticancer drugs associated with neutropenia, AND 2) patients with FN at high risk for infection-associated complications. Acute radiation syndrome (ARS): Patient was/will be acutely exposed to myelosuppressive doses of radiation (hematopoietic subsyndrome of ARS).</p>
Age Restrictions	N/A
Prescriber Restrictions	All uses: Prescribed by or in consultation with a hematologist/oncologist
Coverage Duration	ARS: 1 mo. CFN, NDDC, FN (prophylaxis, treatment): 3 mo or duration of tx.
Other Criteria	N/A

Prior Authorization Criteria
 Scott and White
 Effective: December 1, 2019

NEXAVAR (S)

Products Affected

- Nexavar

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Renal cell carcinoma (RCC): Diagnosis of RCC. One of the following: Relapsed disease OR both medically/surgically unresectable tumor and dx of Stage IV disease. Hepatocellular carcinoma (HCC): Diagnosis of HCC. One of the following: patient has metastatic disease, or patient has extensive liver tumor burden, or patient is inoperable by performance status or comorbidity (local disease or local disease with minimal extrahepatic disease only), or disease is unresectable. Differentiated thyroid carcinoma (DTC): Diagnosis of DTC (ie, follicular carcinoma, Hurthle cell carcinoma, or papillary carcinoma). One of the following: locally recurrent disease or metastatic disease. One of the following: patient has symptomatic disease or patient has progressive disease. Disease is refractory to radioactive iodine (RAI) treatment. Medullary thyroid carcinoma (MTC): Diagnosis of MTC. One of the following: 1) Disease is progressive or 2) Disease is symptomatic with distant metastases. Trial and failure, contraindication, or intolerance to Caprelsa (vandetanib) or Cometriq (cabozantinib).
Age Restrictions	N/A
Prescriber Restrictions	DTC, MTC: Prescribed by or in consultation with an oncologist. RCC: Prescribed by or in consultation with an oncologist or nephrologist. HCC: Prescribed by or in consultation with an oncologist, hepatologist, or gastroenterologist.
Coverage Duration	12 months
Other Criteria	Approve for continuation of prior therapy.

Prior Authorization Criteria
Scott and White
Effective: December 1, 2019

NINLARO (S)

Products Affected

- Ninlaro

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Multiple myeloma: Diagnosis of multiple myeloma. Used in combination with Revlimid (lenalidomide) and dexamethasone. Patient has received at least one prior therapy for multiple myeloma [eg, Revlimid (lenalidomide), Thalomid (thalidomide), Velcade (bortezomib)].
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with a hematologist/oncologist.
Coverage Duration	12 months
Other Criteria	Approve for continuation of prior therapy.

Prior Authorization Criteria
 Scott and White
 Effective: December 1, 2019

NON-PREFERRED TIRF (S)

Products Affected

- Abstral
- Fentanyl Citrate TABS
- Fentora TABS 100MCG, 200MCG, 400MCG, 600MCG, 800MCG
- Lazanda

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	For the management of breakthrough cancer pain. Patient is currently taking a long-acting opioid around the clock for cancer pain. Patient must have at least a one week history of ONE of the following medications to demonstrate tolerance to opioids: Morphine sulfate at doses of greater than or equal to 60 mg/day, Fentanyl transdermal patch at doses greater than or equal to 25 µg/hr, Oxycodone at a dose of greater than or equal to 30 mg/day, Oral hydromorphone at a dose of greater than or equal to 8 mg/day, Oral oxymorphone at a dose of greater than or equal to 25 mg/day, or an alternative opioid at an equianalgesic dose (e.g., oral methadone greater than or equal to 20 mg/day). Trial and failure or intolerance to generic fentanyl lozenge.
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with one of the following: Pain specialist, Oncologist, Hematologist, Hospice care specialist, or Palliative care specialist.
Coverage Duration	12 months
Other Criteria	N/A

Prior Authorization Criteria
Scott and White
Effective: December 1, 2019

NORTHERA (S)

Products Affected

- Northera

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Neurogenic orthostatic hypotension (NOH) (init): Diagnosis of symptomatic NOH. NOH is caused by one of the following conditions: primary autonomic failure (eg, Parkinson's disease, multiple system atrophy, pure autonomic failure), dopamine beta-hydroxylase deficiency, non-diabetic autonomic neuropathy. Trial and failure, contraindication, or intolerance to one of the following agents: fludrocortisone acetate, midodrine.
Age Restrictions	N/A
Prescriber Restrictions	NOH (init): Prescribed by or in consultation with a cardiologist, neurologist, or nephrologist
Coverage Duration	NOH (init): 1 month (reauth): 12 months
Other Criteria	NOH (reauth): Documentation of positive clinical response to therapy.

Prior Authorization Criteria
 Scott and White
 Effective: December 1, 2019

NOVANTRONE (S)

Products Affected

- Mitoxantrone Hcl INJ 2MG/ML

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Multiple Sclerosis (MS): Diagnosis (dx) of one of the following: secondary progressive MS: gradually worsening disability with or without superimposed relapses, progressive relapsing MS: progression of disability from the onset with superimposed relapses, or worsening relapsing-remitting MS: neurological status remains significantly abnormal in between MS relapses. Trial and failure, contraindication, or intolerance to one of the following disease-modifying therapies for MS: Avonex, Aubagio, Betaseron, Copaxone/Glatopa, Extavia, Gilenya, Lemtrada, Ocrevus, Plegridy, Rebif, Tecfidera, Tysabri, Zinbryta. Left ventricular ejection fraction (LVEF) greater than or equal to 50%. Neutrophil count greater than or equal to 1500 cell/mm ³ . Lifetime cumulative dose less than 140 mg/m ² . Prostate Cancer (PC): Dx of advanced hormone-refractory (castration-resistant) PC. Used in combination with corticosteroids (eg, prednisone, methylprednisolone). LVEF greater than or equal to 50%. Neutrophil count greater than or equal to 1500 cell/mm ³ . Acute Non-Lymphocytic Leukemia (ANLL): Dx of ANLL (eg, myelogenous, promyelocytic, monocytic, and erythroid). Used in combination with other medications used for the treatment of ANLL. LVEF greater than or equal to 50%.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	All Uses: 6 months
Other Criteria	Approve for continuation of prior therapy.

Prior Authorization Criteria
 Scott and White
 Effective: December 1, 2019

NPLATE (S)

Products Affected

- Nplate

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Chronic immune (idiopathic) thrombocytopenic purpura (ITP) (Initial): Diagnosis of relapsed/refractory chronic ITP for greater than 6 months. Baseline platelet count is less than 50,000/mcL. Patient's degree of thrombocytopenia and clinical condition increase the risk of bleeding. Trial and failure, contraindication, or intolerance to one of the following: corticosteroids or immunoglobulins or splenectomy.
Age Restrictions	N/A
Prescriber Restrictions	ITP (initial): Prescribed by or in consultation with a hematologist/oncologist.
Coverage Duration	ITP (initial, reauth): 12 months
Other Criteria	ITP (reauth): Documentation of positive clinical response to Nplate therapy as evidenced by an increase in platelet count to a level sufficient to avoid clinically important bleeding.

Prior Authorization Criteria
 Scott and White
 Effective: December 1, 2019

NUBEQA (S)

Products Affected

- Nubeqa

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Non-metastatic castration-resistant or castration-recurrent prostate cancer (nmCRPC): Diagnosis of non-metastatic castration-resistant (chemical or surgical) or castration-recurrent prostate cancer. One of the following: 1) Used in combination with a gonadotropin-releasing hormone (GnRH) analog OR 2) Patient received bilateral orchiectomy. Trial and failure, contraindication, or intolerance to Xtandi (enzalutamide).
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with an oncologist or urologist
Coverage Duration	12 months
Other Criteria	Approve for continuation of prior therapy.

NUCALA (S)

Products Affected

- Nucala

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Severe asthma (init): Diagnosis of severe asthma. Asthma is an eosinophilic phenotype as defined by one of the following: baseline (pre-treatment) peripheral blood eosinophil level is greater than or equal to 150 cells/microliter or peripheral blood eosinophil levels were greater than or equal to 300 cells/microliter within the past 12 months. Patient has had at least one or more asthma exacerbations requiring systemic corticosteroids within the past 12 months or Patient has had any prior intubation for an asthma exacerbation or Patient has had a prior asthma-related hospitalization within the past 12 months. Patient is currently being treated with both a high-dose inhaled corticosteroid (ICS) [eg, greater than 500 mcg fluticasone propionate equivalent/day] and an additional asthma controller medication [eg, leukotriene receptor antagonist, long-acting beta-2 agonist (LABA), theophylline], OR one maximally-dosed combination ICS/LABA product [eg, Advair (fluticasone propionate/salmeterol), Dulera (mometasone/formoterol), Symbicort (budesonide/formoterol)], unless there is a contraindication or intolerance to these medications. Eosinophilic Granulomatosis with Polyangiitis (EGPA) (init): Diagnosis of EGPA. Patient's disease has relapsed or is refractory to standard of care therapy (i.e., corticosteroid treatment with or without immunosuppressive therapy). Patient is currently receiving corticosteroid therapy (e.g., prednisolone, prednisone).
Age Restrictions	Severe asthma (init): Age greater than or equal to 12 years
Prescriber Restrictions	Severe asthma (init, reauth): Prescribed by or in consultation with a pulmonologist or allergy/immunology specialist. EGPA (init): Prescribed by or in consultation with a pulmonologist, rheumatologist or allergist/immunologist.
Coverage Duration	Severe asthma (init, reauth): 12 months. EGPA (init, reauth): 12 months

Prior Authorization Criteria

Scott and White

Effective: December 1, 2019

Other Criteria	Severe asthma (reauth): Documentation of positive clinical response (eg, reduction in exacerbations). Patient is currently being treated with both an inhaled corticosteroid (ICS) and an additional asthma controller medication [eg, leukotriene receptor antagonist, long-acting beta-2 agonist (LABA), theophylline], OR a combination ICS/LABA product [eg, Advair (fluticasone propionate/salmeterol), Dulera (mometasone/formoterol), Symbicort (budesonide/formoterol)], unless there is a contraindication or intolerance to these medications. EGPA (reauth): Documentation of positive clinical response to therapy (e.g., increase in remission time).
-----------------------	--

Prior Authorization Criteria
Scott and White
Effective: December 1, 2019

NUEDEXTA (S)

Products Affected

- Nuedexta

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Pseudobulbar affect (PBA) (initial): Diagnosis of PBA. (Reauthorization): Documentation of clinical benefit from ongoing therapy with Nuedexta.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	PBA (initial/reauth): 12 months
Other Criteria	N/A

Prior Authorization Criteria
Scott and White
Effective: December 1, 2019

NULOJIX (S)

Products Affected

- Nulojix

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Kidney transplant: The medication is being used for prevention of kidney transplant organ rejection AND The patient is immune to the Epstein-Barr virus (i.e. EBV seropositive) AND The patient is prescribed concurrent therapy with mycophenolate and corticosteroids.
Age Restrictions	Kidney transplant: 18 years of age or older
Prescriber Restrictions	Kidney transplant: Prescriber is experienced in immunosuppressive therapy and management of transplant patients
Coverage Duration	12 months
Other Criteria	Approve for continuation of prior therapy.

Prior Authorization Criteria
Scott and White
Effective: December 1, 2019

NUPLAZID (S)

Products Affected

- Nuplazid

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Parkinson's disease psychosis: Diagnosis of Parkinson's disease. Patient has at least one of the following: hallucinations or delusions.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	Approve for continuation of prior therapy.

NUVIGIL (S)

Products Affected

- Armodafinil

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Obstructive sleep apnea/hypopnea syndrome (OSAHS) (Initial): Diagnosis (dx) of OSAHS defined by one of the following: a) 15 or more obstructive respiratory events per hour of sleep confirmed by a sleep study (unless prescriber provides justification confirming that a sleep study is not feasible), or b) both of the following: 5 or more obstructive respiratory events per hour of sleep confirmed by a sleep study (unless prescriber provides justification confirming that a sleep study is not feasible), AND 1 of the following symptoms: unintentional sleep episodes during wakefulness, daytime sleepiness, unrefreshing sleep, fatigue, insomnia, waking up breath holding/gasping/choking, loud snoring, or breathing interruptions during sleep. Shift-work sleep disorder (SWSD) (Initial):Dx of SWSD confirmed by one of the following: 1) symptoms of excessive sleepiness or insomnia for at least 3 months, which is associated with a work period (usually night work) that occurs during the normal sleep period, OR 2) A sleep study demonstrating loss of a normal sleep-wake pattern (ie, disturbed chronobiologic rhythmicity). No other medical condition or medication accounts for the symptoms. Narcolepsy (initial): Dx of narcolepsy as confirmed by sleep study (unless prescriber provides justification confirming that a sleep study is not feasible).
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	OSAHS, SWSD: Initial, Reauth: 6 mo. Narcolepsy: Initial, Reauth: 12 mo
Other Criteria	OSAHS, Narcolepsy (Reauth): Documentation of positive clinical response to armodafinil therapy. SWSD (Reauth): Documentation of positive clinical response to armodafinil therapy.

Ocaliva (S)

Products Affected

- Ocaliva

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Primary Biliary Cholangitis (PBC) (initial): Diagnosis of PBC (aka primary biliary cirrhosis). One of the following: a) patient has failed to achieve an alkaline phosphatase (ALP) level of less than 1.67 times the upper limit of normal (ULN) after at least 12 consecutive months of treatment with ursodeoxycholic acid (UDCA) (e.g., Urso, Urso Forte, ursodiol) AND used in combination with UDCA, OR b) contraindication or intolerance to UDCA. Patients with moderate to severe hepatic impairment (Child-Pugh class B or C) will be subject to a quantity limit of 5 mg or 10 mg twice weekly (MDD = 0.34).
Age Restrictions	N/A
Prescriber Restrictions	PBC (initial): Prescribed by or in consultation with a hepatologist or gastroenterologist.
Coverage Duration	PBC (initial): 6 months, (reauth): 12 months
Other Criteria	PBC (reauthorization): Submission of medical records (eg, laboratory values) documenting a reduction in ALP level from pre-treatment baseline (ie, prior Ocaliva therapy) while on Ocaliva therapy. Patients with moderate to severe hepatic impairment (Child-Pugh class B or C) will be subject to a quantity limit of 5 mg or 10 mg twice weekly (MDD = 0.34).

OCREVUS (S)

Products Affected

- Ocrevus

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	<p>Relapsing forms of multiple sclerosis (initial): Diagnosis of a relapsing form of multiple sclerosis (MS) (e.g., relapsing-remitting MS, secondary-progressive MS with relapses, progressive-relapsing MS with relapses). One of the following: a) Failure after a trial of at least 4 weeks, contraindication, or intolerance to two of the following: Aubagio (teriflunomide), Avonex (interferon beta-1a), Betaseron (interferon beta-1b), Copaxone/Glatopa (glatiramer acetate), Extavia (interferon beta-1b), Gilenya (fingolimod), Plegridy (peginterferon beta-1a), Rebif (interferon beta-1a), Tecfidera (dimethyl fumarate), OR b) Patient is not a candidate for any of the drugs listed as prerequisites due to the severity of their multiple sclerosis, OR c) For continuation of prior Ocrevus therapy.</p> <p>Primary progressive MS (initial): Diagnosis of primary progressive multiple sclerosis (PPMS). All indications (initial): Not used in combination with another disease-modifying therapy for MS. Not used in combination with another B-cell targeted therapy (e.g., rituximab [Rituxan], belimumab [Benlysta], ofatumumab [Arzerra]). Not used in combination with another lymphocyte trafficking blocker (e.g., alemtuzumab [Lemtrada], mitoxantrone). Hepatitis B virus (HBV) screening has been performed.</p>
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	All uses (initial, reauth): 12 months

Prior Authorization Criteria

Scott and White

Effective: December 1, 2019

Other Criteria	All indications (reauth): Documentation of positive clinical response to Ocrevus therapy. Not used in combination with another disease-modifying therapy for MS. Not used in combination with another B-cell targeted therapy (e.g., rituximab [Rituxan], belimumab [Benlysta], ofatumumab [Arzerra]). Not used in combination with another lymphocyte trafficking blocker (e.g., alemtuzumab [Lemtrada], mitoxantrone).
-----------------------	--

Prior Authorization Criteria
Scott and White
Effective: December 1, 2019

ODOMZO (S)

Products Affected

- Odomzo

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Basal cell carcinoma: Diagnosis of locally advanced basal cell carcinoma AND One of the following: 1) Cancer has recurred following surgery or radiation therapy or 2) Patient is not a candidate for surgery or radiation therapy.
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with an oncologist or dermatologist
Coverage Duration	12 months
Other Criteria	Approve for continuation of prior therapy.

Prior Authorization Criteria
 Scott and White
 Effective: December 1, 2019

OFEV (S)

Products Affected

- Ofev

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Idiopathic pulmonary fibrosis (IPF) (initial): Both of the following: 1) diagnosis of IPF as documented by all of the following: a) exclusion of other known causes of interstitial lung disease (ILD) (eg, domestic and occupational environmental exposures, connective tissue disease, drug toxicity) AND b) one of the following: i) in patients not subjected to surgical lung biopsy, the presence of a usual interstitial pneumonia (UIP) pattern on high-resolution computed tomography (HRCT) revealing IPF or probable IPF, OR ii) in patients subjected to a lung biopsy, both HRCT and surgical lung biopsy pattern revealing IPF or probable IPF, AND 2) not used in combination with Esbriet (pirfenidone).
Age Restrictions	N/A
Prescriber Restrictions	IPF (initial): Prescribed by a pulmonologist
Coverage Duration	Initial, reauth: 12 months
Other Criteria	IPF (reauth): Documentation of positive clinical response to Ofev therapy.

Prior Authorization Criteria
 Scott and White
 Effective: December 1, 2019

OLUMIANT (S)

Products Affected

- Olumiant TABS 2MG

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Rheumatoid arthritis (RA) (Initial): Diagnosis of moderately to severely active RA. One of the following: Trial and failure, contraindication, or intolerance to both Enbrel (etanercept) and Humira (adalimumab), or attestation demonstrating a trial may be inappropriate, OR patient has a documented needle-phobia to the degree that the patient has previously refused any injectable therapy or medical procedure (refer to DSM-IV-TR F40.2 for specific phobia diagnostic criteria), OR for continuation of prior Olumiant therapy. Patient is not receiving Olumiant in combination with a potent immunosuppressant (e.g., azathioprine, cyclosporine).
Age Restrictions	N/A
Prescriber Restrictions	Initial: Prescribed by or in consultation with a rheumatologist.
Coverage Duration	Initial, reauth: 12 months
Other Criteria	Reauth: Documentation of positive clinical response to Olumiant therapy. Patient is not receiving Olumiant in combination with a potent immunosuppressant (e.g., azathioprine, cyclosporine).

OLYSIO (S)

Products Affected

- Olysio

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Criteria will be applied consistent with current AASLD/IDSA guideline. Both of the following: A) Diagnosis of chronic hepatitis C AND B) Patient is without decompensated liver disease (defined as Child-Pugh Class B or C). For Olysio plus peginterferon and ribavirin: One of the following: 1) Diagnosis of genotype 1a infection AND patient does not have the NS3 Q80K polymorphism OR 2) Diagnosis of genotype 1b infection OR 3) Diagnosis of genotype 4 infection. One of the following: 1) Trial and failure, intolerance or contraindication to both of the following: a) Harvoni OR Epclusa and b) Mavyret, or 2) for continuation of prior Olysio therapy. All Olysio plus Sovaldi therapy: One of the following: 1) Trial and failure, intolerance, or contraindication to both of the following: a) Harvoni OR Epclusa and b) Mavyret, 2) Both of the following: Trial and failure of a NS5A containing regimen (e.g., Harvoni, Epclusa, Zepatier) and patient has NS5A inhibitor resistant-associated variants detected using commercially available assays, or 3) for continuation of prior Olysio therapy.
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with one of the following: Hepatologist, Gastroenterologist, Infectious disease specialist, HIV specialist certified through the American Academy of HIV Medicine.
Coverage Duration	12 to 24 weeks. Criteria will be applied consistent with current AASLD/IDSA guideline.
Other Criteria	N/A

Prior Authorization Criteria
Scott and White
Effective: December 1, 2019

ONMEL (S)

Products Affected

- Onmel

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	All of the following: 1) Diagnosis of onychomycosis of the toenail as confirmed by one of the following: a) positive potassium hydroxide (KOH) preparation, OR b) culture, OR c) histology, AND 2) patient has had a trial and inadequate response, intolerance or hypersensitivity to oral terbinafine.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	3 months
Other Criteria	N/A

OPDIVO (S)

Products Affected

- Opdivo

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Melanoma: Diagnosis (dx) of melanoma and one of the following: disease is unresectable, metastatic, or Opdivo will be used in the adjuvant setting following complete resection of Stage IIIB/C (lymph node involvement) or Stage IV (metastatic) disease. Non-Small Cell Lung Cancer (NSCLC): Dx of NSCLC, disease is metastatic, disease progression on or after platinum-based chemotherapy (eg, cisplatin, carboplatin), and one of the following: 1) pt does not have epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) genomic tumor aberrations OR 2) pt has EGFR genomic tumor aberrations AND disease progression on one anti-EGFR therapy [e.g., Gilotrif (afatinib), Iressa (gefitinib), Tarceva (erlotinib)] OR 3) pt has an ALK genomic tumor aberration AND disease progression on one ALK inhibitor [eg Alecensa (alectinib), Xalkori (crizotinib), Zykadia (ceritinib)]. Renal cell carcinoma (RCC): Dx of RCC. Disease is advanced, pt has received prior anti-angiogenic therapy [eg Sutent (sunitinib), Nexavar (sorafenib)]. Classical Hodgkin Lymphoma (cHL): Dx of cHL. One of the following: A) Patient has had relapse or progression after autologous hematopoietic stem cell transplantation (HSCT) and Adcetris (brentuximab vedotin) OR B) Patient has had relapse or progression after three or more lines of systemic therapy that includes autologous HSCT. Head and Neck Squamous Cell Carcinoma (HNSCC): Dx of recurrent or metastatic HNSCC. Patient has disease progression on or after platinum-based therapy (eg, cisplatin, carboplatin). Urothelial Carcinoma: Dx of urothelial carcinoma. Disease is locally advanced or metastatic. One of the following: Patient has disease progression during or following platinum-containing chemotherapy OR Patient has disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.
Age Restrictions	Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Metastatic Colorectal Cancer: Patient is 12 years of age or older.

Prior Authorization Criteria

Scott and White

Effective: December 1, 2019

Prescriber Restrictions	Prescribed by or in consultation with an oncologist.
Coverage Duration	12 months
Other Criteria	Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Metastatic Colorectal Cancer: Dx of MSI-H or dMMR metastatic colorectal cancer (CRC). Patient has experienced progression following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan. Hepatocellular Carcinoma (HCC): Dx of HCC AND previously treated with Nexavar (sorafenib). All indications: Approve for continuation of prior therapy.

Prior Authorization Criteria
Scott and White
Effective: December 1, 2019

OPSUMIT (S)

Products Affected

- Opsumit

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Pulmonary arterial hypertension (PAH) (Initial): Diagnosis of PAH. PAH is symptomatic. One of the following: A) Diagnosis of PAH was confirmed by right heart catheterization or B) Patient is currently on any therapy for the diagnosis of PAH.
Age Restrictions	N/A
Prescriber Restrictions	PAH (initial): Prescribed by or in consultation with a pulmonologist or cardiologist.
Coverage Duration	PAH: Initial: 6 months. Reauth: 12 months.
Other Criteria	PAH (Reauth): Documentation of positive clinical response to therapy.

Prior Authorization Criteria
 Scott and White
 Effective: December 1, 2019

ORENCIA IV (S)

Products Affected

- Orenzia INJ 250MG

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Rheumatoid Arthritis (RA) (Initial): Diagnosis of moderately to severely active RA. Juvenile Idiopathic Arthritis (JIA) (Initial): Diagnosis of moderately to severely active polyarticular JIA. Psoriatic Arthritis (PsA) (Initial): Diagnosis of active PsA. All indications (Initial): One of the following: Trial and failure, contraindication, or intolerance to both Enbrel (etanercept) and Humira (adalimumab), or attestation demonstrating a trial may be inappropriate, OR for continuation of prior Orenzia therapy. All indications (Initial, reauth): Patient is not receiving Orenzia in combination with a biologic DMARD [eg, Enbrel (etanercept), Humira (adalimumab), Cimzia (certolizumab), Simponi (golimumab)].
Age Restrictions	N/A
Prescriber Restrictions	RA, JIA (initial): Prescribed by or in consultation with a rheumatologist. PsA (initial): Prescribed by or in consultation with a dermatologist or rheumatologist.
Coverage Duration	All uses (initial, reauth): 12 months
Other Criteria	All indications (Reauth): Documentation of positive clinical response to Orenzia therapy.

Prior Authorization Criteria
 Scott and White
 Effective: December 1, 2019

ORENCIA SC (S)

Products Affected

- Orencia INJ 125MG/ML, 50MG/0.4ML, 87.5MG/0.7ML

- Orencia Clickject

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Rheumatoid Arthritis (RA) (Initial): Diagnosis of moderately to severely active RA. Juvenile Idiopathic Arthritis (JIA) (Initial): Diagnosis of moderately to severely active polyarticular JIA. Psoriatic Arthritis (PsA) (Initial): Diagnosis of active PsA. All indications (Initial): One of the following: Trial and failure, contraindication, or intolerance to both Enbrel (etanercept) and Humira (adalimumab), or attestation demonstrating a trial may be inappropriate, OR for continuation of prior Orencia therapy.
Age Restrictions	N/A
Prescriber Restrictions	RA, JIA (initial): Prescribed by or in consultation with a rheumatologist. PsA (initial): Prescribed by or in consultation with a dermatologist or rheumatologist.
Coverage Duration	All uses (initial, reauth): 12 months
Other Criteria	All indications (Reauth): Documentation of positive clinical response to Orencia therapy.

Prior Authorization Criteria
 Scott and White
 Effective: December 1, 2019

ORENITRAM (S)

Products Affected

- Orenitram

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Pulmonary arterial hypertension (PAH) (Initial): Diagnosis of PAH. PAH is symptomatic. One of the following: A) Diagnosis of PAH was confirmed by right heart catheterization or B) Patient is currently on any therapy for the diagnosis of PAH.
Age Restrictions	N/A
Prescriber Restrictions	PAH (initial): Prescribed by or in consultation with a pulmonologist or cardiologist.
Coverage Duration	PAH: Initial: 6 months. Reauth: 12 months.
Other Criteria	PAH (Reauth): Documentation of positive clinical response to therapy.

ORILISSA (S)

Products Affected

- Orilissa

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Endometriosis (EM) (initial - 150 mg): Diagnosis of moderate to severe pain associated with EM. One of the following: 1) History of inadequate pain control response following a trial of at least 3 months, or history of intolerance or contraindication to one of the following: danazol, combination (estrogen/progesterone) oral contraceptive, or progestins, or 2) Patient has had surgical ablation to prevent recurrence. EM (200 mg): Diagnosis of moderate to severe pain associated with EM. One of the following: 1) History of inadequate pain control response following a trial of at least 3 months, or history of intolerance or contraindication to one of the following: danazol, combination (estrogen/progesterone) oral contraceptive, or progestins, or 2) Patient has had surgical ablation to prevent recurrence.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	EM (init, reauth-150mg): 6 mo. EM (200mg): 6 mo.
Other Criteria	EM (reauthorization - 150 mg): Patient has improvement in pain associated with endometriosis (e.g., improvement in dysmenorrhea and nonmenstrual pelvic pain). Treatment duration of Orilissa has not exceeded a total of 24 months.

Prior Authorization Criteria
 Scott and White
 Effective: December 1, 2019

ORKAMBI (S)

Products Affected

- Orkambi TABS

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Cystic Fibrosis (CF) (Initial): Diagnosis of CF. Patient is homozygous for the F508del mutation in the CF transmembrane conductance regulator (CFTR) gene as detected by an FDA-cleared cystic fibrosis mutation test or at a Clinical Laboratory Improvement Amendments-approved facility.
Age Restrictions	CF (Initial): Patient is 6 years of age or older
Prescriber Restrictions	CF (initial): Prescribed by or in consultation with a specialist affiliated with a CF care center or pulmonologist
Coverage Duration	CF (initial, reauth): 12 months
Other Criteria	CF (Reauth): Patient is benefiting from treatment (i.e. improvement in lung function [forced expiratory volume in one second (FEV1)], decreased number of pulmonary exacerbations).

Prior Authorization Criteria
Scott and White
Effective: December 1, 2019

ORKAMBI GRANULES (S)

Products Affected

- Orkambi PACK

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Cystic Fibrosis (CF) (Initial): Diagnosis of CF. Patient is homozygous for the F508del mutation in the CF transmembrane conductance regulator (CFTR) gene as detected by an FDA-cleared cystic fibrosis mutation test or at a Clinical Laboratory Improvement Amendments-approved facility. One of the following: A) Patient is 2 through 5 years of age, OR B) Both of the following: Patient is 6 years of age or greater AND Patient is unable to swallow oral tablets.
Age Restrictions	N/A
Prescriber Restrictions	CF (Initial): Prescribed by or in consultation with a specialist affiliated with a CF care center or pulmonologist
Coverage Duration	CF (initial, reauth): 12 months
Other Criteria	CF (Reauth): Patient is benefiting from treatment (i.e., improvement in lung function [forced expiratory volume in one second (FEV1)], decreased number of pulmonary exacerbations). One of the following: A) Patient is 2 through 5 years of age, OR B) Both of the following: Patient is 6 years of age or greater AND Patient is unable to swallow oral tablets.

Prior Authorization Criteria
Scott and White
Effective: December 1, 2019

OSPHENA (S)

Products Affected

- Osphena

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Dyspareunia (initial): Diagnosis of moderate to severe dyspareunia due to vulvar and vaginal atrophy associated with menopause. Vaginal dryness (initial): Diagnosis of moderate to severe vaginal dryness due to vulvar and vaginal atrophy associated with menopause.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	All uses (Initial, reauth): 12 months
Other Criteria	Dyspareunia, Vaginal dryness (reauth): Documentation of positive clinical response to therapy.

Prior Authorization Criteria
 Scott and White
 Effective: December 1, 2019

OTEZLA (S)

Products Affected

- Otezla

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Psoriatic arthritis (PsA, initial): Diagnosis of active PsA. Plaque psoriasis (Initial): Diagnosis of moderate to severe plaque psoriasis. PsA, plaque psoriasis (initial): Trial and failure, contraindication, or intolerance to both Humira and Enbrel, or attestation demonstrating a trial may be inappropriate, OR for continuation of prior Otezla therapy. Oral ulcers associated with Behcet's Disease (Initial): Diagnosis of Behcet's Disease. Patient has active oral ulcers.
Age Restrictions	N/A
Prescriber Restrictions	PsA (init): Prescribed by or in consultation with a dermatologist or rheumatologist. Plaque psoriasis (init): Prescribed by or in consultation with a dermatologist.
Coverage Duration	Initial, Reauth: 12 months
Other Criteria	Reauth (PsA, plaque psoriasis): Documentation of positive clinical response to Otezla therapy. Reauth (oral ulcers associated with Behcet's Disease): Documentation of positive clinical response to Otezla therapy (eg, reduction in pain from oral ulcers or reduction in number of oral ulcers).

Prior Authorization Criteria
 Scott and White
 Effective: December 1, 2019

OXANDRIN (S)

Products Affected

- Oxandrolone TABS

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Promote weight gain (initial): Medication will be used as an adjunct therapy to promote weight gain AND One of the following: Extensive surgery, Chronic infections, Severe trauma, Failure to gain or maintain at least 90% of ideal body weight without definite pathophysiologic reasons AND a nutritional consult was performed. Counterbalance protein catabolism (initial): Oxandrin will be used to counterbalance protein catabolism associated with chronic corticosteroid administration. Bone pain (initial): Diagnosis of bone pain associated with osteoporosis.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	bone pain (initial, reauth): 1 month. Others (initial, reauth): 3 months
Other Criteria	All diagnoses (reauth): patient has experienced an objective improvement (i.e. weight gain, increase in lead body mass, or reduction in muscle pain/weakness).

Prior Authorization Criteria
Scott and White
Effective: December 1, 2019

OXERVATE (S)

Products Affected

- Oxervate

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Neurotrophic keratitis (NK): Diagnosis of NK.
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with an ophthalmologist or optometrist.
Coverage Duration	8 weeks.
Other Criteria	N/A

Prior Authorization Criteria
Scott and White
Effective: December 1, 2019

PEGASYS (S)

Products Affected

- Pegasys

- Pegasys Proclick

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Chronic hepatitis B: Diagnosis of chronic hepatitis B infection, and patient is without decompensated liver disease. Chronic Hepatitis C: Criteria will be applied consistent with current AASLD-IDSA guidance.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	HepB: 48 wks. HepC: Initial: 28 wks. Reauth: 20 wks.
Other Criteria	N/A

Prior Authorization Criteria
 Scott and White
 Effective: December 1, 2019

PEG-INTRON (S)

Products Affected

- Pegintron
- Peg-intron INJ 120MCG/0.5ML, 150MCG/0.5ML, 80MCG/0.5ML
- Peg-intron Redipen
- Peg-intron Redipen Pak 4 INJ 120MCG/0.5ML

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Chronic Hepatitis C:Criteria will be applied consistent with current AASLD-IDSA guidance.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	HepC: Initial: 28 wks. Reauth: 20 wks.
Other Criteria	HepC (reauth): patient has an undetectable HCV RNA at week 24, additional treatment weeks of peginterferon are required to complete treatment regimen, and patient has not exceeded 48 wks of therapy with peginterferon.

Prior Authorization Criteria
 Scott and White
 Effective: December 1, 2019

PENNSAID (S)

Products Affected

- Diclofenac Sodium TRANSDERMAL SOLN 1.5%

- Pennsaid SOLN 2%

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Osteoarthritis of the knees (initial): Diagnosis of osteoarthritis of the knees. Patient meets one of the following: 1) Treatment failure with at least two prescription strength oral non-steroidal anti-inflammatory drugs (NSAIDs) OR 2) Documented swallowing disorder OR 3) History of peptic ulcer disease/gastrointestinal bleed OR 4) Patient is older than 65 years of age with one additional risk factor for gastrointestinal adverse events (e.g. use of anticoagulants, chronic corticosteroids).
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Initial, reauth: 12 months
Other Criteria	Osteoarthritis of the knees (reauth): Patient has experienced a response to therapy (e.g., improvement in pain symptoms of osteoarthritis).

PERJETA (S)

Products Affected

- Perjeta

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Metastatic breast cancer: Diagnosis of human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer. One of the following: a) patient has not received prior anti-HER2 therapy or chemotherapy for metastatic disease AND used in combination with Herceptin (trastuzumab) and a taxane (eg, docetaxel, paclitaxel), OR b) patient was previously treated with chemotherapy and Herceptin (trastuzumab) without Perjeta AND used in combination with Herceptin (trastuzumab). Non-metastatic breast cancer: One of the following diagnoses: HER2-positive early stage breast cancer, HER2-positive locally advanced breast cancer, or HER2-positive inflammatory breast cancer. Used in combination with both Herceptin (trastuzumab) and chemotherapy. Early Breast Cancer Adjuvant Treatment: Diagnosis of HER2-positive early breast cancer. Patient is at high risk of recurrence. Used in combination with both of the following: Herceptin (trastuzumab) and chemotherapy.
Age Restrictions	N/A
Prescriber Restrictions	All uses: Prescribed by or in consultation with an oncologist.
Coverage Duration	12 months
Other Criteria	Approve for continuation of prior therapy.

Prior Authorization Criteria
 Scott and White
 Effective: December 1, 2019

PIQRAY (S)

Products Affected

- Piqray 200mg Daily Dose
- Piqray 250mg Daily Dose
- Piqray 300mg Daily Dose

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Breast Cancer (BC): Diagnosis of advanced or metastatic BC. Disease is hormone receptor (HR)-positive, and human epidermal growth factor receptor 2 (HER2)-negative. Cancer is PIK3CA-mutated as detected by an FDA-approved test (therascreen PIK3CA RGQ PCR Kit) or a test performed at a facility approved by Clinical Laboratory Improvement Amendments (CLIA). Patient is a postmenopausal woman or male. Used in combination with fulvestrant. Disease has progressed on or after an endocrine-based regimen.
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with an oncologist.
Coverage Duration	12 months
Other Criteria	Approve for continuation of prior therapy.

Prior Authorization Criteria
 Scott and White
 Effective: December 1, 2019

POMALYST (S)

Products Affected

- Pomalyst

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Multiple Myeloma (MM): Diagnosis of MM. Used in combination with dexamethasone. Patient has received two prior therapies, including Revlimid (lenalidomide) and a proteasome inhibitor [eg, Velcade (bortezomib) or Kyprolis (carfilzomib)] or has a contraindication or intolerance to Revlimid and proteasome inhibitors. Patient has experienced disease progression on or within 60 days of completion of last therapy.
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with an oncologist/hematologist
Coverage Duration	12 months
Other Criteria	Approve for continuation of prior therapy.

Prior Authorization Criteria
Scott and White
Effective: December 1, 2019

PORTRAZZA (S)

Products Affected

- Portrazza

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Non-small cell lung cancer (NSCLC): All of the following: A) Diagnosis of metastatic squamous NSCLC AND B) Portrazza will be used in combination with gemcitabine and cisplatin AND C) Portrazza will be used as first-line treatment.
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	12 months
Other Criteria	Approve for continuation of prior therapy.

PRALUENT (S)

Products Affected

- Praluent

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	<p>Initial: One of the following diagnoses: A) HeFH as confirmed by one of the following: (1) Both of the following: a) Untreated/pre-treatment LDL-C greater than 190 mg/dL in an adult, AND b) One of the following: i) Family history (hx) of tendinous xanthomas and/or arcus cornealis in 1st degree relative, or 2nd degree relative, ii) Hx of myocardial infarction (MI) in 1st-degree relative less than 60 years of age, iii) Family hx of MI in 2nd-degree relative less than 50 years of age, iv) Family hx of LDL-C greater than 190 mg/dL in 1st- or 2nd-degree relative, v) Family hx of FH in 1st- or 2nd-degree relative, or (2) Untreated/pre-treatment LDL-C greater than 190 mg/dL in an adult AND submission of MR (e.g., chart notes, laboratory values) documenting one of the following: presence of tendinous xanthoma in pt, arcus cornealis before age 45, or functional mutation in the LDL receptor, ApoB, or PCSK9 gene. OR B) Atherosclerotic cardiovascular disease (ASCVD) as confirmed by acute coronary syndromes, history of MI, stable or unstable angina, coronary or other arterial revascularization, stroke, transient ischemic attack, or peripheral arterial disease presumed to be of atherosclerotic origin. One of the following: set A) Both of the following: a) One of the following LDL-C values while on max tolerated lipid lowering regimen within the last 120 days: (1) LDL-C greater than or equal to 100 mg/dL with ASCVD, or (2) LDL-C greater than or equal to 130 mg/dL without ASCVD. AND b) One of the following: (1) Pt has been receiving at least 12 consecutive weeks of one high-intensity (HI) statin therapy (tx) and will continue to receive a HI statin [ie, atorvastatin 40-80 mg, Crestor (rosuvastatin) 20-40 mg] at max tolerated dose, OR (2) Both of the following: A) Pt unable to tolerate HI statin as evidenced by intolerable and persistent (ie, more than 2 wks) myalgia (muscle symptoms w/o CK elevations) or myositis (muscle symptoms w/ CK elevations less than 10 times ULN)</p>
Age Restrictions	N/A
Prescriber Restrictions	Initial/Reauth: Prescribed by or in consultation with a cardiologist, endocrinologist, or lipid specialist

Prior Authorization Criteria
 Scott and White
 Effective: December 1, 2019

Coverage Duration	Initial: 6 months. Reauth: 12 months
Other Criteria	<p>Set A (continued, initial): AND B) One of the following: a) Pt has been receiving at least 12 consecutive weeks of one moderate-intensity or low-intensity statin tx and will continue to receive a MODERATE-INTENSITY or LOW-INTENSITY statin [ie, atorvastatin 10-20 mg, Crestor (rosuvastatin) 5-10 mg, simvastatin 10-40 mg, pravastatin 10-80 mg, lovastatin 20-40 mg, Lescol XL (fluvastatin XL) 80 mg, fluvastatin 20-40 mg, or Livalo (pitavastatin) 1-4 mg] at max tolerated dose, OR b) Pt is unable to tolerate moderate-intensity or low-intensity statin as evidenced by intolerable and persistent (ie, more than 2 weeks) myalgia (muscle symptoms without CK elevations) or myositis (muscle symptoms with CK elevations less than 10 times ULN), OR (3) Submission of MR documenting pt has a labeled contraindication to all statins, OR (4) Pt has experienced rhabdomyolysis or muscle symptoms with statin treatment with CK elevations greater than 10 times ULN on one statin tx. OR set B) Both of the following: a) One of the following LDL-C values while on maximally tolerated lipid lowering regimen within the last 120 days: (1) LDL-C b/t 70 and 99 mg/dL with ASCVD. (2) LDL-C b/t 100 and 129 mg/dL without ASCVD. AND b) Both of the following: (1) One of the following: i) Pt has been receiving at least 12 consecutive weeks of one maximally-tolerated statin tx and will continue to receive a statin at maximally tolerated dose, ii) pt is unable to tolerate statin tx as evidenced by intolerable and persistent (ie, more than 2 wks) myalgia (muscle symptoms without CK elevations) or myositis (muscle symptoms with CK elevations less than 10 times ULN, iii) Submission of MR documenting patient has a labeled contraindication to all statins, or iv) Pt has experienced rhabdomyolysis or muscle symptoms with statin tx with CK elevations greater than 10 times ULN on one statin tx and (2) Pt has been receiving at least 12 consecutive weeks of ezetimibe (Zetia) tx as adjunct to maximally tolerated statin tx OR Pt has a history of contraindication or intolerance to ezetimibe. Reauth: Pt continues to receive other lipid-lowering tx (eg statins, ezetimibe) at the maximally tolerated dose (unless pt has documented inability to take these medications). Submission of MR (eg, lab values) documenting LDL-C reduction while on Praluent therapy. All indications (initial/reauth): Prescriber attests to the following: the information provided is true and accurate to the best of their knowledge and they understand that OptumRx may perform a routine audit and request the medical information necessary to verify the accuracy of the information provided.</p>

Prior Authorization Criteria
Scott and White
Effective: December 1, 2019

PROCYSBI (S)

Products Affected

- Procysbi

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Nephropathic cystinosis: Diagnosis of nephropathic cystinosis, confirmed by elevated leukocyte cystine levels (LCL) or genetic analysis of the CTNS gene AND Trial and failure or intolerance to therapy with Cystagon (immediate-release cysteamine bitartrate).
Age Restrictions	1 year of age or older
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	N/A

PROMACTA (S)

Products Affected

- Promacta

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	<p>Chronic immune (idiopathic) thrombocytopenic purpura (ITP) (initial): Diagnosis of one of the following: relapsed/refractory ITP or chronic ITP. Baseline platelet count is less than 50,000/mcL. Patient's degree of thrombocytopenia and clinical condition increase the risk of bleeding. Trial and failure, intolerance, contraindication to corticosteroids or immunoglobulins or splenectomy. Chronic hepatitis C (initial): Diagnosis of chronic hepatitis C-associated thrombocytopenia. One of the following: 1) Planning to initiate and maintain interferon-based treatment, or 2) currently receiving interferon-based treatment. First-line for severe aplastic anemia (SAA): Diagnosis of SAA. Used for first-line treatment (i.e., patient has not received prior immunosuppressive therapy with any equine antithymocyte globulin plus cyclosporine, alemtuzumab, or high dose cyclophosphamide). Used in combination with standard immunosuppressive therapy (e.g., Atgam [antithymocyte globulin equine] and cyclosporine). Patient meets at least two of the following: 1) absolute neutrophil count less than 500/mcL, 2) platelet count less than 20,000/mcL, 3) absolute reticulocyte count less than 60,000/mcL. Refractory SAA (initial): Diagnosis of refractory severe aplastic anemia. Patient has a platelet count less than 30,000/mcL. Trial and failure, intolerance, or contraindication to immunosuppressive therapy with antithymocyte globulin and cyclosporine.</p>
Age Restrictions	N/A
Prescriber Restrictions	Chronic ITP and SAA: Prescribed by or in consultation with a hematologist/oncologist. Chronic hepatitis C associated thrombocytopenia: Prescribed by or in consultation with a hematologist/oncologist, gastroenterologist, hepatologist, infectious disease specialist, or HIV specialist certified through the American Academy of HIV Medicine.
Coverage Duration	ITP(init,reauth):12mo.HepC:3mo(init),12mo(reauth).1stline SAA:6mo.RefractSAA:16wk-init,12mo-reauth

Prior Authorization Criteria

Scott and White

Effective: December 1, 2019

Other Criteria	ITP (reauth): Documentation of positive clinical response to Promacta therapy as evidenced by an increase in platelet count to a level sufficient to avoid clinically important bleeding. Hepatitis C (reauth): One of the following: 1) For patients that started treatment with Promacta prior to initiation of treatment with interferon, Promacta will be approved when both of the following are met: a) Currently on antiviral interferon therapy for treatment of chronic hepatitis C and b) Documentation that the patient reached a threshold platelet count that allows initiation of antiviral interferon therapy with Promacta treatment by week 9, OR 2) For patients that started treatment with Promacta while on concomitant treatment with interferon, Promacta will be approved based on the following: Currently on antiviral interferon therapy for treatment of chronic hepatitis C. Refractory SAA (reauth): Documentation of positive clinical response to Promacta therapy as evidenced by an increase in platelet count.
-----------------------	---

PROVIGIL (S)

Products Affected

- Modafinil

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	<p>Obstructive sleep apnea/hypopnea syndrome (OSAHS) (Initial): Diagnosis (dx) of OSAHS defined by one of the following: 15 or more obstructive respiratory events per hour of sleep confirmed by a sleep study (unless prescriber provides justification confirming that a sleep study is not feasible), or both of the following: 5 or more obstructive respiratory events per hour of sleep confirmed by a sleep study (unless prescriber provides justification confirming that a sleep study is not feasible), and 1 of the following symptoms: unintentional sleep episodes during wakefulness, daytime sleepiness, unrefreshing sleep, fatigue, insomnia, waking up breath holding/gasping/choking, loud snoring, or breathing interruptions during sleep. Shift-work sleep disorder (SWSD) (Initial):Dx of SWSD confirmed by one of the following: 1) Symptoms of excessive sleepiness or insomnia for at least 3 months, which is associated with a work period (usually night work) that occurs during the normal sleep period, OR 2) A sleep study demonstrating loss of a normal sleep-wake pattern (ie, disturbed chronobiologic rhythmicity). No other medical condition or medication accounts for the symptoms. Narcolepsy (initial): Dx of narcolepsy as confirmed by a sleep study (unless prescriber provides justification confirming that a sleep study is not feasible). MS Fatigue (initial): Dx of multiple sclerosis (MS). Patient is experiencing fatigue. Depression (initial): Treatment-resistant depression defined as diagnosis of major depressive disorder (MDD) or bipolar depression, AND trial and failure, contraindication, or intolerance to at least two antidepressants from different classes (eg, SSRIs, SNRIs, bupropion). Used as adjunctive therapy. Idiopathic Hypersomnia (Initial): Diagnosis of idiopathic hypersomnia as confirmed by a sleep study (unless prescriber provides justification confirming that a sleep study is not feasible).</p>
Age Restrictions	N/A
Prescriber Restrictions	N/A

Prior Authorization Criteria

Scott and White

Effective: December 1, 2019

Coverage Duration	Narcolepsy: Init, Reauth: 12 mo. All other indications: Init, Reauth: 6 mo.
Other Criteria	OSAHS, Narcolepsy, Idiopathic Hypersomnia (Reauth): Documentation of positive clinical response to modafinil therapy. SWSD (Reauth): Documentation of positive clinical response to modafinil therapy. MS Fatigue (reauth): Patient is experiencing relief of fatigue with modafinil therapy. Depression (reauth): Documentation of positive clinical response to modafinil therapy. Used as adjunctive therapy.

Prior Authorization Criteria
Scott and White
Effective: December 1, 2019

PULMOZYME (S)

Products Affected

- Pulmozyme

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Cystic Fibrosis (CF) (Initial, Reauth): Diagnosis of CF.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	CF (initial, reauth): 12 months
Other Criteria	Part B vs D determination applies. CF (reauth): Patient is benefiting from treatment (i.e. improvement in lung function [forced expiratory volume in one second (FEV1)], decreased number of pulmonary exacerbations).

Prior Authorization Criteria
Scott and White
Effective: December 1, 2019

QUALAQUIN (S)

Products Affected

- Quinine Sulfate CAPS 324MG

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Malaria: Diagnosis of uncomplicated malaria. One of the following: 1) Treatment in areas of chloroquine-sensitive malaria, and trial and failure, contraindication, or intolerance to chloroquine or hydroxychloroquine, OR 2) Treatment in areas of chloroquine-resistant malaria. Not used for the treatment or prevention of nocturnal leg cramps.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	7 days
Other Criteria	N/A

Prior Authorization Criteria
 Scott and White
 Effective: December 1, 2019

RADICAVA (S)

Products Affected

- Radicava

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Amyotrophic lateral sclerosis (ALS) (initial): Submission of medical records (e.g., chart notes, previous medical history, diagnostic testing including: imaging, nerve conduction studies, laboratory values) to support a diagnosis of “definite” or “probable” ALS per the revised El Escorial diagnostic criteria. Patient has scores of greater than or equal to 2 in all items of the ALS Functional Rating Scale-Revised (ALSFRS-R) criteria at the start of treatment. Patient has a percent forced vital capacity (%FVC) of greater than or equal to 80% at the start of treatment.
Age Restrictions	N/A
Prescriber Restrictions	ALS (initial): Prescribed by or in consultation with a neurologist.
Coverage Duration	Initial, reauth: 6 months
Other Criteria	ALS (reauthorization): Documentation of a benefit from therapy (e.g., slowing in the decline of functional abilities), and Patient is not dependent on invasive ventilation or tracheostomy.

Prior Authorization Criteria
Scott and White
Effective: December 1, 2019

RAVICTI (S)

Products Affected

- Ravicti

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Urea cycle disorders (UCDs) (Initial): Diagnosis of UCDs.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	UCDs (Initial, reauth): 12 months
Other Criteria	UCDs (reauth): Documentation of positive clinical response to Ravicti therapy.

Prior Authorization Criteria
Scott and White
Effective: December 1, 2019

REGRANEX (S)

Products Affected

- Regranex

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Diabetic neuropathic ulcers: Patient has a lower extremity diabetic neuropathic ulcer. Treatment will be given in combination with ulcer wound care (eg, debridement, infection control, and/or pressure relief).
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	5 months
Other Criteria	N/A

Prior Authorization Criteria
 Scott and White
 Effective: December 1, 2019

RELISTOR (S)

Products Affected

- Relistor INJ

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Opioid-induced constipation (OIC) (Initial): Diagnosis of OIC. Patient has used opioid medication for a minimum of 4 weeks. Patient is experiencing fewer than 3 bowel movements in a week or no bowel movement for longer than 2 days. One of the following: A) Patient has chronic non-cancer pain, or chronic pain related to prior cancer or its treatment AND trial and failure, contraindication, or intolerance to Amitiza (lubiprostone), OR B) Patient is receiving palliative care for an advanced illness or pain caused by active cancer.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	OIC (initial, reauth): 4 months
Other Criteria	OIC (Reauth): Diagnosis of OIC. One of the following: A) Patient has chronic non-cancer pain or chronic pain related to prior cancer or its treatment, OR B) Patient is receiving palliative care for an advanced illness or pain caused by active cancer. Documentation of positive clinical response to Relistor therapy (e.g., increase in bowel movements).

Prior Authorization Criteria
Scott and White
Effective: December 1, 2019

RELISTOR TABLETS (S)

Products Affected

- Relistor TABS

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Opioid-induced constipation (OIC) (non-cancer pain, initial): Diagnosis of OIC. Patient has chronic non-cancer pain, or chronic pain related to prior cancer or its treatment. Patient has used an opioid medication for a minimum of 4 weeks. Patient is experiencing fewer than 3 bowel movements in a week or no bowel movement for longer than 2 days. Trial and failure, contraindication, or intolerance to Amitiza (lubiprostone).
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	6 months
Other Criteria	OIC (Reauth): Diagnosis of OIC. Patient has chronic non-cancer pain, or chronic pain related to prior cancer or its treatment. Documentation of a positive clinical response to Relistor therapy (e.g., increase in bowel movements).

REMICADE (S)

Products Affected

- Remicade

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	<p>Crohn's Disease (CD) and Fistulizing Crohn's Disease (FCD) (Initial): Diagnosis (Dx) of moderately to severely active CD or FCD. Failure, contraindication, or intolerance to one of the following conventional therapies: 6-mercaptopurine, Imuran (azathioprine), corticosteroid (eg, prednisone, methylprednisolone), methotrexate (Rheumatrex/Trexall).</p> <p>Ulcerative colitis (UC) (Initial): Dx of moderately to severely active UC. Trial and failure, contraindication, or intolerance (TF/C/I) to one of the following conventional therapies: 6-mercaptopurine, Imuran (azathioprine), corticosteroid (eg, prednisone, methylprednisolone), aminosalicylate [eg, mesalamine (Asacol/Pentasa/Rowasa), Dipentum (olsalazine), Azulfidine (sulfasalazine)].</p> <p>Rheumatoid arthritis (RA) (Initial): Dx of moderately to severely active RA. One of the following: Receiving concurrent therapy with methotrexate (Rheumatrex/Trexall), OR TF/C/I to methotrexate (Rheumatrex/Trexall).</p> <p>Ankylosing spondylitis (AS) (Initial): Dx of active AS. TF/C/I to two NSAIDs.</p> <p>Psoriatic arthritis (PsA) (Initial): Dx of active PsA.</p> <p>Plaque psoriasis (Initial): Dx of chronic severe (ie, extensive and/or disabling) plaque psoriasis.</p> <p>Sarcoidosis (initial): TF/C/I to one immunosuppressant [eg, methotrexate (Rheumatrex/Trexall), cyclophosphamide, or azathioprine (Imuran)] AND TF/C/I to one corticosteroid (eg, prednisone).</p> <p>All indications (Initial): Patient is not receiving Remicade in combination with a biologic DMARD [eg, Enbrel (etanercept), Rituxan (rituximab), Orencia (abatacept), Kineret (anakinra)].</p>
Age Restrictions	N/A
Prescriber Restrictions	<p>CD, FCD, UC (initial): Prescribed by or in consultation with a gastroenterologist.</p> <p>RA, AS (initial): Prescribed by or in consultation with a rheumatologist.</p> <p>PsA (initial): Prescribed by or in consultation with a rheumatologist or dermatologist.</p> <p>Plaque Psoriasis (initial): Prescribed by or in consultation with a dermatologist.</p> <p>Sarcoidosis (initial): Prescribed by or in consultation with a pulmonologist, dermatologist, ophthalmologist.</p>

Prior Authorization Criteria

Scott and White

Effective: December 1, 2019

Coverage Duration	All uses (initial, reauth): 12 months
Other Criteria	Reauth (all indications): Documentation of positive clinical response to infliximab therapy. All indications (re-auth): Excluded if patient is receiving infliximab in combination with a Biologic Disease Modifying Antirheumatic Drug (DMARD) [eg, Enbrel (etanercept), Orencia (abatacept), Rituxan (rituximab), Kineret (anakinra), Cimzia (certolizumab)].

Prior Authorization Criteria
 Scott and White
 Effective: December 1, 2019

REMODULIN (S)

Products Affected

- Remodulin

- Treprostinil

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Pulmonary arterial hypertension (PAH) (Initial): Diagnosis of PAH. PAH is symptomatic. One of the following: A) Diagnosis of PAH was confirmed by right heart catheterization or B) Patient is currently on any therapy for the diagnosis of PAH.
Age Restrictions	N/A
Prescriber Restrictions	PAH (initial): Prescribed by or in consultation with a pulmonologist or cardiologist.
Coverage Duration	PAH: Initial: 6 months. Reauth: 12 months.
Other Criteria	Subject to Part B vs. D Review. PAH (Reauth): Documentation of positive clinical response to therapy.

Prior Authorization Criteria
 Scott and White
 Effective: December 1, 2019

RENFLEXIS (S)

Products Affected

- Renflexis

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Crohn's Disease (CD) and Fistulizing Crohn's Disease (FCD) (initial): Diagnosis (Dx) of moderately to severely active CD or FCD. Ulcerative colitis (UC) (initial): Dx of moderately to severely active UC. Rheumatoid arthritis (RA) (initial): Dx of moderately to severely active RA. Ankylosing spondylitis (AS) (initial): Dx of active AS. Psoriatic arthritis (PsA) (initial): Dx of active PsA. Plaque psoriasis (initial): Dx of chronic severe (ie, extensive and/or disabling) plaque psoriasis. Reauthorization for all indications: Documentation of positive clinical response to infliximab therapy.
Age Restrictions	N/A
Prescriber Restrictions	RA, AS (initial): Prescribed by or in consultation with a rheumatologist. PsA (initial): Prescribed by or in consultation with a rheumatologist or dermatologist. CD, FCD, UC (initial): Prescribed by or in consultation with a gastroenterologist. Plaque Psoriasis (initial): Prescribed by or in consultation with a dermatologist.
Coverage Duration	All uses (initial, reauth): 12 months

Prior Authorization Criteria

Scott and White

Effective: December 1, 2019

Other Criteria	CD, FCD (initial): Trial and failure, contraindication or intolerance (TF/C/I) to one of the following conventional therapies: 6-mercaptopurine (Purinethol), azathioprine (Imuran), corticosteroids (eg, prednisone, methylprednisolone), methotrexate (Rheumatrex, Trexall). UC (initial): TF/C/I to one of the following conventional therapies: corticosteroids, aminosalicylate [eg, mesalamine (Asacol/Pentasa/Rowasa), olsalazine (Dipentum), sulfasalazine (Azulfidine/Sulfazine)], azathioprine (Imuran), 6-mercaptopurine (Purinethol). RA (initial): Receiving concurrent therapy with methotrexate (Rheumatrex/Trexall), or TF/C/I to methotrexate. AS (initial): TF/C/I to two or more NSAIDs. All indications (initial): One of the following: 1) Trial and failure or intolerance to Remicade or 2) For continuation of prior Renflexis therapy. All indications (Initial and re-auth): Excluded if patient is receiving infliximab in combination with a Biologic Disease Modifying Antirheumatic Drug (DMARD) [eg, Enbrel (etanercept), Orencia (abatacept), Rituxan (rituximab), Kineret (anakinra), Cimzia (certolizumab)].
-----------------------	--

REPATHA (S)

Products Affected

- Repatha
- Repatha Pushtronex System
- Repatha Sureclick

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	<p>HeFH/ASCVD (init): One of the following dx: A) HeFH as confirmed by one of the following: (1) Both of the following: a) Untreated/pre-treatment LDL greater than 190 mg/dL in an adult, AND b) One of the following: i) Family hx of tendinous xanthomas and/or arcus cornealis in 1st degree relative, or 2nd degree relative, ii) Hx of myocardial infarction (MI) in 1st-degree relative less than 60 years of age, iii) Family hx of MI in 2nd-degree relative less than 50 years of age, iv) Family hx of LDL-C greater than 190 mg/dL in 1st- or 2nd-degree relative, v) Family hx of FH in 1st- or 2nd-degree relative, or (2) Untreated/pre-treatment LDL-C greater than 190 mg/dL in an adult AND submission of MR (e.g., chart notes, laboratory values) documenting one of the following: presence of tendinous xanthoma in pt, arcus cornealis before age 45, or functional mutation in the LDL receptor, ApoB, or PCSK9 gene. OR B) ASCVD as confirmed by ACS, hx of MI, stable or unstable angina, coronary or other arterial revascularization, stroke, TIA, or peripheral arterial disease presumed to be of atherosclerotic origin. HoFH (initial): Sub of MR (eg, chart notes, lab values) documenting dx of HoFH as confirmed by one of the following: (1) Gen confirmation of 2 mutations in LDL receptor, ApoB, PCSK9, or LDLRAP1 or ARH, or (2) either untreated LDL greater than 500 or treated LDL greater than 300, AND either xanthoma before 10 yo or evidence of HeFH in both parents. HeFH/ASCVD (init): One of the following: set A) Both of the following: a) One of the following LDL values while on max tolerated lipid lowering regimen w/in the last 120 days: (1) LDL greater than or equal to 100 mg/dL w/ ASCVD, or (2) LDL greater than or equal to 130 mg/dL w/o ASCVD. AND b) One of the following: (1) Pt has been receiving at least 12 consecutive weeks of one high-intensity (HI) statin therapy (tx) and will continue to receive a HI statin [ie, atorvastatin 40-80 mg, Crestor (rosuvastatin) 20-40 mg] at max tolerated dose,</p>
Age Restrictions	N/A

Prior Authorization Criteria

Scott and White

Effective: December 1, 2019

Prescriber Restrictions	HeFH/ASCVD/HoFH (init, reauth): Prescribed by or in consultation with a cardiologist, endocrinologist, or lipid specialist
Coverage Duration	HeFH/ASCVD/HoFH (init): 6 mon.HeFH/ASCVD/HoFH (reauth): 12 monts

Prior Authorization Criteria

Scott and White

Effective: December 1, 2019

Other Criteria	<p>Set A (cont, initial): OR (2) Both of the following: A) Pt unable to tolerate HI statin as evidenced by intolerable and persistent (ie, more than 2 wks) myalgia (muscle symptoms w/o CK elevations) or myositis (muscle symptoms w/ CK elevations less than 10 times ULN) AND B) One of the following: a) Pt has been receiving at least 12 consec wks of one moderate-intensity (MI) or low-intensity (LI) statin tx and will continue to receive a MI or LI statin [ie, atorvastatin 10-20 mg, Crestor (rosuvastatin) 5-10 mg, simvastatin 10-40 mg, pravastatin 10-80 mg, lovastatin 20-40 mg, Lescol XL (fluvastatin XL) 80 mg, fluvastatin 20-40 mg, or Livalo (pitavastatin) 1-4 mg] at max tolerated dose, OR b) Pt is unable to tolerate MI or LI statin as evidenced by intolerable and persistent (ie, more than 2 weeks) myalgia (muscle symptoms w/o CK elevations) or myositis (muscle symptoms w/ CK elevations less than 10 times ULN), OR (3) Submission of MR documenting pt has a labeled contraindication to all statins, OR (4) Pt has experienced rhabdomyolysis or muscle symptoms w/ statin treatment w/ CK elevations greater than 10 times ULN on one statin tx. OR set B) Both of the following: a) One of the following LDL values while on max tolerated statin tx w/in the last 120 days: (1) LDL b/t 70 and 99 mg/dL w/ ASCVD. (2) LDL b/t 100 and 129 mg/dL w/o ASCVD. AND b) Both of the following: (1) One of the following: i) Pt has been receiving at least 12 consec wks of one max-tolerated statin tx and will continue to receive a statin at max tolerated dose, ii) pt is unable to tolerate statin tx as evidenced by intolerable and persistent (ie, more than 2 wks) myalgia (muscle symptoms w/o CK elevations) or myositis (muscle symptoms w/ CK elevations less than 10 times ULN, iii) Submission of MR documenting patient has a labeled contraindication to all statins, or iv) Pt has experienced rhabdomyolysis or muscle symptoms w/ statin tx w/ CK elevations greater than 10 times ULN on one statin tx and (2) Pt has been receiving at least 12 consecutive weeks of ezetimibe (Zetia) tx as adjunct to max tolerated statin tx OR Pt has a hx of contraindication or intolerance to ezetimibe. HoFH (init): Pt is receiving other lipid-lowering tx (eg statin, ezetimibe).HeFH/ASCVD (reauth): Pt continues to receive other lipid-lowering tx (eg statins, ezetimibe) at max tolerated dose (unless pt has documented inability to take these medications). HoFH (reauth): Pt continues to receive other lipid-lowering tx (eg statin, ezetimibe). HeFH/ASCVD/HoFH (reauth): Sub of MR (eg, lab values) documenting LDL reduction while on Repatha tx. HeFH/ASCVD/HoFH (Init, reauth): Prescriber attests that the info provided is true and accurate to the best of their knowledge and they understand that OptumRx may perform a routine audit and request the medical info necessary to verify the accuracy of the info provided. HoFH (Init, reauth): Not used in combo w/ Juxtapid.</p>
-----------------------	--

Prior Authorization Criteria
Scott and White
Effective: December 1, 2019

REVATIO (S)

Products Affected

- Sildenafil Citrate TABS 20MG

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Pulmonary arterial hypertension (PAH) (Initial): Diagnosis of PAH. PAH is symptomatic. One of the following: A) Diagnosis of PAH was confirmed by right heart catheterization or B) Patient is currently on any therapy for the diagnosis of PAH.
Age Restrictions	N/A
Prescriber Restrictions	PAH (initial): Prescribed by or in consultation with a pulmonologist or cardiologist.
Coverage Duration	PAH: Initial: 6 months. Reauth: 12 months.
Other Criteria	PAH (Reauth): Documentation of positive clinical response to therapy.

Prior Authorization Criteria
Scott and White
Effective: December 1, 2019

REVATIO INJECTION (S)

Products Affected

- Sildenafil INJ

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Pulmonary arterial hypertension (PAH) (Initial): Diagnosis of PAH. PAH is symptomatic. One of the following: A) Diagnosis of PAH was confirmed by right heart catheterization or B) Patient is currently on any therapy for the diagnosis of PAH. Patient is unable to take oral medications.
Age Restrictions	N/A
Prescriber Restrictions	PAH (initial): Prescribed by or in consultation with a pulmonologist or cardiologist.
Coverage Duration	PAH: Initial: 6 months. Reauth: 12 months.
Other Criteria	PAH (Reauth): Documentation of positive clinical response to therapy.

Prior Authorization Criteria
 Scott and White
 Effective: December 1, 2019

REVATIO SUSPENSION (S)

Products Affected

- Revatio SUSR

- Sildenafil Citrate SUSR

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Pulmonary arterial hypertension (PAH) (Initial): Diagnosis of PAH. PAH is symptomatic. One of the following: A) Diagnosis of PAH was confirmed by right heart catheterization or B) Patient is currently on any therapy for the diagnosis of PAH. One of the following: A) Intolerance to generic Revatio tablets, OR B) Patient is unable to ingest a solid dosage form (e.g., an oral tablet or capsule) due to one of the following: age, oral-motor difficulties, or dysphagia.
Age Restrictions	N/A
Prescriber Restrictions	PAH (initial): Prescribed by or in consultation with a pulmonologist or cardiologist.
Coverage Duration	PAH: Initial: 6 months. Reauth: 12 months.
Other Criteria	PAH (Reauth): Documentation of positive clinical response to therapy.

Prior Authorization Criteria
 Scott and White
 Effective: December 1, 2019

REVLIMID (S)

Products Affected

- Revlimid

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Multiple myeloma (MM): Diagnosis of MM. Either used as 1) combination therapy with dexamethasone, or 2) maintenance therapy following autologous hematopoietic stem cell transplantation (auto-HSCT). Myelodysplastic syndromes (MDS): Diagnosis of transfusion-dependent anemia due to low- or intermediate-1-risk MDS associated with a deletion. Mantle cell lymphoma (MCL): Diagnosis of MCL. Disease has relapsed after, is refractory to, or progressed after at least one prior therapy (eg, bortezomib, bendamustine, cladribine, rituximab). Follicular Lymphoma (FL): Diagnosis of FL that has been previously treated. Used in combination with a rituximab product. Marginal Zone Lymphoma (MZL): Diagnosis of MZL that has been previously treated. Used in combination with a rituximab product.
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with an oncologist/hematologist
Coverage Duration	12 months
Other Criteria	Approve for continuation of prior therapy.

Prior Authorization Criteria
Scott and White
Effective: December 1, 2019

RILUTEK (S)

Products Affected

- Riluzole

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Amyotrophic lateral sclerosis (ALS): Diagnosis of amyotrophic lateral sclerosis (ALS).
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	ALS: 12 months
Other Criteria	N/A

Prior Authorization Criteria
 Scott and White
 Effective: December 1, 2019

RINVOQ (S)

Products Affected

- Rinvoq

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Rheumatoid arthritis (RA) (initial): Diagnosis of moderately to severely active RA. One of the following: Trial and failure, contraindication, or intolerance to both Enbrel (etanercept) and Humira (adalimumab), or attestation demonstrating a trial may be inappropriate, OR patient has a documented needle-phobia to the degree that the patient has previously refused any injectable therapy or medical procedure (refer to DSM-V-TR 300.29/F40.2 for specific phobia diagnostic criteria), OR for continuation of prior Rinvoq therapy. Patient is not receiving Rinvoq in combination with a potent immunosuppressant (e.g., azathioprine, cyclosporine).
Age Restrictions	N/A
Prescriber Restrictions	RA (initial): Prescribed by or in consultation with a rheumatologist.
Coverage Duration	RA (initial, reauth): 12 months.
Other Criteria	RA (reauth): Documentation of positive clinical response to therapy. Patient is not receiving Rinvoq in combination with a potent immunosuppressant (e.g., azathioprine, cyclosporine).

RITUXAN (S)

Products Affected

- Rituxan

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	Rheumatoid Arthritis (RA) (init): Patient is not receiving Rituxan in combination with a biologic DMARD [eg, Enbrel (etanercept), Orencia (abatacept), Kineret (anakinra)].
Required Medical Information	Non-Hodgkin's Lymphoma (NHL): As first-line treatment of diffuse large B-cell, CD20-positive, NHL in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) or other anthracycline-based chemotherapy regimens, or as first-line treatment of follicular, CD20-positive, B-cell NHL in combination with chemotherapy, or for the treatment of follicular, CD20-positive, B-cell NHL in patients achieving a complete or partial response to Rituxan in combination with chemotherapy, used as monotherapy for maintenance therapy, or for the treatment of low-grade, CD20-positive, B-cell NHL in patients with stable disease following first-line treatment with CVP (cyclophosphamide, vincristine, prednisolone/prednisone) chemotherapy or who achieve a partial or complete response following first-line treatment with CVP (cyclophosphamide, vincristine, prednisolone/prednisone) chemotherapy, or diagnosis of relapsed or refractory, low grade or follicular CD20-positive, B-cell non-Hodgkin's lymphoma. Rheumatoid Arthritis (RA) (init): Concurrently on or contraindication, or intolerance to methotrexate. Trial and failure, contraindication, or intolerance (TF/C/I) to a TNF antagonist (eg, adalimumab, etanercept, infliximab). Wegener's Granulomatosis (WG) and Microscopic Polyangiitis (MPA): Patient is concurrently on glucocorticoids (eg, prednisone) OR contraindication or intolerance to glucocorticoids (eg, prednisone). Immune or idiopathic thrombocytopenic purpura (ITP): TF/C/I to one of the following: corticosteroids, immunoglobulins, or splenectomy. Documented platelet count of less than $50 \times 10^9 /L$.
Age Restrictions	N/A
Prescriber Restrictions	ITP: Prescribed by or in consultation with a hematologist or oncologist. RA: Prescribed by or in consultation with a rheumatologist. WG, MPA: Prescribed by or in consultation with a nephrologist, pulmonologist, or rheumatologist.

Prior Authorization Criteria

Scott and White

Effective: December 1, 2019

Coverage Duration	All uses except RA, WG, MPA: 12 mos. RA: 3 months. WG, MPA: 3 months only.
Other Criteria	Approve for continuation of prior therapy.

RITUXAN HYCELA (S)

Products Affected

- Rituxan Hycela

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	<p>Follicular Lymphoma: 1) Diagnosis of follicular CD20-positive lymphoma AND 2) One of the following: 2.1) Disease is relapsed or refractory OR 2.2) Patient exhibited complete or partial response to prior treatment with rituximab in combination with chemotherapy OR 2.3) Disease is non-progressing or stable following prior treatment with first-line cyclophosphamide, vincristine, and prednisone (CVP) chemotherapy OR 2.4) Both of the following: 2.4.1) Disease is previously untreated AND 2.4.2) Medication is used in combination with first-line chemotherapy AND 3) Patient receives a full induction dose of intravenous rituximab prior to initiation of therapy. Diffuse Large B-Cell Lymphoma: 1) Diagnosis of diffuse large B-cell lymphoma AND 2) Disease is previously untreated AND 3) Medication is being used in combination with cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) or other anthracycline-based chemotherapy AND 4) Patient receives a full induction dose of intravenous rituximab prior to initiation of therapy. Chronic Lymphocytic Leukemia: 1) Diagnosis of chronic lymphocytic leukemia AND 2) Medication is being used in combination with fludarabine and cyclophosphamide (FC) therapy AND 3) Patient receives a full induction dose of intravenous rituximab prior to initiation of therapy.</p>
Age Restrictions	N/A
Prescriber Restrictions	All uses: Prescribed by or in consultation with a hematologist or oncologist.
Coverage Duration	12 months
Other Criteria	Approve for continuation of prior therapy.

Prior Authorization Criteria
 Scott and White
 Effective: December 1, 2019

ROZLYTREK (S)

Products Affected

- Rozlytrek

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Non-small cell lung cancer (NSCLC): Diagnosis of metastatic non-small cell lung cancer (NSCLC). Patient has ROS1 rearrangement positive tumor(s). Solid Tumors: Patient has solid tumors with a neurotrophic tyrosine receptor kinase (NTRK) gene fusion (e.g., ETV6-NTRK3, TPM3-NTRK1, TPR-NTRK1, etc.). Disease is without a known acquired resistance mutation (e.g., TRKA G595R, TRKA G667C or TRKC G623R substitutions). Disease is one of the following: metastatic or unresectable (including cases where surgical resection is likely to result in severe morbidity). One of the following: disease has progressed following previous treatment (e.g., surgery, radiation therapy, or systemic therapy) or disease has no satisfactory alternative treatments.
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with an oncologist.
Coverage Duration	12 months
Other Criteria	Approve for continuation of prior therapy.

Prior Authorization Criteria
 Scott and White
 Effective: December 1, 2019

RUBRACA (S)

Products Affected

- Rubraca

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Ovarian cancer: Diagnosis of ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. One of the following: 1) Both of the following: a) Presence of deleterious BRCA mutation as detected by an FDA-approved diagnostic test (e.g., FoundationFocus CDxBRCA Assay) or performed at a Clinical Laboratory Improvement Amendments-approved facility and b) Trial and failure, contraindication, or intolerance to two or more chemotherapies (e.g., cisplatin, carboplatin), OR 2) Both of the following: a) Disease is recurrent and b) Used for maintenance treatment in patients who are in a complete or partial response to platinum-based chemotherapy (e.g., cisplatin, carboplatin).
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	12 months
Other Criteria	Approve for continuation of prior therapy

Prior Authorization Criteria
Scott and White
Effective: December 1, 2019

RUCONEST (S)

Products Affected

- Ruconest

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Treatment of hereditary angioedema (HAE) attacks: Diagnosis of HAE. For the treatment of acute HAE attacks. Not used in combination with other approved treatments for acute HAE attacks.
Age Restrictions	N/A
Prescriber Restrictions	HAE: Prescribed by or in consultation with an immunologist, allergist, or rheumatologist
Coverage Duration	12 months
Other Criteria	N/A

Prior Authorization Criteria
Scott and White
Effective: December 1, 2019

RUZURGI (S)

Products Affected

- Ruzurgi

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Lambert-Eaton Myasthenic Syndrome (LEMS) (initial): Diagnosis of LEMS.
Age Restrictions	N/A
Prescriber Restrictions	LEMS (initial): Prescribed by or in consultation with a neurologist.
Coverage Duration	LEMS (initial): 3 months. LEMS (reauth): 12 months.
Other Criteria	LEMS (reauth): Documentation of positive clinical response to therapy (e.g., improvement in dynamometry, Timed 25-Foot Walk Test, Timed Up and Go Test).

Prior Authorization Criteria
 Scott and White
 Effective: December 1, 2019

RYDAPT (S)

Products Affected

- Rydapt

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Acute Myeloid Leukemia (AML): Newly diagnosed acute myeloid leukemia (AML), FMS-like tyrosine kinase 3 (FLT3) mutation-positive as detected by a U.S. Food and Drug Administration (FDA)-approved test or a test performed at a facility approved by Clinical Laboratory Improvement Amendments (CLIA), used in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation. Aggressive Systemic Mastocytosis (ASM), Systemic Mastocytosis with Associated Hematological Neoplasm (SM-AHN), Mast Cell Leukemia (MCL): Diagnosis of one of the following: aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated hematological neoplasm (SM-AHN), or mast cell leukemia (MCL).
Age Restrictions	N/A
Prescriber Restrictions	All uses: Prescribed by or in consultation with a hematologist or oncologist.
Coverage Duration	12 months
Other Criteria	Approve for continuation of prior therapy.

Prior Authorization Criteria
Scott and White
Effective: December 1, 2019

SABRIL (S)

Products Affected

- Sabril TABS

- Vigabatrin
- Vigadrone

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Complex Partial Seizures (CPS): For use as adjunctive therapy. Failure, contraindication, or intolerance to two formulary anticonvulsants [eg, Lamictal (lamotrigine), Depakene (valproic acid), Dilantin (phenytoin)]. Infantile Spasms (IS): Diagnosis of infantile spasms.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	Approve for continuation of prior therapy.

Prior Authorization Criteria
 Scott and White
 Effective: December 1, 2019

SANDOSTATIN (S)

Products Affected

- Octreotide Acetate

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Acromegaly (initial): Diagnosis of acromegaly. One of the following: A) History of failure to surgical resection and/or pituitary irradiation OR B) Patient is not a candidate for surgical resection or pituitary irradiation. Trial and failure or intolerance to a dopamine agonist (e.g., bromocriptine or cabergoline) at maximally tolerated doses. Carcinoid tumor (initial): Diagnosis of metastatic carcinoid tumor requiring symptomatic treatment of severe diarrhea or flushing episodes. Vasoactive intestinal peptide tumor (initial): Diagnosis of vasoactive intestinal peptide tumor requiring treatment of profuse watery diarrhea.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	All uses (initial, reauth): 12 months
Other Criteria	Acromegaly (reauth): Patient has had a clinical response to therapy (e.g., reduction or normalization of IGF-1/GH level for same age and sex, reduction in tumor size). Carcinoid tumor (reauth): Patient has improvement in number of diarrhea or flushing episodes. Vasoactive intestinal peptide tumor (reauth): Patient has improvement in number of diarrhea episodes.

SANDOSTATIN LAR (S)

Products Affected

- Sandostatin Lar Depot

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Acromegaly (initial): Diagnosis of acromegaly. One of the following: A) History of failure to surgical resection and/or pituitary irradiation OR B) Patient is not a candidate for surgical resection or pituitary irradiation. Trial and failure or intolerance to a dopamine agonist (e.g., bromocriptine or cabergoline) at maximally tolerated doses. Patient had a trial of short-acting octreotide and responded to and tolerated therapy. Carcinoid tumor (initial): Diagnosis of metastatic carcinoid tumor requiring symptomatic treatment of severe diarrhea or flushing episodes. Patient had a trial of short-acting octreotide and responded to and tolerated therapy. Vasoactive peptide tumor (initial): Diagnosis of vasoactive intestinal peptide tumor requiring treatment of profuse watery diarrhea. Patient had a trial of short-acting octreotide and responded to and tolerated therapy.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	All uses (initial, reauth): 12 months
Other Criteria	Acromegaly (reauth): Patient has had a clinical response to therapy (e.g., reduction or normalization of IGF-1/GH level for same age and sex, reduction in tumor size). Carcinoid tumor (reauth): Patient has improvement in number of diarrhea or flushing episodes. Vasoactive intestinal peptide tumor (reauth): Patient has improvement in number of diarrhea episodes.

SCIG (S)

Products Affected

- Cutaquig
- Cuvitru INJ 1GM/5ML, 2GM/10ML, 4GM/20ML, 8GM/40ML
- Hyqvia
- Xembify

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	All uses (initial, reauth): Contraindications to immune globulin therapy (i.e., IgA deficiency with antibodies to IgA and a history of hypersensitivity or product specific contraindication).
Required Medical Information	Initial: Immune globulin will be administered at the minimum effective dose and appropriate frequency for the prescribed diagnosis. Medication is being used subcutaneously. Diagnosis of chronic inflammatory demyelinating polyneuropathy (CIDP) OR one of the following FDA-approved or literature supported diagnoses: 1) Common variable immunodeficiency (CVID), OR 2) Congenital agammaglobulinemia (X-linked or autosomal recessive), OR 3) Severe combined immunodeficiencies (SCID), OR 4) Wiskott-Aldrich syndrome, OR 5) Other primary immunodeficiency with an immunologic evaluation including IgG levels below the normal laboratory value for the patient's age at the time of diagnosis and the patient lacks an adequate response to protein and polysaccharide antigens (i.e., tetanus toxoid or diphtheria toxoid and pneumovax or HiB vaccine).
Age Restrictions	N/A
Prescriber Restrictions	All uses (initial, reauth): Prescribed by or in consultation with a physician who has specialized expertise in managing patients on SCIG therapy (e.g., immunologist, hematologist, neurologist, etc.).
Coverage Duration	Initial, reauth: 12 months
Other Criteria	Subject to Part B vs. Part D review. All uses (reauth): Patient has experienced an objective improvement on immune globulin therapy and the immune globulin will be administered at the minimum effective dose (by decreasing the dose, increasing the frequency, or implementing both strategies) for maintenance therapy.

SEROSTIM (S)

Products Affected

- Serostim INJ 4MG, 5MG, 6MG

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	HIV wasting (Initial): Diagnosis of HIV-associated wasting syndrome or cachexia, and one of the following: unintentional weight loss greater than 10% over the last 12 months, or unintentional weight loss greater than 7.5% over the last 6 months, or loss of 5% body cell mass (BCM) within 6 months, or body mass index (BMI) less than 20 kg/m ² , or patient is male and has BCM less than 35% of total body weight (TBW) and BMI less than 27 kg/m ² , or patient is female and has BCM less than 23% of TBW and BMI less than 27 kg/m ² . Nutritional evaluation since onset of wasting first occurred. Anti-retroviral tx has been optimized to decrease the viral load. Patient has not had weight loss as a result of other underlying treatable conditions (eg, depression, mycobacterium avium complex, chronic infectious diarrhea, or malignancy with the exception of Kaposi's sarcoma limited to skin or mucous membranes). Patient has tried and had an inadequate response or intolerance to dronabinol or megestrol acetate.
Age Restrictions	N/A
Prescriber Restrictions	Initial/Reauth: Prescribed by or in consultation with an infectious disease specialist.
Coverage Duration	Initial: 3 months. Reauth: 6 months
Other Criteria	HIV wasting (reauth): Evidence of positive response to therapy. One of the following targets or goals has not been achieved: weight, BCM, BMI. Patient is currently receiving treatment with antiretrovirals.

Prior Authorization Criteria
Scott and White
Effective: December 1, 2019

SIGNIFOR (S)

Products Affected

- Signifor

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Cushing's disease (initial): Diagnosis of Cushing's disease AND failure to or patient is not a candidate for pituitary surgery.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Initial: 12 months. Reauth: 12 months.
Other Criteria	Cushing's disease (reauth): a clinically meaningful reduction in 24-hour urinary free cortisol levels or improvement in signs or symptoms of the disease.

Prior Authorization Criteria
Scott and White
Effective: December 1, 2019

SIGNIFOR LAR (S)

Products Affected

- Signifor Lar

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Acromegaly (initial): Diagnosis of acromegaly AND failure to surgery or patient is not a candidate for surgery.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Initial: 6 months. Reauth: 12 months.
Other Criteria	Acromegaly (reauth): patient's growth hormone (GH) level or insulin-like growth factor 1 (IGF-1) level for age and gender has normalized/improved.

Prior Authorization Criteria
Scott and White
Effective: December 1, 2019

SILIQ (S)

Products Affected

- Siliq

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Plaque psoriasis (Initial): Diagnosis of moderate to severe plaque psoriasis. One of the following: a) Trial and failure, contraindication, or intolerance to Cosentyx (secukinumab) AND one of the following: Enbrel (etanercept) or Humira (adalimumab), OR b) for continuation of prior Siliq therapy.
Age Restrictions	N/A
Prescriber Restrictions	Plaque psoriasis (initial): Prescribed by or in consultation with a dermatologist.
Coverage Duration	Plaque psoriasis (Initial, reauth): 12 months
Other Criteria	Plaque psoriasis (Reauth): Documentation of positive clinical response to Siliq therapy.

SIMPONI (S)

Products Affected

- Simponi

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Rheumatoid Arthritis (RA) (Initial): Diagnosis of moderately to severely active RA. One of the following: Receiving concurrent therapy with methotrexate (Rheumatrex/Trexall) OR trial and failure, contraindication, or intolerance (TF/C/I) to methotrexate (Rheumatrex/Trexall). One of the following: TF/C/I to both Enbrel (etanercept) and Humira (adalimumab), or attestation demonstrating a trial may be inappropriate, OR for continuation of prior therapy. Psoriatic Arthritis (PsA) (Initial): Diagnosis of active PsA. One of the following: TF/C/I to both Enbrel (etanercept) and Humira (adalimumab), or attestation demonstrating a trial may be inappropriate, OR for continuation of prior therapy. Ankylosing Spondylitis (AS) (Initial): Diagnosis of active AS. One of the following: TF/C/I to both Enbrel (etanercept) and Humira (adalimumab), or attestation demonstrating a trial may be inappropriate, OR for continuation of prior therapy. Ulcerative Colitis (UC) (Initial): Diagnosis of moderately to severely active UC. Patient is corticosteroid dependent (ie, an inability to successfully taper corticosteroids without a return of the symptoms of UC), OR TF/C/I to one of the following: oral aminosalicylate, oral corticosteroid, azathioprine, 6-mercaptopurine. One of the following: TF/C/I to Humira (adalimumab), OR for continuation of prior Simponi therapy. All indications (Initial, reauth): Patient is not receiving Simponi in combination with a biologic DMARD [eg, Enbrel (etanercept), Humira (adalimumab), Cimzia (certolizumab), Orencia (abatacept)].
Age Restrictions	N/A
Prescriber Restrictions	RA, AS (initial): Prescribed by or in consultation with a rheumatologist. PsA (initial): Prescribed by or in consultation with a rheumatologist or dermatologist. UC (initial): Prescribed by or in consultation with a gastroenterologist.
Coverage Duration	UC (Initial): 12 weeks. UC (Reauth): 12 months. RA, AS, PsA (Initial, reauth): 12 months

Prior Authorization Criteria

Scott and White

Effective: December 1, 2019

Other Criteria	All indications (Reauth): Documentation of positive clinical response to Simponi therapy.
-----------------------	---

SIMPONI ARIA (S)

Products Affected

- Simponi Aria

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Rheumatoid arthritis (RA) (Initial): Diagnosis of moderately to severely active RA. One of the following: Receiving concurrent therapy with methotrexate (Rheumatrex/Trexall), OR trial and failure, contraindication, or intolerance (TF/C/I) to methotrexate (Rheumatrex/Trexall). One of the following: trial and failure, contraindication, or intolerance to both Enbrel (etanercept) and Humira (adalimumab), or attestation demonstrating a trial may be inappropriate, OR for continuation of prior therapy. Psoriatic Arthritis (PsA) (Initial): Diagnosis of active PsA. One of the following: TF/C/I to both Enbrel (etanercept) and Humira (adalimumab), or attestation demonstrating a trial may be inappropriate, OR for continuation of prior therapy. Ankylosing Spondylitis (AS) (Initial): Diagnosis of active AS. One of the following: TF/C/I to both Enbrel (etanercept) and Humira (adalimumab), or attestation demonstrating a trial may be inappropriate, OR for continuation of prior therapy. All indications (initial, reauth): Patient is not receiving Simponi in combination with a biologic DMARD [eg, Enbrel (etanercept), Humira (adalimumab), Cimzia (certolizumab), Orencia (abatacept)].
Age Restrictions	N/A
Prescriber Restrictions	RA, AS (initial): Prescribed by or in consultation with a rheumatologist. PsA (initial): Prescribed by or in consultation with a rheumatologist or dermatologist.
Coverage Duration	RA, AS, PsA (Initial, reauth): 12 months
Other Criteria	All Indications (Reauth): Documentation of positive clinical response to Simponi therapy.

Prior Authorization Criteria
 Scott and White
 Effective: December 1, 2019

SKYRIZI (S)

Products Affected

- Skyrizi

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Plaque psoriasis (Initial): Diagnosis of moderate to severe plaque psoriasis. One of the following: a) Trial and failure, contraindication, or intolerance to Cosentyx (secukinumab) AND one of the following: Enbrel (etanercept) or Humira (adalimumab), OR b) for continuation of prior Skyrizi therapy.
Age Restrictions	N/A
Prescriber Restrictions	Plaque psoriasis (initial): Prescribed by or in consultation with a dermatologist.
Coverage Duration	Plaque psoriasis (Initial, reauth): 12 months
Other Criteria	Plaque psoriasis (Reauth): Documentation of positive clinical response to Skyrizi therapy.

Prior Authorization Criteria
 Scott and White
 Effective: December 1, 2019

SOLIRIS (S)

Products Affected

- Soliris

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Paroxysmal Nocturnal Hemoglobinuria (PNH), Atypical Hemolytic Uremic Syndrome (aHUS) (initial): The member has diagnosis of PNH or aHUS. Generalized Myasthenia Gravis (gMG) (initial): Diagnosis of gMG. Patient is anti-acetylcholine (AChR) antibody positive. One of the following: 1) Trial and failure, contraindication, or intolerance (TF/C/I) to two immunosuppressive therapies (e.g., glucocorticoids, azathioprine, cyclosporine, mycophenolate mofetil, methotrexate, tacrolimus), or 2) TF/C/I to one immunosuppressive therapy (e.g., glucocorticoids, azathioprine, cyclosporine, mycophenolate mofetil, methotrexate, tacrolimus), and TF/C/I to chronic plasmapheresis/plasma exchange (PE) or intravenous immunoglobulin (IVIG).
Age Restrictions	N/A
Prescriber Restrictions	gMG (initial): Prescribed by or in consultation with a neurologist.
Coverage Duration	All uses (initial, reauth): 12 months
Other Criteria	All indications (reauth): Documentation of positive clinical response to Soliris therapy.

Prior Authorization Criteria
 Scott and White
 Effective: December 1, 2019

SOMATULINE DEPOT (S)

Products Affected

- Somatuline Depot

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Acromegaly: Diagnosis of acromegaly AND One of the following: A) Failure to one of the following: surgery or radiotherapy, OR B) not a candidate for one of the following: surgery or radiotherapy. Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) (120mg/0.5mL strength only): Diagnosis of GEP-NETs. Disease is one of the following: (a) unresectable, locally advanced or (b) metastatic. Carcinoid syndrome (120mg/0.5mL strength only): Diagnosis of carcinoid syndrome. Used to reduce the frequency of short-acting somatostatin analog rescue therapy.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	All uses: 12 months
Other Criteria	All Indications: Approve for continuation of prior therapy.

Prior Authorization Criteria
Scott and White
Effective: December 1, 2019

SOMAVERT (S)

Products Affected

- Somavert

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Acromegaly (initial): Diagnosis of acromegaly AND Failure to surgery and/or radiation therapy and/or other medical therapies (such as dopamine agonists [e.g., bromocriptine, cabergoline]) unless patient is not a candidate for these treatment options AND trial and failure or intolerance to generic octreotide (a somatostatin analogue).
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Initial, reauth: 12 months
Other Criteria	Acromegaly (reauth): Patient has experienced an objective response to therapy (biochemical control, decrease or normalization of IGF-1 levels).

Prior Authorization Criteria
 Scott and White
 Effective: December 1, 2019

SOVALDI (S)

Products Affected

- Sovaldi

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Criteria will be applied consistent with current AASLD/IDSA guideline. Diagnosis of chronic hepatitis C. All GT1 (except Sovaldi plus Daklinza therapy in liver transplant (tx) patients) and GT4: 1) trial and failure, intolerance or contraindication (TF/I/C) to both of the following: a) Harvoni OR Epclusa and b) Mavyret OR 2) For continuation of prior Sovaldi therapy. For GT2 (except liver tx patients, or pediatric patients 12 years of age and older or weighing at least 35 kg) or GT3 patients (except pediatric patients 12 years of age and older or weighing at least 35 kg), using Sovaldi plus ribavirin: TF/I/C to a) Epclusa AND Mavyret OR b) for continuation of prior Sovaldi therapy. (continued in Other Criteria).
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with one of the following: Hepatologist, Gastroenterologist, Infectious disease specialist, HIV specialist certified through the American Academy of HIV Medicine.
Coverage Duration	12 to 48 weeks. Criteria will be applied consistent with current AASLD/IDSA guideline.

Prior Authorization Criteria

Scott and White

Effective: December 1, 2019

Other Criteria	All Sovaldi plus Daklinza therapy: One of the following: 1) Patient has not failed a prior HCV NS5A-containing regimen (eg, Daklinza) therapy, OR 2) patient has failed prior therapy with an NS5A-containing regimen AND patient does not have NS5A inhibitor resistance-associated variants detected using commercially available assays. For GT2 and GT3 (except liver tx patients) patients, using Sovaldi plus Daklinza: TF/I/C to Epclusa AND Mavyret, OR for continuation of prior Sovaldi therapy. For GT2 or 3 liver tx recipients without cirrhosis, ONE of the following: 1) Patient has had a TF/I/C to Mavyret OR 2) For continuation of prior Sovaldi therapy. For GT2 or 3 liver tx recipients with decompensated cirrhosis, ONE of the following: 1) Patient has had a TF/I/C to Epclusa OR 2) For continuation of prior Sovaldi therapy. For GT1 liver tx patients using Sovaldi plus Daklinza, TF/I/C to a) Harvoni OR Mavyret OR b) continuation of prior Sovaldi therapy.
-----------------------	---

SPINRAZA (S)

Products Affected

- Spinraza

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Spinal muscular atrophy (SMA) (initial): Diagnosis of spinal muscular atrophy (SMA) type I, II, or III. Both of the following: a) The mutation or deletion of genes in chromosome 5q resulting in one of the following: 1) Homozygous gene deletion or mutation (e.g., homozygous deletion of exon 7 at locus 5q13) or 2) Compound heterozygous mutation (e.g., deletion of SMN1 exon 7 [allele 1] and mutation of SMN1 [allele 2]) AND b) Patient has at least 2 copies of SMN2. Patient is not dependent on either of the following: 1) Invasive ventilation or tracheostomy or 2) Use of non-invasive ventilation beyond use for naps and nighttime sleep. At least one of the following exams (based on patient age and motor ability) has been conducted to establish baseline motor ability: Hammersmith Infant Neurological Exam (HINE) (infant to early childhood), Hammersmith Functional Motor Scale Expanded (HFMSE), Upper Limb Module (ULM) Test (Non ambulatory), or Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND). Spinraza is to be administered intrathecally by, or under the direction of, healthcare professionals experienced in performing lumbar punctures.
Age Restrictions	N/A
Prescriber Restrictions	SMA (initial, reauth): Prescribed by or in consultation with a neurologist with expertise in the diagnosis of SMA
Coverage Duration	Initial: 3 months. Reauth: 6 months.

Prior Authorization Criteria

Scott and White

Effective: December 1, 2019

Other Criteria	<p>SMA (reauth): Documentation of positive clinical response to Spinraza therapy from pretreatment baseline status as demonstrated by the most recent results (less than 1 month prior to request) from one of the following exams: A) Both of the following HINE milestones: 1) One of the following: a) Improvement or maintenance of a previous improvement of at least a 2 point (or maximal score) increase in ability to kick or b) Improvement or maintenance of a previous improvement of at least a 1 point increase in any other HINE milestone (e.g., head control, rolling, sitting, crawling, etc.), excluding voluntary grasp AND 2) One of the following: a) Improvement or maintenance of a previous improvement in more HINE motor milestones than worsening from pretreatment baseline (net positive improvement) or b) Patient has achieved and maintained any new motor milestones from pretreatment baseline when they would otherwise be unexpected to do so (e.g., sit unassisted, stand, walk) OR B) One of the following HFMSE milestones: 1) Improvement or maintenance of a previous improvement of at least a 3 point increase in score from pretreatment baseline OR 2) Patient has achieved and maintained any new motor milestone from pretreatment baseline when they would otherwise be unexpected to do so OR C) One of the following ULM test milestones: 1) Improvement or maintenance of a previous improvement of at least a 2 point increase in score from pretreatment baseline OR 2) Patient has achieved and maintained any new motor milestone from pretreatment baseline when they would otherwise be unexpected to do so OR D) One of the following CHOP INTEND milestones: 1) Improvement or maintenance of a previous improvement of at least a 4 point increase in score from pretreatment baseline OR 2) Patient has achieved and maintained any new motor milestone from pretreatment baseline when they would otherwise be unexpected to do so. Patient continues to not be dependent on either of the following: 1) Invasive ventilation or tracheostomy or 2) use of non-invasive ventilation beyond use for naps and nighttime sleep. Spinraza is to be administered intrathecally by, or under the direction of, healthcare professionals experienced in performing lumbar punctures.</p>
-----------------------	--

Prior Authorization Criteria
 Scott and White
 Effective: December 1, 2019

SPORANOX (S)

Products Affected

- Itraconazole CAPS
- Itraconazole SOLN
- Sporanox SOLN

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	One of the following: 1) patient has a systemic fungal infection (e.g., aspergillosis, histoplasmosis, blastomycosis), OR 2) all of the following: a) patient has a diagnosis of onychomycosis confirmed by one of the following (CAPSULE ONLY): i) positive potassium hydroxide (KOH) preparation, OR ii) culture, OR iii) histology, AND b) the patient's condition is causing debility or a disruption in their activities of daily living, AND c) patient has had a trial and inadequate response, intolerance or hypersensitivity to oral terbinafine, OR 3) patient has a diagnosis of candidiasis (esophageal or oropharyngeal) that is refractory to treatment with fluconazole (ORAL SOLUTION ONLY).
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Systemic fungal infxn:6mo.Candidiasis:1mo.Fingernail onycho:5wks.Toenail onycho, other:3mo.
Other Criteria	N/A

Prior Authorization Criteria
Scott and White
Effective: December 1, 2019

SPRYCEL (S)

Products Affected

- Sprycel

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Philadelphia chromosome positive (Ph+)/BCR ABL chronic myelogenous leukemia (CML): Diagnosis of Ph+/BCR ABL CML. Ph+/BCR ABL acute lymphoblastic leukemia (ALL): Diagnosis of Ph+/BCR ABL ALL.
Age Restrictions	N/A
Prescriber Restrictions	All Uses: Prescribed by or in consultation with an oncologist or hematologist
Coverage Duration	All Uses: 12 months
Other Criteria	All Uses: Approve for continuation of prior therapy.

Prior Authorization Criteria
 Scott and White
 Effective: December 1, 2019

STELARA (IV) (S)

Products Affected

- Stelara INJ 130MG/26ML

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Diagnosis of moderately to severely active Crohn's disease. One of the following: a) trial and failure, contraindication, or intolerance to Humira (adalimumab), or (b) trial and failure, contraindication, or intolerance to treatment with at least one immunomodulator or corticosteroid [e.g., Purinethol (6-mercaptopurine), Imuran (azathioprine), Sandimmune (cyclosporine A), Prograf (tacrolimus), MTX (methotrexate)]. Patient is not receiving Stelara in combination a biologic DMARD [eg, Enbrel (etanercept), Humira (adalimumab), Cimzia (certolizumab), Simponi (golimumab)].
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with a gastroenterologist.
Coverage Duration	One time
Other Criteria	Stelara is to be administered as an intravenous induction dose. Stelara induction dosing is in accordance with the United States Food and Drug Administration approved labeled dosing for Crohn's Disease: 260 mg for patients weighing 55 kg or less, 390 mg for patients weighing more than 55 kg to 85 kg, or 520 mg for patients weighing more than 85 kg.

STELARA (S)

Products Affected

- Stelara INJ 45MG/0.5ML, 90MG/ML

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	<p>Plaque psoriasis (Initial - 45mg/0.5mL): Diagnosis of moderate to severe plaque psoriasis. Plaque psoriasis (Initial - 90mg/1mL): Diagnosis of moderate to severe plaque psoriasis. Patient's weight is greater than 100 kg (220 lbs). Psoriatic arthritis (PsA) (Initial - 45mg/0.5mL): Diagnosis of active PsA. PsA (Initial - 90mg/1mL): Diagnosis of active PsA. Patient's weight is greater than 100 kg (220 lbs). Diagnosis of co-existent moderate to severe psoriasis. Plaque psoriasis (Initial): One of the following: a) Trial and failure, contraindication, or intolerance (TF/C/I) to Cosentyx (secukinumab) AND one of the following: Enbrel (etanercept) OR Humira (adalimumab) OR b) for continuation of prior Stelara therapy. PsA (Initial): One of the following: a) TF/C/I to Cosentyx (secukinumab) AND one of the following: Enbrel (etanercept) or Humira (adalimumab), OR b) for continuation of prior Stelara therapy. Crohn's disease (CD) (Initial): Diagnosis of moderately to severely active Crohn's disease. One of the following: a) TF/C/I to Humira (adalimumab) OR b) TF/C/I to treatment with at least one immunomodulator or corticosteroid [e.g., Purinethol (6-mercaptopurine), Imuran (azathioprine), Sandimmune (cyclosporine A), Prograf (tacrolimus), MTX (methotrexate)], OR c) for continuation of prior Stelara therapy.</p>
Age Restrictions	N/A
Prescriber Restrictions	<p>Plaque psoriasis (initial): Prescribed by or in consultation with a dermatologist. PsA (initial): Prescribed by or in consultation with a dermatologist or rheumatologist. CD (initial): Prescribed by or in consultation with a gastroenterologist.</p>
Coverage Duration	All uses (Initial, reauth): 12 months
Other Criteria	Reauth (all indications): Documentation of positive clinical response to Stelara therapy.

Prior Authorization Criteria
 Scott and White
 Effective: December 1, 2019

STIVARGA (S)

Products Affected

- Stivarga

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Metastatic colorectal cancer (mCRC): All of the following: 1) diagnosis of mCRC, AND 2) trial and failure, contraindication or intolerance to fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, AND 3) trial and failure, contraindication or intolerance to an anti-VEGF therapy (e.g. Avastin [bevacizumab]), AND 4) one of the following: a) RAS mutation, OR b) both of the following: RAS wild-type and trial and failure, contraindication or intolerance to an anti-EGFR therapy [e.g. Vectibix (panitumumab), Erbitux (cetuximab)]. Gastrointestinal stromal tumor (GIST): All of the following: 1) diagnosis of locally advanced, unresectable or metastatic GIST, AND 2) trial and failure, contraindication or intolerance to both of the following: a) Gleevec (imatinib mesylate), AND b) Sutent (sunitinib malate). Hepatocellular Carcinoma (HCC): Diagnosis of HCC. Trial and failure or intolerance to Nexavar (sorafenib tosylate).
Age Restrictions	N/A
Prescriber Restrictions	mCRC, GIST: Prescribed by or in consultation with an oncologist. HCC: Prescribed by or in consultation with an oncologist, hepatologist, or gastroenterologist.
Coverage Duration	12 months
Other Criteria	Approve for continuation of prior therapy.

Prior Authorization Criteria
Scott and White
Effective: December 1, 2019

STRENSIQ (S)

Products Affected

- Strensiq

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Hypophosphatasia: Diagnosis of perinatal/infantile or juvenile-onset hypophosphatasia AND for patients requesting the 80 mg/0.8 mL vial only: Patient's weight is greater than or equal to 40 kg.
Age Restrictions	N/A
Prescriber Restrictions	Hypophosphatasia: Prescribed by or in consultation with a specialist experienced in the treatment of inborn errors of metabolism or endocrinologist
Coverage Duration	Hypophosphatasia: 12 months
Other Criteria	N/A

Prior Authorization Criteria
 Scott and White
 Effective: December 1, 2019

SUPPRELIN LA (S)

Products Affected

- Supprelin La

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Central Precocious Puberty (CPP) (initial): Diagnosis of CPP (idiopathic or neurogenic). Early onset of secondary sexual characteristics in females less than age 8 or males less than age 9. Advanced bone age of at least one year compared with chronologic age. One of the following: a) patient has undergone gonadotropin-releasing hormone agonist (GnRHa) testing AND Peak luteinizing hormone (LH) level above pre-pubertal range, or b) patient has a random LH level in the pubertal range.
Age Restrictions	N/A
Prescriber Restrictions	CPP (initial, reauth): Prescribed by or in consultation with a pediatric endocrinologist.
Coverage Duration	CPP (init, reauth): 12 months
Other Criteria	CPP (reauthorization): LH levels have been suppressed to pre-pubertal levels.

Prior Authorization Criteria
 Scott and White
 Effective: December 1, 2019

SUTENT (S)

Products Affected

- Sutent

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Renal cell carcinoma: Diagnosis of advanced or metastatic renal cell carcinoma. Gastrointestinal stromal tumor (GIST): Diagnosis of GIST after disease progression on, or contraindication or intolerance to Gleevec (imatinib). Pancreatic neuroendocrine tumors: Diagnosis of progressive, well-differentiated pancreatic neuroendocrine tumor that is unresectable locally advanced or metastatic disease. Adjuvant treatment of renal cell carcinoma: Diagnosis of renal cell carcinoma (RCC). Used as adjuvant therapy. Patient is at high risk of recurrent RCC following nephrectomy.
Age Restrictions	N/A
Prescriber Restrictions	All uses: Prescribed by or in consultation with an oncologist
Coverage Duration	All uses: 12 months
Other Criteria	All Indications: Approve for continuation of prior therapy.

Prior Authorization Criteria
Scott and White
Effective: December 1, 2019

SYLATRON (S)

Products Affected

- Sylatron

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Melanoma: Diagnosis of melanoma with microscopic or gross nodal involvement AND The prescribed medication will be used as adjuvant therapy within 84 days of definitive surgical resection, including complete lymphadenectomy.
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with an oncologist or dermatologist
Coverage Duration	12 months
Other Criteria	Approve for continuation of prior therapy.

Prior Authorization Criteria
Scott and White
Effective: December 1, 2019

SYLVANT (S)

Products Affected

- Sylvant

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Multicentric Castleman's disease (MCD) (Initial): Diagnosis of MCD. Patient is human immunodeficiency virus (HIV) negative and human herpesvirus-8 (HHV-8) negative.
Age Restrictions	N/A
Prescriber Restrictions	MCD (initial): Prescribed by or in consultation with hematologist/oncologist or rheumatologist.
Coverage Duration	MCD (initial, reauth): 6 months
Other Criteria	MCD (reauth): Documentation of positive clinical response to Sylvant therapy. Patient is HIV negative and HHV-8 negative.

SYMDEKO (S)

Products Affected

- Symdeko

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Initial: Diagnosis of cystic fibrosis. One of the following: 1) Patient is homozygous for the F508del mutation as detected by a FDA-cleared cystic fibrosis mutation test or at a Clinical Laboratory Improvement Amendments (CLIA)-approved facility OR 2) Patient has one of the following mutations on at least one allele in the CF transmembrane conductance regulator (CFTR) gene as detected by FDA-cleared cystic fibrosis mutation test or at a Clinical Laboratory Improvement Amendments (CLIA) -approved facility: E56K, P67L, R74W, D110E, D110H, R117C, E193K, L206W, R347H, R352Q, A455E, D579G, 711+3A-G, E831X, S945L, S977F, F1052V, K1060T, A1067T, R1070W, F1074L, D1152H, D1270N, 2789+5G-A, 3272-26A-G, 3849+10kbC-T.
Age Restrictions	Initial: Patient is 6 years of age or older
Prescriber Restrictions	Initial: Prescribed by or in consultation with a pulmonologist or specialist affiliated with a CF care center
Coverage Duration	12 months
Other Criteria	Reauth: Documentation of a positive clinical response to Symdeko (tezacaftor/ivacaftor) therapy (e.g., improvement in lung function or decreased number of pulmonary exacerbations).

Prior Authorization Criteria
Scott and White
Effective: December 1, 2019

SYMLIN (S)

Products Affected

- Symlinpen 120
- Symlinpen 60

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	One of the following diagnoses: A) Type 1 diabetes OR B) Type 2 diabetes.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	N/A

Prior Authorization Criteria
 Scott and White
 Effective: December 1, 2019

SYNAGIS (S)

Products Affected

- Synagis INJ 100MG/ML, 50MG/0.5ML

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	<p>Patient will use palivizumab for immunoprophylaxis of respiratory syncytial virus (RSV) during the peak months of infection in the patient's geographic region AND Patient meets one of the following criteria: 1) Infants born at 28 weeks, six days gestation or earlier and who are younger than 12 months of age at the start of the RSV season OR 2) Diagnosis of chronic lung disease of prematurity, born before 32 weeks, 0 days gestation, received greater than 21% oxygen for at least the first 28 days after birth, and one of the following: a) 12 months of age or younger at the start of the RSV season OR b) greater than 12 months of age to 24 months of age at the start of the RSV season and received medical support (i.e., chronic corticosteroid therapy, diuretic therapy, or supplemental oxygen) within 6 months before the start of the second RSV season. OR 3) Patient is 12 months of age or younger at the start of the RSV season and has one of the following: a) acyanotic heart failure that will require a cardiac surgical procedure and the patient is receiving medication to control congestive heart failure, OR b) moderate to severe pulmonary hypertension OR c) cyanotic heart defect. OR 4) patient is younger than 24 months of age and will or has undergone a cardiac transplantation during the RSV season. OR 5) Patient is 12 months of age or younger at the start of the RSV season with a congenital abnormality or neuromuscular disorder and has an impaired ability to clear secretions from the upper airway due to an ineffective cough. OR 6) Patient is younger than 24 months of age with a lymphocyte count below the normal range for patient's age and has received or will receive a solid organ transplant, hematopoietic stem cell transplant recipient, or chemotherapy during the RSV season.</p>
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with a pediatric specialist (i.e., pulmonologist, neonatologist, neurologist, cardiologist, pediatric intensivist, or infectious disease specialist).

Prior Authorization Criteria

Scott and White

Effective: December 1, 2019

Coverage Duration	5 months (5 doses) during RSV season.
Other Criteria	N/A

Prior Authorization Criteria
 Scott and White
 Effective: December 1, 2019

SYNDROS (S)

Products Affected

- Syndros

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Nausea and Vomiting Associated with Cancer Chemotherapy (CINV): Patient is receiving cancer chemotherapy. Trial and failure, contraindication, or intolerance (TF/C/I) to a 5HT-3 receptor antagonist (eg, Anzemet [dolasetron], Kytril [granisetron], or Zofran [ondansetron]). TF/C/I to one of the following: Compazine (prochlorperazine), Decadron (dexamethasone), Haldol (haloperidol), Zyprexa (olanzapine). AIDS anorexia: Diagnosis of anorexia with weight loss in patients with AIDS. Patient is on antiretroviral therapy.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	CINV: 6 months. AIDS anorexia: 3 months.
Other Criteria	Subject to Part B vs. Part D review. CINV: Approve for continuation of therapy for treatment covered under Part B when patient is receiving chemotherapy.

Prior Authorization Criteria
Scott and White
Effective: December 1, 2019

SYNRIBO (S)

Products Affected

- Synribo

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Chronic myelogenous leukemia (CML): Diagnosis of CML in the chronic or accelerated phase AND Patient has tried and has had resistance, relapse, inadequate response, intolerance or is contraindicated to TWO tyrosine kinase inhibitors (i.e., Gleevec [imatinib], Sprycel, Tassigna, and Bosulif, Iclusig).
Age Restrictions	CML: 18 years of age or older
Prescriber Restrictions	CML: Prescribed by or in consultation with a hematologist/oncologist
Coverage Duration	12 months
Other Criteria	Approve for continuation of prior therapy.

Prior Authorization Criteria
 Scott and White
 Effective: December 1, 2019

TAFAMIDIS (S)

Products Affected

- Vyndamax

- Vyndaqel

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Transthyretin-mediated amyloidosis with cardiomyopathy (ATTR-CM) (initial): Diagnosis of transthyretin-mediated amyloidosis with cardiomyopathy (ATTR-CM). One of the following: 1) Patient has a transthyretin (TTR) mutation (e.g., V122I), 2) Cardiac or noncardiac tissue biopsy demonstrating histologic confirmation of TTR amyloid deposits, OR 3) All of the following: i) echocardiogram or cardiac magnetic resonance imaging suggestive of amyloidosis, ii) scintigraphy scan suggestive of cardiac TTR amyloidosis, and iii) absence of light-chain amyloidosis. One of the following: 1) History of heart failure (HF), with at least one prior hospitalization for HF, OR 2) Presence of clinical signs and symptoms of HF (e.g., dyspnea, edema). Patient has New York Heart Association (NYHA) Functional Class I, II, or III heart failure.
Age Restrictions	N/A
Prescriber Restrictions	ATTR-CM (initial, reauth): Prescribed by or in consultation with a cardiologist
Coverage Duration	ATTR-CM (initial, reauth): 12 months
Other Criteria	ATTR-CM (reauth): Documentation of positive clinical response to therapy. Patient continues to have New York Heart Association (NYHA) Functional Class I, II, or III heart failure.

TAFINLAR (S)

Products Affected

- Tafinlar

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	<p>Melanoma: Diagnosis of unresectable or metastatic melanoma AND cancer is BRAF V600E or V600K mutant type as detected by an FDA-approved test (THxID-BRAF Kit) or performed at a facility approved by Clinical Laboratory Improvement Amendments (CLIA). Adjuvant Treatment for Melanoma: Diagnosis of melanoma. Cancer is BRAF V600E or V600K mutant type as detected by an FDA-approved test (THxID-BRAF Kit) or performed at a facility approved by Clinical Laboratory Improvement Amendments (CLIA). Involvement of lymph nodes following complete resection. Used as adjunctive therapy. Medication is used in combination with Mekinist (trametinib). Non-small Cell Lung Cancer (NSCLC): All of the following: diagnosis of metastatic non-small cell lung cancer AND cancer is BRAF V600E mutant type as detected by an FDA-approved test (THxID-BRAF Kit) or performed at a facility approved by Clinical Laboratory Improvement Amendments (CLIA) AND medication is used in combination with Mekinist (trametinib). Anaplastic Thyroid Cancer (ATC): Diagnosis of locally advanced or metastatic anaplastic thyroid cancer. Cancer is BRAF V600E mutant type as detected by an FDA-approved test (THxID-BRAF Kit) or performed at a facility approved by Clinical Laboratory Improvement Amendments (CLIA). Cancer may not be treated with standard locoregional treatment options. Medication is used in combination with Mekinist (trametinib) .</p>
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with an oncologist.
Coverage Duration	12 months
Other Criteria	Approve for continuation of prior therapy.

Prior Authorization Criteria
Scott and White
Effective: December 1, 2019

TAGRISO (S)

Products Affected

- Tagrisso

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Non-small cell lung cancer (NSCLC): Diagnosis of NSCLC. One of the following: 1) Tumors are positive for epidermal growth factor receptor (EGFR) exon 19 deletions, OR 2) Tumors are positive for EGFR exon 21 L858R mutations, OR 3) Both of the following: a) Tumors are positive for EGFR T790M mutation and b) The patient has experienced disease progression on or after one of the following EGFR Tyrosine Kinase Inhibitors (TKIs): Gilotrif (afatinib), Iressa (gefitinib), Tarceva (erlotinib).
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with an oncologist.
Coverage Duration	12 months
Other Criteria	Approve for continuation of prior therapy.

Prior Authorization Criteria
Scott and White
Effective: December 1, 2019

TAKHZYRO (S)

Products Affected

- Takhzyro

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Prophylaxis of hereditary angioedema (HAE) attacks: Diagnosis of HAE. For prophylaxis against HAE attacks.
Age Restrictions	N/A
Prescriber Restrictions	HAE (prophylaxis): Prescribed by or in consultation with an immunologist, allergist, or rheumatologist
Coverage Duration	12 months
Other Criteria	N/A

TALTZ (S)

Products Affected

- Taltz

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Plaque psoriasis (Initial): Diagnosis of moderate to severe plaque psoriasis. One of the following: a) Trial and failure, contraindication, or intolerance to Cosentyx (secukinumab) AND one of the following: Enbrel (etanercept) or Humira (adalimumab), OR b) for continuation of prior Taltz therapy. Psoriatic Arthritis (PsA) (initial): Diagnosis of active PsA. One of the following: a) Trial and failure, contraindication, or intolerance to Cosentyx (secukinumab) AND one of the following: Enbrel (etanercept) or Humira (adalimumab), OR b) for continuation of prior Taltz therapy. Ankylosing spondylitis (AS) (initial): Diagnosis of active AS. One of the following: a) Trial and failure, contraindication, or intolerance to Cosentyx (secukinumab) AND one of the following: Enbrel (etanercept) or Humira (adalimumab), OR b) for continuation of prior Taltz therapy.
Age Restrictions	N/A
Prescriber Restrictions	Plaque Psoriasis (initial): Prescribed by or in consultation with a dermatologist. PsA (initial): Prescribed by or in consultation with a dermatologist or rheumatologist. AS (initial): Prescribed by or in consultation with a rheumatologist.
Coverage Duration	Initial, reauth: 12 months
Other Criteria	All indications (Reauth): Documentation of positive clinical response to Taltz therapy.

Prior Authorization Criteria
Scott and White
Effective: December 1, 2019

TALZENNA (S)

Products Affected

- Talzenna

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Breast cancer: Diagnosis of breast cancer. Disease is one of the following: a) locally advanced or b) metastatic. Presence of a deleterious or suspected deleterious germline BRCA-mutation (gBRCAm) as detected by an FDA-approved test or at a Clinical Laboratory Improvement Amendments (CLIA)-approved facility. Disease is human epidermal growth factor receptor 2 (HER2)-negative.
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	12 months
Other Criteria	Approve for continuation of prior therapy.

Prior Authorization Criteria
 Scott and White
 Effective: December 1, 2019

TARCEVA (S)

Products Affected

- Erlotinib Hydrochloride
- Tarceva

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Non-small cell lung cancer (NSCLC): Diagnosis of locally advanced or metastatic (Stage III or IV) NSCLC AND Patient has known active epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutation as detected by an FDA-approved test or at a Clinical Laboratory Improvement Amendments-approved facility. Pancreatic Cancer: Diagnosis of locally advanced, unresectable, or metastatic pancreatic cancer AND erlonitib will be used in combination with gemcitabine.
Age Restrictions	N/A
Prescriber Restrictions	All uses: Prescribed by or in consultation with an oncologist
Coverage Duration	All uses: 12 months
Other Criteria	All Indications: Approve for continuation of prior therapy.

Prior Authorization Criteria
Scott and White
Effective: December 1, 2019

TARGRETIN (S)

Products Affected

- Bexarotene

- Targretin GEL

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Cutaneous T-Cell Lymphoma (CTCL): Diagnosis of CTCL. Trial and failure, contraindication, or intolerance to at least one prior therapy (including skin-directed therapies [eg, corticosteroids {ie, clobetasol, diflorasone, halobetasol, augmented betamethasone dipropionate}] or systemic therapies [eg, interferons]).
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with an oncologist or dermatologist
Coverage Duration	12 months
Other Criteria	Approve for continuation of prior therapy.

Prior Authorization Criteria
Scott and White
Effective: December 1, 2019

TASIGNA (S)

Products Affected

- Tasigna

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Chronic myelogenous leukemia (CML): Diagnosis of Ph+/BCR ABL CML
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with an oncologist or hematologist
Coverage Duration	12 months
Other Criteria	Approve for continuation of prior therapy.

Prior Authorization Criteria
 Scott and White
 Effective: December 1, 2019

TAVALISSE (S)

Products Affected

- Tavalisse

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Chronic Idiopathic Thrombocytopenic Purpura (ITP) (initial): Diagnosis of chronic immune ITP or relapsed/refractory ITP. Baseline platelet count is less than 30,000/mcL. Trial and failure, contraindication, or intolerance to at least one of the following: corticosteroids, immunoglobulins, splenectomy, thrombopoietin receptor agonists (e.g., Nplate, Promacta), or Rituxan (rituximab). Patient's degree of thrombocytopenia and clinical condition increase the risk of bleeding.
Age Restrictions	N/A
Prescriber Restrictions	ITP (initial): Prescribed by or in consultation with a hematologist/oncologist.
Coverage Duration	ITP (initial, reauth): 12 months
Other Criteria	ITP (reauth): Documentation of positive clinical response to Tavalisse therapy as evidenced by an increase in platelet count to a level sufficient to avoid clinically important bleeding.

TECENTRIQ (S)

Products Affected

- Tecentriq

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Urothelial Carcinoma: Diagnosis (dx) of locally advanced or metastatic urothelial carcinoma. One of the following: A) Patient is not eligible for cisplatin-containing chemotherapy, OR B) Patient has disease progression during or following any platinum-containing chemotherapy, OR C) Patient has disease progression within 12 months of neoadjuvant or adjuvant chemotherapy. Non-Small Cell Lung Cancer (NSCLC): Dx of metastatic NSCLC. Patient has disease progression during or following platinum-containing chemotherapy. One of the following: 1) Patient does not have epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) genomic tumor aberrations, OR 2) Both of the following: patient has an EGFR genomic tumor aberration AND disease progression on one anti-EGFR therapy [e.g., Gilotrif (afatinib), Iressa (gefitinib), Tarceva (erlotinib)], OR 3) Both of the following: patient has an ALK genomic tumor aberration AND disease progression on one ALK inhibitor [e.g., Alecensa (alectinib), Xalkori (crizotinib), Zykadia (ceritinib)].
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with an oncologist.
Coverage Duration	12 months.
Other Criteria	All Indications: Approve for continuation of prior therapy.

Prior Authorization Criteria
Scott and White
Effective: December 1, 2019

TECFIDERA (S)

Products Affected

- Tecfidera

- Tecfidera Starter Pack

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Multiple Sclerosis (MS): Diagnosis of a relapsing form of MS (eg, relapsing-remitting MS, secondary-progressive MS with relapses, progressive-relapsing MS with relapses).
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	N/A

Prior Authorization Criteria
Scott and White
Effective: December 1, 2019

TECHNIVIE (S)

Products Affected

- Technivie

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Criteria will be applied consistent with current AASLD/IDSA guideline. Diagnosis of chronic hepatitis C. Patient is not receiving Technivie in combination with another HCV direct acting antiviral agent [eg, Harvoni (ledipasvir-sofosbuvir), Sovaldi (sofosbuvir)]. ONE of the following: Trial and failure, intolerance, or contraindication to a) Harvoni OR Epclusa and b) Mavyret, OR for continuation of prior Technivie therapy.
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with one of the following: Hepatologist, Gastroenterologist, Infectious disease specialist, HIV specialist certified through the American Academy of HIV Medicine.
Coverage Duration	12 weeks. Criteria will be applied consistent with current AASLD/IDSA guideline.
Other Criteria	N/A

TEGSEDI (S)

Products Affected

- Tegsedi

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis) (initial): Diagnosis of hATTR amyloidosis with polyneuropathy. Patient has a transthyretin (TTR) mutation (e.g., V30M). One of the following: 1) Patient has a baseline polyneuropathy disability (PND) score less than or equal to IIIb, 2) Patient has baseline familial amyloidotic polyneuropathy (FAP) stage of 1 or 2, OR 3) Patient has a baseline neuropathy impairment score (NIS) between 10 and 130. Presence of clinical signs and symptoms of the disease (e.g., peripheral/autonomic neuropathy).
Age Restrictions	N/A
Prescriber Restrictions	hATTR amyloidosis (initial): Prescribed by or in consultation with a neurologist
Coverage Duration	hATTR amyloidosis (initial, reauth): 12 months
Other Criteria	hATTR amyloidosis (reauth): Patient has demonstrated a benefit from therapy (e.g., improved neurologic impairment, slowing of disease progression, quality of life assessment). One of the following: 1) Patient continues to have a PND score less than or equal to IIIb, 2) Patient continues to have a FAP stage of 1 or 2, OR 3) Patient continues to have a NIS between 10 and 130.

Prior Authorization Criteria
 Scott and White
 Effective: December 1, 2019

TESTOSTERONE (S)

Products Affected

- Androderm PT24 2MG/24HR, 4MG/24HR
- AndroGel GEL 20.25MG/1.25GM, 40.5MG/2.5GM
- AndroGel Pump GEL 1.62%
- Striant
- Testosterone GEL 1.62%, 20.25MG/1.25GM, 25MG/2.5GM, 40.5MG/2.5GM, 50MG/5GM
- Testosterone SOLN
- Testosterone Cypionate INJ 100MG/ML, 200MG/ML
- Testosterone Pump
- Testosterone Topical Solution
- Xyosted

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Hypogonadism (HG) (Initial): Diagnosis (dx) of HG AND male patient at birth AND one of the following: 1) Two pre-treatment serum total testosterone (T) levels less than reference range for the lab OR 2) Both of the following: a) Has a condition that may cause altered sex-hormone binding globulin (SHBG) (eg, thyroid disorder, HIV disease, liver disorder, diabetes, obesity), and b) one pre-treatment calculated free or bioavailable T level less than 5 ng/dL (0.17 nmol/L) or less than reference range for the lab, OR 3) History of bilateral orchiectomy, panhypopituitarism, or a genetic disorder known to cause HG (eg, congenital anorchia, Klinefelter's syndrome). Gender Identity Disorder or Gender Dysphoria (GID/GD) (off-label): Dx of GID/GD. Patient is a female-to-male transsexual.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	HG(init): (New to T tx:6 mo. New to plan and cont T tx:12 mo), (reauth): 12 mo. GID/GD: 12 mo.

Prior Authorization Criteria

Scott and White

Effective: December 1, 2019

Other Criteria	HG (Reauth): 1) Follow-up total serum T level within or below the normal limits of the reporting lab, or 2) Follow-up total serum T level outside of upper limits of normal for the reporting lab and the dose is adjusted, OR 3) Has a condition that may cause altered SHBG (eg, thyroid disorder, HIV disease, liver disorder, diabetes, obesity), and one of the following: Follow-up calculated free or bioavailable T level within or below the normal limits of the reporting lab, or follow-up calculated free or bioavailable T level outside of upper limits of normal for the reporting lab and the dose is adjusted.
-----------------------	--

TESTOSTERONE ENANTHATE (S)

Products Affected

- Testosterone Enanthate INJ

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Hypogonadism (HG) (Initial): Diagnosis (dx) of HG AND male patient at birth AND one of the following: 1) Two pre-treatment serum total testosterone (T) levels less than reference range for the lab OR 2) Both of the following: a) Has a condition that may cause altered sex-hormone binding globulin (SHBG) (eg, thyroid disorder, HIV disease, liver disorder, diabetes, obesity), and b) one pre-treatment calculated free or bioavailable T level less than 5 ng/dL (0.17 nmol/L) or less than reference range for the lab, OR 3) History of bilateral orchiectomy, panhypopituitarism, or a genetic disorder known to cause HG (eg, congenital anorchia, Klinefelter's syndrome). Delayed puberty (DP): Dx of DP AND male patient at birth. Breast cancer (BC): Dx of inoperable BC AND used for palliative treatment AND female patient at birth. Gender Identity Disorder or Gender Dysphoria (GID/GD) (off-label): Dx of GID/GD. Patient is a female-to-male transsexual.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	HG(init): (New to T tx:6 mo. Cont T tx:12 mo), (reauth): 12 mo. BC, GID/GD: 12 mo. DP: 6 mo.
Other Criteria	HG (Reauth): 1) Follow-up total serum T level within or below the normal limits of the reporting lab, or 2) Follow-up total serum T level outside of upper limits of normal for the reporting lab and the dose is adjusted, OR 3) Has a condition that may cause altered SHBG (eg, thyroid disorder, HIV disease, liver disorder, diabetes, obesity), and one of the following: Follow-up calculated free or bioavailable T level within or below the normal limits of the reporting lab, or follow-up calculated free or bioavailable T level outside of upper limits of normal for the reporting lab and the dose is adjusted.

Prior Authorization Criteria
 Scott and White
 Effective: December 1, 2019

THALOMID (S)

Products Affected

- Thalomid

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Multiple myeloma (MM): Diagnosis of MM. Used in combination with dexamethasone, unless the patient has an intolerance to steroids. Erythema nodosum leprosum (ENL): Diagnosis of moderate to severe ENL with cutaneous manifestations. Thalomid is not used as monotherapy if moderate to severe neuritis is present.
Age Restrictions	N/A
Prescriber Restrictions	MM: Prescribed by or in consultation with an oncologist/hematologist
Coverage Duration	12 months
Other Criteria	Approve for continuation of prior therapy.

Prior Authorization Criteria
 Scott and White
 Effective: December 1, 2019

THYROGEN (S)

Products Affected

- Thyrogen

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Patient requires Blood Tg testing or Radioiodine ablation of remnant thyroid tissue after a thyroidectomy. One of the following: 1) Patient is unable to tolerate thyroid hormone withdrawal (i.e., intolerable hypothyroid symptoms), OR 2) Thyroid hormone withdrawal is medically contraindicated (i.e., exacerbation of comorbid conditions), OR 3) Patient had inadequate thyroid stimulating hormone (TSH) response to thyroid hormone withdrawal, OR 4) Patient has an undetectable Tg on thyroid hormone suppressive therapy, to exclude the diagnosis of residual or recurrent thyroid cancer.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	N/A

Prior Authorization Criteria
 Scott and White
 Effective: December 1, 2019

TIBSOVO (S)

Products Affected

- Tibsovo

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Relapsed or refractory Acute Myeloid Leukemia (AML): Diagnosis of AML. Disease is relapsed or refractory. Patient has an isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test (e.g., Abbott RealTime IDH1 assay) or performed at a facility approved by Clinical Laboratory Improvement Amendments (CLIA). Newly-Diagnosed AML: Diagnosis of newly-diagnosed AML. Patient has an isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test (e.g., Abbott RealTime IDH1 assay) or a test performed at a facility approved by Clinical Laboratory Improvement Amendments (CLIA). One of the following: 1) patient is greater than or equal to 75 years old OR 2) patient has comorbidities that preclude use of intensive induction chemotherapy.
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with a hematologist/oncologist.
Coverage Duration	12 months
Other Criteria	Approve for continuation of prior therapy.

Prior Authorization Criteria
Scott and White
Effective: December 1, 2019

TIGLUTIK (S)

Products Affected

- Tiglutik

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Amyotrophic Lateral Sclerosis (ALS): Diagnosis of ALS. Trial and failure or intolerance to generic riluzole tablets.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	N/A

Prior Authorization Criteria
Scott and White
Effective: December 1, 2019

TOLSURA (S)

Products Affected

- Tolsura

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Diagnosis of one of the following: Blastomycosis, Histoplasmosis, or Aspergillosis. Trial and failure or intolerance to generic itraconazole capsules.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	6 months
Other Criteria	N/A

Prior Authorization Criteria
Scott and White
Effective: December 1, 2019

TOPICAL RETINOID (S)

Products Affected

- Avita
- Tretinoin CREA
- Tretinoin GEL
- Tretinoin Microsphere
- Tretinoin Microsphere Pump

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Acne vulgaris: Diagnosis of acne vulgaris (i.e., acne).
Age Restrictions	PA applies to members 26 years of age or older
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	N/A

Prior Authorization Criteria
 Scott and White
 Effective: December 1, 2019

TRACLEER (S)

Products Affected

- Bosentan

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Pulmonary arterial hypertension (PAH) (Initial): Diagnosis of PAH AND PAH is symptomatic AND One of the following: A) Diagnosis of PAH was confirmed by right heart catheterization or B) Patient is currently on any therapy for the diagnosis of PAH.
Age Restrictions	N/A
Prescriber Restrictions	PAH (initial): Prescribed by or in consultation with a pulmonologist or cardiologist.
Coverage Duration	PAH (Initial): 6 months. PAH (Reauth): 12 months
Other Criteria	PAH (Reauth): Documentation of positive clinical response to therapy.

Prior Authorization Criteria
Scott and White
Effective: December 1, 2019

TRELSTAR (S)

Products Affected

- Trelstar

- Trelstar Mixject

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Prostate Cancer: Diagnosis of advanced or metastatic prostate cancer. Trial and failure, contraindication, or intolerance to Lupron Depot (7.5 mg, 22.5 mg, 30 mg, and 45 mg).
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	12 months
Other Criteria	Approve for continuation of prior therapy.

Prior Authorization Criteria
 Scott and White
 Effective: December 1, 2019

TREMFYA (S)

Products Affected

- Tremfya

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Plaque psoriasis (Initial): Diagnosis of moderate to severe plaque psoriasis. One of the following: set A) 1) Trial and failure, contraindication, or intolerance (TF/C/I) to Enbrel (etanercept) or Humira (adalimumab) AND 2) TF/C/I to Cosentyx (secukinumab), OR set B) for continuation of prior Tremfya therapy.
Age Restrictions	N/A
Prescriber Restrictions	Plaque psoriasis (initial): Prescribed by or in consultation with a dermatologist.
Coverage Duration	Plaque psoriasis (Initial, reauth): 12 months
Other Criteria	Plaque psoriasis (Reauth): Documentation of positive clinical response to Tremfya therapy.

Prior Authorization Criteria
 Scott and White
 Effective: December 1, 2019

TRIPTODUR (S)

Products Affected

- Triptodur

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Central Precocious Puberty (CPP) (initial): Diagnosis of CPP (idiopathic or neurogenic). Early onset of secondary sexual characteristics in females less than age 8 or males less than age 9. Advanced bone age of at least one year compared with chronologic age. One of the following: a) patient has undergone gonadotropin-releasing hormone agonist (GnRHa) testing AND Peak luteinizing hormone (LH) level above pre-pubertal range, or b) patient has a random LH level in the pubertal range. Trial and failure or intolerance to Lupron Depot-Ped.
Age Restrictions	N/A
Prescriber Restrictions	CPP (initial): Prescribed by or in consultation with a pediatric endocrinologist.
Coverage Duration	CPP (Initial, reauth): 12 months
Other Criteria	CPP (reauthorization): LH levels have been suppressed to pre-pubertal levels.

Prior Authorization Criteria
Scott and White
Effective: December 1, 2019

TURALIO (S)

Products Affected

- Turalio

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Tenosynovial Giant Cell Tumor (TGCT): Diagnosis of TGCT. Patient is symptomatic. Patient is not a candidate for surgery due to worsening functional limitation or severe morbidity with surgical removal.
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with a hematologist/oncologist
Coverage Duration	12 months
Other Criteria	Approve for continuation of prior therapy.

Prior Authorization Criteria
Scott and White
Effective: December 1, 2019

TYKERB (S)

Products Affected

- Tykerb

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Breast Cancer: Diagnosis of human epidermal growth factor receptor 2 (HER2)-positive metastatic or recurrent breast cancer. Used in combination with one of the following: Trastuzumab, Xeloda (capecitabine), or aromatase inhibitors [eg, Aromasin (exemestane), Femara (letrozole), Arimidex (anastrozole)].
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with an oncologist.
Coverage Duration	12 months
Other Criteria	Approve for continuation of prior therapy.

TYMLOS (S)

Products Affected

- Tymlos

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Diagnosis of postmenopausal osteoporosis or osteopenia. One of the following: Set I) Both of the following: A) Bone mineral density (BMD) T-score of -2.5 or lower in the lumbar spine, femoral neck, total hip, or radius (one-third radius site) AND B) One of the following: 1) history of low-trauma fracture of the hip, spine, proximal humerus, pelvis, or distal forearm, or 2) trial and failure, contraindication, or intolerance (TF/C/I) to one osteoporosis treatment (e.g., alendronate, risedronate, zoledronic acid, Prolia [denosumab]), or Set II) Both of the following: A) BMD T-score between -1.0 and -2.5 in the lumbar spine, femoral neck, total hip, or radius (one-third radius site) AND B) One of the following: 1) history of low-trauma fracture of the hip, spine, proximal humerus, pelvis, or distal forearm, or 2) both of the following: i) TF/C/I to one osteoporosis treatment (e.g., alendronate, risedronate, zoledronic acid, Prolia [denosumab]) and ii) one of the following FRAX (Fracture Risk Assessment Tool) 10-year probabilities: a) major osteoporotic fracture at 20% or more in the U.S., or the country-specific threshold in other countries or regions, or b) hip fracture at 3% or more in the U.S., or the country-specific threshold in other countries or regions. Treatment duration of parathyroid hormones (e.g., Forteo [teriparatide], Tymlos [abaloparatide]) has not exceeded a total of 24 months during the patient's lifetime.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	24 months (max 24 months of therapy per lifetime)
Other Criteria	N/A

Prior Authorization Criteria
Scott and White
Effective: December 1, 2019

TYSABRI (S)

Products Affected

- Tysabri

Prior Authorization Criteria
 Scott and White
 Effective: December 1, 2019

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	<p>Multiple Sclerosis (MS): Diagnosis of a relapsing form of MS (eg, relapsing-remitting MS, secondary-progressive MS with relapses, progressive-relapsing MS with relapses). One of the following: 1) Trial and failure, contraindication, or intolerance (TF/C/I) to two of the following disease-modifying therapies for MS: Aubagio (teriflunomide), Avonex (interferon beta-1a), Betaseron (interferon beta-1b), Copaxone/Glatopa (glatiramer acetate), Extavia (interferon beta-1b), Gilenya (fingolimod), Plegridy (peginterferon beta-1a), Rebif (interferon beta-1a), or Tecfidera (dimethyl fumarate), or 2) Patient is not a candidate for any of the drugs listed as prerequisites due to the severity of their MS. Not used in combination with another disease-modifying therapy for MS.</p> <p>Crohn's Disease (CD) (initial): Diagnosis of moderate to severe CD with evidence of inflammation (eg, elevated C-reactive protein [CRP], elevated erythrocyte sedimentation rate, presence of fecal leukocytes). TF/C/I to one of the following conventional therapies: corticosteroids, 6-mercaptopurine (6MP [Purinethol], azathioprine (Imuran), methotrexate, aminosaliclates (eg, sulfasalazine, mesalamine, olsalazine). TF/C/I to a TNF-inhibitor (eg, Cimzia [certolizumab pegol], Humira [adalimumab], Remicade [infliximab]). CD (initial and reauth): Not used in combination with an immunosuppressant (eg, 6-MP, azathioprine, cyclosporine, or methotrexate). Not used in combination with a TNF-inhibitor (eg, Enbrel [etanercept], Humira [adalimumab], or Remicade [infliximab]).</p>
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	MS: 12mo. CD (Init): 3 mo. CD (Reauth): 6 mo if not on steroids. Otherwise, 3 mo.
Other Criteria	CD (reauth): Documentation of positive clinical response (eg, improved disease activity index) to Tysabri therapy.

UDENYCA (S)

Products Affected

- Udenyca

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Primary prophylaxis of chemotherapy-induced febrile neutropenia (CFN): One of the following: 1) patient is receiving chemotherapy regimens associated with a greater than 20% incidence of FN, OR 2) both of the following: a) patient receiving chemotherapy regimen associated with 10-20% incidence of FN, AND b) one or more risk factors associated with chemotherapy-induced infection, FN, or neutropenia. Secondary prophylaxis of FN: Both of the following: 1) patients receiving myelosuppressive anticancer drugs associated with neutropenia, AND 2) patients with a history of FN or dose-limiting event during a previous course of chemotherapy. Neutropenia associated with dose-dense chemotherapy (NDDC): One of the following: 1) patient is receiving National Cancer Institute's Breast Intergroup, INT C9741 dose dense chemotherapy protocol for primary breast cancer, OR 2) patient is receiving a dose-dense chemotherapy regimen for which the incidence of FN is unknown. Treatment of FN (off-label): Both of the following: 1) patients who have received or are receiving myelosuppressive anticancer drugs associated with neutropenia, AND 2) patients with FN at high risk for infection-associated complications. Acute radiation syndrome (ARS): Patient was/will be acutely exposed to myelosuppressive doses of radiation (hematopoietic subsyndrome of ARS).
Age Restrictions	N/A
Prescriber Restrictions	All uses: Prescribed by or in consultation with a hematologist/oncologist
Coverage Duration	ARS: 1 mo. CFN, NDDC, FN (prophylaxis, treatment): 3 mo or duration of tx.
Other Criteria	N/A

UPTRAVI (S)

Products Affected

- Upravi

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Pulmonary arterial hypertension (PAH) (initial): Diagnosis of PAH AND Patient is symptomatic AND One of the following: a) Diagnosis of PAH was confirmed by right heart catheterization OR b) patient is currently on any therapy for the diagnosis of PAH. One of the following: a) History of trial and failure, contraindication, or intolerance to a PDE5 inhibitor [i.e., Adcirca (tadalafil), Revatio (sildenafil)] or Adempas (riociguat), and History of trial and failure, contraindication, or intolerance to an endothelin receptor antagonist [e.g. Letairis (ambrisentan), Opsumit (macitentan), or Tracleer (bosentan)] OR b) For continuation of prior Upravi therapy. Not taken in combination with a prostanoid/prostacyclin analogue [e.g., Flolan (epoprostenol), Ventavis (iloprost), Tyvaso/Remodulin/Orenitram (treprostinil)].
Age Restrictions	N/A
Prescriber Restrictions	PAH (initial): Prescribed by or in consultation with a pulmonologist or cardiologist.
Coverage Duration	Initial: 6 months. Reauth: 12 months
Other Criteria	PAH (Reauth): Documentation of positive clinical response to Upravi therapy. Not taken in combination with a prostanoid/prostacyclin analogue [e.g., Flolan (epoprostenol), Ventavis (iloprost), Tyvaso/Remodulin/Orenitram (treprostinil)].

Prior Authorization Criteria
Scott and White
Effective: December 1, 2019

VALCHLOR (S)

Products Affected

- Valchlor

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Mycosis fungoides-type cutaneous T-cell lymphoma (MF-CTCL) (initial): All of the following: 1) diagnosis of Stage IA MF-CTCL, OR diagnosis of Stage IB MF-CTCL, AND 2) patient has received at least one prior skin-directed therapy [e.g., topical corticosteroids, bexarotene topical gel (Targretin topical gel), topical nitrogen mustard, etc.].
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with an oncologist or dermatologist
Coverage Duration	12 months
Other Criteria	Approve for continuation of prior therapy.

Prior Authorization Criteria
 Scott and White
 Effective: December 1, 2019

VARIZIG (S)

Products Affected

- Varizig INJ 125UNIT/1.2ML

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	Presence of contraindications to immune globulin therapy (i.e., IgA deficiency with antibodies to IgA and a history of hypersensitivity or product specific contraindication).
Required Medical Information	Immune globulin is being used intramuscularly. The immune globulin is being used for passive immunization or post exposure-prophylaxis of varicella. Patient is considered a high risk individual (i.e., immune compromised, pregnant woman, newborn of mother with varicella, premature infant, and infant less than 1 year old).
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	3 months (approve one dose only)
Other Criteria	N/A

Prior Authorization Criteria
Scott and White
Effective: December 1, 2019

VELCADE (S)

Products Affected

- Velcade

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Multiple myeloma (MM): Diagnosis of MM. Mantle cell lymphoma (MCL): Diagnosis of MCL.
Age Restrictions	N/A
Prescriber Restrictions	MM, MCL: Prescribed by or in consultation with an oncologist/hematologist
Coverage Duration	12 months
Other Criteria	Approve for continuation of prior therapy.

Prior Authorization Criteria
 Scott and White
 Effective: December 1, 2019

VENCLEXTA (S)

Products Affected

- Venclexta

- Venclexta Starting Pack

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Chronic lymphocytic leukemia (CLL)/Small lymphocytic lymphoma (SLL): Diagnosis of CLL or SLL. Acute Myeloid Leukemia (AML): Diagnosis of newly diagnosed AML. Used in combination with azacitidine, or decitabine, or low-dose cytarabine. One of the following: 1) age 75 years or older OR 2) comorbidities that preclude use of intensive induction chemotherapy.
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with a hematologist or oncologist
Coverage Duration	12 months
Other Criteria	Approve for continuation of prior therapy.

Prior Authorization Criteria
 Scott and White
 Effective: December 1, 2019

VENTAVIS (S)

Products Affected

- Ventavis

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Pulmonary arterial hypertension (PAH) (Initial): Diagnosis of PAH. PAH is symptomatic. One of the following: A) Diagnosis of PAH was confirmed by right heart catheterization or B) Patient is currently on any therapy for the diagnosis of PAH.
Age Restrictions	N/A
Prescriber Restrictions	PAH (initial): Prescribed by or in consultation with a pulmonologist or cardiologist.
Coverage Duration	PAH (Initial): 6 months. (Reauth): 12 months
Other Criteria	Subject to Part B vs D review. PAH (Reauth): Documentation of positive clinical response to therapy.

Prior Authorization Criteria
 Scott and White
 Effective: December 1, 2019

VERZENIO (S)

Products Affected

- Verzenio

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Breast Cancer: Diagnosis of advanced or metastatic breast cancer. Disease is hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative. One of the following: a) used in combination with an aromatase inhibitor (e.g., Arimidex [anastrozole], Aromasin [exemestane], Femara [letrozole]) and patient is a postmenopausal woman, OR b) used in combination with Faslodex (fulvestrant) and disease has progressed following endocrine therapy, OR c) used as monotherapy and disease has progressed following endocrine therapy and patient has already received at least one prior chemotherapy regimen.
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with an oncologist.
Coverage Duration	12 months
Other Criteria	Approve for continuation of prior therapy.

Prior Authorization Criteria
 Scott and White
 Effective: December 1, 2019

VIEKIRA (S)

Products Affected

- Viekira Pak

- Viekira Xr

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Criteria will be applied consistent with current AASLD/IDSA guideline. Diagnosis of chronic hepatitis C. ONE of the following: 1) Patient has a trial and failure, contraindication, or intolerance to a) Harvoni OR Eplclusa and b) Mavyret, OR 2) For continuation of prior Viekira therapy. Patient is not receiving Viekira in combination with another HCV direct acting antiviral agent [e.g., Harvoni (ledipasvir-sofosbuvir), Sovaldi (sofosbuvir)]. Patient is without decompensated liver disease (e.g., Child-Pugh Class B or C). ONE of the following: 1) Patient has not experienced prior failure with an NS5A inhibitor or NS3/4A protease inhibitor-containing regimen OR 2) patient has failed prior therapy with an NS5A inhibitor or NS3/4A protease inhibitor AND patient does not have NS3 protease inhibitor or NS5A inhibitor resistance-associated variants detected using commercially available assays.
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with one of the following: Hepatologist, Gastroenterologist, Infectious disease specialist, HIV specialist certified through the American Academy of HIV Medicine.
Coverage Duration	12 to 24 weeks. Criteria will be applied consistent with current AASLD/IDSA guideline.
Other Criteria	N/A

Prior Authorization Criteria
 Scott and White
 Effective: December 1, 2019

VIMIZIM (S)

Products Affected

- Vimizim

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Mucopolysaccharidosis (initial): Diagnosis of Mucopolysaccharidosis type IVA (MPS IVA, Morquio A syndrome) confirmed by both of the following: a) documented clinical signs and symptoms of the disease (e.g., kyphoscoliosis, genu valgum, pectus carinatum, gait disturbance, growth deficiency, etc.) and b) documented reduced fibroblast or leukocyte GALNS enzyme activity or molecular genetic testing of GALNS.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Initial, reauth: 12 months
Other Criteria	Reauth: Documentation of positive clinical response to Vimizim therapy.

VITRAKVI (S)

Products Affected

- Vitrakvi

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Presence of solid tumors (e.g., salivary gland, soft tissue sarcoma, infantile fibrosarcoma, thyroid cancer, lung, melanoma, colon, etc.). Disease is positive for neurotrophic receptor tyrosine kinase (NTRK) gene fusion (e.g. ETV6-NTRK3, TPM3-NTRK1, LMNA-NTRK1, etc.). Disease is without a known acquired resistance mutation [e.g., TRKA G595R substitution, TRKA G667C substitution, or other recurrent kinase domain (solvent front and xDFG) mutations]. Disease is one of the following: metastatic or unresectable (including cases where surgical resection is likely to result in severe morbidity). One of the following: Disease has progressed on previous treatment (e.g., surgery, radiotherapy, or systemic therapy) OR Disease has no satisfactory alternative treatments.
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	12 months
Other Criteria	Approve for continuation of prior therapy.

Prior Authorization Criteria
Scott and White
Effective: December 1, 2019

VIZIMPRO (S)

Products Affected

- Vizimpro

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Non-small cell lung cancer (NSCLC): Diagnosis of NSCLC. Disease is metastatic. Disease is positive for one of the following epidermal growth factor receptor (EGFR) mutations: exon 19 deletion or exon 21 L858R substitution.
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	12 months
Other Criteria	Approve for continuation of prior therapy.

Prior Authorization Criteria
 Scott and White
 Effective: December 1, 2019

VOSEVI (S)

Products Affected

- Vosevi

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Criteria will be applied consistent with current AASLD/IDSA guideline. All patients: Diagnosis of chronic hepatitis C, patient is without decompensated liver disease (defined as Child-Pugh Class B or C), and patient is not receiving Vosevi in combination with another HCV direct acting antiviral agent [e.g., Harvoni, Zepatier].
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with one of the following: Hepatologist, Gastroenterologist, Infectious disease specialist, HIV specialist certified through the American Academy of HIV Medicine.
Coverage Duration	12 weeks. Criteria will be applied consistent with current AASLD/IDSA guideline.
Other Criteria	N/A

Prior Authorization Criteria
Scott and White
Effective: December 1, 2019

VOTRIENT (S)

Products Affected

- Votrient

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Renal cell carcinoma (RCC): Diagnosis of advanced/metastatic RCC. Soft tissue sarcoma: Diagnosis of advanced soft tissue sarcoma and patient received at least one prior chemotherapy (e.g., ifosfamide, doxorubicin, cisplatin, dacarbazine, docetaxel, oxaliplatin, etc.).
Age Restrictions	N/A
Prescriber Restrictions	All uses: Prescribed by or in consultation with an oncologist
Coverage Duration	12 months
Other Criteria	Approve for continuation of prior therapy.

Prior Authorization Criteria
Scott and White
Effective: December 1, 2019

VPRIV (S)

Products Affected

- Vpriv

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Gaucher disease: Diagnosis of type 1 Gaucher disease. Patient has evidence of symptomatic disease (e.g., moderate to severe anemia, thrombocytopenia, bone disease, hepatomegaly, or splenomegaly).
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Gaucher disease: 12 months
Other Criteria	N/A

Prior Authorization Criteria
Scott and White
Effective: December 1, 2019

VYXEOS (S)

Products Affected

- Vyxeos

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Newly diagnosed therapy related acute myeloid leukemia (t-AML): Diagnosis of t-AML. Acute myeloid leukemia myelodysplasia-related changes (AML-MRC): Diagnosis of AML-MRC.
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with a hematologist/oncologist.
Coverage Duration	12 months
Other Criteria	Approve for continuation of prior therapy.

Prior Authorization Criteria
 Scott and White
 Effective: December 1, 2019

XALKORI (S)

Products Affected

- Xalkori

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Non-small cell lung cancer (NSCLC): Diagnosis of advanced or metastatic NSCLC AND One of the following: A) Patient has an anaplastic lymphoma kinase (ALK)-positive tumor as detected with an FDA-approved test or at a Clinical Laboratory Improvement Amendments-approved facility or B) Patient has MET amplification- or ROS1 rearrangements-positive tumor as detected with an FDA-approved test or at a Clinical Laboratory Improvement Amendments-approved facility.
Age Restrictions	N/A
Prescriber Restrictions	NSCLC: Prescribed by or in consultation with an oncologist
Coverage Duration	12 months
Other Criteria	Approve for continuation of prior therapy.

XELJANZ (S)

Products Affected

- Xeljanz
- Xeljanz Xr

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Xeljanz/Xeljanz XR: Rheumatoid arthritis (RA) (Initial): Diagnosis of moderately to severely active RA. Psoriatic arthritis (PsA) (Initial): Diagnosis of active PsA. RA/PsA (initial): One of the following: Failure, contraindication, or intolerance to both Enbrel (etanercept) and Humira (adalimumab), or attestation demonstrating a trial may be inappropriate, OR patient has a documented needle-phobia to the degree that the patient has previously refused any injectable therapy or medical procedure (refer to DSM-IV-TR 300.29 for specific phobia diagnostic criteria), OR for continuation of prior tofacitinib therapy. Xeljanz only: Ulcerative colitis (UC) (Initial): Diagnosis of moderately to severely active UC. Trial and failure, contraindication or intolerance to one of the following conventional therapies: 6-mercaptopurine (Purinethol), aminosalicylate [e.g., mesalamine (Asacol, Pentasa, Rowasa), olsalazine (Dipentum), sulfasalazine (Azulfidine, Sulfazine)], azathioprine (Imuran), or corticosteroids (e.g., prednisone, methylprednisolone). Trial and failure, contraindication, or intolerance to Humira (adalimumab), OR patient has a documented needle-phobia to the degree that the patient has previously refused any injectable therapy or medical procedure (refer to DSM-V-TR F40.2 for specific phobia diagnostic criteria), OR for continuation of prior Xeljanz therapy. All indications: Patient is not receiving tofacitinib in combination with a potent immunosuppressant (eg, azathioprine, cyclosporine).
Age Restrictions	N/A
Prescriber Restrictions	RA (initial): Prescribed by or in consultation with a rheumatologist. PsA (initial): Prescribed by or in consultation with a dermatologist or rheumatologist. UC (initial): Prescribed by or in consultation with a gastroenterologist.
Coverage Duration	RA/PsA (initial, reauth): 12 months. UC (init): 4 mo. UC (reauth): 12 mo.

Prior Authorization Criteria

Scott and White

Effective: December 1, 2019

Other Criteria	All Indications (Reauth): Documentation of positive clinical response to tofacitinib therapy. Patient is not receiving tofacitinib in combination with a potent immunosuppressant (eg, azathioprine, cyclosporine).
-----------------------	---

Prior Authorization Criteria
 Scott and White
 Effective: December 1, 2019

XENAZINE (S)

Products Affected

- Tetrabenazine

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Chorea associated with Huntington's Disease (HD) (Initial): Diagnosis of chorea in patients with Huntington's disease. Tardive dyskinesia (Initial): Patient has stereotypies associated with tardive dyskinesia. Tourette's syndrome (Initial): Patient has tics associated with Tourette's syndrome. Failure, contraindication, or intolerance to Haldol (haloperidol).
Age Restrictions	Tardive dyskinesia (Initial): Age greater than or equal to 18 years.
Prescriber Restrictions	HD (initial): Prescribed by or in consultation with a neurologist. Tardive dyskinesia, Tourette's syndrome (initial): Prescribed by or in consultation with neurologist or psychiatrist.
Coverage Duration	All uses: (initial) 3 months. (Reauth) 12 months.
Other Criteria	All indications (Reauth): Documentation of clinical response and benefit from therapy.

Prior Authorization Criteria
 Scott and White
 Effective: December 1, 2019

XEOMIN (S)

Products Affected

- Xeomin

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Cervical Dystonia (CD) (init): Diagnosis of CD (also known as spasmodic torticollis). Blepharospasm (initial): Diagnosis of blepharospasm. History of previous use of Botox (onabotulinumtoxinA) for the treatment of blepharospasm. Upper limb spasticity (ULS) (init): Diagnosis of upper limb spasticity.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	All uses (initial, reauth): 3 months (for 1 dose)
Other Criteria	All indications (reauth): Confirmed improvement in symptoms with initial Xeomin treatment. At least 3 months have elapsed since the last treatment with Xeomin.

Prior Authorization Criteria
Scott and White
Effective: December 1, 2019

XERMELO (S)

Products Affected

- Xermelo

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Carcinoid syndrome diarrhea (Initial): Diagnosis of carcinoid syndrome diarrhea AND diarrhea is inadequately controlled by a stable dose of somatostatin analog (SSA) therapy (e.g., octreotide [Sandostatin, Sandostatin LAR], lanreotide [Somatuline Depot]) for at least 3 months AND used in combination with SSA therapy.
Age Restrictions	N/A
Prescriber Restrictions	Initial: Prescribed by or in consultation with an oncologist, endocrinologist, or gastroenterologist
Coverage Duration	Initial: 6 months. Reauth: 12 months
Other Criteria	Carcinoid syndrome diarrhea (Reauthorization): Documentation of a positive clinical response to Xermelo therapy AND Xermelo will continue to be used in combination with SSA therapy.

Prior Authorization Criteria
 Scott and White
 Effective: December 1, 2019

XGEVA (S)

Products Affected

- Xgeva

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Multiple Myeloma (MM)/Bone metastasis from solid tumors (BMST): One of the following: 1) Diagnosis of multiple myeloma OR 2) diagnosis of solid tumors (eg, breast cancer, kidney cancer, lung cancer, prostate cancer, thyroid cancer), AND documented evidence of one or more metastatic bone lesions. Giant cell tumor of bone (GCTB): Both of the following: 1) diagnosis of giant cell tumor of bone AND 2) One of the following: a) tumor is unresectable, OR b) surgical resection is likely to result in severe morbidity. Hypercalcemia of malignancy (HCM): Both of the following: 1) diagnosis of hypercalcemia of malignancy, AND 2) Trial and failure, contraindication, or intolerance to one intravenous bisphosphonate (eg, Aredia (pamidronate), Zometa (zoledronic acid).
Age Restrictions	N/A
Prescriber Restrictions	GCTB, HCM: Prescribed by or in consultation with an oncologist
Coverage Duration	MM/BMST, GCTB: 12 mo. HCM: 2 mo.
Other Criteria	Approve for continuation of prior therapy.

XIAFLEX (S)

Products Affected

- Xiaflex

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Dupuytren's contracture (DC) (initial, reauth): Diagnosis of Dupuytren's contracture with a palpable cord AND Prescriber is enrolled in the Xiaflex REMS program for Dupuytren's contracture AND Patient has a positive "table top test" (defined as the inability to simultaneously place the affected finger and palm flat against a table top) AND Patient has a documented contracture of at least 20 degrees flexion for a metacarpophalangeal joint or a proximal interphalangeal joint AND Patient has a flexion deformity that results in functional limitations. Peyronie's disease (PD) (initial, reauth): Diagnosis of Peyronie's disease AND Prescriber is enrolled in the Xiaflex REMS program for Peyronie's disease AND Patient has a palpable plaque and curvature deformity of at least 30 degrees at the start of therapy AND The plaques do not involve the penile urethra AND Patient has a curvature deformity that results in pain (e.g., pain upon erection or intercourse).
Age Restrictions	Initial (DC, PD): 18 years of age or older
Prescriber Restrictions	N/A
Coverage Duration	DC, PD (Initial and reauth): 12 months
Other Criteria	Peyronie's disease (reauth): patient has a new plaque that results in a curvature deformity.

XIFAXAN (S)

Products Affected

- Xifaxan

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Travelers' diarrhea (TD) (200 mg strength only): Diagnosis of travelers' diarrhea, AND one of the following: a) Trial and failure, contraindication, or intolerance to one of the following: Cipro (ciprofloxacin), Levaquin (levofloxacin), ofloxacin, Zithromax (azithromycin) OR b) resistance to all of the following: Cipro (ciprofloxacin), Levaquin (levofloxacin), ofloxacin, Zithromax (azithromycin). Prophylaxis of hepatic encephalopathy (HE) recurrence (550mg strength only): Used for the prophylaxis of hepatic encephalopathy recurrence, AND trial and failure, contraindication or intolerance to lactulose. Treatment of HE: Used for the treatment of HE. Trial and failure, contraindication, or intolerance to lactulose. Irritable bowel syndrome with diarrhea (IBS-D) (550mg strength only) (initial): Diagnosis of IBS-D, AND trial and failure, contraindication or intolerance to an antidiarrheal agent [eg, loperamide].
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	TD: One time only. HE (prophylaxis, treatment): 12 months. IBS-D (initial, reauth): 2 weeks.
Other Criteria	IBS-D (reauth): Patient experiences IBS-D symptom recurrence.

XOLAIR (S)

Products Affected

- Xolair

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	<p>Asthma (init): Diagnosis of moderate to severe persistent allergic asthma. Positive skin test or in vitro reactivity to a perennial aeroallergen. Pretreatment serum immunoglobulin (Ig)E level between 30 to 700 IU/mL for patients 12 years of age and older OR 30 to 1300 IU/mL for patients 6 years to less than 12 years of age. Symptoms are not adequately controlled with use of ONE of the following, unless there is a contraindication or intolerance to these medications: 1) high-dose inhaled corticosteroid (ICS) [e.g., greater than 500 mcg fluticasone propionate equivalent/day] and additional asthma controller medication [e.g., leukotriene receptor antagonist, long-acting beta-2 agonist (LABA), theophylline] OR 2) One maximally-dosed inhaled corticosteroid (ICS) and a long-acting beta2-agonist combination. Chronic Idiopathic Urticaria (CIU) (init): Diagnosis of CIU. Persistent symptoms (itching and hives) for at least 4 consecutive weeks despite titrating to an optimal dose with a second generation H1 antihistamine, unless there is a contraindication or intolerance to H1 antihistamines. Patient has tried and had an inadequate response or intolerance or contraindication to at least one of the following additional therapies: H2 antagonist, leukotriene receptor antagonist, H1 antihistamine, hydroxyzine, doxepin. Used concurrently with an H1 antihistamine, unless there is a contraindication or intolerance to H1 antihistamines.</p>
Age Restrictions	N/A
Prescriber Restrictions	<p>Asthma (init): Prescribed by or in consultation with an allergist, immunologist, or pulmonologist. CIU (init): Prescribed by or in consultation with an allergist, immunologist, or dermatologist</p>
Coverage Duration	<p>Asthma (init): 6 months, Asthma (reauth): 12 months. CIU (init): 3 months, (reauth) 6 months</p>

Prior Authorization Criteria

Scott and White

Effective: December 1, 2019

Other Criteria	Asthma (reauth): Positive clinical response to therapy (e.g., Reduction in number of asthma exacerbations from baseline, Improvement in forced expiratory volume in 1 second (FEV1) from baseline or Decreased use of rescue medications from baseline). CIU (reauth): Patient's disease status has been re-evaluated since the last authorization to confirm the patient's condition warrants continued treatment. Patient has experienced one or both of the following: Reduction in itching severity from baseline or Reduction in the number of hives from baseline.
-----------------------	--

Prior Authorization Criteria
Scott and White
Effective: December 1, 2019

XOSPATA (S)

Products Affected

- Xospata

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Diagnosis of acute myeloid leukemia (AML). Disease is relapsed or refractory. Patient has a FMS-like tyrosine kinase (FLT3) mutation as determined by a U.S. Food and Drug Administration (FDA)-approved test (e.g., LeukoStrat CDx FLT3 Mutation Assay) or performed at a facility approved by Clinical Laboratory Improvement Amendments (CLIA).
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with a hematologist or oncologist.
Coverage Duration	12 months
Other Criteria	Approve for continuation of prior therapy.

Prior Authorization Criteria
 Scott and White
 Effective: December 1, 2019

XPOVIO (S)

Products Affected

- Xpovio 100 Mg Once Weekly
- Xpovio 60 Mg Once Weekly
- Xpovio 80 Mg Once Weekly
- Xpovio 80 Mg Twice Weekly

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Diagnosis of relapsed or refractory multiple myeloma (RRMM). Patient has received at least four prior therapies. Disease is refractory to all of the following: 1) Two proteasome inhibitors (e.g., bortezomib, carfilzomib), 2) Two immunomodulatory agents (e.g., lenalidomide, thalidomide), and 3) An anti-CD38 monoclonal antibody (e.g. daratumumab). Used in combination with dexamethasone.
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with an oncologist/hematologist
Coverage Duration	12 months
Other Criteria	Approve for continuation of prior therapy.

Prior Authorization Criteria
Scott and White
Effective: December 1, 2019

XTANDI (S)

Products Affected

- Xtandi

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Castration-resistant or castration-recurrent prostate cancer (CRPC): Diagnosis of castration-resistant or castration-recurrent prostate cancer.
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with an oncologist or urologist
Coverage Duration	12 months
Other Criteria	Approve for continuation of prior therapy.

Prior Authorization Criteria
Scott and White
Effective: December 1, 2019

XURIDEN (S)

Products Affected

- Xuriden

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Hereditary orotic aciduria (Initial): Diagnosis of hereditary orotic aciduria.
Age Restrictions	N/A
Prescriber Restrictions	Initial: Prescribed by or in consultation with a medical geneticist or other specialist that treats inborn errors of metabolism
Coverage Duration	Initial, reauth: 12 months
Other Criteria	Hereditary orotic aciduria (reauth): Documentation of positive clinical response to Xuriden therapy.

XYREM (S)

Products Affected

- Xyrem

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Narcolepsy with cataplexy (Narcolepsy Type 1)(initial): Diagnosis of narcolepsy as confirmed by sleep study (unless the prescriber provides justification confirming that a sleep study would not be feasible), AND symptoms of cataplexy are present, AND symptoms of excessive daytime sleepiness (eg, irrepressible need to sleep or daytime lapses into sleep) are present. Narcolepsy without cataplexy (Narcolepsy Type 2)(initial): Diagnosis of narcolepsy as confirmed by sleep study (unless the prescriber provides justification confirming that a sleep study would not be feasible), AND symptoms of cataplexy are absent, AND symptoms of excessive daytime sleepiness (eg, irrepressible need to sleep or daytime lapses into sleep) are present, AND trial and failure, contraindication, or intolerance to one of the following: 1) amphetamine-based stimulant (eg, amphetamine, dextroamphetamine), OR 2) methylphenidate-based stimulant.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	All uses (initial, reauth): 12 months
Other Criteria	Narcolepsy Type 1 (reauth): Documentation demonstrating a reduction in the frequency of cataplexy attacks associated with Xyrem therapy, OR documentation demonstrating a reduction in symptoms of excessive daytime sleepiness associated with Xyrem therapy. Narcolepsy Type 2 (reauth): Documentation demonstrating a reduction in symptoms of excessive daytime sleepiness associated with Xyrem therapy.

Prior Authorization Criteria
Scott and White
Effective: December 1, 2019

YERVOY (S)

Products Affected

- Yervoy

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Unresectable or metastatic melanoma: Diagnosis of unresectable, metastatic melanoma. Cutaneous melanoma: Diagnosis of cutaneous melanoma with pathologic involvement of regional lymph nodes of more than 1 mm. Patient has undergone resection, including total lymphadenectomy.
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	12 months
Other Criteria	Approve for continuation of prior therapy.

Prior Authorization Criteria
Scott and White
Effective: December 1, 2019

YONSA (S)

Products Affected

- Yonsa

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Prostate Cancer: Diagnosis of metastatic castration-resistant (chemical or surgical) or recurrent prostate cancer. Used in combination with methylprednisolone. One of the following: 1) Used in combination with a gonadotropin-releasing hormone (GnRH) analog or 2) Patient received a bilateral orchiectomy. Trial and failure or intolerance to Xtandi (enzalutamide).
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with an oncologist or urologist
Coverage Duration	12 months
Other Criteria	Approve for continuation of prior therapy

Prior Authorization Criteria
Scott and White
Effective: December 1, 2019

ZALTRAP (S)

Products Affected

- Zaltrap

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Colon and/or rectal cancer: Diagnosis of metastatic colon and/or rectal cancer. Ziv-aflibercept is being used in combination with 5-fluorouracil, leucovorin, and irinotecan (FOLFIRI) regimen. Patient has disease that is resistant to or has progressed following an oxaliplatin-containing regimen [e.g., 5-fluorouracil, leucovorin, and oxaliplatin (FOLFOX)].
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	12 months
Other Criteria	Approve for continuation of prior therapy.

Prior Authorization Criteria
Scott and White
Effective: December 1, 2019

ZAVESCA (S)

Products Affected

- Miglustat

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Gaucher disease: Diagnosis of mild to moderate type 1 Gaucher disease. Patient is unable to receive enzyme replacement therapy due to one of the following conditions: allergy or hypersensitivity to enzyme replacement therapy, poor venous access, unavailability of enzyme replacement therapy (e.g., Cerezyme, VPRIV).
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Gaucher disease: 12 months
Other Criteria	N/A

Prior Authorization Criteria
Scott and White
Effective: December 1, 2019

ZEJULA (S)

Products Affected

- Zejula

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer: Diagnosis of recurrent epithelial ovarian cancer, recurrent fallopian tube cancer, or recurrent primary peritoneal cancer. Used for maintenance treatment in patients who are in a complete or partial response to platinum-based chemotherapy (e.g., cisplatin, carboplatin).
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	12 months
Other Criteria	Approve for continuation of prior therapy.

Prior Authorization Criteria
 Scott and White
 Effective: December 1, 2019

ZELBORAF (S)

Products Affected

- Zelboraf

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Melanoma: Diagnosis of unresectable melanoma or metastatic melanoma. Cancer is BRAFV600 mutant type (MT) as detected by an FDA-approved test (eg, cobas 4600 BRAFV600 Mutation Test) or performed at a facility approved by Clinical Laboratory Improvement Amendments (CLIA). Erdheim-Chester Disease: Diagnosis of Erdheim-Chester disease AND Disease is BRAFV600 mutant type (MT).
Age Restrictions	N/A
Prescriber Restrictions	Melanoma: Prescribed by or in consultation with an oncologist. Erdheim-Chester Disease: Prescribed by or in consultation with a hematologist/oncologist.
Coverage Duration	12 months
Other Criteria	All indications: Approve for continuation of therapy.

Prior Authorization Criteria
 Scott and White
 Effective: December 1, 2019

ZEPATIER (S)

Products Affected

- Zepatier

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Criteria will be applied consistent with current AASLD/IDSA guideline. All patients: Diagnosis of chronic hepatitis C, ONE of the following: 1) Patient has a trial and failure, contraindication or intolerance to a) Harvoni OR Epclusa AND b) Mavyret, OR 2) For continuation of prior Zepatier therapy. Patient does not have moderate to severe hepatic impairment (eg, Child-Pugh Class B or C). For genotype 1a, patient has been tested for the presence of NS5A resistance-associated polymorphisms (ie, polymorphisms at amino acid positions 28, 30, 31, or 93).
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with one of the following: Hepatologist, Gastroenterologist, Infectious disease specialist, HIV specialist certified through the American Academy of HIV Medicine.
Coverage Duration	12 to 16 weeks. Criteria will be applied consistent with current AASLD/IDSA guideline.
Other Criteria	N/A

Prior Authorization Criteria
Scott and White
Effective: December 1, 2019

ZOLINZA (S)

Products Affected

- Zolinza

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Cutaneous T-cell lymphoma (CTCL): Diagnosis of CTCL. Progressive, persistent or recurrent disease on or contraindication or intolerance to two systemic therapies (e.g., bexarotene, romidepsin, etc.).
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with a hematologist/oncologist.
Coverage Duration	12 months
Other Criteria	Approve for continuation of prior therapy.

Prior Authorization Criteria
Scott and White
Effective: December 1, 2019

ZORBTIVE (S)

Products Affected

- Zorbtive

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Short Bowel Syndrome (SBS): Diagnosis of SBS. Patient is currently receiving specialized nutritional support (eg, intravenous parenteral nutrition, fluid, and micronutrient supplements). Patient has not previously received 4 weeks of treatment with Zorbtive.
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with a gastroenterologist.
Coverage Duration	SBS: 4 weeks.
Other Criteria	N/A

Prior Authorization Criteria
 Scott and White
 Effective: December 1, 2019

ZORTRESS (S)

Products Affected

- Zortress

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Prevention of kidney transplant organ rejection: The medication is being used for prevention of kidney transplant organ rejection. Patient is at low-to-moderate immunologic risk. Patient is prescribed concurrent therapy with reduced doses of cyclosporine AND corticosteroids. Prevention of liver transplant organ rejection: The medication is being used for prevention of liver transplant organ rejection. Thirty (30) or more days have passed since the transplant procedure. Patient is prescribed concurrent therapy with reduced doses of tacrolimus and corticosteroids.
Age Restrictions	All indications: 18 years of age or older
Prescriber Restrictions	All uses: Prescriber is experienced in immunosuppressive therapy and management of transplant patients.
Coverage Duration	12 months
Other Criteria	Subject to Part B vs. Part D review. Approve for continuation of prior therapy.

ZYDELIG (S)

Products Affected

- Zydelig

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Chronic lymphocytic leukemia (CLL): Diagnosis of CLL. Used in combination with Rituxan (rituximab). The patient has relapsed on at least one prior therapy (eg, purine analogues [fludarabine, pentostatin, cladribine], alkylating agents [chlorambucil, cyclophosphamide], or monoclonal antibodies [rituximab]). Patient is a candidate for Rituxan (rituximab) monotherapy due to presence of other comorbidities (eg, coronary artery disease, peripheral vascular disease, diabetes mellitus, pulmonary disease [COPD]). Follicular Lymphoma (FL): Diagnosis of FL. The patient has relapsed on at least two prior systemic therapies (eg, rituximab, alkylating agents [cyclophosphamide, chlorambucil], anthracyclines [doxorubicin, daunorubicine], purine analogs [fludarabine]). Small lymphocytic lymphoma (SLL): Diagnosis of SLL. The patient has relapsed on at least two prior systemic therapies (eg, rituximab, alkylating agents [cyclophosphamide, chlorambucil], anthracyclines [doxorubicin, daunorubicine], purine analogs [fludarabine]).
Age Restrictions	N/A
Prescriber Restrictions	All uses: Prescribed by or in consultation with an oncologist/hematologist.
Coverage Duration	12 months
Other Criteria	Approve for continuation of prior therapy.

Prior Authorization Criteria
Scott and White
Effective: December 1, 2019

ZYKADIA (S)

Products Affected

- Zykadia

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Non-small cell lung cancer (NSCLC): Diagnosis of NSCLC that is metastatic or recurrent. Tumor is anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test or at a Clinical Laboratory Improvement Amendments-approved facility.
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by or in consultation with an oncologist
Coverage Duration	12 months
Other Criteria	Approve for continuation of prior therapy.

Prior Authorization Criteria
 Scott and White
 Effective: December 1, 2019

ZYTIGA (NON-PREFERRED) (S)

Products Affected

- Zytiga

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Metastatic Castration-Resistant Prostate Cancer (mCRPC): Diagnosis of metastatic castration-resistant (chemical or surgical) or recurrent prostate cancer. Used in combination with prednisone. One of the following: 1) Used in combination with a gonadotropin-releasing hormone (GnRH) analog or 2) Patient received a bilateral orchiectomy. Trial and failure, or intolerance to Xtandi (enzalutamide). Metastatic Castration-Sensitive Prostate Cancer (mCSPC): Diagnosis of metastatic high-risk castration-sensitive prostate cancer. Used in combination with prednisone. One of the following: 1) Used in combination with a gonadotropin-releasing hormone (GnRH) analog or 2) Patient received a bilateral orchiectomy.
Age Restrictions	N/A
Prescriber Restrictions	mCRPC, mCSPC: Prescribed by or in consultation with an oncologist or urologist
Coverage Duration	mCRPC, mCSPC: 12 months
Other Criteria	Approve for continuation of prior therapy.

Prior Authorization Criteria
 Scott and White
 Effective: December 1, 2019

ZYTIGA (PREFERRED) (S)

Products Affected

- Abiraterone Acetate

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Metastatic Castration-Resistant Prostate Cancer (mCRPC): Diagnosis of metastatic castration-resistant (chemical or surgical) or recurrent prostate cancer. Used in combination with prednisone. One of the following: 1) Used in combination with a gonadotropin-releasing hormone (GnRH) analog or 2) Patient received a bilateral orchiectomy. Metastatic Castration-Sensitive Prostate Cancer (mCSPC): Diagnosis of metastatic high-risk castration-sensitive prostate cancer. Used in combination with prednisone. One of the following: 1) Used in combination with a gonadotropin-releasing hormone (GnRH) analog or 2) Patient received a bilateral orchiectomy.
Age Restrictions	N/A
Prescriber Restrictions	mCRPC, mCSPC: Prescribed by or in consultation with an oncologist or urologist
Coverage Duration	mCRPC, mCSPC: 12 months
Other Criteria	Approve for continuation of prior therapy

PART B VERSUS PART D

Products Affected

- Abelcet
- Acetylcysteine SOLN
- Acyclovir Sodium INJ 1000MG, 500MG, 50MG/ML
- Adriamycin INJ 10MG, 2MG/ML, 50MG
- Adrucil INJ 2.5GM/50ML, 500MG/10ML, 5GM/100ML
- Akynzeo CAPS
- Albuterol Sulfate NEBU
- Ambisome
- Amino Acid INJ 50MG/ML; 50MG/ML
- Aminosyn INJ 148MEQ/L; 1280MG/100ML; 980MG/100ML; 1280MG/100ML; 300MG/100ML; 720MG/100ML; 940MG/100ML; 720MG/100ML; 400MG/100ML; 440MG/100ML; 860MG/100ML; 420MG/100ML; 520MG/100ML; 160MG/100ML; 44MG/100ML; 800MG/100ML
- Aminosyn 7%/electrolytes INJ 124MEQ/L; 900MG/100ML; 690MG/100ML; 96MEQ/L; 900MG/100ML; 210MG/100ML; 510MG/100ML; 660MG/100ML; 510MG/100ML; 10MEQ/L; 280MG/100ML; 310MG/100ML; 30MMOLE/L; 65MEQ/L; 610MG/100ML; 300MG/100ML; 65MEQ/L; 370MG/100ML; 120MG/100ML; 44MG/100ML; 560MG/100ML
- Aminosyn 8.5%/electrolytes INJ 142MEQ/L; 1100MG/100ML; 850MG/100ML; 98MEQ/L; 1100MG/100ML; 260MG/100ML; 620MG/100ML; 810MG/100ML; 624MG/100ML; 10MEQ/L; 340MG/100ML; 380MG/100ML; 30MEQ/L; 65MEQ/L; 750MG/100ML; 370MG/100ML; 65MEQ/L; 460MG/100ML; 150MG/100ML; 44MG/100ML; 680MG/100ML
- Aminosyn II INJ 50.3MEQ/L; 695MG/100ML; 713MG/100ML; 490MG/100ML; 517MG/100ML; 350MG/100ML; 210MG/100ML; 462MG/100ML; 700MG/100ML; 735MG/100ML; 120MG/100ML; 209MG/100ML; 505MG/100ML; 371MG/100ML; 31.3MEQ/L; 280MG/100ML; 140MG/100ML; 189MG/100ML; 350MG/100ML; 71.8MEQ/L; 993MG/100ML; 1018MG/100ML; 700MG/100ML; 738MG/100ML; 500MG/100ML; 300MG/100ML; 660MG/100ML; 1000MG/100ML; 1050MG/100ML; 172MG/100ML; 298MG/100ML; 722MG/100ML; 530MG/100ML; 38MEQ/L; 400MG/100ML; 200MG/100ML; 270MG/100ML; 500MG/100ML
- Aminosyn II 8.5%/electrolytes
- Aminosyn M INJ 65MEQ/L; 448MG/100ML; 343MG/100ML; 40MEQ/L; 448MG/100ML; 105MG/100ML; 252MG/100ML; 329MG/100ML; 252MG/100ML; 3MEQ/L; 140MG/100ML; 154MG/100ML; 3.5MMOLE/L; 13MEQ/L; 300MG/100ML; 147MG/100ML; 40MEQ/L; 182MG/100ML; 56MG/100ML; 31MG/100ML; 280MG/100ML

Prior Authorization Criteria

Scott and White

Effective: December 1, 2019

- Aminosyn-hbc INJ 7.1MEQ/100ML; 660MG/100ML; 507MG/100ML; 660MG/100ML; 154MG/100ML; 789MG/100ML; 1576MG/100ML; 265MG/100ML; 206MG/100ML; 1.12GM/100ML; 228MG/100ML; 448MG/100ML; 221MG/100ML; 272MG/100ML; 88MG/100ML; 33MG/100ML; 789MG/100ML
- Aminosyn-pf INJ 46MEQ/L; 698MG/100ML; 1227MG/100ML; 527MG/100ML; 820MG/100ML; 385MG/100ML; 312MG/100ML; 760MG/100ML; 1200MG/100ML; 677MG/100ML; 180MG/100ML; 427MG/100ML; 812MG/100ML; 495MG/100ML; 3.4MEQ/L; 70MG/100ML; 512MG/100ML; 180MG/100ML; 44MG/100ML; 673MG/100ML
- Aminosyn-pf 7%
- Aminosyn-rf INJ 113MEQ/L; 600MG/100ML; 429MG/100ML; 462MG/100ML; 726MG/100ML; 535MG/100ML; 726MG/100ML; 726MG/100ML; 330MG/100ML; 165MG/100ML; 528MG/100ML
- Amphotec
- Amphotericin B INJ
- Anzemet TABS
- Aprepitant
- Astagraf XL
- Azasan
- Azathioprine INJ
- Azathioprine TABS
- Baclofen INJ
- Bethkis
- Bleomycin
- Bleomycin Sulfate INJ
- Budesonide SUSP
- Cladribine
- Clinimix 2.75%/dextrose 5%
- Clinimix 4.25%/dextrose 10%
- Clinimix 4.25%/dextrose 20%
- Clinimix 4.25%/dextrose 25%
- Clinimix 5%/dextrose 15%
- Clinimix 5%/dextrose 20%
- Clinimix 5%/dextrose 25%
- Clinimix E 2.75%/dextrose 10% INJ 570MG/100ML; 317MG/100ML; 33MG/100ML; 10GM/100ML; 283MG/100ML; 132MG/100ML; 165MG/100ML; 201MG/100ML; 159MG/100ML; 51MG/100ML; 110MG/100ML; 454MG/100ML; 154MG/100ML; 261MG/100ML; 187MG/100ML; 138MG/100ML; 217MG/100ML; 112MG/100ML; 116MG/100ML; 50MG/100ML; 11MG/100ML; 160MG/100ML
- Clinimix E 2.75%/dextrose 5%
- Clinimix E 4.25%/dextrose 10%
- Clinimix E 4.25%/dextrose 25%
- Clinimix E 4.25%/dextrose 5%
- Clinimix E 5%/dextrose 15%
- Clinimix E 5%/dextrose 20%
- Clinimix E 5%/dextrose 25%
- Clinimix N14g30e
- Clinimix N9g15e
- Clinimix N9g20e
- Clinisol Sf 15%
- Clinolipid
- Clonidine Hcl INJ
- Cromolyn Sodium NEBU
- Cyclophosphamide CAPS
- Cyclosporine CAPS
- Cyclosporine Modified
- Cytarabine INJ 100MG/ML, 20MG/ML
- Cytarabine Aqueous
- Deferoxamine Mesylate
- Dobutamine Hcl INJ 250MG/20ML, 500MG/40ML
- Dobutamine Hcl/d5w INJ 5%; 1MG/ML
- Dobutamine Hydrochloride/dextrose
- Dobutamine/dextrose 5% INJ 5%; 2MG/ML, 5%; 4MG/ML

Prior Authorization Criteria

Scott and White

Effective: December 1, 2019

- Dopamine Hcl
- Dopamine Hydrochloride/dextrose
- Dopamine/d5w INJ 5%; 3.2MG/ML
- Doxorubicin Hcl INJ 10MG, 2MG/ML, 50MG
- Emend SUSR
- Engerix-b
- Envarsus Xr
- Fentanyl Citrate INJ 1000MCG/20ML, 100MCG/2ML, 2500MCG/50ML, 250MCG/5ML, 500MCG/10ML, 50MCG/ML
- Floxuridine INJ
- Fluorouracil INJ 1GM/20ML, 2.5GM/50ML, 500MG/10ML, 5GM/100ML
- Freamine Hbc 6.9%
- Freamine III INJ 89MEQ/L; 710MG/100ML; 950MG/100ML; 3MEQ/L; 24MG/100ML; 1400MG/100ML; 280MG/100ML; 690MG/100ML; 910MG/100ML; 730MG/100ML; 530MG/100ML; 560MG/100ML; 10MMOLE/L; 120MG/100ML; 1120MG/100ML; 590MG/100ML; 10MEQ/L; 400MG/100ML; 150MG/100ML; 660MG/100ML
- Gablofen
- Ganciclovir INJ 500MG, 500MG/10ML
- Gengraf
- Granisetron Hcl TABS
- Hecoria CAPS 0.5MG, 1MG
- Hepagam B
- Hepatamine
- Heplisav-b
- Hyperhep B S/d
- Hyperrab
- Hyperrab S/d INJ 1500UNIT/10ML, 300UNIT/2ML
- Imogam Rabies-ht
- Imovax Rabies (h.d.c.v.)
- Intralipid INJ 20GM/100ML
- Ipratropium Bromide INHALATION SOLN 0.02%
- Ipratropium Bromide/albuterol Sulfate
- Kedrab
- Levalbuterol NEBU
- Levalbuterol Hcl NEBU
- Levalbuterol Hydrochloride NEBU 0.31MG/3ML
- Lioresal Intrathecal
- Milrinone In Dextrose INJ 5%; 20MG/100ML, 5%; 40MG/200ML
- Milrinone Lactate INJ 10MG/10ML, 20MG/20ML, 50MG/50ML
- Morphine Sulfate INJ 150MG/30ML, 1MG/ML
- Mycophenolate Mofetil
- Mycophenolic Acid Dr
- Nabi-hb
- Nebupent
- Nephramine
- Nutrilipid
- Ondansetron Hcl SOLN
- Ondansetron Hcl TABS 24MG
- Ondansetron Hydrochloride TABS
- Ondansetron Odt
- Perforomist
- Plenamine
- Premasol
- Procalamine
- Prograf PACK
- Prosol
- Rabavert
- Rapamune SOLN
- Recombivax Hb
- Sandimmune SOLN
- Sirolimus SOLN
- Sirolimus TABS
- Synthamin 17
- Tacrolimus CAPS
- Tobramycin NEBU

Prior Authorization Criteria

Scott and White

Effective: December 1, 2019

- Travasol INJ 52MEQ/L;
1760MG/100ML; 880MG/100ML;
34MEQ/L; 1760MG/100ML;
372MG/100ML; 406MG/100ML;
526MG/100ML; 492MG/100ML;
492MG/100ML; 526MG/100ML;
356MG/100ML; 500MG/100ML;
356MG/100ML; 390MG/100ML;
34MG/100ML; 152MG/100ML
- Trimethobenzamide Hydrochloride
- Trophamine INJ 97MEQ/L;
0.54GM/100ML; 1.2GM/100ML;
0.32GM/100ML; 0; 0; 0.5GM/100ML;
0.36GM/100ML; 0.48GM/100ML;
0.82GM/100ML; 1.4GM/100ML;
1.2GM/100ML; 0.34GM/100ML;
0.48GM/100ML; 0.68GM/100ML;
0.38GM/100ML; 5MEQ/L;
0.025GM/100ML; 0.42GM/100ML;
0.2GM/100ML; 0.24GM/100ML;
0.78GM/100ML
- Vinblastine Sulfate INJ 1MG/ML
- Vincasar Pfs
- Vincristine Sulfate INJ
- Yupelri

Details

This drug may be covered under Medicare Part B or D depending upon the circumstances. Information may need to be submitted describing the use and setting of the drug to make the determination.

INDEX

7	
7t Lido Gel.....	195
A	
Abelcet	422
Abiraterone Acetate.....	421
Abstral.....	234
Acetylcysteine	422
Actemra	2, 3
Actemra Actpen	3
Actemra IV (s).....	2
Actemra Sc (s).....	3
Acthar.....	125
Actimmune	4
Actimmune (s)	4
Acyclovir Sodium	422
Adagen	5
Adagen (s)	5
Adcirca	6
Adcirca (s).....	6
Adderall Xr (s).....	7
Adempas.....	8
Adempas (s).....	8
Adriamycin.....	422
Adrucil	422
Afinitor	9
Afinitor (s).....	9
Afinitor Disperz	10
Afinitor Disperz (s)	10
Aimovig.....	11
Aimovig (s).....	11
Akynzeo	422
Albuterol Sulfate	422
Aldurazyme	13
Aldurazyme (s)	13
Alecensa	14
Alecensa (s).....	14
Aliqopa	15
Aliqopa (s)	15
Alosetron Hydrochloride	199
Alpha-1 Proteinase Inhibitor, Non-preferred (s) .	16
Alpha-1 Proteinase Inhibitor, Prolastin (s)	17
Alprazolam.....	35
Alprazolam Er	35
Alprazolam Intensol.....	35
Alprazolam Odt	35
Alprazolam Xr.....	35
Alunbrig.....	18
Alunbrig (s).....	18
Alyq.....	6
Ambisome	422
Ambrisentan	192
Amino Acid.....	422
Aminosyn.....	422
Aminosyn 7%/electrolytes	422
Aminosyn 8.5%/electrolytes	422
Aminosyn II	422
Aminosyn II 8.5%/electrolytes	422
Aminosyn M	422
Aminosyn-hbc	423
Aminosyn-pf	423
Aminosyn-pf 7%	423
Aminosyn-rf	423
Amitriptyline Hcl.....	144
Amitriptyline Hydrochloride	144
Amnesteem	165
Amphetamine (s)	19
Amphetamine/dextroamphetamine	7, 19
Amphotec	423
Amphotericin B	423
Ampyra	20
Ampyra (s).....	20
Anadrol-50	21
Anadrol-50 (s)	21

Prior Authorization Criteria

Scott and White

Effective: December 1, 2019

Androderm.....	358
Androge1.....	358
Androge1 Pump	358
Androxy	22
Androxy (s).....	22
Anzemet	423
Apokyn.....	23
Apokyn (s).....	23
Aprepitant.....	423
Aralast Np.....	16
Aranesp (s)	24
Aranesp Albumin Free.....	24
Arcalyst	26
Arcalyst (s)	26
Armodafinil	244
Arzerra	27
Arzerra (s).....	27
Ascomp/codeine	139
Astagraf XL.....	423
Aubagio	28
Aubagio (s)	28
Auryxia.....	29
Auryxia (s).....	29
Austedo	30
Austedo (s)	30
Avita.....	366
Avonex	224
Avonex Pen	224
Azasan.....	423
Azathioprine	423

B

Baclofen	423
Balversa.....	31
Balversa (s).....	31
Bavencio.....	32
Bavencio (s).....	32
Beleodaq.....	33
Beleodaq (s).....	33
Benlysta.....	34
Benlysta (s).....	34
Benzodiazepines (s).....	35
Berinert.....	36

Berinert (s)	36
Besponsa	37
Besponsa (s)	37
Betaseron	224
Bethkis	423
Bexarotene	351
Bivigam	167
Bleomycin.....	423
Bleomycin Sulfate	423
Blincyto	38
Blincyto (s).....	38
Bortezomib.....	39
Bortezomib (s).....	39
Bosentan	367
Bosulif	40
Bosulif (s)	40
Botox	41
Botox (s)	41
Braftovi.....	43
Braftovi (s)	43
Budesonide.....	423
Butalbital Compound/codeine	139
Butalbital/acetaminophen	139
Butalbital/acetaminophen/caffeine	139
Butalbital/acetaminophen/caffeine/codeine	139
Butalbital/aspirin/caffeine	139
Butalbital/aspirin/caffeine/codeine.....	139

C

Cabliivi	44
Cabliivi (s)	44
Cabometyx	45
Cabometyx (s)	45
Calquence.....	46
Calquence (s).....	46
Capacet	139
Caprelsa	47
Caprelsa (s)	47
Carimune Nanofiltered.....	167
Carisoprodol.....	48
Carisoprodol (s)	48
Cayston	49
Cayston (s)	49

Prior Authorization Criteria

Scott and White

Effective: December 1, 2019

Cephadyn.....	139	Clinimix N9g20e	423
Cerdelga	50	Clinisol Sf 15%	423
Cerdelga (s)	50	Clinolipid	423
Cerezyme.....	51	Clonidine Hcl.....	423
Cerezyme (s).....	51	Cometriq	59
Chlordiazepoxide Hcl.....	35	Cometriq (s)	59
Chlordiazepoxide Hydrochloride	35	Copaxone	119
Chlordiazepoxide/amitriptyline.....	144	Copiktra	60
Chlorzoxazone	143	Copiktra (s)	60
Cholbam	52	Corlanor	61
Cholbam (s)	52	Corlanor (s)	61
Chorionic Gonadotropin	53	Cosentyx	62
Chorionic Gonadotropin (s)	53	Cosentyx (s)	62
Cialis (s)	54	Cosentyx Sensoready Pen	62
Ciclodan	55	Cotellic.....	63
Ciclopirox (s).....	55	Cotellic (s).....	63
Ciclopirox Nail Lacquer	55	Crinone	64
Cimzia	56	Crinone (s)	64
Cimzia (s)	56	Cromolyn Sodium.....	423
Cimzia Starter Kit	56	Cutaquig.....	312
Cinryze	58	Cuvitru.....	312
Cinryze (s).....	58	Cyclobenzaprine Hydrochloride	143
Cladribine	423	Cyclobenzaprine Hydrochloride Er.....	143
Claravis	165	Cyclophosphamide	423
Clinimix 2.75%/dextrose 5%	423	Cyclosporine	423
Clinimix 4.25%/dextrose 10%	423	Cyclosporine Modified	423
Clinimix 4.25%/dextrose 20%	423	Cyproheptadine Hcl.....	133
Clinimix 4.25%/dextrose 25%	423	Cyramza.....	65
Clinimix 4.25%/dextrose 5%	423	Cyramza (s).....	65
Clinimix 5%/dextrose 15%	423	Cystaran.....	66
Clinimix 5%/dextrose 20%	423	Cystaran (s).....	66
Clinimix 5%/dextrose 25%	423	Cytarabine	423
Clinimix E 2.75%/dextrose 10%	423	Cytarabine Aqueous.....	423
Clinimix E 2.75%/dextrose 5%	423		
Clinimix E 4.25%/dextrose 10%	423	D	
Clinimix E 4.25%/dextrose 25%	423	Dacogen (s).....	67
Clinimix E 4.25%/dextrose 5%	423	Daklinza	68
Clinimix E 5%/dextrose 15%	423	Daklinza (s).....	68
Clinimix E 5%/dextrose 20%	423	Dalfampridine Er	20
Clinimix E 5%/dextrose 25%	423	Daliresp.....	69
Clinimix N14g30e	423	Daliresp (s).....	69
Clinimix N9g15e.....	423	Daraprim	70
		Daraprim (s)	70

Prior Authorization Criteria

Scott and White

Effective: December 1, 2019

Darzalex	71	Eligard (s)	82
Darzalex (s)	71	Emend	424
Daurismo	72	Emflaza	83
Daurismo (s)	72	Emflaza (s)	83
Decitabine	67	Empliciti	84
Deferasirox	73	Empliciti (s)	84
Deferasirox (s)	73	Enbrel	85
Deferoxamine Mesylate	423	Enbrel (s)	85
Dexchlorpheniramine Maleate	133	Enbrel Mini	85
Dexedrine	75	Enbrel Sureclick	85
Dexmethylphenidate (s)	74	Endari	86
Dexmethylphenidate Hcl	74	Endari (s)	86
Dexmethylphenidate Hcl Er	74	Engerix-b	424
Dexmethylphenidate Hydrochloride	74	Entyvio	87
Dextroamphetamine (s)	75	Entyvio (s)	87
Dextroamphetamine Sulfate	75	Envarsus Xr	424
Dextroamphetamine Sulfate Er	75	Epclusa	88
Diclofenac Sodium	268	Epclusa (s)	88
Diphenatol	136	Epidiolex	89
Diphenoxylate/atropine	136	Epidiolex (s)	89
Dobutamine Hcl	423	Epoetin Alfa (s)	90
Dobutamine Hcl/d5w	423	Epoprostenol (s)	92
Dobutamine Hydrochloride/dextrose	423	Epoprostenol Sodium	92
Dobutamine/dextrose 5%	423	Erbitux	93
Dopamine Hcl	424	Erbitux (s)	93
Dopamine Hydrochloride/dextrose	424	Erivedge	94
Dopamine/d5w	424	Erivedge (s)	94
Doxepin Hcl	144	Erleada	95
Doxepin Hydrochloride	76, 144	Erleada (s)	95
Doxepin Topical (s)	76	Erlotinib Hydrochloride	350
Doxorubicin Hcl	424	Esbriet	96
Dronabinol	209	Esbriet (s)	96
Duobrii	77	Esgic	139
Duobrii (s)	77	Estazolam	35
Dupixent	78	Eszopiclone	142
Dupixent (s)	78	Evenity	97
E		Evenity (s)	97
Egrifta	80	Exjade	73
Egrifta (s)	80	Exondys 51	98
Elaprase	81	Exondys 51 (s)	98
Elaprase (s)	81	Extavia	224
Eligard	82	Eylea	99

Prior Authorization Criteria

Scott and White

Effective: December 1, 2019

Eylea (s) 99

F

Fabrazyme 100

Fabrazyme (s) 100

Farydak..... 101

Farydak (s)..... 101

Fasenra 102

Fasenra (s)..... 102

Fasenra Pen..... 102

Fentanyl (s)..... 104

Fentanyl Citrate..... 234, 424

Fentanyl Citrate Oral Transmucosal 104

Fentora 234

Ferriprox..... 105

Ferriprox (s)..... 105

Firazyr 106

Firazyr (s) 106

Firdapse 107

Firdapse (s) 107

Firmagon 108

Firmagon (s) 108

Flebogamma Dif 167

Floxuridine 424

Fluorouracil 424

Folotyn 109

Folotyn (s) 109

Forteo 110

Forteo (s) 110

Freamine Hbc 6.9% 424

Freamine III 424

Fulphila 112

Fulphila (s) 112

G

Gablofen 424

Galafold 113

Galafold (s) 113

Gamastan 114

Gamastan S/d..... 114

Gamastan S/d (s) 114

Gammagard Liquid 167

Gammagard S/d Iga Less Than 1mcg/ml..... 167

Formulary ID 19406 Version 20

Last Updated: 11/01/2019

Gammaked167

Gammaplex167

Gamunex-c167

Ganciclovir.....424

Gattex115

Gattex (s)115

Gazyva116

Gazyva (s).....116

Gengraf424

Genotropin122

Genotropin Miniquick.....122

Gilenya.....117

Gilenya (s).....117

Gilotrif118

Gilotrif (s)118

Glassia 16

Glatiramer Acetate.....119

Glatiramer Acetate (s).....119

Glatopa.....119

Gleevec (s)120

Glydo.....195

Gocovri121

Gocovri (s)121

Granisetron Hcl424

Growth Hormone (s).....122

H

H.p. Acthar Gel (s).....125

Haegarda.....127

Haegarda (s).....127

Halaven128

Halaven (s)128

Harvoni129

Harvoni (s)129

Hecoria.....424

Hepagam B.....424

Hepatamine424

Heplisav-b.....424

Herceptin.....130

Herceptin (s).....130

Hetlioz131

Hetlioz (s)131

Hizentra132

Prior Authorization Criteria

Scott and White

Effective: December 1, 2019

Hizentra (s)	132
Hrm - Antihistamines	133
Hrm - Antihypertensive Agents	134
Hrm - Antipsychotics	135
Hrm - Antispasmodics	136
Hrm - Cardiovascular, Calcium Channel Blocker	137
Hrm - Endocrine	138
Hrm - Pain Medications	139
Hrm - Phenobarbital, Pentobarbital	140
Hrm - Platelet Inhibitors	141
Hrm - Sedative Hypnotic Agents	142
Hrm - Skeletal Muscle Relaxants	143
Hrm - Tca	144
Humatrope	122
Humatrope Combo Pack	122
Humira	145
Humira (s)	145
Humira Pediatric Crohns Disease Starter Pack ..	145
Humira Pen	145
Humira Pen-cd/uc/hs Starter	145
Humira Pen-ps/uv Starter	145
Hydroxyprogesterone (s)	147
Hydroxyprogesterone Caproate	147, 208
Hydroxyzine Hcl	133
Hydroxyzine Hydrochloride	133
Hydroxyzine Pamoate	133
Hyperhep B S/d	424
Hyperrab	424
Hyperrab S/d	424
Hyqvia	312

I

Ibrance	148
Ibrance (s)	148
Icatibant Acetate	106
Iclusig	149
Iclusig (s)	149
Idhifa	150
Idhifa (s)	150
Ilaris	151
Ilaris (s)	151
Ilumya	152

Ilumya (s)	152
Imatinib Mesylate	120
Imbruvica	153
Imbruvica (s)	153
Imfinzi	154
Imfinzi (s)	154
Imogam Rabies-ht	424
Imovax Rabies (h.d.c.v.)	424
Invexxy (s)	155
Invexxy Maintenance Pack	155
Invexxy Starter Pack	155
Inbrija	156
Inbrija (s)	156
Increlex	157
Increlex (s)	157
Indomethacin	139
Inflectra	158
Inflectra (s)	158
Ingrezza	160
Ingrezza (s)	160
Inlyta	161
Inlyta (s)	161
Inrebic	162
Inrebic (s)	162
Intralipid	424
Intron A	163
Intron A (s)	163
Intron A W/diluent	163
Ipratropium Bromide	424
Ipratropium Bromide/albuterol Sulfate	424
Iressa	164
Iressa (s)	164
Isotretinoin	165
Isotretinoin (s)	165
Istodax	166
Istodax (overfill)	166
Istodax (s)	166
Itraconazole	328
Ivig (s)	167

J

Jadenu	73
Jadenu Sprinkle	73

Prior Authorization Criteria

Scott and White

Effective: December 1, 2019

Jakafi.....	170
Jakafi (s).....	170
Jevtana.....	171
Jevtana (s).....	171
Juxtapid.....	172
Juxtapid (s).....	172

K

Kadcyla.....	173
Kadcyla (s).....	173
Kalbitor.....	174
Kalbitor (s).....	174
Kalydeco.....	175
Kalydeco (s).....	175
Kanuma.....	176
Kanuma (s).....	176
Kedrab.....	424
Ketorolac Tromethamine.....	139
Keveyis.....	177
Keveyis (s).....	177
Kevzara.....	178
Kevzara (s).....	178
Keytruda.....	179
Keytruda (s).....	179
Kineret.....	181
Kineret (s).....	181
Kisqali.....	182
Kisqali (s).....	182
Kisqali Femara 200 Dose.....	183
Kisqali Femara 400 Dose.....	183
Kisqali Femara 600 Dose.....	183
Kisqali-femara Pack (s).....	183
Korlym.....	184
Korlym (s).....	184
Krystexxa.....	185
Krystexxa (s).....	185
Kuvan.....	186
Kuvan (s).....	186
Kynamro.....	187
Kynamro (s).....	187
Kyprolis.....	188
Kyprolis (s).....	188

L

Lartruvo.....	189
Lartruvo (s).....	189
Lazanda.....	234
Ledipasvir/sofosbuvir.....	129
Lemtrada.....	190
Lemtrada (s).....	190
Lenvima (s).....	191
Lenvima 10 Mg Daily Dose.....	191
Lenvima 12mg Daily Dose.....	191
Lenvima 14 Mg Daily Dose.....	191
Lenvima 18 Mg Daily Dose.....	191
Lenvima 20 Mg Daily Dose.....	191
Lenvima 24 Mg Daily Dose.....	191
Lenvima 4 Mg Daily Dose.....	191
Lenvima 8 Mg Daily Dose.....	191
Letairis.....	192
Letairis (s).....	192
Leukine.....	193
Leukine (s).....	193
Leuprolide Acetate.....	202
Levalbuterol.....	424
Levalbuterol Hcl.....	424
Levalbuterol Hydrochloride.....	424
Lidocaine.....	195, 196
Lidocaine And Tetracaine Cream.....	195
Lidocaine Hcl.....	195
Lidocaine Hcl Jelly.....	195
Lidocaine Topical (s).....	195
Lidocaine/prilocaine.....	195
Lidocaine-prilocaine-cream Base.....	195
Lidoderm (s).....	196
Lioresal Intrathecal.....	424
Lonsurf.....	197
Lonsurf (s).....	197
Lorazepam.....	35
Lorazepam Intensol.....	35
Lorbrena.....	198
Lorbrena (s).....	198
Lotronex (s).....	199
Lumizyme.....	200
Lumizyme-myozyme (s).....	200

Prior Authorization Criteria

Scott and White

Effective: December 1, 2019

Lupaneta Pack.....	201
Lupaneta Pack (s).....	201
Lupron (s)	202
Lupron Depot (1-month).....	203
Lupron Depot (3-month).....	203
Lupron Depot (4-month).....	203
Lupron Depot (6-month).....	203
Lupron Depot (s).....	203
Lupron Depot Ped (s)	204
Lupron Depot-ped (1-month)	204
Lupron Depot-ped (3-month)	204
Lynparza.....	205, 206
Lynparza (s).....	205
Lynparza Tablet (s)	206

M

Makena.....	208
Makena (s).....	208
Margesic	139
Marinol (s)	209
Marten-tab	139
Mavenclad	210
Mavenclad (s)	210
Mavyret	211
Mavyret (s)	211
Mayzent	212
Mayzent (s)	212
Mayzent Starter Pack.....	212
Meclizine Hcl.....	133
Megestrol Acetate	138
Mekinist.....	213
Mekinist (s).....	213
Mektovi	214
Mektovi (s)	214
Metadate Er	215
Metadate Er-ritalin Sr (s)	215
Methitest.....	220
Methocarbamol.....	143
Methotrexate Injection (s).....	216
Methyldopate Hcl.....	134
Methylin Chew (s).....	217
Methylphenidate (s).....	218
Methylphenidate Er (s).....	219

Methylphenidate Hcl Sr	215
Methylphenidate Hydrochloride	217, 218
Methylphenidate Hydrochloride CD	219
Methylphenidate Hydrochloride Er.....	215, 219
Methylphenidate Hydrochloride Er (la).....	219
Methyltestosterone	220
Methyltestosterone (s).....	220
Miglustat	411
Milrinone In Dextrose	424
Milrinone Lactate	424
Mirvaso	222
Mirvaso (s)	222
Mitoxantrone Hcl.....	236
Modafinil	278
Morphine Sulfate	424
Mozobil.....	223
Mozobil (s).....	223
Ms Inteferons (s).....	224
Mulpleta.....	225
Mulpleta (s).....	225
Myalept	226
Myalept (s)	226
Mycophenolate Mofetil.....	424
Mycophenolic Acid Dr.....	424
Mylotarg	227
Mylotarg (s).....	227
Myorisan	165
Myozyme	200

N

Nabi-hb	424
Naglazyme	228
Naglazyme (s)	228
Natpara.....	229
Natpara (s).....	229
Nebupent	424
Nephramine	424
Nerlynx	230
Nerlynx (s)	230
Neulasta	231
Neulasta (s)	231
Neulasta Onpro Kit	231
Nexavar.....	232

Prior Authorization Criteria

Scott and White

Effective: December 1, 2019

Nexavar (s)	232
Nifedipine	137
Ninlaro	233
Ninlaro (s).....	233
Non-preferred Tirf (s).....	234
Norditropin Flexpro.....	122
Norditropin Nordiflex Pen	122
Northera.....	235
Northera (s).....	235
Novantrone (s)	236
Novarel.....	53
Nplate	237
Nplate (s).....	237
Nubeqa	238
Nubeqa (s)	238
Nucala	239
Nucala (s)	239
Nuedexta.....	241
Nuedexta (s).....	241
Nulojix	242
Nulojix (s).....	242
Nuplazid	243
Nuplazid (s)	243
Nutrilipid	424
Nutropin Aq Nuspin 10	122
Nutropin Aq Nuspin 20	122
Nutropin Aq Nuspin 5	122
Nutropin Aq Pen	122
Nuvigil (s).....	244

O

Ocaliva	245
Ocaliva (s)	245
Ocrevus	246
Ocrevus (s)	246
Octagam	167
Octreotide Acetate.....	310
Odomzo	248
Odomzo (s)	248
Ofev	249
Ofev (s)	249
Olumiant.....	250
Olumiant (s).....	250

Olyseo	251
Olyseo (s)	251
Omnitrope	122
Ondansetron Hcl.....	424
Ondansetron Hydrochloride	424
Ondansetron Odt.....	424
Onmel	252
Onmel (s)	252
Opdivo	253
Opdivo (s)	253
Opsumit	255
Opsumit (s).....	255
Orencia.....	256, 257
Orencia Clickject	257
Orencia IV (s).....	256
Orencia Sc (s).....	257
Orenitram	258
Orenitram (s)	258
Orilissa	259
Orilissa (s).....	259
Orkambi	260, 261
Orkambi (s)	260
Orkambi Granules (s).....	261
Orphenadrine Citrate Er	143
Osphena	262
Osphena (s)	262
Otezla.....	263
Otezla (s).....	263
Oxandrin (s)	264
Oxandrolone	264
Oxazepam	35
Oxervate.....	265
Oxervate (s).....	265

P

Panzyga	167
Part B Versus Part D.....	422
Pegasys	266
Pegasys (s)	266
Pegasys Proclick	266
Pegintron	267
Peg-intron.....	267
Peg-intron (s).....	267

Prior Authorization Criteria

Scott and White

Effective: December 1, 2019

Peg-intron Redipen.....	267	Promethazine Vc Plain.....	133
Peg-intron Redipen Pak 4.....	267	Promethazine/phenylephrine.....	133
Pennsaid.....	268	Promethegan.....	133
Pennsaid (s).....	268	Prosol.....	424
Pentobarbital Sodium.....	140	Provigil (s).....	278
Perforomist.....	424	Pulmozyme.....	280
Perjeta.....	269	Pulmozyme (s).....	280
Perjeta (s).....	269	Q	
Perphenazine/amitriptyline.....	144	Qualaquin (s).....	281
Phenadoz.....	133	Quinine Sulfate.....	281
Phenergan.....	133	R	
Phenobarbital.....	140	Rabavert.....	424
Phenobarbital Sodium.....	140	Radicava.....	282
Phrenilin Forte.....	139	Radicava (s).....	282
Piqray (s).....	270	Rapamune.....	424
Piqray 200mg Daily Dose.....	270	Rasuvo.....	216
Piqray 250mg Daily Dose.....	270	Ravicti.....	283
Piqray 300mg Daily Dose.....	270	Ravicti (s).....	283
Plegridy.....	224	Rebif.....	224
Plegridy Starter Pack.....	224	Rebif Rebidose.....	224
Plenamine.....	424	Rebif Rebidose Titration Pack.....	224
Pliaglis.....	195	Rebif Titration Pack.....	224
Pomalyst.....	271	Recombivax Hb.....	424
Pomalyst (s).....	271	Regranex.....	284
Portrazza.....	272	Regranex (s).....	284
Portrazza (s).....	272	Relexxii.....	219
Praluent.....	273	Relistor.....	285, 286
Praluent (s).....	273	Relistor (s).....	285
Pregnyl W/diluent Benzyl Alcohol/nacl.....	53	Relistor Tablets (s).....	286
Premasol.....	424	Remicade.....	287
Privigen.....	167	Remicade (s).....	287
Procalamine.....	424	Remodulin.....	289
Procrit.....	90	Remodulin (s).....	289
Procysbi.....	275	Renflexis.....	290
Procysbi (s).....	275	Renflexis (s).....	290
Prograf.....	424	Repatha.....	292
Prolastin-c.....	17	Repatha (s).....	292
Promacta.....	276	Repatha Pushtronex System.....	292
Promacta (s).....	276	Repatha Sureclick.....	292
Promethazine Hcl.....	133	Revatio.....	297
Promethazine Hcl Plain.....	133	Revatio (s).....	295
Promethazine Hydrochloride.....	133		

Prior Authorization Criteria

Scott and White

Effective: December 1, 2019

Revatio Injection (s)	296	Sildenafil Citrate	295, 297
Revatio Suspension (s)	297	Siliq	316
Revlimid	298	Siliq (s)	316
Revlimid (s)	298	Simponi.....	317
Rilutek (s)	299	Simponi (s).....	317
Riluzole	299	Simponi Aria	319
Rinvoq.....	300	Simponi Aria (s)	319
Rinvoq (s)	300	Sirolimus.....	424
Rituxan	301	Skyrizi.....	320
Rituxan (s)	301	Skyrizi (s).....	320
Rituxan Hycela	303	Sofosbuvir/velpatasvir	88
Rituxan Hycela (s).....	303	Soliris.....	321
Romidepsin.....	166	Soliris (s).....	321
Rozlytrek	304	Somatuline Depot	322
Rozlytrek (s)	304	Somatuline Depot (s)	322
Rubraca	305	Somavert	323
Rubraca (s)	305	Somavert (s)	323
Ruconest.....	306	Sovaldi.....	324
Ruconest (s).....	306	Sovaldi (s).....	324
Ruzurgi.....	307	Spinraza	326
Ruzurgi (s).....	307	Spinraza (s)	326
Ryclora	133	Sporanox	328
Rydapt	308	Sporanox (s)	328
Rydapt (s)	308	Sprycel.....	329
S			
Sabril.....	309	Sprycel (s).....	329
Sabril (s).....	309	Stelara	330, 331
Saizen.....	122	Stelara (iv) (s).....	330
Saizen Click.easy	122	Stelara (s)	331
Saizenprep Reconstitutionkit	122	Stivarga	332
Sandimmune	424	Stivarga (s).....	332
Sandostatin (s)	310	Strensiq	333
Sandostatin Lar (s)	311	Strensiq (s)	333
Sandostatin Lar Depot	311	Striant	358
Scig (s)	312	Supprelin La	334
Serostim.....	313	Supprelin La (s)	334
Serostim (s).....	313	Sutent	335
Signifor.....	314	Sutent (s).....	335
Signifor (s).....	314	Sylatron.....	336
Signifor Lar	315	Sylatron (s).....	336
Signifor Lar (s).....	315	Sylvant	337
Sildenafil	296	Sylvant (s).....	337
Formulary ID 19406 Version 20			
Last Updated: 11/01/2019			

Prior Authorization Criteria

Scott and White

Effective: December 1, 2019

Symdeko (s).....	338
Symlyn (s).....	339
Symlynpen 120.....	339
Symlynpen 60.....	339
Synagis.....	340
Synagis (s).....	340
Syndros.....	342
Syndros (s).....	342
Synribo.....	343
Synribo (s).....	343
Synthamin 17.....	424

T

Tacrolimus.....	424
Tadalafil.....	6, 54
Tafamidis (s).....	344
Tafinlar.....	345
Tafinlar (s).....	345
Tagrisso.....	346
Tagrisso (s).....	346
Takhzyro.....	347
Takhzyro (s).....	347
Taltz.....	348
Taltz (s).....	348
Talzenna.....	349
Talzenna (s).....	349
Tarceva.....	350
Tarceva (s).....	350
Targretin.....	351
Targretin (s).....	351
Tasigna.....	352
Tasigna (s).....	352
Tavalisse.....	353
Tavalisse (s).....	353
Tecentriq.....	354
Tecentriq (s).....	354
Tecfidera.....	355
Tecfidera (s).....	355
Tecfidera Starter Pack.....	355
Technivie.....	356
Technivie (s).....	356
Tegsedi.....	357
Tegsedi (s).....	357

Temazepam.....	35
Tencon.....	139
Testosterone.....	358
Testosterone (s).....	358
Testosterone Cypionate.....	358
Testosterone Enanthate.....	360
Testosterone Enanthate (s).....	360
Testosterone Pump.....	358
Testosterone Topical Solution.....	358
Tetrabenazine.....	395
Thalomid.....	361
Thalomid (s).....	361
Thioridazine Hcl.....	135
Thyrogen.....	362
Thyrogen (s).....	362
Tibsovo.....	363
Tibsovo (s).....	363
Ticlopidine Hcl.....	141
Tiglutik.....	364
Tiglutik (s).....	364
Tobramycin.....	424
Tolsura.....	365
Tolsura (s).....	365
Topical Retinoid (s).....	366
Tracleer (s).....	367
Travasol.....	425
Trelstar.....	368
Trelstar (s).....	368
Trelstar Mixject.....	368
Tremfya.....	369
Tremfya (s).....	369
Treprostinil.....	289
Tretinoin.....	366
Tretinoin Microsphere.....	366
Tretinoin Microsphere Pump.....	366
Trimethobenzamide Hydrochloride.....	425
Triptodur.....	370
Triptodur (s).....	370
Trophamine.....	425
Turalio.....	371
Turalio (s).....	371
Tykerb.....	372

Prior Authorization Criteria

Scott and White

Effective: December 1, 2019

Tykerb (s) 372
 Tymlos 373
 Tymlos (s)..... 373
 Tysabri 374
 Tysabri (s)..... 374

U

Udenyca..... 376
 Udenyca (s)..... 376
 Uptravi 377
 Uptravi (s)..... 377

V

Valchlor 378
 Valchlor (s) 378
 Vanatol Lq..... 139
 Varizig 379
 Varizig (s)..... 379
 Velcade..... 380
 Velcade (s)..... 380
 Veletri 92
 Venclexta 381
 Venclexta (s)..... 381
 Venclexta Starting Pack..... 381
 Ventavis 382
 Ventavis (s)..... 382
 Verzenio 383
 Verzenio (s) 383
 Viekira (s)..... 384
 Viekira Pak 384
 Viekira Xr 384
 Vigabatrin 309
 Vigadrone 309
 Vimizim..... 385
 Vimizim (s)..... 385
 Vinblastine Sulfate 425
 Vincasar Pfs..... 425
 Vincristine Sulfate 425
 Vitrakvi 386
 Vitrakvi (s) 386
 Vizimpro..... 387
 Vizimpro (s)..... 387
 Vosevi 388

Vosevi (s) 388
 Votrient 389
 Votrient (s) 389
 Vpriv 390
 Vpriv (s)..... 390
 Vyndamax 344
 Vyndaqel..... 344
 Vyxeos 391
 Vyxeos (s) 391

X

Xalkori 392
 Xalkori (s) 392
 Xeljanz..... 393
 Xeljanz (s)..... 393
 Xeljanz Xr 393
 Xembify 312
 Xenazine (s) 395
 Xeomin 396
 Xeomin (s) 396
 Xermelo 397
 Xermelo (s) 397
 Xgeva 398
 Xgeva (s)..... 398
 Xiaflex 399
 Xiaflex (s) 399
 Xifaxan 400
 Xifaxan (s) 400
 Xolair 401
 Xolair (s) 401
 Xospata 403
 Xospata (s) 403
 Xpovio (s) 404
 Xpovio 100 Mg Once Weekly 404
 Xpovio 60 Mg Once Weekly 404
 Xpovio 80 Mg Once Weekly 404
 Xpovio 80 Mg Twice Weekly 404
 Xtandi 405
 Xtandi (s) 405
 Xuriden 406
 Xuriden (s) 406
 Xyosted 358
 Xyrem 407

Prior Authorization Criteria

Scott and White

Effective: December 1, 2019

Xyrem (s)..... 407

Y

Yervoy..... 408

Yervoy (s)..... 408

Yonsa 409

Yonsa (s) 409

Yupelri 425

Z

Zaleplon..... 142

Zaltrap 410

Zaltrap (s) 410

Zavesca (s)..... 411

Zebutal 139

Zejula 412

Zejula (s) 412

Zelboraf 413

Zelboraf (s) 413

Zemaira 16

Zenatane.....165

Zenzedi 75

Zepatier414

Zepatier (s)414

Zolinza415

Zolinza (s)415

Zolpidem Tartrate142

Zolpidem Tartrate Er.....142

Zorbtive416

Zorbtive (s).....416

Zortress417

Zortress (s)417

Zydelig.....418

Zydelig (s).....418

Zykadia419

Zykadia (s)419

Zytiga.....420

Zytiga (non-preferred) (s).....420

Zytiga (preferred) (s).....421